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ABSTRACT 
 
Colorectal cancer (CRC) is the second most common cancer in both men and 
women in Australia. The upregulation of cyclooxygenase-2 (COX-2), an enzyme 
involved in the inflammation response, has been linked to a number of cancers, 
including CRC.  This has prompted a number of epidemiological and clinical studies 
that suggest that prolonged administration of non-steroidal anti-inflammatory drugs 
(NSAIDs) can reduce the incidence of cancer, in particular, CRC.  However, side effects 
such as gastrointestinal (GI) bleeding limit the prolonged daily use of (NSAIDs) for the 
chemoprevention of cancer.  
Bismuth, a group 15 post-transition metal, has been used for centuries to treat an 
array of GI diseases.  The Bi formulations exhibit an acceptable toxicity profile when 
administered at low doses over extended periods.  Thus, it is hypothesised that the 
combination of Bi and NSAID in a single compound may potentially relieve the adverse 
GI side effects of NSAIDs if used daily as a chemopreventive agent.   
The aim of this Thesis was to determine the suitability of Bi complexes of NSAIDs 
(BiNSAIDs) as potential chemotherapeutic or chemopreventive agents.  The starting 
point was to assess the ability of BiNSAIDs to interact with transformed cells (HCT-8 
human ileocecal colon cancer cells) using a selection of BiNSAIDs of the general 
formula [Bi(L)3]n, (where L = diflunisal (difl), mefenamate (mef) or tolfenamate (tolf)). 
The hydrolytic stability of the BiNSAIDs in cell medium was investigated to 
determine the biologically relevant structures that the cancer cells were exposed to in 
the cell assays.  NMR spectroscopy of high concentrations of BiNSAIDs in cell 
medium (24 h, 37 °C) indicated that their structural stability and interactions with cell 
medium components were specific to the complex.  Specifically, Bi(tolf)3 appeared to 
remain intact, whereas Bi(mef)3 and Bi(difl)3 were affected by interactions with the 
cell medium. 
The in vitro cytotoxicity, mode of cell death, and the ability of the BiNSAIDs to 
inhibit COX in HCT-8 cells were investigated.  Assessment of cell viability using the 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium] bromide (MTT) assay showed 
that the toxicity ranking of the BiNSAIDs paralleled those of the respective free 
NSAIDs: diflH < mefH < tolfH.  While the IC50 values of the BiNSAIDs (ranging between 
16 and 81 μM) were lower than the free NSAIDs (ranging between 37 and 403 μM), 
it was apparent that the toxicity of the BiNSAIDs was in reasonable agreement with 
the molar ratio of the three NSAIDs per BiNSAID, with the exception of Bi(difl)3. 
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Phase contrast microscopy and Annexin-V/7AAD staining showed that treatment with 
all BiNSAIDs and NSAIDs induced morphological changes indicative of cell death via 
apoptosis.  Recognising that over-expression of COX-2 is associated with CRC, the 
ability of the BiNSAIDs to inhibit the production of PGE2 (and COX) in HCT-8 cells was 
assessed.  It was observed that the inhibition of PGE2 production by the BiNSAIDs 
paralleled that of the respective free NSAIDs: diflH < mefH < tolfH.  These results 
indicated that the COX inhibition of the examined NSAIDs was not substantially 
diminished by their coordination to Bi (in the BiNSAIDs). 
Bismuth uptake was quantified using graphite furnace atomic absorption 
spectroscopy (GFAAS) to establish whether BiNSAID stability and toxicity correlated 
with cellular uptake.  The highest cellular Bi content was observed following 
treatment with Bi(tolf)3.  Since NMR studies indicated that Bi(tolf)3 was the most 
stable BiNSAID it appears that Bi uptake is assisted by the NSAID.  Furthermore, 
microprobe synchrotron radiation X-ray fluorescence (SRXRF) imaging was utilised to 
determine the subcellular fate of the Bi contained in the BiNSAID complexes.  
Microprobe SRXRF imaging showed that Bi generally accumulated in the cytoplasm 
within 24-h exposure regardless of the BiNSAID treatment.  The size and location of 
the hot spots (0.3–5.8 μm2) were consistent with two intracellular fates.  The first is 
accumulation into lysosomes, which would be indicative of a cellular detoxification 
mechanism.  The second relates to the hot spots that are in close proximity to the 
nuclear membrane (and potentially COX-2), which indicates the intracellular 
movement of Bi.  However, the specific targeting of COX-2 by the BiNSAID would 
require further investigation. 
Synchrotron radiation infrared microspectroscopy (SR-IRMS) was utilised in 
order to assess the global biomolecular changes induced by BiNSAID treatment 
compared to NSAIDs alone.  Live HCT-8 cells were examined using a demountable cell 
holder in order to maintain hydration.  The results from 4-h experiments differed to 
24-h experiments suggesting that the cells undergo time-dependent changes.  In most 
cases, it was observed that BiNSAID or NSAID treatment substantially affected the IR 
bands associated with lipids. 
Based on the results from the SR-IRMS study and literature precedence, the 
effects of BiNSAID- and NSAID-induced cell death on the distribution and quantity of 
three glycerophospholipids, phosphatidylcholine (PC), phosphatidylethanolamine 
(PE) and phosphatidylserine (PS), in the HCT-8 cells was examined using electrospray 
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ionisation tandem mass spectrometry (ESI-MS/MS).  The results showed that 
treatment with Bi(tolf)3 or Bi(difl)3 caused alterations to the profile and concentration 
of individual PC, PE and PS molecules.  Additionally, specific trends were identified, 
whereby changes to the saturation levels of the fatty acids comprising the PC, PE and 
PS were observed.  Treatment with both BiNSAIDs or NSAIDs caused an increase in 
the proportion of the ether-linked PC and PE molecules relative to the overall profile 
of PC and PE in the HCT-8 cells, which was accompanied by a significant increase in 
the relative concentration of ether-linked PE molecules (but not PC) in the 
BiNSAID-treated cells. 
Encouraged by the promising in vitro anti-cancer activity of the BiNSAIDs against 
the HCT-8 cells, several Bi(III) derivatives of aminoarenesulfonates, 
indole-carboxylates, hydroxamates were screened for anti-cancer activity using the 
MTT assay.  A small selection of complexes from each class showed promising in vitro 
toxicity, that warrants further investigation into the chemotherapeutic potential of 
non-NSAID Bi(III) complexes.  
The results presented in this Thesis reveal that BiNSAIDs, Bi(tolf)3, Bi(mef)3 and 
Bi(difl)3, exhibit promising anti-cancer action against CRC cells in vitro.  These findings 
set the precedence to establish if the chemotherapeutic and chemopreventive 
potential of the BiNSAIDs translates to an in vivo model of CRC.   
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Chapter 1.  
Introduction  
 
 
Colorectal cancer (CRC) is the second most common cancer in both men and women in 
Australia.  Since the incidence of CRC has not improved since the 1980s, prevention 
strategies are needed to reduce the burden of this disease.   The upregulation of 
cyclooxygenase-2 (COX-2), an enzyme involved in the inflammation response, has 
been linked to a number of cancers, including CRC.  This has led to a large number of 
studies that subsequently showed that several over-the-counter non-steroidal 
anti-inflammatory drugs (NSAIDs) reduced the risk of CRC when taken regularly over 
periods of months to years.  This Chapter provides a review of the relevant literature 
with a focus on the potential use of NSAIDs as chemopreventive and chemotherapeutic 
agents for CRC, the advantages of coordinating NSAIDs to metals, and finally, the 
medicinal use and anti-cancer activity of bismuth(III) complexes, including Bi(III) 
complexes of NSAIDs (BiNSAIDs). 
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1.1   Cancer 
Cancer, in the simplest of terms, is a genetic disease that is characterised by the 
uncontrolled propagation of cells that have acquired defects in regulatory circuits that 
control normal cell proliferation and homeostasis [1].  The accumulation of sequential 
chromosomal mutations allows a cancer cell to resist cell death, undergo limitless 
cycles of cell division, resist anti-growth signals, maintain autonomous growth 
signaling, sustain angiogenesis (the formation of blood vessels in the tumour), and 
eventually acquire metastasis (the ability to invade tissues at distal locations) [1]. 
Collectively, these six features are described as the “hallmarks of cancer” [1].  Over 100 
distinct types of cancer have been identified and the order of acquisition of the 
aforementioned characteristics varies considerably between cell types [1]. 
The American Cancer Society estimates that cancer causes the death of one in seven 
people worldwide [2].  In 2012, cancer represented the second leading, and third 
leading, cause of death in economically developed, and economically developing 
countries, respectively, highlighting the serious global nature of this disease [2]. 
1.1.1 Colorectal cancer 
Worldwide, colorectal cancer (CRC) or bowel cancer, is the third most common 
cancer in men (following lung and prostate cancers), and the second most common 
cancer in women (following breast cancer) [2].  CRC commonly develops from 
adenomatous polyps, which are non-malignant growths that propagate in the 
epithelium of the digestive tract [3].  Owing to the slow accumulation of multiple 
genetic mutations, conservative estimates suggest that adenomatous polyps can 
remain non-malignant for periods of 5–10 years, or more [4]; this is reflected in the 
diagnosis of over 90% of CRC cases in individuals over the age of 50 [5].  
Alarmingly, Australia and New Zealand exhibit the highest incidence (per 100,000 
people) of CRC in the world [6].  In Australia alone, CRC represents the second most 
common cancer in both men and women [7].  Approximately 31% of individuals 
diagnosed with CRC do not survive beyond five years [7].  In 2017, the Australian 
Institute of Health and Welfare reported that a total of 4,144 deaths were directly 
attributable to CRC [7].  Despite reductions in the age-standardised mortality rates 
from CRC in Australia (Fig. 1.1) over the past three decades, the age-standardised 
incidence of CRC has remained steady between 1982–2014 (Fig. 1.1) [7], with 16,682 
new cases of CRC diagnosed in Australia in 2017 [7].  
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Figure 1.1: Age-standardised incidence and mortality rates (1982–2014) of colorectal cancers 
by sex in Australia.  Source: Australian Institute of Health and Welfare [7]. 
Although the estimated lifetime risk of developing CRC in the general population 
is 5.6% [8], 70–80% of CRC cases occur in individuals with no family history of the 
disease [9, 10].  Largely preventable lifestyle factors, including high alcohol 
consumption, diet (high fat, high intake of red and processed meats) and lack of 
physical activity, are believed to contribute to the development of CRC [5].  
Family history accounts for approximately 20% of CRC cases, while 5–10% of cases 
are associated with the genetic syndromes, familial adenomatous polyposis (FAP) and 
Lynch syndrome (also called hereditary non-polyposis CRC) [9, 10].  The estimated 
lifetime risk of developing CRC in genetically susceptible subpopulations increases to 
17% for individuals with two affected first-degree relatives, and up to 95% and 70% 
for individuals with FAP and Lynch syndrome, respectively [11].  
Successful methods of early detection such as faecal occult blood testing and 
endoscopic surveillance (flexible sigmoidoscopy and colonoscopy), and the removal of 
pre-carcinogenic lesions (polypectomy) are available in Australia [12-14].  
However, primary prevention strategies have been suggested as an important 
complement to established screening methods to reduce the incidence of CRC [15], 
and an alternative approach to reducing mortality from cancer [16]. 
Chemoprevention, which is the use of a pharmacological or nutritional agent to 
prevent, reverse, or delay the progression of carcinogenesis, represents one example 
of a primary prevention strategy that has been widely studied in the context of 
CRC [16].  Ideally, chemopreventive agents should be effective, easily administered 
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(i.e.  oral administration), of low cost, involve a dosing schedule that enables 
compliance (no more than once daily), and have no or limited side effects (i.e. the 
benefit to risk ratio must be high) [16].  Therapeutic and nutritional agents that have 
been shown to reduce CRC incidence in observational studies include non-steroidal 
anti-inflammatory drugs (NSAIDs), folic acid, calcium (in conjunction with vitamin D in 
some studies), antioxidants (including vitamins A, C, and E, beta-carotene or 
selenium), statins and bisphosphonates [15].  Of the aforementioned agents, calcium 
and vitamin D appear to exhibit modest clinical benefit, while NSAID therapies appear 
to reduce the incidence of CRC substantially [15].  
NSAIDs are readily available over-the-counter drugs that are commonly used to 
relieve the symptoms of inflammation, pain, redness, swelling, and calor [17].  
NSAIDs  are commonly used for the treatment of pain and inflammation associated 
with transient inflammatory conditions and tissue damage (including post-operative 
pain, dysmenorrhoea, headaches, migraines, and pericarditis), and chronic conditions, 
including osteoarthritis and rheumatoid arthritis [17].  The chemopreventive and 
chemotherapeutic potential of NSAIDs, and the drawbacks of NSAID use, will be the 
focus of discussion in Section 1.2.  
1.2   Non-Steroidal Anti-Inflammatory Drugs 
The term NSAID describes several classes of organic molecules that exert their 
quintessential anti-inflammatory, anti-pyretic and analgesic actions through the 
inhibition of the cyclooxygenase-1/-2 (COX-1/-2) enzymes [17].  This subsequently 
decreases the production of prostaglandins, the potent lipid autocrine and paracrine 
factors involved in the mediation of the inflammatory response [18].  Over 30 million 
people worldwide are estimated to use prescription NSAIDs on a daily basis [19], 
making NSAIDs one of the most commonly used pharmaceutical class in the world.  In 
the USA alone, more than 111 million prescriptions are written for NSAIDs annually; in 
addition, NSAIDs that are purchased over-the-counter account for approximately 60% 
of all analgesics sold in the USA [20].  
Historically, NSAID administration can be traced back thousands of years to the 
use of bark from the white willow (Salix alba) by the physicians, Hippocrates (~460–
377 BC) and Dioscorides (~40–90 AD), for the alleviation of fever and musculoskeletal 
pain [21].  Salicylic acid (2-hydroxybenzoic acid), a derivative of the active ingredient 
salicin was first produced industrially in 1874 [22]; however, due to poor palatability, 
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acetylsalicylic acid (Fig. 1.2) was developed by Felix Hoffman in 1897, and marketed 
by Frederick Bayer & Company as aspirin (aspH) in 1899 [23].  Non-salicylate NSAIDs, 
indomethacin (indoH, Fig. 1.2) and ibuprofen (ibuH, Fig. 1.2), were first introduced to 
the market in 1964 and 1969, respectively [24].  This was followed by the introduction 
of diclofenac (dicloH, Fig 1.2) and ketoprofen (ketoH, Fig 1.2) in the mid-1970s [24].  
As shown in Figure 1.2, arylalkanoic acids (of the general formula ArCRHCOOH, 
where Ar = aryl or heteroaryl; R = H, CH3, alkyl), including salicylic acids (e.g. aspH, 
diflunisal (diflH), and salsalate), indolic acids (e.g. indoH), acetic acids (e.g. sulindac), 
propionic acids (e.g. ibuH, naproxen (napH), flurbiprofen, and ketoH), and fenamates 
(e.g.  mefenamic acid (mefH), tolfenamic acid (tolfH), flufenamic acid (fluH), 
meclofenamic acid (mecloH), and dicloH), comprise the largest chemical group of 
NSAIDs [25].  Notably, the arylalkanoic acid-based NSAIDs contain a carboxylate 
moiety (Fig. 1.2).  The selectivity preference of NSAIDs from these structural classes 
for COX-1 and COX-2 varies depending on the individual NSAID [26, 27].   
In the 1980s, Pfizer developed enolic acid NSAIDs, termed ‘oxicams’, which are 
derivatives of 4-hydroxy-1,2-benzothiazine 3-carboxamides [28].  Piroxicam (pirox, 
Fig. 1.2), marketed as Feldene® (Pfizer, New York, USA), was successfully introduced 
into the market in 1982 [28]. Shortly following this other oxicams including 
meloxicam (melox, Fig. 1.2), isoxicam (isox), lornoxicam, and tenoxicam (tenox) were 
introduced to the market [28]. Oxicams are able to interact with both COX                
isoforms [27, 29]; for instance, pirox has been shown to bind preferentially to 
COX-1 [27], while melox has been shown to be moderately selective for COX-2 [29].   
NSAIDs that are highly selective for COX-2 (termed ‘coxibs’, Fig. 1.2), celecoxib 
(Celebrex®, Pfizer, New York, USA), rofecoxib (Vioxx®, Merck & Co. Inc., New Jersey, 
USA), and parecoxib (Dynastat®, Pfizer, New York, USA), were introduced to the 
market in the late 1990s [30]. The coxibs incorporate a sulfonyl moiety in their 
chemical structures (Fig. 1.2), an important chemical feature that allows the molecules 
to interact preferentially with the COX-2 active site [30].  The concept of COX-1 and 
COX-2 selectivity, and the subsequent physiological consequences, will be discussed 
further in Section 1.2.1.  
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Figure 1.2: Chemical classes of non-steroidal anti-inflammatory drugs (NSAIDs).  The chemical 
structure, generic name and IUPAC name of selected NSAIDs representative of each class are 
presented to highlight the diversity of molecules that comprise NSAIDs [25, 31].   
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1.2.1 Mechanism of action of NSAIDs  
Studies performed by Vane and colleagues in the 1970s established that the 
primary mechanism through which NSAIDs exert their therapeutic action was through 
the inhibition of prostaglandin endoperoxide G/H synthase, the enzyme commonly 
referred to as COX [18, 32].  In the early 1990s, several studies established that there 
were two distinct forms of the COX enzyme, COX-1 and COX-2 [33-35].  Importantly, 
COX-1 and COX-2 differ in their subcellular location, constitutive levels of expression 
in tissues throughout the body, and the structure of their active sites.  
Immunocytofluorescence studies have established that both isoforms are present in 
the endoplasmic reticulum [36].  COX-1 is also located close to the plasma membrane, 
whereas COX-2 is specifically associated with the nuclear envelope [37].  COX-1 is 
constitutively expressed in most human tissues and is responsible for regulating 
essential physiological functions, including platelet aggregation, gastric protection, 
and renal function [38].  Conversely, under normal physiological conditions, COX-2 
expression is low to negligible in most tissues [39].  Growth factors, as well as 
cytokines (including tumour necrosis factor-α, interferon-γ, and interleukins (ILs), 
IL-1α and IL-1β) stimulate COX-2 expression [39].  As such, COX-2 is commonly 
referred to as the ‘inducible’ form of the enzyme.  It is notable that COX-2 is 
constitutively expressed in specific regions of the brain [40] and renal tubular cells 
[41]. The upregulation of COX-2 occurs primarily in response to inflammatory stimuli 
and thus plays a crucial role in mediating pain and inflammation [39].  It is notable 
that COX-3, a splice-variant of COX-1 has been identified [42].  Interestingly, some 
NSAIDs including dicloH, and the non-NSAID acetaminophen, have been shown to 
interact preferentially with COX-3 in vitro [42]; however, the physiological significance 
of COX-3 in humans remains poorly understood [43]. 
COX-1 and COX-2 consist of two catalytic sites, one with COX activity, and the 
other with peroxidase (POX) activity, which are located in two narrow channels on 
opposite sides of the catalytic domain [44].  The COX catalytic site is responsible for 
the oxidation of arachidonic acid to prostaglandin G2 (PGG2).  Subsequently, this short-
lived intermediate is reduced to PGH2 by the POX catalytic site (Fig. 1.3) [38].  The 
second intermediate, prostaglandin H2 (PGH2), is used as the substrate to form a 
number of prostaglandins, namely prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), 
prostaglandin F2α (PGF2α), and prostaglandin I2 (PGI2) via prostaglandin-specific 
synthases,  and  thromboxane  A2  (TXA2)  via  thromboxane  synthase  (Fig.  1.3)   [38]. 
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Figure 1.3: The conversion of arachidonic acid to prostaglandins via the COX and POX active 
sites of COX-1/-2.  Adapted from Vane et al. [38]. 
The eicosanoids (the collective term for prostaglandins, thromboxanes and 
leukotrienes) are autocrine and paracrine factors that are responsible for the 
mediation of specific physiological processes, including maintenance of gastric 
mucosa, platelet aggregation, bronchoconstriction, and vascular patency [45]. 
NSAIDs explicitly interact with the active site in the COX channel, leaving the POX 
catalytic    site    unaffected,    preventing    the    conversion    of    arachidonic    acid   to 
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PGG2 [38].  The COX-selectivity of NSAIDs is based on the structure of the NSAID, and 
the structure of the COX active sites.  The homology of the COX active site is highly 
conserved, except for the substitution of a few key residues, as demonstrated in 
Figure 1.4 [30].  Specifically, the substitution of Ile523 (COX-1) for Val523 (COX-2) 
allows unhindered access of bulkier substituents into a side pocket in the COX-2 
channel due to the reduced size of the Val residue (Fig. 1.4) [30].  Additionally, the 
substitution of Phe503 (COX-1) for Leu503 (COX-2) increases the space available at 
the top of the COX-2 channel (Fig. 1.4) [30].  Non-selective NSAIDs are able to interact 
with both the COX-1 and COX-2 active sites via interactions with Arg120 and 
Tyr355 (Fig. 1.4), which are stabilised by the carboxylate moiety present in the NSAID 
structures, while the phenyl group interacts with Tyr385 further up the hydrophobic 
channel (Fig. 1.4) [30]. 
The ‘coxibs’ incorporate sulfonyl moieties by design to specifically interact (via 
hydrogen bonding) with Arg513 in the accessible side pocket (Fig. 1.4), hence their 
high selectivity for COX-2 [30].  The majority of NSAIDs interact reversibly with the 
COX active site, thus competing with the natural substrate, arachidonic acid [46].  The 
exception is aspH, which irreversibly inhibits COX activity via the acetylation of 
Ser530 in COX-1 [47] and Ser516 in COX-2 [48].  The irreversible inhibition of COX by 
aspH triggers de novo synthesis of COX by cells [49]. 
 
Figure 1.4: The key structural residues of the COX-1 and COX-2 active sites.  Notably, substitution 
of Phe503 for Leu503, and Ile523 for Val523 increases the size of the COX-2 active site allowing for 
the incorporation of bulkier side groups present in COX-2 selective inhibitors.  An equivalent 
numbering system for both isoforms was adopted for clarity.  Adapted from Flower [30].   
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1.2.2 NSAIDs: Chemopreventive agents for CRC? 
Numerous observational, epidemiological, and clinical studies collectively suggest 
that daily use of NSAIDs reduces the occurrence of adenomatous polyps, and 
decreases the overall incidence and mortality of CRC in both high- and average-risk 
populations ([50], references within).  Since Narisawa et al. [51] first described the 
suppression of chemical-induced carcinoma in rats by indoH in 1981, over 40 other 
rodent studies have shown that NSAIDs (including aspH, indoH, sulindac, ibuH, ketoH, 
pirox and celecoxib) inhibit CRC or aberrant crypt formation induced by injection of 
azoxymethane or other chemicals known to induce carcinogenesis ([50], references 
within).  
The chemopreventive effect of sulindac in humans was first recognised by 
Waddell et al. [52, 53], whereby sulindac was effective in reducing the number of 
polyps in patients with FAP in clinical studies.  Given the inherent risk of developing 
CRC by the third or fourth decade of life for FAP sufferers [54], a number of studies 
focusing on the use of NSAIDs in this population have been performed.  Several studies 
in ApcMin mice and other murine models of human FAP have shown significant 
inhibition of tumour development by NSAIDs including aspH [55], sulindac [56, 57], 
and celecoxib [58].  One of the largest randomised, placebo-controlled trials conducted 
in the setting of FAP (n = 133), the Colorectal Adenoma/Carcinoma Prevention 
Programme [59], found no significant reduction in polyp number in the rectum and 
sigmoid colon with daily aspH (600 mg) treatment over a period of one to seven years, 
although a trend of reduced polyp size was observed.  The suppression of the 
formation of adenomatous polyps, and regression of existing polyps by sulindac has 
been demonstrated in a number of randomised clinical trials in patients with            
FAP [60-62], although one study [63] reported no significant reduction in the 
formation of adenomas between the sulindac-treated and placebo groups.  In the late 
1990s, 77 patients participated in a pivotal trial that demonstrated that compared to 
the placebo, a twice-daily dose of celecoxib (100 mg or 400 mg) over six months 
significantly reduced the mean number of colorectal polyps and polyp burden [64].  
The U.S. Food and Drug Administration (FDA) approved the use of celecoxib as an 
adjunctive treatment for FAP (in conjunction with usual care procedures) under 
subpart H (accelerated approval) in 2000; however, permanent FDA approval was not 
pursued by the manufacturer and the preliminary approval was removed in 2011 [65]. 
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The NSAID, aspH, has been shown to reduce the incidence and recurrence of CRC 
in individuals with Lynch syndrome [66], and previous adenomatous polyps [67].  The 
second Colorectal Adenoma/Carcinoma Prevention Programme trial [66] investigated 
the effects of aspH on 1,000 individuals with Lynch syndrome, which was the first 
large-scale genetically targeted chemoprevention trial of aspH with cancer as the 
primary endpoint.  The results suggested that following an average observation period 
of 55.7 months cancer incidence was substantially reduced in hereditary CRC carriers 
dosed with 600 mg of aspH once daily for a minimum of two years [66].  In a 
randomised, double-blind study involving 635 patients that had previously suffered 
from CRC [67], those dosed with aspH 325 mg once daily exhibited a significantly 
lower risk of recurring colon adenomas (17% incidence of adenomas compared to 
27% with the placebo).  Furthermore, a randomised, placebo-controlled study, the 
Adenoma Prevention with Celecoxib trial [68], evaluated the ability of celecoxib to 
reduce the occurrence of endoscopically detected colorectal adenomas.  Celecoxib 
administration in patients who had previously had adenomatous polyps removed, 
showed that following three years the incidence of recurrence of adenomas was 
reduced in celecoxib-treated groups to 43.2% (200 mg twice daily) and 37.5% 
(400 mg) compared to the placebo group (60.7%) [68]; however, the authors 
concluded that due to cardiovascular (CV) risks celecoxib could not be recommended 
for routine use for CRC prevention [68]. 
The results from 35 non-randomised epidemiological studies collectively suggest 
that regular use of NSAIDs lowers the incidence of adenomatous polyps, and reduces 
the incidence and mortality from CRC in individuals in the general population ([50], 
references within).  These observations are promising since the highest incidence of 
CRC occurs in non-genetically predisposed populations.  A recent meta-analysis [69] 
compared data from observational studies to data from randomised controlled 
trials.  Encouragingly, the results from methodically rigorous observational studies 
were consistent with the data obtained from randomised trials that regular use of 
aspH reduces the long-term risk of CRC (and several other cancers) and the risk of 
distant metastasis [69].  However, two large scale randomised placebo-controlled 
studies, the Physicians’ Health Study (325 mg aspH, every other day) [70] and the 
Women’s Health Study (100 mg of aspH, every other day) [71], showed no reduced 
risk of CRC in individuals dosed with aspH compared to the placebo group.  The lack of 
effect has been debated in the literature; for instance, it is plausible that alternate day 
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dosing and relatively short follow-up periods may not produce a significant 
result  [72].  Importantly, a significant reduction in mortality from CRC was not 
observed until 10 to 20 years post-intervention in a pooled analysis of three trials 
examining the effect of daily aspH use [73]. 
Interestingly, the analysis of data from randomised trials that examined daily 
aspH use for other endpoints, such as vascular events, have provided a large 
population of aspH-dosed subjects in order to assess anti-cancer effects as a secondary 
end point.  For instance, pooled analysis of 34 randomised trials of daily aspH for 
prevention of vascular events showed that risk of mortality from all cancers decreased 
following a follow up period of more than five years [74].  Additionally, pooled analysis 
of five large randomised trials (n = 17,285) of daily aspH (≥ 75 mg) versus placebo for 
the prevention of vascular events suggested that daily aspH use could reduce the risk 
of cancer with distant metastasis [75].  It should be noted that these analyses excluded 
results from the Women’s Health Study [72].  
In conclusion, the results from numerous epidemiological studies suggest there is 
an inverse relationship between the regular use of NSAIDs and the incidence of CRC 
and adenomas in a variety of populations.  However, given the lack of strong clinical 
evidence (from randomised placebo-controlled studies) to show an unequivocal 
reduction in the CRC incidence of NSAID-treated subjects, combined with the risk of 
adverse side effects, such as gastrointestinal (GI) bleeding, there are currently no 
recommendations for the use of NSAIDs in CRC prevention [76, 77]. 
1.2.3 The role of COX-2 in CRC 
In 1994, Eberhart et al. [78] determined that COX-2, but not COX-1, gene 
expression was upregulated in approximately 86% of human colorectal carcinomas 
and approximately 50% of adenomas compared to levels in adjacent healthy mucosal 
cells. Other investigators [79-81] have confirmed the upregulation of COX-2 
expression in CRC in human colon cancer tissues and animal models.  Additionally, 
elevated COX-2 expression has been identified in other types of cancer tissue including 
non-small cell lung [81, 82], bladder [83], breast [81, 84], and head and neck [85] 
cancers.  A number of studies [86-88] have suggested that elevated COX-2 expression 
in tumour tissue is associated with increased tumour invasiveness and poor prognosis 
for the patient.  As demonstrated in Figure 1.5, several molecular pathways are 
impacted by the over-expression of COX-2 that ultimately promotes cancer cell growth 
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by: (i) mounting resistance to cell death, (ii) increasing cell proliferation, 
(iii) increasing angiogenesis, and (iv) increasing the ability of the cells to metastasise.  
Perhaps the most obvious effect of COX-2 over-expression is the increased 
production of prostanoids.  As demonstrated in Figure 1.5, the production of TXA2, 
PGE2 and PGI2 collectively stimulate the normal growth of endothelial cells; however, 
in the neoplastic environment, an over-production of prostaglandins can promote 
cancer cell growth and proliferation [89].  In particular, an increase in PGE2 
concentration triggers an increase in anti-apoptotic B-cell lymphoma 2 (Bcl-2) levels 
resulting in the closing of mitochondrial pores, reducing the release of pro-apoptotic 
cytochrome C, and thereby diminishing apoptosis [89].  Additionally, there is evidence 
to suggest that the delayed progression of the cell cycle may also play a role in the 
growth of COX-2 over-expressing cancer cells by increasing the resistance of cells to 
apoptosis, thus increasing their tumourigenic potential [90].  The over-production of 
PGE2 is believed to suppress dendritic cells, natural killer cells, T cells, and type-1 
immunity, but promote type-2 immunity, which promotes tumour immune 
evasion [91]. 
 
Figure 1.5: Selected molecular pathways affected by the over-expression of COX-2 in 
neoplasia [89-97].  Bcl-2 = B-cell lymphoma 2; Hp = haptoglobin; IL = interleukin; MMP = 
metalloproteinase; PGE2 = prostaglandin E2; PGI2 = prostaglandin I2, TXA2 = thromboxane 
A2; VEGF = vascular endothelial growth factor. 
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The over-expression of COX-2, and subsequently, the increased levels of TXA2, 
a critical intermediary of angiogenesis [92], and PGE2, which is associated with 
increased expression of vascular endothelial growth factor (VEGF) in human tumour 
mucosa [93], promotes the production of blood vessels (angiogenesis) necessary for 
tumour growth and survival.  Additionally, the increased production of PGE2 induces 
IL-6, which subsequently induces haptoglobin (Hp), an important protein involved in 
angiogenesis [89].  Matrix metalloproteinases (MMPs), which are enzymes that assist 
in tumour and vascular cell invasion, have also been shown to be upregulated in COX-2 
expressing tumours [91, 94].  A reduction in the expression of IL-12, a potent 
anti-angiogenic cytokine, has also been observed in cells expressing COX-2 [95].  
The pro-angiogenic effects of COX-2 were demonstrated in one study that employed 
COX-2 over-expressing Caco-2 cells (versus low COX-2 expressing Caco-2 cells) 
co-cultured with HUVEC endothelial cells [96].  The results showed that when 
compared to the low COX-2 expressing Caco-2 cells, the endothelial cells were able to 
penetrate a matrix eight-fold faster when co-cultured with COX-2 over-expressing 
Caco-2 cells [96], suggesting COX-2 over-expression promotes a local environment 
conducive to tumour growth. 
The ability of cancer cells to invade distal tissue is an important feature of 
metastatic cancers.  Experimental evidence suggests that COX-2 over-expression is 
associated with increased invasiveness of cancer cells [97].  The activation of MMP-2 
and increased RNA levels for the membrane-type MMP-1 were observed in Caco-2 
cells programmed to constitutively produce COX-2, compared to regular, low COX-2 
producing Caco-2 cells [97].  The production of enzymes such as MMP-2 is associated 
with the ability of cancer cells to invade basement membranes through the proteolysis 
of aminin, fibronectin, type IV collagen, and proteoglycan [97].  
1.2.4 NSAIDs mediate cell death via COX, and non-COX related mechanisms 
 Given the role that COX-2 plays in many cancers, it is implied that the 
anti-neoplastic effects of NSAIDs are potentially associated with the inhibition of 
COX-2 in cancer cells.  The reversal of the pro-neoplastic effects of COX-2 
over-expression has been demonstrated by NSAIDs in a number of studies [92, 96-99]. 
For instance, increased invasiveness and PGE2 production of Caco-2 cells programmed 
to constitutively produce COX-2 was dose-dependently reversed by sulindac 
treatment [97].  Additionally, treatment with aspH or the COX-2 inhibitor, 
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NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide), inhibited PGE2 
production in a dose-dependent manner in the same COX-2-expressing Caco-2 cell 
line [96].  Experiments performed by Chan et al. [98] suggest that indoH and sulindac 
sulfide mediate colon cancer cell death by increasing arachidonic acid levels (rather 
than a decrease in prostaglandin levels), which stimulates the conversion of 
sphingomyelin to ceramide, a known mediator in apoptosis.  In another study [92] the 
selective COX-2 inhibitor, VU08 (N-(2-phenylethyl)indomethacin amide), decreased 
TXA2 production which resulted in reduced endothelial migration and a decline in 
fibroblast growth factor-induced corneal angiogenesis.  Finally, the inhibition of COX-2 
by celecoxib has been shown to reduce tumour growth and metastasis in xenograft 
tumour models and suppress basic fibroblast growth factor 2-induced angiogenesis of 
the rodent cornea [99]. 
The concept that inhibition of COX-2 in cancer cells contributes to the anti-cancer 
activity of NSAIDs is somewhat oversimplified; an abundance of experimental 
evidence suggests that not all NSAIDs induce cell death via COX-2 regulated pathways. 
For instance, a number of studies have shown that NSAIDs are toxic towards tumour 
cells that exhibit little to no COX-2 expression [100-102].  Furthermore, exogenously 
applied prostaglandins have failed to prevent the inhibitory effects of NSAIDs on 
cancer cell growth [103, 104].  The diversity of molecular pathways that NSAIDs affect 
is presented in Table 1.1 (for more detailed reviews refer to [105] and [106]). 
1.2.5 The drawbacks of prolonged NSAID use 
The prolonged use of NSAIDs is associated with a number of side effects.  These 
side effects are mainly attributable to the mechanism of action of the NSAIDs 
responsible for the desired therapeutic effects, and as such, the cells that produce 
constitutive COX-1 (GI mucosa, kidneys, and platelets) can be affected adversely by 
prolonged NSAID use.  The decrease in the constitutive expression of protective 
prostaglandins in the gastric mucosa as a result of COX-1 inhibition is understood to 
be responsible for the manifestation of GI symptoms, including ulceration, perforation 
and bleeding in the GI tract [107].  Of concern, the risk of GI bleeding associated with 
aspH therapy has been shown to increase with age [108].  The GI side effects induced 
by NSAID use encompass mild symptoms, including heartburn, nausea, dyspepsia and 
abdominal pain, as well as endoscopically identified mucosal lesions and serious GI 
complications   [19].      NSAID-related   GI   problems   are   estimated   to   account   for 
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Table 1.1: The major COX-2 dependent or independent pro-apoptotic pathways induced 
by NSAIDs.  
Apoptosis-inducing pathways NSAIDs 
COX-2-dependent 
COX-2 dependent accumulation of arachidonic acid and 
ceramide synthesis 
sulindac [98], indoH [98] 
Inhibition of IL-1β and phorbol 12-myristate 13-acetate 
induction preventing COX-2 mRNA and protein 
expression 
aspH [109],  
sodium salicylate [109] 
COX-2-independent 
Oxidative stress and disruption of redox balance aspH [110], sulindac [111], 
indoH [112], tolfH [113] 
Inhibition of Wnt/β-catenin signalling aspH [114], indoH [114], 
dicloH [115], sulindac [116] 
Modulation of cyclins sulindac [117], tolfH [118] 
Depletion of polyamines aspH [119], sulindac [120], 
indoH [121] 
Inhibition of proteasomal function aspH [122] 
Increased expression of mda/IL24 sulindac [123] 
Depletion of survivin aspH [124], tolfH [125] 
Modulation of nuclear factor kappa B signalling 
aspH [126], sulindac [127], 
ibuH [128], indoH [129], 
dicloH [115], tolfH [130] 
Mitogen activated protein kinase modulation aspH [131], indoH [132] 
Caspase activation and Bcl-2 protein modulation aspH [133, 134], indoH [134] 
Inhibition of store-operated calcium entry sulindac [135], mefH [135] 
Increased activity of caspase-3 to cleave PARP1 mefH [136] 
Interactions with cell membrane phospholipids mefH [137], celecoxib [138] 
Suppression of specificity protein 1 tolfH [139] 
Activation of NSAID-activated gene-1 tolfH [113], sulindac [140] 
Increased production of gastric glutathione-S-transferase aspH [141], ibuH [141], indoH [141] 
 
100,000 hospitalisations per year in the USA [19].  Additionally, an estimated 16,500 
deaths per year in the USA are attributable to NSAID use [142].  The production of 
prostaglandins (particularly PGE2 and PGI2) by COX-1 in the kidneys is important for 
renal function; inhibition can lead to dysfunction of normal renal regulation of blood 
pressure [143].  The inhibition of TXA2 production by COX-1 in platelets can result in 
prolonged bleeding time and a mild, systemic haemostatic defect [144].  
In the case of selective COX-2 inhibition, PGI2 production is decreased and TXA2 is 
left unchecked leading to the development of CV issues [145].  While a number of 
clinical studies have shown that COX-2 selective inhibitors, celecoxib and rofecoxib, 
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reduce the risk of GI and renal toxicity, their long-term use has been associated with 
an increased risk of CV events [146, 147].  In 2004, Merck announced the early 
termination of the Adenomatous Polyp Prevention on Vioxx trial [148].  In this trial, 
2,586 patients with a history of colorectal adenomas received either 25 mg of 
rofecoxib daily (n = 1,257) or placebo (n = 1,299) [146].  The trial was terminated due 
to an increased risk of CV events (including myocardial infarctions and ischemic 
cerebrovascular events) in patients receiving the drug for more than 18 months [148]. 
Vioxx (rofecoxib) was subsequently withdrawn from the market [148].  This prompted 
an investigation into the risk of CV events for patients prescribed celecoxib in the 
Adenoma Prevention with Celecoxib trial [147].  Celecoxib (200 mg or 400 mg, twice 
daily) was also determined to increase the risk of CV events 2.5-fold and 3.4-fold, 
respectively, compared to the placebo group leading to the discontinuation of the trial 
in late 2004 [147] and the FDA issuing a black box warning for celecoxib in 
2005 [149].  One report suggests that the CV risk of the non-selective NSAID, dicloH, is 
comparable to the COX-2 selective NSAID, rofecoxib [150].  Due to elevated risks of 
hepatotoxicity, the COX-2 selective NSAID, lumiracoxib, was not approved for use in 
the USA, and was withdrawn from the market in Australia and Europe in 2007 [151].  
Additionally, a several non-selective NSAIDs (including dicloH, sulindac, and 
nimesulide) are associated with increased risk of liver toxicity resulting in function 
abnormalities and fatal liver injury [152, 153]. 
Given the current risk of side effects, it has been argued that the daily use of 
NSAIDs for chemoprevention in the general population (where the risk of developing 
CRC is less than 6%) would not be beneficial unless other health endpoints could be 
achieved [50].  As such, the safety of NSAIDs needs to be improved.  Strategies to 
improve NSAID safety include: (i) the synthesis of novel modified NSAIDs, including 
nitric oxide releasing NSAIDs [154], phospho-NSAIDs [155], and sulfide releasing 
NSAIDs [156]; (ii) the development of dual COX and lipoxygenase           
inhibitors [157-160]; and (iii) the coordination of NSAIDs to metal ions.  The latter 
approach is the focus of this Thesis. 
1.3   Metal complexes of NSAIDs (metal-NSAIDs) 
The coordination of organic ligands to a metal ion(s), offers a number of potential 
medicinal advantages over the administration of organic ligands alone. 
These advantages include: (i) the alleviation of undesirable side effects; (ii) sustained 
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in vivo delivery of the organic ligand, i.e. increased/prolonged bioavailability (thus the 
metal complex essentially acts as a ‘pro-drug’); and (iii) synergism between the metal 
and the organic ligand resulting in the improvement of the original intended biological 
effect.  A wide variety of metal-NSAID combinations have displayed biological actions 
including anti-inflammatory activity [161-169], analgesia [164], anti-ulcer 
activity  [161-165], anti-cancer activity [162], and anti-microbial activity  [170-175]  
(for concision, the latter will not be discussed).  Of particular interest to the research 
presented in this Thesis is the complexation of metals with phenylalkanonic acids, and 
more specifically, fenamic acid NSAIDs (i.e. fluH, mecloH, mefH and tolfH) and 
salicylates (i.e. aspH and diflH).  For brevity, the following Sections will focus on the 
discussion of data from studies pertaining to metal complexes with phenylalkanonic 
acid NSAIDs, with brief mention of some studies examining metal-NSAIDs containing 
oxicam ligands. 
1.3.1 Anti-inflammatory and anti-ulcerative properties of metal-NSAIDs 
A number of metal-NSAID complexes have shown improved (or similar) in vivo 
anti-inflammatory and analgesic activities compared to their parent NSAID [161-169], 
as summarised in Table 1.2.  One of the perceived advantages of the employment of 
metal-NSAIDs over uncomplexed NSAIDs is the alleviation of common dose-limiting 
side effects, in particular, GI ulcerations.  Encouragingly, in vivo studies performed 
using rodent models [161, 162, 164, 165] have shown that gastric ulceration induced 
by commonly used NSAIDs (including ibuH, indoH and napH) was reduced by 
complexation with Cu(II), Ru(II), and Zn(II), as demonstrated by a decrease in lesion 
index scores (Table 1.2).  Additionally, [Cu2(indo)4(DMF)2] (where DMF = N,N-
dimethylformamide) and [Zn2(indo)4(DMA)2] (where DMA = N,N-dimethylacetamide) 
have been shown to reduce intestinal ulceration in rats when compared to indoH 
alone [163].  However, unlike [Cu2(indo)4(DMF)2], the [Zn2(indo)4(DMA)2] complex 
induced the same degree of ulceration in the stomach as indoH alone [163].  As 
demonstrated in Table 1.2, this result was in concordance with previous studies [169].  
These results validate the importance of the choice of the metal centre on the 
biological activity of the complexes. The Ru(III)-oxicam complexes, 
[RuCl2(piroxH2)(piroxH)] and [RuCl2(tenoxH2)(tenoxH)], demonstrated significant 
anti-inflammatory activity in the carrageenan-induced rat paw oedema assay, albeit a 
smaller     effect     was     achieved     than     equimolar    pirox    [176].      The     authors  
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concluded that the two complexes were superior anti-inflammatory agents compared 
to pirox due to the reduction in gastric damage in rats treated with the two complexes 
compared to the damage induced by pirox alone. 
The in vivo success of [Cu2(indo)4(DMF)2] has led to the development of 
commercially available therapeutic products.  For instance, these Cu-based NSAIDs 
have been used in oral dosage forms for veterinary use, and for topical human 
use [31].  An ethanolic gel-base of Cu-salicylate (marketed as Alcusal® by Australian 
company Mentholatum) was formerly available for topical temporal relief of pain and 
inflammation in humans [31]. Cu-Algesic® (containing [Cu2(indo)4(DMF)2]) is 
available for veterinary use (dogs and horses) in Australasia, South East Asia and 
South Africa due to its low toxicity profile compared to uncomplexed indoH [31]. 
 
1.3.2 Chemotherapeutic properties of metal-NSAIDs 
Given the considerable evidence that NSAIDs possess chemopreventive and 
chemotherapeutic properties (discussed in Section 1.2.2-1.2.4), it is reasonable to 
hypothesise that metal-NSAID complexes may also possess this property.  To this end, 
a number of studies [167, 168, 175, 177-180] have assessed the toxicity of 
metal-NSAIDs towards transformed (cancer) cells in vitro.  As shown in Table 1.3, the 
IC50 values (i.e. the concentration of drug required to produce 50% inhibition) 
obtained from in vitro cancer cell studies allow a direct comparison of the toxicity of 
the metal-NSAIDs to the analogous free NSAID, and the commonly used anti-cancer 
drug, cisplatin (cis-diamminedichloroplatinum(II)). Encouragingly, a number of metal-
NSAID complexes possess improved (or similar) potency compared to the analogous 
free NSAID (when considering the molar ratio of NSAID in the metal-complex) and 
cisplatin against a number of cancer cell lines in vitro (Table 1.3).  Many of these 
studies varied the metal centre while employing the same NSAID ligands, revealing the 
importance of the identity of the metal centre and the anti-cancer potential of the 
complexes (Table 1.3).  These studies also reveal that each of the metal-NSAID 
complexes showed increased potency (i.e. selectivity) towards specific cancer cell lines 
(Table 1.3).  
Recently, a series of organometallic Ru(II)- and Os(II)-p-cymene complexes were 
studied where the NSAIDs, indoH or dicloH, were attached to the organometallic 
moieties via monodentate (pyridine/phosphine) or bidentate (bipyridine) ligands, 
producing piano-stool Ru(II) and Os(II) arene complexes [181].    The modified NSAIDs  
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Table 1.3: Results from in vitro studies comparing the anti-cancer activity of metal-NSAID 
complexes with uncomplexed NSAIDs, and the anti-cancer agent, cisplatin (CisPt).  
Metal-NSAID* Cell line† Assay‡ Time IC50 value (μM) Ref 
    M+-NSAID NSAID CisPt  
[Co(tolf)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
38.3 
44.9 
76.8 
33.4 
62.4  
87.9 
145  
214 
41.7  
8.0  
1.5  
0.7 
[167] 
[Cu(tolf)2(H2O)]2  T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
13.9 
26.1 
31.4  
5.3  
62.4 
87.9  
145  
214  
41.7  
8.0  
1.5  
0.7 
[167] 
[Mn(tolf)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
3.9 
41.6 
65.3 
149 
62.4 
87.9 
145  
214  
41.7 
8.0 
1.5  
0.7 
[167] 
[Ni(tolf)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
35.3 
54.5 
54.1 
100.1 
62.4 
87.9 
145  
214 
41.7 
8.0  
1.5  
0.7 
[167] 
[Zn(tolf)2(H2O)] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
41.0 
41.3 
57.9 
123 
62.4 
87.9 
145  
214 
41.7 
8.0  
1.5  
0.7 
[167] 
[Co(mef)2(H2O)2]  
 
 
 
T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
27.0 
93.6 
115.9 
< 174.4 
81.2 
149.2 
168.3 
178.2 
41.7  
8.0  
1.5  
0.7 
[168] 
[Cu(mef)2(H2O)]2 T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
7.77 
25.1 
< 100.3 
19.5 
81.2 
149.2 
168.3 
178.2 
41.7 
8.0  
1.5  
0.7 
[168] 
[Mn(mef)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
35.1 
72.6 
< 175.6 
< 175.6 
81.2 
149.2 
168.3 
178.2 
41.7 
8.0  
1.5  
0.7 
[168] 
[Ni(mef)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
24.0 
59.3 
86.6 
63.4 
81.2 
149.2 
168.3 
178.2 
41.7 
8.0  
1.5  
0.7 
[168] 
[Zn(mef)2]  
 
T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
37.7 
40.7 
111.2 
74.4 
81.2 
149.2 
168.3 
178.2 
41.7 
8.0  
1.5  
0.7 
[168] 
[Cd(mef)2(CH3OH)]n T-24 
MCF-7 
MTT 
MTT 
72 h 
72 h 
0.86 
0.12 
81.2 
149.2 
40.9 
1.84 
[175] 
[Ph3Sn(mef)] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
0.29 
0.68 
7.21 
7.23 
80.1 
146.4 
167.8 
168.5 
7.99 
41.66 
0.69 
1.53 
[177] 
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Table 1.3: (cont.) Results from in vitro studies comparing the anti-cancer activity of 
metal-NSAID complexes with uncomplexed NSAIDs, and the anti-cancer agent, cisplatin 
(CisPt). 
Metal-NSAID* Cell line† Assay Time IC50 value (μM) Ref 
    M+-NSAID NSAID CisPt  
[Ph3Sn(flu)] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
4.78 
1.26 
60.44 
5.85 
99.6 
120.9 
171.8 
192.0 
7.99 
41.66 
0.69 
1.53 
[177] 
[Cd(meclo)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
3.3 
5.1 
29.8 
22.7 
70.2 
63.1 
139.1 
133.0 
41.7 
8.0 
1.5 
0.7 
[178] 
[Cu(meclo)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
5.3 
38.2 
41.2 
61.9 
70.2 
63.1 
139.1 
133.0 
41.7 
8.0 
1.5 
0.7 
[178] 
[Mn(meclo)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
3.8 
39.8 
27.4 
25.3 
70.2 
63.1 
139.1 
133.0 
41.7 
8.0 
1.5 
0.7 
[178] 
[Zn(meclo)2(H2O)2] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
3.2 
32.5 
>244 
24.2 
70.2 
63.1 
139.1 
133.0 
41.7 
8.0 
1.5 
0.7 
[178] 
[Ph3Sn(meclo)] T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
0.29 
0.68 
7.21 
7.23 
63.1 
70.2 
133 
139.1 
7.99 
41.66 
0.69 
1.53 
[177] 
[Cd2(diclo)41.5(MeOH). 
2(H2O)]n 
 
T-24 
MCF-7 
A549 
L-929 
MTT 
SRB 
SRB 
SRB 
72 h 
72 h 
72 h 
72 h 
4.4 
5.8 
30.2 
24.6 
71.2 
62.8 
138.9 
132.8 
40.9 
7.8 
1.5 
0.7 
[179] 
cis-[Pt(NH3)2(melox)2]  
 
 
 
 
CH1  
HeLa 
SW480 
HCT-15 
HCT-11 
MTT 
MTT 
MTT 
MTT 
MTT 
96 h 
96 h 
96 h 
96 h 
96 h 
0.6  
92  
96 
194 
119 
>160 
230 
≥285 
≥300 
>320 
0.16 
0.37 
3.5 
n.d. 
2.7 
[180] 
cis-[Pt(NH3)2(isox)2] CH1  
HeLa 
SW480 
HCT-15 
HCT-116 
MTT 
MTT 
MTT 
MTT 
MTT 
96 h 
96 h 
96 h 
96 h 
96 h 
0.37  
3.5 
35 
116 
90 
>80 
>160 
>320 
>320 
>320 
0.16 
0.37 
3.5 
n.d. 
2.7 
[180] 
* In this instance the NSAID is deprotonated: tolf = tolfenamic acid; mef = mefenamic acid; flu = 
flufenamic acid; meclo = meclofenamic acid; diclo = diclofenac; tolm = tolmetin; indo = 
indomethacin; melox = meloxicam; isox = isoxicam. en = ethylenediamine.  †A549 = human small 
cell lung cancer; C6 = rat glioma; CH1 = human ovarian carcinoma; HCT-116 = human colorectal 
cancer; HCT-15 = human colorectal cancer; HeLa = human cervical cancer; L-929 = murine 
fibroblast; MCF-7 = human breast cancer; SW480 = human colorectal cancer; T-24 = human bladder 
cancer; T-47D = human breast cancer.  ‡MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, SRB = sulforhodamine B.  “n.d.” = not determined.  Value in bold text indicates the metal-
complex IC50 value is comparable or superior to cisplatin.    
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in complexation with Ru(II)- and Os(II) showed promising in vitro anti-proliferative 
activity against human ovarian cancer cells (A2780, and cisplatin-resistant 
A2780cisR) [181].  
The Pt-oxicam complexes, cis-[Pt(NH3)2(melox)2] and cis-[Pt(NH3)2(isox)2], 
demonstrated greater cytotoxicity compared to melox and isox alone against a panel 
of cancer cell lines ([180], Table 1.3).  The complexes were particularly effective 
against CH1 human ovarian carcinoma cells, with IC50 values almost equal to that of 
cisplatin [180].  The Cu(II), Zn(II), Co(II), and Ni(II) complexes of melox were found to 
have a more pronounced cytotoxic/cytostatic effect than melox alone against HeLa 
human cervical cancer cells and 8MGBA glioblastoma multiforme cells [182]. 
Pirox complexes with transition metal ions, V(IV), Mo(VI), Mn(II), U(VI) and Fe(III), 
induce apoptosis within 24 h in HL-60 leukaemia cells, where little activity was 
possessed by pirox until treatment for 57 h [183].  
While there have been a substantial number of studies that have evaluated the 
toxicity of metal-NSAIDs towards cancer cell lines in vitro (Table 1.3), the in vivo 
anti-cancer effects of these complexes have been marginally explored.  The effects of 
[Cu2(indo)4(DMF)2] or indoH on the prevention of aberrant crypt foci (ACF) formation 
in the colon of rats has been evaluated [162].  In the study, male Sprague-Dawley rats 
were dosed with [Cu2(indo)4(DMF)2] for a 4-week period in conjunction with 
azoxymethane (an inducer of ACF formation).  The results from the study showed that 
[Cu2(indo)4(DMF)2] treatment (3.8 mg/kg) reduced the formation of ACF by 43%, 
while indoH treatment (3 mg/kg) resulted in 73% reduction. Although indoH was 
more effective at preventing ACF formation, the [Cu2(indo)4(DMF)2]-treated rats 
suffered significantly less gastric and intestinal ulceration ([162], Table 1.2).  
1.3.3 Other biologically relevant properties of metal-NSAIDs 
It is notable that a variety of metal-NSAIDs have shown strong protein binding 
in vitro, and exhibited the ability to intercalate with DNA and exacerbate free radical 
scavenging properties. These properties have been particularly well-studied in 
metal-NSAID complexes of Co(II) or Cu(II) containing dicloH [184], diflH [185], 
fluH [186], indoH [187], mefH [188], napH [184, 189], or tolfH [190, 191] ligands, or 
the complexes, [M(II)(NSAID)n(L)n], where L represents incorporated nitrogen donor 
heterocyclic ligands such as 2,2’-bipyridine (bipy), 1,10-phenanthroline (phen), and 
pyridine (py).  Additionally, the DNA binding activity of Mn(II) or Ni(II) derivatives 
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containing dicloH [192, 193], mefH [194] or nifH have been reported [195].  
For instance, the Co(II) derivative of mef, [Co(mef)2(MeOH)4] (MeOH = methanol), and 
Co(II)-mef complexes incorporating nitrogen donor heterocyclic ligands, 
[Co(mef)2(bipy)(MeOH)2], [Co(mef)2(phen)(MeOH)2] and [Co(mef)2(py)2(MeOH)2], 
possess relatively strong binding affinities for calf thymus DNA [188].  The four Co(II)-
mef complexes exhibited relatively high DNA binding constants (Kb); 
however, [Co(mef)2(py)(MeOH)2] was the only complex with increased DNA binding 
affinity compared to mefH alone (Kb values of 3.32 × 105 M−1 and 1.05 × 105 M−1, 
respectively) [188]. Furthermore, competitive studies with ethidium bromide 
indicated mefH and the Co(II)-mef complexes most likely interact with calf thymus 
DNA by the intercalative mode [188].  Additionally, all four Co(II)-mef complexes 
exhibited superior superoxide and free radical scavenging ability, and similar or 
superior hydroxyl free scavenging ability in comparison to mefH [188].  Given that 
NSAIDs exhibit anionic charge in vivo (deprotonated at pH 7) their interaction with the 
polyanionic backbone of DNA is unlikely [196].  Uncharged metal-NSAIDs, however, 
might overcome these repulsion forces [196], depending on their intracellular 
stability.  The ability of the aforementioned metal-NSAIDs to intercalate with DNA 
with high binding affinity may be an important chemotherapeutic property given that 
many clinically established anti-cancer agents exert their anti-neoplastic effects 
through DNA interactions. 
1.4   Bismuth 
One vital consideration in the rational drug development of metal-NSAIDs is the 
choice of metal centre, since many metals are inherently toxic at low doses.  Bi has no 
essential physiological role [197].  However, Bi induces therapeutic effects in humans 
and has been used in healthcare for centuries, predominantly to treat GI disorders, and 
as an anti-microbial agent ([198] and references within).  Bi remains employed in 
contemporary medicine primarily for its anti-ulcerative and anti-bacterial actions 
(discussed in Sections 1.4.1.2 and 1.4.1.3, respectively).  Importantly, the use of Bi in 
medicinal formulations is associated with low systemic toxicity and transient side 
effects [199].  Several novel Bi compounds show promising in vitro and in vivo 
anti-cancer activity (discussed in Section 1.4.1.4).  As such, complexation of Bi with 
NSAIDs may prove to be a successful strategy to reduce NSAID-induced GI injury and 
improve the desired chemopreventive and chemotherapeutic activity of the NSAID. 
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Located in group 15 of the periodic table, Bi (atomic number 83) is considered 
metallic (or semi-metallic) in character, as opposed to other group 15 elements, 
arsenic and antimony, which are classified as metalloids [200].  Bi is found in the 
trivalent or pentavalent oxidation state (Bi(III) and Bi(V)), where the former is the 
more stable and the most biologically relevant oxidation state [201].  Given Bi(V) 
possesses powerful antioxidant properties in aqueous solution (Bi(V)/Bi(III) potential 
E° = 2.03 V), Bi(V) is not believed to be stable in biological systems [201].  Bi(III) is 
readily hydrolysed (pKa = 1.51) in aqueous solution, and has a high affinity for oxygen, 
nitrogen and thiolate containing ligands [201].  It is thought that the Bi(III) ion has 
high mobility within cells due to the kinetic lability of thiolate ligands and resultant 
millisecond time scale required for exchange with free thiols [202]. 
Furthermore,   there is a wealth of experimental evidence that shows that the 
therapeutic and anti-bacterial actions of Bi arise primarily through interactions with 
proteins (discussed further in Sections 1.4.1.1–1.4.1.3). 
1.4.1 Bismuth in medicine 
Louis Odier first described the use of bismuth subnitrate for medicinal purposes 
in 1786 as a treatment for dyspepsia [203].  For over two centuries, Bi preparations 
have been used medicinally to treat an assortment of diseases, primarily 
gastroenterological and microbiological in nature, as demonstrated in Table 1.4. 
Currently, three Bi drugs are marketed for the treatment of GI conditions and 
Helicobacter pylori infection in combination therapies with antibiotics.   These include: 
bismuth subsalicylate (BSS; Pepto-Bismol®, the Procter & Gamble Company, 
Cincinnati, Ohio, USA), colloidal bismuth subcitrate (CBS; De-Nol®, Gist Brocades, Delft, 
The Netherlands), and ranitidine bismuth citrate (RBC; Tritec® and Pylorid®, 
GlaxoWellcome, Hertfordshire, UK) [204].  RBC combines the mucosal protection of Bi 
with the anti-secretory properties of ranitidine (N,N-dimethyl-5-(3-nitromethylene-7-
thia-2,4-diaaoctyl)-furan-2-meth-amine) [204].  The chemical structures of bismuth 
salicylate (bismuth 2-hydroxybenzoate), bismuth citrate (bismuth 2-hydroxypropane-
1,2,3-tricarboxylate) and RBC are shown in Table 1.4.  The ‘sub’ prefixes of BSS and 
CBS refers to the poorly understood chemical structure of the formulations, although 
recent studies have shed light on the possible conformation and polymerisation of BSS 
[205] and CBS [206] in acidic environments.  
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Table 1.4: Historical and currently used medicinal bismuth compounds.  
Compound;  
trade name/s 
Chemical structure* Medical disorder 
Bibrocathol; 
Noviform®, 
Posiformin® 
 
 
 
Eye infections [207] 
Bismuth 
potassium (or 
sodium) tartrate 
 
 
 
Syphilis [208] 
 
Bismuth 
subcarbonate 
 
 
Antacid [208] 
Gastric/duodenal  
ulcer [209] 
Gastritis [208] 
Wounds [208] 
Bismuth sodium 
thioglycollate; 
Thio-Bismol, 
Bistrimate® 
 
 
Syphilis [208, 210] 
Malaria [211] 
Bismuth 
subgallate; 
Devrom® 
 
 
 
Gastritis [208] 
Haemostatic adjunct 
during tonsillectomy [212] 
Internal  
deodorant [213, 214] 
Wounds [208] 
Bismuth 
subnitrate 
 
 
Gastritis [208] 
Gastric/duodenal  
ulcer [215, 216] 
H. pylori  
infection [215-217] 
Hypertension [218] 
Wounds [208, 219] 
Bismuth 
subsalicylate, 
BSS; Pepto-
Bismol® 
 
 
 
Diarrhea [220, 221] 
Gastric/duodenal 
ulcers [222] 
H. pylori infection [223] 
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Table 1.4: cont. Historical and currently used medicinal bismuth compounds.  
Compound;  
trade name/s 
Chemical structure* Medical disorder 
Colloidal 
bismuth 
subcitrate (CBS); 
De-Nol® 
 
 
 
 
Dyspepsia [224] 
Gastric/duodenal  
ulcers [225, 226] 
H. pylori infection [227] 
 
Bismuth 
tribromophen-
ate; Xeroform® 
dressing gauze 
 
 
 
Wounds [208, 228] 
Ranitidine 
bismuth citrate 
(RBC); Tritec®, 
Pylorid® 
 
 
 
Gastric/duodenal ulcers [229] 
H. pylori infection [223, 229] 
*Basic chemical structure shown. The exact chemical structures of the compounds with the 
“sub” prefix are generally unknown or poorly defined. 
The development of new Bi drugs with superior activity against H. pylori has been 
an active area of research over the past decade (recently reviewed in [200] and [230]). 
It is notable that recent in vitro studies have shown that Bi-containing complexes 
possess anti-fungal (Saccharomyces cerevisiae) [231], anti-viral (severe acute 
respiratory syndrome coronavirus) [232, 233] and anti-parasitic (Leishmania 
major)   [234-236] activities, highlighting the broad medicinal potential of Bi 
compounds.  The following Sections of this review will briefly describe the current 
primary medicinal use of Bi as a GI protective (Section 1.4.1.2), and an anti-bacterial 
agent (Section 1.4.1.3), and the potential use of Bi complexes as anti-cancer 
agents (Section 1.4.1.4). 
 
1.4.1.1 Absorption, transport and distribution of Bi(III)  
The mechanisms of absorption, transport and systemic distribution of Bi(III) in 
mammals are poorly understood.  Studies have shown that up to 99% of ingested Bi is 
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passed through the feces without alteration [237].  However, it has also been reported 
that Bi levels in the gastric mucosa significantly increase to a peak level of 30–60 μg/L 
(0.14–0.28 μM) following a single oral dose of BSS, CBS or RBC [238].  Bi levels in the 
blood have been reported to increase 51- to 1483-fold following ingestion [238], with 
a relatively rapid rate of systemic uptake (15–60 min) [239].  Once absorbed, binding 
to plasma proteins conceivably facilitates the systemic transport of Bi.  Experimental 
evidence suggests that Bi binds strongly to the iron transport enzyme, transferrin 
[240, 241].  It has also been reported that Bi bound to lactoferrin (a member of the 
transferrin family) was recognised by IEC-6 rat intestinal cells and blocked the uptake 
of the native Fe–lactoferrin complex, leading to the suggestion that Bi is transported 
into cells by transferrin receptor pathways [242].  Bi has also been shown to bind to 
human serum albumin [243], one of the most abundant proteins in the bloodstream.  
However, in the presence of a large excess of albumin (albumin/transferrin 13:1, at pH 
7.4, 10 mM bicarbonate), 70% of Bi was bound to transferrin [243], suggesting 
transferrin is the most likely target of Bi in the bloodstream. 
In addition to iron transport proteins, Bi(III) has been shown to bind to other 
cellular peptides and proteins that are believed to confer intracellular uptake 
pathways. For instance, it has been reported [244] that Bi has a high affinity for 
glutathione, a tripeptide that is present in cells in relatively high concentrations     
(0.5–7 mM) and is believed to play a role in Bi transport in cells and biofluids. 
Found in most tissues, metallothioneins (MTs), are low molecular mass proteins 
(~ 60 amino acids) comprised of a cysteine-rich amino acid sequence [245].  
The cysteine-rich character provides a high capacity for the metals ion (such as Zn(II), 
Cu(I), Cd(II) and Bi(III)) to bind.  As such, the primary functions of MTs are believed to 
be metal sequestration, metal homeostasis and metabolism, and the detoxification of 
metals [245].  Studies by Sun et al. [246] have shown that Bi binds strongly to the 
cysteine residues of MT in a stoichiometry of Bi:MT = 7:1 and can readily replace 
Zn(II) and Cd(II) ions.  Additionally, Bi administration has been shown to increase MT 
production in humans [247, 248].  A number of studies [249-253] suggest that 
intracellular Bi accumulates in lysosomes, which are acidic organelles that are used to 
remove debris from within the cell, most likely as part of cellular detoxification events.  
1.4.1.2 Bismuth as a GI protective agent 
The success of Bi as a GI protective agent is due in part to its anti-bacterial action 
against H. pylori (discussed in more detail in Section 1.4.1.3).  However, common Bi 
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compounds such as BSS and CBS have been shown to exert non-bactericidal effects in 
the GI system, and have been employed as clinically effective agents for the treatment 
of a variety of GI ailments (Table 1.4).  It has been suggested that the protective GI 
properties of Bi compounds, such as those produced by BSS and CBS, are due to the 
interaction of colloidal particles of Bi(III) with the acidic conditions of the stomach 
resulting in the formation of precipitated polymeric Bi(III) structures [254]. 
For instance, BSS can undergo ligand exchange and form insoluble bismuth 
oxychloride (BiOCl) ions in the stomach [255].  Studies performed with CBS led to the 
suggestion that [Bi(cit)2Bi]2– molecules form colloidal particles such as [Bi6O4(cit)4]6– 
and [Bi12O8(cit)8]12– at neutral pH [256], but rearrange to form sheets and 3D polymers 
under acidic conditions due to ligand exchange reactions [206].  It is likely that the 
precipitation of BSS or CBS products and the formation of a polymeric coating on ulcer 
craters prevents further erosion of the mucosa [254].  Additionally, it has been 
suggested that the stabilisation of the mucous layer by CBS increases the resistance to 
back-diffusion of hydrogen ions without significantly modifying the ion-exchange 
properties of the mucous [257].  Other means by which Bi has been suggested to 
attenuate GI protection include scavenging reactive oxygen species (ROS) [258, 259], 
inactivating the digestive enzyme pepsin [260, 261], stimulating luminal release of 
PGE2 [226], stimulating epidermal growth factor [262], restoration of 
phosphoinositide specific phospholipase C activity in response to injury, thus 
increasing mucosal cell proliferation [263], and the activation of the calcium-sensing 
receptor and the intracellular increase in Ca2+ concentration, increasing mitogen-
activated protein kinase activity, which leads to the proliferation of normal human 
gastric mucous epithelial cells [264]. 
 
1.4.1.3 Bismuth as an anti-bacterial agent 
In 1984, Marshall and Warren discovered that H. pylori, a bacterium that localises 
in human gastric mucosa, was present in the stomach lining of patients suffering from 
gastritis and stomach ulcerations [265].  A decade later, the World Health Organisation 
classified H. pylori as a class I carcinogen, since chronic infection can lead to the 
formation of dysplasia and eventually gastric cancer if left untreated [266].  While only 
a small proportion (< 3%) of individuals infected with H. pylori are expected to 
develop gastric malignancies as a result of H. pylori colonisation, it is estimated that up 
to 50% of the world’s population carry H. pylori [267].  Two Bi-based H. pylori 
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treatment regimens were approved by the FDA in the mid-1990s [223]. 
These consisted of: (i) a two week course of RBC (400 mg twice daily), and 
clarithromycin (500 mg three times daily), followed by a further two week course of 
RBC (400 mg twice daily), or (ii) a two week quadruple regime combining 
BSS  (525 mg four times daily), metronidazole (250 mg four times daily), and 
tetracycline (500 mg four times daily), in combination with a histamine-2 receptor 
antagonist (ulcer healing agent) as directed over 4 weeks [223].  However, Bi-based 
therapies were often employed in relapsed forms of H. pylori treatment after primary 
treatment with a triple-therapy of antibiotics had failed [268].  
More recently, concerns have been raised over increasing antibiotic resistance, 
particularly clarithromycin resistance in H. pylori [268].  Given there is no evidence 
that H. pylori are able to develop resistance to Bi, it has been suggested that Bi-based 
regimes (including the Bi-based quadruple therapy, comprising of a three-in-one 
capsule of potassium bismuth subcitrate, metronidazole, and tetracycline (marketed 
as Pylera®), and a proton pump inhibitor) may be considered a more suitable 
first-line treatment for H. pylori infection over the coming decades [268].  
While many Bi compounds are active against H. pylori, the exact mechanism of 
action remains unclear.  Experimental evidence from in vitro studies suggests that the 
anti-bacterial activity of Bi may be multimodal; for instance, proposed mechanisms 
include the disruption of the glycocalyx cell wall through the formation of Bi 
aggregates [269], disruption of the adherence of the bacterium to gastric cells [255], 
cessation of ATP synthesis [270], the inhibition of urease, an enzyme which protects 
the bacterium from the acidic environment of the stomach [271], and inhibition of 
other enzymes which are responsible for toxicity to gastric mucosal cells, such as 
bacterial alcohol dehydrogenase [272].  Additionally, evidence shows that H. pylori 
sequesters iron through the utilisation of host-specific lactoferrin, thus Bi(III) binding 
to lactoferrin may disrupt bacterial iron acquisition [273].  In many cases the 
interaction of Bi with the cells is physicochemical in nature, thus potentially explaining 
the lack of bacterial resistance to Bi compounds [269]. 
 
1.4.1.4 Bismuth as an anti-cancer agent: Diagnostic and therapeutic roles 
In addition to the GI protective and anti-bacterial properties of Bi, there is 
growing substantiation that Bi compounds have the potential to play a significant and 
diverse role in cancer diagnostics and anti-cancer therapies. For instance, isotopes of 
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Bi (212Bi or 213Bi) conjugated to various monoclonal antibodies have been investigated 
as a method of targeted radiotherapy [274, 275].  Nanoparticles of Bi have shown 
promise as contrast agents for computed tomography, providing equal or superior 
quality imaging to currently used contrast agents, owing to the large atomic number of 
Bi [276].  Bi has also displayed synergism when administered with chemotherapeutic 
agents in vivo.  For example, co-administration of Bi and cisplatin reduced the 
nephrotoxic side effects induced by cisplatin [277-279]; Bi-induced MT synthesis was 
determined as the primary mechanism of this effect [247, 248].  The induction of MT 
synthesis by Bi has been shown to reduce the cardiotoxic side effects of adriamycin in 
mice [280, 281].  
A variety of novel Bi(III) complexes have shown promising in vitro 
chemotherapeutic activity.  Heterocyclic organobismuth(III) complexes, N-tert-butyl-
bi-chlorodibenzo[c,f][1,5]azabismocine (Fig. 1.6, 1), bi-chlorodibenzo[c,f][1,5]-
thiabismocine (Fig. 1.6, 2) and bi-chlorophenothiabismin-S,S-dioxide (Fig. 1.6, 3) have 
shown potent cytotoxicity against leukaemia cell lines; Molt-4, U937, HL-60, NB4 and 
K562 [282].  Apoptosis induced by 2 (Fig. 1.6) in HL-60 cells and was associated with 
enhanced generation of intracellular ROS, loss of mitochondrial transmembrane 
potential (Δψm), cytochrome C release from the mitochondria to the cytosol, and 
activation of caspases -3, -8, and -9, suggesting the main mechanism of action of the 
compound involves mitochondrial damage.  In further work, 2 (Fig. 1.6) was shown to 
cause G2/M cell cycle arrest in HeLa cells at low concentrations (~1.0 µM) leading to 
apoptosis [283].  This was accompanied by the disruption of the microtubule network 
in the cells, suggesting the compound may be a novel tubulin polymerisation 
inhibitor [283].  
The organobismuth complex, 1-[(2-di-p-tolylbismuthanophenyl)diazenyl]-
pyrrolidine (Fig. 1.6, 4), showed anti-proliferative activity against several human 
cancer cell lines (IC50 values 0.880−8.478 µM), with particularly high potency towards 
the human acute promyelocytic leukaemia cell line, NB4 [284].  Treatment of the NB4 
cells with 4 (Fig. 1.6) induced apoptosis, decreased Δψm and increased the production 
of ROS, similar to the cellular effects induced by 2 (Fig. 1.6); however, 4 (Fig. 1.6) did 
not show any disruption of tubulin polymerisation in vitro.  It is notable that 
substitution of the metal centre of 4 (Fig. 1.6) with Sb(III) resulted in no cytotoxicity in 
NB4 cells (up to 10 μM) suggesting the combination of the Bi(III) centre and the 
conjugated structure of the diazenylpyrrolidine moiety were essential for bioactivity. 
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Figure 1.6: Chemical structures of Bi compounds that have shown potential anti-cancer 
activity in vitro. 
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The [Bi(AcPhH)Cl2], [Bi(AcpClPhH)Cl2] and [Bi(AcpNO2PhH)Cl2] complexes 
(Fig. 1.6, 5, where AcPhH2 = 2,6-diacetylpyridine bis(benzoylhydrazone), AcpClPhH2 = 
2,6-diacetylpyridine bis(para-chlorobenzoylhydrazone), and AcpNO2PhH2 = 2,6-
diacetylpyridine     bis(para-nitrobenzoylhydrazone))     showed     enhanced     toxicity  
compared to the free ligands and analogous Sb(III) complexes, against a panel of 
human cancer cell lines (IC50 values ranging from 0.09−10.56 µM).  Importantly, 
[Bi(AcpClPhH)Cl2] and [Bi(AcpNO2PhH)Cl2] showed relatively low potency towards 
human peripheral blood mononuclear cells (IC50 values 117.0 µM and 22.94 µM, 
respectively), demonstrating selectivity towards cancer cell lines [285].  More 
recently, the same research group synthesised Bi(III) complexes with 
2-acetylpyridine- and 2-benzoylpyridine-derived hydrazones [286], which also 
showed promising cytotoxic activities against HL-60, Jurkat and THP-1 leukaemia 
cells, and on MCF-7 and HCT-116 solid tumour cells.  The IC50 values of the 
AcpNO2PhH2 ligand and [Bi(2AcpNO2Ph)Cl2] complex (where AcpNO2PhH2 = 
2-acetylpyridine-para-nitro-phenylhydrazone) were three-fold smaller when HCT-116 
cells were cultured in soft-agar (3D) than when cells were cultured in monolayer (2D), 
suggesting these compounds may show potential against solid tumours in vivo [286].  
In other studies, the seven-coordinated Bi(III) complex [Bi(L)(NO3)2(CH3CH2OH)] 
(HL = 2-acetylpyridine N(4)phenylthiosemicarbazone) (Fig. 1.6, 6) exhibited 
comparable cytotoxicity to cisplatin (5.22 µM and 1.2 µM), and higher toxicity than the 
free ligand (IC50 = 94.7 µM) [287].  The complex was also active against HCT-116, HeLa 
and HepG2 cells [287].  Similar to other Bi(III) complexes discussed in this Section, 
6 (Fig. 1.6) induced apoptotic cell death via an increase in ROS production and 
reduced Δψm in HepG2 cells [287]. 
The Bi(III) complex, BiTPC (where TPC = 1,4,7,10-tetrakis(2-pyridylmethyl)-
1,4,7,10-tetraazacyclododecane) (Fig. 1.6, 7), a water soluble Bi compound, was found 
to exhibit potent cytotoxicity towards melanoma B16-BL6 cells (IC50 = 41 nM) which 
was 100 times more potent than cisplatin [288].  Although it is generally accepted that 
the most likely targets of Bi compounds are proteins, DNA binding studies showed that 
BiTPC could bind non-covalently to DNA under physiologically relevant 
conditions [288].  
While the aforementioned Bi complexes have demonstrated encouraging in vitro 
activity, evaluation of a number of other Bi compounds have shown varied success in 
animal models.  For instance, the arylbismuth(III) oxinates, Bi(Ox)3, Bi(Ox)2I, 
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PhBi(Ox)2.EtOH, PhBi(MeOx)2, [NaPhBi(Ox)3] and [KPhBi(Ox)3] (where Ox = 
quinolin-8-olate and MeOx = 2-methylquinolin-8-olate) showed promising anti-cancer 
activity against murine leukaemia cells, L1210 (≤ 0.56 µM), the corresponding 
cisplatin resistant cell line, L1210/DDP (≤ 0.37 µM), and human ovarian cancer cells, 
SKOV-3 (≤ 2.9 µM) in vitro [289].  However, the compounds, PhBi(Ox)2.EtOH and 
[KPhBi(Ox)3], showed no significant anti-tumour activity against murine 
plasmacytoma, and [KPhBi(Ox)3] showed no significant anti-tumour activity against 
P388 leukaemia in murine models [289].  The lack of in vivo activity was attributed to 
problems with delivery of the compounds due to their poor solubility in biological 
fluids [289].   
Similarly, dithiocarbamate Bi complexes including, Bi(N,N-dimethyldithio-
carbamato)3, Bi(N,N-diethyldithiocarbamato)3, Bi(pyrrolidyldithio-carbamato)3 and 
Bi(morpholidyldithiocarbamato)3 were found to be cytotoxic against several cancer 
cell lines and, in many cases, more potent than established organic drugs [290]. 
Treatment with the Bi(N,N-diethyldithiocarbamato)3 complex slowed tumour growth 
in mice inoculated with HT-29 cells relative to tumour growth in untreated mice [290].  
The complex showed greater anti-tumour activity in OVCAR-3 inoculated mice 
whereby tumour size began to reduce after 15 days of Bi(N,N-diethyldithio-
carbamato)3 treatment [290].   
Finally, a nine-coordinate Bi(III) complex, [Bi(H2L)(NO3)2]NO3 (where H2L = 2,6-
diacetylpyridine bis(4N-methylthiosemicarbazone)) (Fig. 1.6, 8) has been synthesised 
and its in vitro and in vivo anti-cancer activity evaluated [291].  The IC50 value of 
8 (Fig. 1.6) was approximately three times lower than the ligand alone against the 
K562 cell line [291].  In mice xenografted with H22 (mice hepatoma) cells, tumour 
growth was inhibited by 61.6% and 43.5% following 7-day treatment with 8 (Fig. 1.6, 
10 mg/kg), and the anti-cancer drug mitoxantrone (0.4 mg/kg), respectively, 
compared to the control group [291].  Despite promising in vitro activity and some 
preliminary success with in vivo studies, currently there are no Bi-containing 
complexes in clinical trials or used in therapies for the treatment of cancer [292]. 
1.4.2 Bismuth toxicity 
It is generally reported in the literature that Bi possesses uncharacteristically low 
toxicity, particularly when compared to the group 15 counterparts, arsenic and 
antimony.  Compared to many medications, the side effect profile for Bi (taken at the 
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appropriate dose) is quite limited [237]; transient, harmless side effects such as 
darkened stools [199] and blackening of the tongue [293] are the most commonly 
reported.  However, in the 1970s, concerns over the safety of Bi compounds (namely 
bismuth subcarbonate, bismuth subgallate, and CBS) were raised due to cases of Bi 
intoxication resulting in cases of encephalopathy in Australia [294, 295] and 
France [296], which led to the withdrawal of some Bi medications from the market in 
these countries.  This severe side effect was reported in patients who consumed high 
doses (3–20 g of Bi per day over a 6–36 month period) [296].  It is notable, however, 
that Bi-induced encephalopathy can be reversed upon the cessation of Bi treatment, 
with full restoration of neurological function over a few weeks [237]. 
A limited number of studies addressing the bioaccumulation of Bi in mammals 
have been reported.  Following a single dose of RBC in mice, Bi deposits have been 
observed in the stomach, duodenum, ileum and kidney (2.5–10 h after dosing) [297].  
Interestingly, Bi was evident in the lymph nodes, liver, spleen, kidney and 
macrophages in the GI lamina propria 1–9 weeks following administration of RBC, 
although Bi was absent from the GI epithelium (consistent with cellular 
turnover) [297].  However, no signs of morphological changes in the Bi-treated tissues 
or adverse effects in the behaviour of the mice were observed [297].  Although the link 
between bioaccumulation and toxicity remains poorly understood, this study 
highlights the potential for systemic accumulation of Bi, even with short-term 
treatments. Another concern is the recent number of studies highlighting the 
biotransformation of Bi into methylated species such as trimethylbismuth (Me3Bi) by 
bacterial species present in intestinal flora in humans (recently reviewed in [255]).  
Given evidence that Me3Bi species are more toxic to bacteria than inorganic 
species [298], there may be implications for the regulation of gut flora in humans; 
however, the health implications of the Me3Bi formation by human microflora requires 
further investigation. 
While the aforementioned toxicity of Bi raises some concern over the safety of 
Bi-based medications, there is also evidence to suggest that when used periodically, Bi 
drugs are generally safe and well tolerated.  A systemic review and meta-analysis of 
35 clinical studies concluded that Bi drugs (namely bismuth subnitrate, BSS, CBS, and 
RBC, Bi dosage ranging from 400–1200 mg/day and duration from 7–56 days) used 
for the treatment of H. pylori infection are safe and well-tolerated when administered 
either alone, or in combination with antibiotics [199].  The only side effect that was 
Chapter 1. Introduction 
 37 
significantly more common in patients assigned Bi-based therapies was darkened 
stools (not to be confused with GI bleeding) [199].  Accordingly, Pepto-Bismol is 
currently available over-the-counter without a prescription in the USA, Canada and 
UK.  Given that the majority of regimes employing Bi for treatment of H. pylori 
infection require less than two weeks of administration, the use of Bi in prolonged 
chemopreventive therapies (months to years) would require careful monitoring to 
determine if any adverse side effects or signs of toxicity negate the potential positive 
therapeutic effects. 
1.5   BiNSAID Complexes 
Despite experimental, epidemiological, and clinical evidence that indicates that 
long-term use of NSAIDs is associated with reduced incidence of CRC (Section 1.2.2), 
the prolonged use of NSAIDs for chemoprevention is not recommended for the general 
population [77].  This is due, in part, to the risks that NSAIDs impose on the GI system. 
It is, therefore, plausible to consider the combination of NSAIDs with GI protective Bi 
(as a single therapeutic agent) in order to alleviate the GI side effects of NSAIDs [299].  
Despite the specific GI protective advantage of Bi compared to other metals, and the 
conceivable synergistic chemotherapeutic action of Bi coordinated to an organic 
ligand, there are a limited number of reports [299, 300] detailing the synthesis and 
biological activity of BiNSAID complexes, highlighting the potential for development in 
this area. 
The use of Bi(III) compounds for protection against NSAID-induced GI injury is 
not without precedence.  A number of studies have shown that pre-treatment or 
co-administration with Bi compounds such as BSS [301, 302], CBS [303, 304], and 
RBC [305] with NSAIDs reduces GI ulceration in vivo.  In a double-blind randomised 
three-way crossover study, healthy male volunteers (n = 24) received nine doses of 
placebo, aspH (900 mg), or aspH and RBC (900 mg and 800 mg, respectively) at 12-h 
intervals, with a two-week washout period between each treatment [305].  The 
authors reported that co-administration with RBC significantly reduced the number of 
aspH-induced erosions and micro-bleeding, suggesting RBC confers substantial 
protection against aspH-related GI injury.  In a more recent study, the GI-protective 
effect of CBS, and other potential agents (misoprostol and omeprazole), against gastric 
injury induced by indoH was evaluated in Wistar albino rats [306]. 
CBS (70 mg/kg/day and 15 mg/kg/day) was administered 30 min prior to indoH 
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(5 mg/kg/day) once daily for five consecutive days.  The authors report that the mean 
ulcer scores achieved by CBS treatment were not significantly reduced compared to 
indoH alone, although the mean ulcer scores and histopathological examination 
suggests that the higher dose CBS had a greater effect than the lower dose CBS. 
Pre-treatment with misoprostol (100 g/kg and 10 g/kg) or omeprazole (5 mg/kg) 
were both found to significantly reduce mean ulcer scores [306]. 
The in situ synthesis of a 1:1 Bi-diclo complex via the addition of diclofenac 
sodium to CBS aqueous solution (3:1 molar ratio, dicloH to Bi) has been 
reported [300].  The study concluded that diclo coordinated through the carboxylate 
moiety to Bi, although the exact composition of the complex was not established. 
Unexpectedly, oral administration of the Bi-diclo complex resulted in a higher stomach 
lesion index than rats treated with diclofenac sodium alone, while a physical mixture 
of diclofenac sodium and CBS induced the lowest lesion index; however, no statistical 
analysis was performed to validate the significance of these results.  The authors 
hypothesised that the ulcerogenic activity of the Bi-diclo complex arose from the 
decomposition of the complex into diclo particles, which were over three times 
smaller than the diclofenac sodium particles, hence allowing diclo from the 
decomposed Bi(III) complex to cover a greater surface area of the stomach mucosa. If 
such an observation holds merit, the stability and resultant decomposition products of 
other BiNSAID complexes in gastric fluid could be understatedly important and should 
be established prior to in vivo studies. 
Several homoleptic Bi(III) tris-carboxylate complexes derived from the 
deprotonated acids of NSAIDs have been synthesised, with the general formula 
[Bi(L)3]n, where L = deprotonated 5-chlorosalicylic acid, diflH, fenbufen, fluH, ibuH, 
ketoH, mefH, napH, sulindac, or tolfH [299].  Elemental analysis determined that three 
NSAID moieties are present for each Bi(III) ion, while complementary infrared (IR) 
and nuclear magnetic resonance (NMR) spectroscopic data suggested that Bi(III) 
adopts a bidentate coordination with the NSAID ligands through the deprotonation of 
the carboxylic acid moiety.  Crystal structures of the complexes could not be obtained, 
hence the exact structural and polymeric propensities of each of the BiNSAID 
complexes has not been definitively ascertained.  As such, a representation of the 
prospective structures of Bi(tolf)3, Bi(mef)3 and Bi(difl)3 is shown in Figure 1.7. 
The anti-bacterial activity of all ten BiNSAIDs against three laboratory strains of 
H. pylori, B128, 251 and 26695, compared favourably to the anti-bacterial activity of 
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BSS and [Bi(Hsal)3]n (≥ 6.25 µg/mL versus ≥ 12.5 µg/mL), while the NSAIDs alone 
showed no inhibitory properties.  
 
 
Figure 1.7: Representation of the chemical structures of: (a) Bi(tolf)3 and Bi(mef)3, and 
(b) Bi(difl)3, as inferred by elemental analysis, IR and NMR data [299].  
The effect of the BiNSAIDs on cancer cell lines is an area that is yet to be explored, 
and subsequently forms the basis of the investigations of this Thesis.  Specifically, the 
in vitro anti-cancer potential of three of the aforementioned BiNSAIDs, Bi(tolf)3, 
Bi(mef)3 and Bi(difl)3, will be investigated. 
1.6   Project Aims 
A number of epidemiological, observational, and clinical studies suggest that 
NSAIDs are able to reduce the incidence of cancer, in particular, CRC; however, side 
effects, such as GI bleeding, limit the prolonged daily use of NSAIDs.  Bi has been used 
to treat an array of GI diseases for centuries, with an acceptable toxicity profile at low 
doses over extended periods of administration.  Thus it is hypothesised that the 
combination of Bi and an NSAID in a single compound may potentially prevent the 
adverse GI side effects of NSAIDs, if used daily as a chemopreventive agent.  
There are several in vitro aspects that need to be investigated before such claims 
could be tested in vivo.  The first of these is the recognition that when administering a 
drug as a chemopreventive, it is expected that the patient is prone to developing 
cancer (specifically adenomatous polyps).  A starting point then is to look at the 
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interaction of BiNSAIDs with transformed (cancer) cells. As the primary proposed 
mechanism for chemoprevention by NSAIDs is COX-2 inhibition. 
Subsequently, the overarching aim of this Thesis was to investigate the in vitro 
potency and biological effects of the BiNSAID complexes, Bi(tolf)3, Bi(mef)3 and 
Bi(difl)3, against a human colon cancer cell line, HCT-8, and hence the suitability of the 
complexes for in vivo studies. 
The specific aims of the project were to: 
1. Evaluate the hydrolytic stability of the complexes in cell medium using NMR 
spectroscopy to ascertain the biologically available structures of the BiNSAIDs 
(Chapter 2). 
2. Evaluate the in vitro drug toxicity and mode of cell death of the BiNSAIDs 
compared to uncomplexed NSAIDs in HCT-8 cells (Chapter 2). 
3. Assess the ability of the BiNSAIDs to inhibit the production of PGE2 by HCT-8 
cells in order to determine if the complexes exhibit COX inhibition (Chapter 2). 
4. Determine the cellular uptake and subcellular localisation of the BiNSAIDs in 
HCT-8 cells to establish whether stability and toxicity correlated with cellular 
uptake and to determine the subcellular fate of the Bi contained in the BiNSAID 
complexes (Chapter 3). 
5. Assess the biomolecular changes induced by BiNSAID treatment compared to 
NSAIDs alone in live HCT-8 cells using synchrotron radiation infrared 
microspectroscopy (SR-IRMS) (Chapter 4). 
6. Examine the effects of BiNSAID- and NSAID-induced cell death on the 
distribution and concentration of abundant cellular glycerophospholipids (PC, 
PE, and PS) using electrospray ionisation tandem mass spectrometry (ESI-
MS/MS) (Chapter 5). 
7. Evaluate the in vitro toxicity of other previously untested Bi(III) complexes of 
aminoarenesulfonic acids, indole-carboxylic acids, and hydroxamic acids 
against HCT-8 colon cancer  cells, and determine whether complexation with Bi 
improves the potency of the ligands (Chapter 6).  
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Chapter	2. 																																																																						
Influence	of	BiNSAID	stability	on	the	toxicity	and	
PGE2	inhibition	in	HCT-8	colon	cancer	cells	
	
	
	
In	 order	 to	 determine	 whether	 BiNSAIDs	 are	 potential	 chemotherapeutics	 or	
chemopreventives	 in	 vivo,	 the	 behaviour	 of	 the	 BiNSAIDs	 first	 needed	 to	 be	 studied	
in	vitro.		In	this	Chapter,	the	stability	of	the	BiNSAIDs	in	cell	medium	was	examined	to	
determine	 the	 biologically	 available	 species.	 	 The	 HCT-8	 colon	 cancer	 cell	 line	 was	
employed	 to	 assess	 the	 toxicity	 of	 the	 BiNSAIDs	 compared	 to	 uncomplexed	NSAIDs,	
and	 cisplatin,	 a	 clinically	used	anti-cancer	drug.	 	Upon	 confirming	 the	 toxicity	of	 the	
BiNSAIDs,	 cell	 death	 assays	 were	 employed	 to	 determine	 the	 mode	 of	 cell	 death	
induced	 by	 the	 BiNSAIDs	 in	 the	 HCT-8	 cells.	 	 Finally,	 the	 ability	 of	 the	 BiNSAIDs	 to	
inhibit	 the	 production	 of	 PGE2	 is	 presented	 with	 the	 respect	 to	 the	 proposed	
mechanism	of	NSAID	chemoprevention,	COX	inhibition.	
	
	
Sections	of	this	Chapter	have	been	published	in:	
Hawksworth,	 E.	 L.,	 Andrews,	 P.	 C.,	 Lie,	 W.,	 Lai,	 B.	 &	 Dillon,	 C.	 T.	 (2014)	 Biological	
evaluation	 of	 bismuth	 non-steroidal	 anti-inflammatory	 drugs	 (BiNSAIDs):	 stability,	
toxicity	 and	 uptake	 in	 HCT-8	 colon	 cancer	 cells,	 J.	 Inorg.	 Biochem.,	 135,	 28-39.
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2.1 Introduction	
As	 discussed	 in	 Section	 1.2.2,	 the	 results	 from	 a	 number	 of	 epidemiological,	
observational	 and	 clinical	 studies	 indicate	 that	 long-term	 administration	 of	 NSAIDs,	
such	as	aspH,	reduces	the	incidence	and	reoccurrence	of	CRC.	 	There	are	two	criteria	
that	 are	 important	 for	 this:	 (i)	eradication	 of	 already	 transformed	 cells,	 and	
(ii)	preventing	the	formation	of	transformed	cells.	
Previously,	NSAIDs	have	been	extensively	studied	in	a	number	of	cancer	cell	lines	
(as	described	in	Section	1.2.4)	to	explore	both	their	ability	to	kill	cancer	cells	and	their	
ability	 to	 prevent	 the	 transformation	 of	 normal	 cells	 to	 cancer	 cells.	 	 In	 addition,	 a	
variety	 of	 Bi(III)	 complexes	 have	 also	 shown	 promising	 anti-cancer	 activity	 in	 vitro	
and	 in	 vivo	 (discussed	 in	 Section	 1.4.1.4)	 indicating	 their	 ability	 to	 kill	 transformed	
cells.		However,	no	work	has	been	performed	to	establish	the	ability	of	BiNSAIDs	to	kill	
cancerous	cells	or	prevent	their	formation.			
There	are	a	number	of	factors	that	need	to	be	addressed	in	order	to	determine	the	
suitability	 of	 BiNSAIDs	 as	 potential	 chemotherapeutic	 or	 chemopreventive	 drug	
candidates	 including	 general	 factors	 such	 as:	 (i)	 solubility/bioavailability,	 and	
(ii)	stability;	and	specific	factors	relating	to	the	chemoprevention	criteria:	(iii)	toxicity	
towards	colon	cancer	cells,	 (iv)	 inhibition	of	COX	(and	subsequent	reduction	 in	PGE2	
release),	 and	 (v)	 cellular	 uptake	 and	 intracellular	 distribution	 (discussed	 in	
Chapter	3).	 	 Factors	 (i)	 and	 (ii)	 are	 also	 important	 for	 in	 vitro	 testing	 whereby	
compromises	need	to	be	considered	for	these	purposes.		As	such,	Sections	2.1.1–2.1.5	
will	 present	 the	 current	 literature	 relevant	 to	 the	 optimal	 factors	 for	 BiNSAID	
chemotherapeutic/chemoprevention	suitability	and	the	rationale	for	the	methodology	
behind	the	experiments	described	in	this	Chapter.	
2.1.1 Solubility/Bioavailability	
Oral	 administration	 is	 the	most	desirable	 route	of	 administration	of	 therapeutics	
and	preventives	due	to	the	ease	of	use	for	the	patient	[1].	 	The	development	of	orally	
administered	 drugs	 is	 often	 hampered	 by	 poor	 aqueous	 solubility	 and	 high	
lipophilicity	 (logP	 >	 3.5)	 which	 then	 leads	 to	 poor	 and	 variable	 absorption/	
bioavailability	 [2].	 	 Drugs	 with	 poor	 solubility	 can	 present	 in	 vivo	 issues	 including	
reduced	oral	bioavailability,	 lack	of	efficacy,	the	need	to	develop	expensive	and	often	
problematic	 formulations,	 and	 the	 burden	 to	 patients	 through	 frequent	 dosing	 to	
achieve	 therapeutic	 effectiveness	 [1].	 	 Nonetheless,	 the	 requirement	 of	 the	 drug	 to	
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traverse	 the	 cell	membrane	 imposes	 a	 requirement	 for	 some	 degree	 of	 lipophilicity	
such	that	a	balance	between	aqueous	solubility	and	lipophilicity	is	essential	[3].	
NSAIDs,	which	represent	one	of	 the	most	highly	prescribed	classes	of	drug	 in	 the	
world	[4],	are	generally	administered	orally	[5];	however,	they	display	poor	aqueous	
solubility	 and	 incomplete	 dissolution	 in	 the	 stomach	 [6].	 	In	 general,	 NSAIDs	 are	
hydrophobic	molecules,	a	property	 that	 is	crucial	 for	 their	mechanism	of	action	as	 it	
allows	the	molecules	to	approach	the	membrane-bound	target	enzyme,	COX,	and	enter	
its	hydrophobic	arachidonate-binding	channel	 [6].	 	Despite	 these	properties,	NSAIDs	
generally	 display	 80–95%	oral	 absorption	 and	 99%	plasma	protein	 binding	 (mainly	
to	albumin)	[6].		
Similarly,	 commonly	 used	 bismuth	 drugs,	 BSS	 (Pepto-Bismol,	 Procter	 &	 Gamble	
Company)	 and	 CBS	 (De-Nol®;	 Gist	 Brocades	 and	 Yamanouchi)	 exhibit	 poor	 aqueous	
solubility	 and	 stability	 (discussed	 in	 more	 detail	 in	 Section	 2.1.2).	 	 However,	 these	
properties	contribute	to	the	gastroprotective	nature	of	these	drugs	as	the	drug	forms	a	
solid	physical	 coating	on	 the	epithelial	 lining	of	 the	 stomach	subsequently	providing	
protection	via	a	physical	barrier	[7].		
While	 the	 poor	 aqueous	 solubility	 of	 the	 BiNSAIDs	 may	 not	 necessarily	 hamper	
in	vivo	 studies	and	potential	patient	administration,	 it	does	pose	an	 issue	 for	 in	vitro	
testing.	 	For	 instance,	 lead	 compounds	 displaying	 poor	 aqueous	 solubility	 are	 often	
considered	 less	 than	 ideal	 candidates	 for	 drug	 development	 as	 a	 number	 issues	 can	
arise	 during	 in	 vitro	 testing,	 including;	 erratic	 assay	 results,	 artificially	 low	 potency,	
and	erroneous	structure−activity	relationships	[1].	 	As	such,	the	aqueous	solubility	of	
the	BiNSAIDs	was	a	factor	that	required	consideration	for	the	assays	reported	in	this	
Chapter.	 	Previous	 studies	 have	 shown	 that	 the	 BiNSAIDs,	 Bi(tolf)3,	 Bi(mef)3	 and	
Bi(difl)3,	display	poor	solubility	in	deionized	water	[8]	and	thus	would	not	dissolve	in	
the	 cell	 culture	 medium	 required	 for	 cell	 testing.	 	Furthermore,	 BiNSAIDs	 display	
limited	 solubility	 in	 organic	 solvents	 such	 as	 toluene,	 acetone	 and	 ethanol	 [8];	
however,	 all	 three	 BiNSAIDs	 showed	 appreciable	 solubility	 in	 dimethyl	
sulphoxide	(DMSO)	 [8].	 	 DMSO	 is	 often	 employed	 as	 a	 solvent	 for	 biological	 in	 vitro	
testing	 of	 compounds	 with	 low	 aqueous	 solubility;	 the	 high	 solvating	 efficiency	 of	
DMSO	stems	from	its	amphiphilic	property,	wide	temperature	range	of	the	liquid	state,	
and	 high	 polarity	 [9].	 	DMSO	 is	 generally	 not	 favoured	 for	 oral	 administration	 to	
humans	 as	 the	 metabolism	 of	 DMSO	 to	 dimethyl	 sulfide	 produces	 a	 sulphuric-like	
odour	 on	 the	 skin	 and	 a	 garlic-like	 after-taste	 and	 breath	 odour	 that	 can	 persist	 for	
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several	 days	 following	 DMSO	 administration	[10].	 	 In	 addition,	 DMSO	 is	 associated	
with	a	number	of	side	effects	including	sedation,	nausea,	headache,	diarrhea,	dizziness	
and	 topical	 irritation	 [10].	 	 However,	 DMSO	 is	 a	 commonly	 acceptable	 vehicle	 for	
cell-based	screening	assays	whereby	the	use	of	small	volumes	of	DMSO	is	commonly	
reported	 for	 the	 purpose	 of	 testing	 metal	 complexes	 [11-16]	 and	 poorly	 soluble	
organic	compounds	[17-20].		
2.1.2 Drug	stability	
There	are	a	number	of	properties	 that	can	be	exploited	by	 the	medicinal	chemist	
when	designing/developing	metal	containing	drugs.	 	For	example,	 the	very	nature	of	
metal-ligand	complexes	provides	a	scaffold	whereby	a	metal	centre	can	be	conjugated	
to	 an	 array	 of	 ligands	 with	 various	 geometries	 and	 dissociation	 rates.	 	 In	order	 to	
ensure	the	metal-complex	reaches	its	biological	target,	the	metal	complex	should	have	
a	sufficiently	high	thermodynamic	stability	to	deliver	the	metal	to	the	biological	target,	
the	 metal-ligand	 binding	 should	 be	 hydrolytically	 stable,	 and	 understanding	 the	
kinetics	with	which	the	metal	ion	undergoes	ligation	or	dissociation	reactions	should	
be	considered	[21].	 	While	presenting	a	significant	challenge,	 it	 is	necessary	to	study	
the	stability	of	the	metal-complexes	in	the	biological	environment	to	ensure	the	metal	
complexes	will	 survive	 long	enough	 in	 vivo	 to	 reach	 their	biological	 target	 and	exert	
the	intended	medicinal	effects	[22].			
Generally,	 medicinal	 Bi	 compounds	 exhibit	 low	 aqueous	 solubility	 and	 lack	
solution	stability;	however,	as	discussed	in	Section	1.4.1.2,	low	aqueous	solubility	may	
be	essential	for	the	gastroprotective	effects	of	Bi	[7].		For	instance,	a	number	of	studies	
have	 explored	 the	 formation	 of	 BSS,	 CBS	 and	 RBC	 polymeric	 products	 in	 acidic	
environments	that	mimic	the	stomach	[23,	24].	 	The	cell	medium	used	to	maintain	 in	
vitro	cell	cultures	is	formulated	to	simulate	the	in	vivo	growth	environment	of	the	cells.		
Buffers	are	present	 in	 the	medium	to	maintain	physiological	pH	7.4,	 the	 ideal	pH	for	
cells	 to	 grow.		 Due	 to	 the	 nature	 of	 Bi(III)	 carboxylates	 (that	 are	 common	 to	 the	
BiNSAIDs)	it	is	essential	to	determine	the	stability	of	the	BiNSAIDs	in	the	cell	medium	
in	order	to	assess	the	structures	of	the	biologically	available	species.		Techniques	often	
used	 to	 study	 drug	 stability	 include	 ultraviolet-visible	 (UV-Vis)	 spectroscopy,	
electrospray	 ionisation	mass	 spectrometry	 (ESI-MS)	 and	NMR	 spectroscopy.	 	UV-Vis	
spectroscopy	 is	 useful	 for	 determining	 if	 there	 is	 a	 change;	 however,	 the	 specific	
chemical	information	is	limited.		ESI-MS	is	often	utilised	as	a	technique	to	characterise	
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complexes	based	on	the	fragmentation	pattern.		However,	ESI-MS	is	a	poor	technique	
for	the	analysis	of	hydrophobic	compounds	in	DMSO	due	to	the	non-volatile	nature	of	
this	 solvent.		 NMR	 spectroscopy	 is	 also	 a	 technique	 that	 is	 commonly	 used	 to	
characterise	 compounds,	 providing	 structural	 information	 based	 on	 the	 chemical	
environment	of	the	nuclei	(commonly	1H	and	13C).		Importantly,	DMSO	(in	the	form	of	
deuterated	DMSO,	DMSO-d6)	 is	 a	 commonly	employed	solvent	 in	NMR	spectroscopy,	
particularly	 for	 compounds	 that	 have	 difficulty	 dissolving	 in	 other	 organic	 solvents	
such	 as	 methanol	 and	 chloroform.		 The	 use	 of	 DMSO-d6	 as	 a	 NMR	 solvent	 is	
particularly	useful	for	compounds	containing	–OH	and	–NH2	groups	due	to	the	strong	
hydrogen	bonding	between	these	proton	donating	groups	and	aprotic	DMSO	[9].		
	
2.1.3 In	vitro	cytotoxicity	towards	colon	cancer	cells		
As	mentioned	in	Section	2.1,	one	of	the	criteria	associated	with	the	administration	
of	 a	CRC	 chemopreventive	 agent	 is	 its	 ability	 to	 eradicate	 already	 transformed	 cells.		
This	 is	 important	 given	 that	 the	 cohort	would	 generally	 include	 patients	 that	 are	 at	
high	risk	of	developing	bowel	cancer.			
	
2.1.3.1 Assessing	in	vitro	drug	toxicity:	The	MTT	assay	
In	order	to	assess	the	potential	chemotherapeutic	activity	of	novel	compounds,	it	is	
necessary	to	screen	them	using	in	vitro	oncology-related	assays	[25].		Ideally,	the	assay	
should	 be	 sensitive,	 reliable,	 inexpensive,	 have	 the	 capacity	 to	 test	 multiple	
drugs/concentrations	at	 the	same	time,	and	be	relatively	easy	to	perform	[25].	 	First	
described	by	Mosmann	 in	1983	 [26],	 the	MTT	assay	 fits	 the	aforementioned	criteria	
and	 is	 commonly	 performed	 using	 cancer	 cell	 lines	 to	 screen	 and	 compare	 the	
chemotherapeutic	 potential	 of	 new	 compounds	 [25].	 While	 there	 are	 several	
variations	 of	 the	 assay	 protocol	 [26-30],	 they	 generally	 employ	 a	 water-soluble	
substrate,	 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	 bromide	 (MTT),	 as	 a	
colorimetric	 measure	 of	 cell	 viability,	 proliferation	 or	 activation	 [25].	 	 The	 assay	 is	
based	on	the	premise	that	only	viable	(or	metabolically-active)	cells	are	able	to	reduce	
yellow	 MTT	 to	 water-insoluble	 purple	 (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-
diphenylformazan	 (formazan)	 by	 cleavage	 of	 the	 tetrazolium	 ring	 via	 the	 enzyme,	
mitochondrial	reductase	(Scheme	2.1)	[25]. 
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Scheme	2.1.		The	reduction	of	MTT	to	Formazan	by	the	mitochondrial	enzyme,	mitochondrial	
reductase,	in	living	cells.	
The	 water-insoluble	 formazan	 can	 be	 dissolved	 using	 an	 organic	 solvent	 or	
detergent	and	analysed	spectrophotometrically	at	570	nm	[26-30].	 	As	the	amount	of	
MTT	reduced	to	formazan	is	directly	proportional	to	the	metabolic	activity	of	the	cells,	
a	 concentration-response	 curve	 can	be	 constructed	based	on	 the	percentage	of	MTT	
converted	 by	 cells	 treated	 with	 increasing	 concentrations	 of	 a	 drug.	 	 This	 can	 be	
compared	 to	 the	 control	 cells	 that	 are	 treated	 with	 the	 vehicle.	 	 As	 such,	 an	
IC50	value	(i.e.	the	concentration	of	drug	required	to	inhibit	50%	enzyme	activity)	can	
be	 determined	 and	 used	 to	 compare	 the	 toxicity	 of	multiple	 compounds	 against	 the	
same	cell	line.		
	
2.1.3.2 Modes	of	cell	death	
The	 identification	 of	 the	 mode	 of	 drug-induced	 cell	 death	 can	 be	 a	 useful	 for	
determining	 the	 affected	 intracellular	 biochemical	 processes	 resulting	 from	 the	
interaction	of	a	drug	within	a	cell.		While	there	are	several	distinct	modes	of	cell	death	
that	 can	 be	 distinguished	 due	 to	 distinct	 differences	 in	 morphological	 effects	 and	
biochemical	 changes	 [31],	 apoptosis	 and	 necrosis	 are	 the	 two	 most	 common	 and	
well-characterised	modes	of	 cell	 death	 that	 can	be	 triggered	 in	 cancer	 cells	due	 to	 a	
chemotherapeutic	 agent.	 As	 apoptosis	 and	 necrosis	 result	 in	 different	 anti-tumour	
responses,	 it	 is	 important	 to	 determine	 which	 mode	 of	 cell	 death	 is	 triggered	 by	
anti-cancer	therapies.			
Apoptosis	is	often	considered	a	‘programmed’	form	of	cell	death	and	occurs	during	
development	 and	 aging	 to	 maintain	 normal	 or	 healthy	 tissue	 populations	 of						
cells	[32,	33].		Apoptosis	can	also	be	triggered	as	a	defence	mechanism	due	to	immune	
Chapter	2.	Stability,	toxicity	and	PGE2	inhibition	of	BiNSAIDs	
	
65	
responses,	 cell	 damage	 via	 disease,	 or	 noxious	 stimuli	 [32].	 	 Notably,	 not	 all	 cells	
respond	 to	 apoptotic	 stimuli	 in	 the	 same	 manner;	 for	 instance,	 some	
chemotherapeutic	 drugs	 can	 initiate	 apoptosis	 in	 cancer	 cells,	 without	 affecting	
normal	 cells	 [32].	 	Distinguishing	 features	 of	 early	 apoptosis	 include	 reduction	 of	
cellular	volume	 (pyknosis)	and	cell	 rounding,	 retraction	of	pseudopods,	 reduction	 in	
nuclear	volume,	externalisation	of	phosphatidylserine	(PS),	and	minor	modification	of	
cytoplasmic	organelles	[31].	 	 	Later	stages	of	apoptotic	cell	death	can	be	identified	by	
nuclear	fragmentation	(karyorrhexis),	membrane	blebbing,	loss	of	plasma	membrane	
integrity,	and	engulfment	by	resident	phagocytes	in	vivo	[31].		Apoptosis	is	one	of	the	
most	common	mechanisms	of	chemotherapy-induced	cell	death	[33].	 	In	cancer	cells,	
normal	apoptotic	pathways	are	often	compromised	[33],	which	is	advantageous	to	the	
fortification	of	 cancer	 cells	 against	 cell	 death.	 	As	 such,	 chemotherapeutics	 are	often	
designed	to	target	a	specific	part	of	the	apoptotic	pathway	in	order	to	circumvent	the	
defunct	signaling	pathways	and	restore	apoptosis	[33].		
In	 contrast,	 necrosis	 is	 a	 form	 of	 cell	 death	 that	 is	 morphologically	 and	
biochemically	 distinct	 from	 apoptosis.	 	 While	 it	 is	 often	 considered	 an	 ‘accidental’,	
uncontrolled	 form	 of	 cell	 death,	 accumulating	 evidence	 suggests	 that	 transduction	
pathways	and	catabolic	mechanisms	are	involved	in	regulating	necrosis	[31].	 	Clearly	
distinct	 key	 features	 of	 necrotic	 cell	 death	 (as	 opposed	 to	 apoptosis)	 include	
cytoplasmic	 swelling	 (oncosis),	 rupture	 of	 plasma	 membrane	 (occurs	 early,	 as	
opposed	 to	 a	 late	 stage	 step	 in	 apoptosis),	 swelling	 of	 cytoplasmic	 organelles,	 and	
moderate	 chromatin	 condensation	[31].	 Unlike	 apoptosis,	 necrosis	 releases	 the	
intracellular	content	and	 tumour	antigens,	which	attracts	 immune	cells	 to	 the	site	of	
the	 tumour	 to	 help	 drive	 anti-tumour	 immune	 responses	 [33].	 	While	 several	
anti-cancer	 compounds	 have	 been	 shown	 to	 induce	 cell	 death	 via	 necrosis	 [34-36],	
triggering	 apoptosis	 is	 generally	 described	 a	 safer	 mechanism	 for	 the	 death	 of	 the	
cancer	cells	[37].			
The	most	common	method	of	assessing	the	mode	of	cell	death	is	via	flow	cytometry	
coupled	with	staining	for	markers	specific	to	the	events	associated	with	apoptosis	or	
necrosis	[31].	 Two	 fluorescent	 probes,	 fluorescein	 isothiocyanate	 (FITC)-labeled	
Annexin	 V	 (referred	 to	 herein	 as	 AnnV)	 and	 7-aminoactinomycin	D	 (7AAD),	 are	
commonly	 used	 to	 distinguish	 between	 apoptotic	 cells	 and	 necrotic	 cells.	 	 AnnV	 is	
utilised	 as	 it	 is	 a	 Ca2+	 dependent	 phospholipid-binding	protein	with	 high	 affinity	 for	
PS	[38].		During	the	early	stages	of	apoptosis,	PS	translocates	from	the	inner	leaflet	of	
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the	plasma	membrane	to	the	outer	leaflet	[39].		AnnV	binding	to	PS	is	not	exclusive	to	
apoptosis.	 During	 the	 later	 stages	 of	 necrosis	 the	 cells	 increase	 in	 permeability	
allowing	entry	of	AnnV	which	can	bind	to	PS	on	the	inner	leaflet	[38].	 	 In	contrast	to	
this,	 during	 the	 early	 stages	 of	 necrosis,	 cells	 lose	 their	 membrane	 integrity	 and	
become	 permeable,	 while	 this	 event	 does	 not	 occur	 until	 the	 later	 stages	 of	
apoptosis	[31].	 	Hence,	 the	 assessment	 of	 cell	 death	 is	 performed	 with	 AnnV	 in	
combination	 with	 another	 fluorescent	 dye	 that	 is	 excluded	 by	 an	 intact	 plasma	
membrane,	but	is	able	to	diffuse	through	pores	of	a	compromised	cell	membrane	[38].		
Traditionally,	 propidium	 iodide	 or	 7AAD	 are	 employed	 to	 this	 end;	 these	molecules	
increase	 in	 fluorescence	 intensity	 when	 they	 intercalate	 with	 DNA	 following	 entry	
through	the	compromised	cell	membrane,	and	provide	a	measure	of	loss	of	membrane	
integrity	[40,	41].			
An	example	of	the	flow	cytometry	data	obtained	from	AnnV	and	7AAD	co-stained	
cells	is	shown	in	Figure	2.1.		Viable	cells	maintain	an	intact	plasma	membrane	and	PS	
remains	 on	 the	 inner	 leaflet,	 thus	 viable	 cells	 do	 not	 bind	 AnnV	 and	 exclude	 7AAD,	
such	 that	 these	 cells	 exhibit	 low	 fluorescent	 intensity	 (AnnV−/7AAD−);	 and	 can	 be	
identified	as	the	population	in	the	bottom-left	quadrant	of	the	bivariate	plot	(Fig.	2.1).		
In	 the	 early	 stages	of	 apoptosis,	 PS	 translocates	 from	 the	 inner	 leaflet	 of	 the	plasma	
membrane	to	the	cell	surface	allowing	AnnV	to	bind;	however,	the	plasma	membrane	
remains	intact	excluding	7AAD	from	the	cell	(AnnV+/7AAD−).		As	shown	in	Figure	2.1,	
these	cells	are	located	in	the	bottom-right	quadrant	of	the	bivariate	plot.	 	In	the	later	
stages	of	apoptosis	pores	appear	 in	 the	cell	membrane	allowing	7AAD	to	enter.	 	The	
population	 in	 the	 top-right	 corner	 is	 indicative	 of	 late	 apoptosis	 or	 late	 necrosis	
(AnnV+/7AAD+,	 as	 shown	 in	 Fig.	 2.1).		 In	 necrosis	 the	 loss	 of	 plasma	 membrane	
integrity	 occurs	 before	 the	 translocation	 of	 AnnV	 (AnnV−/7AAD+).	 	As	 such,	 early	
necrotic	cells	appear	in	the	top-left	quadrant	in	Figure	2.1.	
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Figure	2.1:	The	use	of	flow	cytometry	to	distinguish	modes	of	cell	death	using	AnnV	and	7AAD.		
The	presence	of	AnnV	(depicted	in	green)	bound	to	PS	(depicted	in	blue)	and	7AAD	(depicted	
in	red)	bound	to	DNA	in	the	cell	nucleus	(depicted	in	light	grey)	in	the	cell	is	dependent	on	the	
mode	of	cell	death	the	cells	have	undergone.	
2.1.4 Inhibition	of	COX:	Reduction	of	PGE2	production	
Since	 one	 of	 the	 proposed	 mechanisms	 of	 chemoprevention	 by	 NSAIDs	 is	 the	
inhibition	of	COX-2,	 it	 is	 important	 to	establish	whether	BiNSAIDs	can	 inhibit	COX	at	
comparable	 concentrations.	 	 This	 information	 can	 provide	 preliminary	 evidence	 to	
determine	their	potential	usefulness	as	chemopreventive	agents	and	form	a	guide	for	
future	studies.		As	discussed	in	Section	1.2.3,	the	upregulation	of	COX-2	production	has	
been	established	in	a	number	of	cancer	cell	lines.		The	upregulation	of	COX-2,	in	turn,	
results	 in	 the	 overproduction	 of	 PGE2,	 a	 PG	 that	 is	 associated	with	 fortifying	 cancer	
cells	 against	 cell	 death	 and	 increasing	 the	 invasiveness	 of	 cancer	 cells	 (as	
demonstrated	in	Fig.	1.5).		While	it	is	of	interest	to	study	COX	inhibition	by	incubation	
of	 the	 BiNSAIDs	with	 purified	 COX-1	 and	 COX-2	 enzymes,	 these	 experiments	would	
not	 take	 into	 account	 the	 conditions	 that	 the	 NSAISDs	 and	 BiNSAIDs	 would	 be	
subjected	to	in	a	cellular	environment	(i.e.	cell	permeability	and	metabolic	pathways).		
The	disadvantage	of	utilising	a	cell	system	to	determine	COX	inhibition	is	that	COX-1	
versus	 COX-2	 inhibition	 cannot	 be	 distinguished.		 However,	 this	 study	 will	 directly	
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compare	 BiNSAID	 versus	 NSAID,	 as	 it	 is	 important	 to	 establish	 if	 the	 BiNSAIDs	 can	
provide	equal	or	superior	COX	inhibition	in	the	cellular	environment.	Thus	the	ability	
of	BiNSAIDs	to	inhibit	PGE2	production	(and	subsequently	the	ability	to	inhibit	COX)	in	
a	transformed	cell	line	will	be	assessed	in	this	Chapter.	
	
2.1.5 Chapter	aims	
The	 establishment	 of	 the	 in	 vitro	 activity	 is	 the	 first	 step	 to	 determine	 whether	
BiNSAIDs	 will	 be	 suitable	 candidates	 for	 in	 vivo	 studies	 as	 chemotherapeutic	 or	
chemopreventive	 agents	 for	 CRC,	 and	 ultimately,	 whether	 BiNSAIDs	 should	 be	
investigated	as	a	potential	medication	 for	 the	reduction	of	 the	accompanying	GI	side	
effects	 of	 long-term	 NSAID	 use.		 The	 experiments	 described	 in	 this	 Chapter	 can	 be	
divided	into	two	purposes:	(i)	to	establish	the	chemotherapeutic	potential	of	BiNSAIDs	
by	determining	whether	BiNSAIDs	are	able	to	kill	transformed	cells	(toxicity	and	cell	
death	assays),	 and	 (ii)	 to	establish	whether	BiNSAIDs	demonstrate	chemopreventive	
potential	by	determining	whether	BiNSAIDs	are	able	to	inhibit	the	production	of	PGE2	
(and	thus	inhibit	COX)	in	transformed	cells.		A	human	epithelial	ileocecal	colon	cancer	
cell	 line,	 HCT-8,	 was	 employed	 as	 a	 model	 CRC	 cell	 line	 for	 the	 evaluation	 of	 the	
BiNSAIDs,	 Bi(tolf)3,	 Bi(mef)3	 and	 Bi(difl)3	 and	 the	 respective	 uncomplexed	 NSAIDs,	
tolfH,	mefH	and	diflH.	
The	specific	aims	of	this	chapter	were	to:	
1. Investigate	 the	 stability	 of	 Bi(tolf)3,	 Bi(mef)3	 and	 Bi(difl)3	 in	 cell	 medium	
using	NMR	spectroscopy	in	order	to	elucidate	the	biologically	active	form	of	
the	complexes	in	the	in	vitro	assays.		
2. Assess	 the	 in	 vitro	 toxicity	 of	 the	BiNSAIDs,	Bi(tolf)3,	 Bi(mef)3	 and	Bi(difl)3,	
and	 compare	 to	 the	 uncomplexed	 NSAIDs	 against	 human	 colon	 cancer	 cell	
line,	HCT-8.	
3. Determine	whether	the	BiNSAIDs,	Bi(tolf)3,	Bi(mef)3	and	Bi(difl)3,	induce	the	
same	 type	of	 cell	death	 (apoptosis	or	necrosis)	 as	 the	 respective	NSAIDs	 in	
HCT-8	cells.	
4. Ascertain	 whether	 complexation	 with	 Bi	 affects	 the	 ability	 of	 the	 NSAIDs,	
tolfH,	 mefH	 and	 diflH,	 to	 interact	 with	 COX	 in	 vitro,	 by	 quantifying	 PGE2	
production	by	HCT-8	cells.	
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2.2 Materials	and	methods	
2.2.1 Materials	
The	 Bi	 complexes	 of	 tolfH,	 mefH	 and	 diflH	 (Bi(tolf)3,	 Bi(mef)3	 and	 Bi(difl)3,	
respectively)	were	chosen	for	this	study.	 	TolfH	has	been	extensively	studied	 in	vitro	
against	 a	 number	 of	 different	 types	 of	 human	 cancer	 cell	 lines	 [42-50].		 MefH	 is	
structurally	 similar	 to	 tolfH	 (both	 belonging	 to	 the	 structural	 class	 called	 fenamic	
acids,	 Fig.	 1.2)	 and	 was	 tested	 as	 a	 direct	 comparison	 to	 tolfH;	 additionally,	 mefH	
exhibits	toxicity	 in	cancer	cell	 lines	 in	vitro	 [51,	52].	 	DiflH	was	 investigated	as	 it	 is	a	
salicylate	 which	 is	 the	 same	 chemical	 class	 that	 aspH	 belongs	
to	(Fig.	1.2).	 	Additionally,	 reports	 suggest	 that	 diflH	 exhibits	 gastroprotective	
properties	[53,	54].	 	The	BiNSAIDs,	Bi(tolf)3,	Bi(mef)3	and	Bi(difl)3,	were	synthesised,	
purified	and	characterised	by	Dr	Ish	Kumar	(School	of	Chemistry,	Monash	University)	
and	 Dr	 Amita	 Pathak	 (School	 of	 Chemistry,	 Monash	 University)	 as	 previously	
published	 by	 Andrews	 et	 al	 [8].	 	The	 NSAIDs,	 diflH	 (≥98%),	 mefH	 (≥98%),	 and	
tolfH	(≥98%),	 were	 purchased	 from	 Sigma-Aldrich	(St	Louis,	 USA).	 	 In	 addition,	
bismuth	 salicylate	 was	 chosen	 to	 represent	 the	 marketed	 Bi	 drug,	 BSS.	 	 Bismuth	
chloride	(BiCl3)	was	chosen	to	represent	a	simple	Bi	compound	with	no	expected	anti-
cancer	activity	or	 toxicity	stemming	 from	the	anion	(Cl−).	 	Cisplatin	was	employed	to	
provide	 a	 comparison	 of	 the	 BiNSAIDs	 to	 a	 standard	 chemotherapeutic	 drug.	 	The	
chemicals,	BSS	 (99.9%),	BiCl3	(≥98%)	and	cisplatin	 (99.999%)	were	purchased	 from	
Sigma-Aldrich	(St	Louis,	USA).	
MilliQ™	(18.2	MΩ/cm	resistivity,	Millipore)	water	was	used	to	prepare	all	aqueous	
solutions.		DMSO	(99.8%)	was	obtained	from	Thermofisher	Scientific	(Waltham,	USA).	
The	 chemicals,	 acetylsalicylic	 acid	 (aspH,	 ≥99.0%),	 deuterated	 DMSO	 (DMSO-d6,	
99.9%),	D-(+)-glucose	(≥99.5%),	4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic	acid	
(HEPES,	 ≥99.5%),	 MTT	 (98%),	 and	 trypan	 blue	 (0.5%	 in	 phosphate	 buffered	 saline	
(PBS)	solution)	were	purchased	from	Sigma-Aldrich	(St	Louis,	USA).		Absolute	ethanol	
was	 sourced	 from	 Ajax	 Finechem	 (Seven	 Hills,	 Australia).		 PBS	 tablets	 (1	tablet	 per	
100	mL	 of	 MilliQ	 water	 contains	 0.8	 g	 sodium	 chloride;	 0.02	 g	 potassium	 chloride;	
0.115	g	di-sodium	hydrogen	phosphate;	0.02g	potassium	dihydrogen	phosphate)	were	
obtained	 from	 Oxoid	 (Basingstoke	 Hampshire,	 England).	 	 Annexin	 V	 binding	 buffer	
and	AnnV	were	acquired	from	BioLegend	(San	Diego,	USA),	and	7AAD	was	purchased	
from	Enzo	Life	Sciences	(Plymouth	Meeting,	USA).		Arachidonic	acid	(0.1	M	in	ethanol,	
Item	 No.	 460103),	 potassium	 hydroxide	 (0.1	M,	 Item	 No.	 460105),	 and	 the	
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Prostaglandin	 E2	 EIA	 kit	 –	 Monoclonal	 kits	 (Item	 No.	 514010)	 were	 obtained	 from	
Cayman	Chemical	(Ann	Arbor,	USA).	
The	 materials	 used	 in	 the	 cell	 culture	 assays	 including,	 Roswell	 Park	
Memorial		 Institute	 (RPMI)-1640	 medium,	 penicillin/streptomycin	 (10,000	IU/mL,	
10,000	μg/mL),	 trypsin	 (2.5%	w/v	 in	 PBS)	 and	 GlutaMAX™	 (200	 mM	 L-alanyl-L-
glutamine	dipeptide	in	0.85%	NaCl)	were	acquired	from	Life	Technologies	(New	York,	
USA).	 	 Australian	 certified	 fetal	 bovine	 serum	 was	 purchased	 from	 Thermofisher	
Scientific	 (Waltham,	 USA)	 and	 was	 heat-inactivated	 before	 use	 (60	 °C,	 1	 h).		
CELLSTAR®	 96-well	 cell	 culture	 plates,	 CELLSTAR®	 60-mm	 culture	 dishes,	 and	
CELLSTAR®	 filter	 cap	 cell	 culture	 flasks	 (75	cm2)	 were	 sourced	 from	 Greiner	
Bio-One	(Kremsmünster,	Austria). 
2.2.2 Stability	studies	
The	 stability	 of	BiNSAIDs	 in	RPMI-1640	 (referred	 to	herein	 as	 cell	medium)	was	
assessed	by	comparison	of	the	NMR	spectra	with	those	for	the	uncomplexed	NSAIDs	to	
determine	 whether	 the	 NSAID	 dissociated	 from	 Bi.	 	These	 studies	 were	 initially	
performed	 by	 dissolving	 the	NSAIDs	 or	 BiNSAIDs	 in	 accordance	with	 the	 procedure	
and	 concentrations	 used	 for	 the	 cell	 assays	 (i.e.	<	100	µM,	 2%	 d6-DMSO/98%	 D2O);	
however,	only	very	weak	1H	NMR	signals	of	the	NSAIDs	were	detected.		Subsequently,	
the	concentrations	of	the	NSAIDs	or	BiNSAIDs	were	increased	such	that	10–40	mg	was	
dissolved	 in	 d6-DMSO	 (200	 µL)	 and	 the	 resultant	 solution	 was	 added	 to	
RPMI-1640	(1.8	mL).	 	The	resultant	suspensions	were	vortexed	and	 incubated	(37°C,	
24	 h).	 Following	 incubation,	 the	 suspended	 compounds	 were	 collected	 by	
centrifugation	(300	g,	5	min)	and	dried	under	a	nitrogen	atmosphere.		The	1H	and	13C	
NMR	 spectra	 of	 the	 BiNSAIDs,	 NSAIDs	 and	 the	 redissolved	 products	 resulting	 from	
incubation	 in	 medium	 were	 recorded	 using	 a	 500	 MHz	 Varian	 spectrometer	 in	
d6-DMSO	 at	 25°C,	 referenced	 to	 DMSO	 (δH	2.49,	 δC	39.5).		 NMR	assignments	 were	
confirmed	with	 2D-NMR,	 specifically	 homonuclear	 correlation	 spectroscopy	 (COSY),	
heteronuclear	 single	 quantum	 coherence	 spectroscopy	 (HSQC),	 and	 heteronuclear	
multiple-bond	correlation	spectroscopy	(HMBC).	
2.2.3 Cell	culture	
The	 human	 ileocecal	 colon	 cancer	 cell	 line,	 HCT-8,	 was	 chosen	 to	 represent	 a	
human	bowel	cancer	cell	line	and	since	a	number	of	publications	report	that	COX-2	is	
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expressed	 in	 the	 HCT-8	 cell	 line	 [55-57].	 	The	 cell	 line	 was	 kindly	 provided	 by	
Associate	 Professor	 Ronald	 Sluyter	 (School	 of	 Biological	 Sciences,	 University	 of	
Wollongong),	 and	 was	 originally	 sourced	 from	 the	 European	 Collection	 of	
Authenticated	Cell	Cultures	(ECACC).		All	experimental	work	involving	the	culture	and	
treatment	of	HCT-8	cells,	and	the	subsequent	handling	and	preparation	of	HCT-8	cell	
samples	was	performed	under	sterile	conditions	in	a	biological	safety	cabinet	(Class	II,	
Email	 Westinghouse	 Pty	 Ltd).		 HCT-8	 cells	 were	 cultured	 in	 growth	 medium	 that	
consisted	 of	 RPMI-1640	 medium	 supplemented	 with	 10%	 fetal	 bovine	 serum,	
GlutaMAX™	(2	mM),	penicillin	and	streptomycin	 (final	concentration	200	 IU/mL	and	
200	µg/mL,	respectively).		Cells	were	incubated	in	a	5%	CO2	atmosphere	at	37	°C	and	
passaged	every	3–4	days	(when	confluent)	after	harvesting	with	trypsin	(0.25%	in	PBS	
solution).	
2.2.4 In	vitro	cytotoxicity	towards	cancer	cells:	MTT	assay	
The	 toxicities	 of	 Bi(tolf)3,	 Bi(mef)3,	 Bi(difl)3,	 tolfH,	mefH,	 diflH,	 BSS	 and	 cisplatin	
were	 assessed	using	 adaptations	of	 the	MTT	assay	described	by	Mosmann	 [26],	 and	
Carmichael	 et	 al	 [29].	 	 Briefly,	 cells	 were	 seeded	 in	 96-well	 plates	 at	 a	 density	 of	
4	×	104	cells	per	well	in	growth	medium	(100	μL)	and	were	incubated	for	24	h	to	allow	
cell	 adhesion	 to	 occur.	 	 Stock	 solutions	 (typically	 50	µM	 to	 100	mM)	of	 the	NSAIDs,	
BiNSAIDs,	 BiCl3	 and	 BSS,	 were	 prepared	 in	 DMSO.	 	 These	 solutions	 (20	 μL)	 were	
pipetted	 into	 RPMI-1640	 (980	 μL),	 vortexed,	 and	 the	 resultant	 solutions	 (100	 μL	
treatment	 solution,	 final	 concentration	 of	 drug	 typically	 1	 to	 2000	 µM)	were	 added	
into	 the	 wells	 of	 the	 96-well	 plate.	 	 Control	 cells	 were	 incubated	 with	 the	 vehicle	
(DMSO	(2	μL)	 and	 RPMI-1640	 (98	 μL))	 containing	 no	 test	 compounds.	 In	 order	 to	
avoid	any	potential	ligand	exchange	reactions	between	DMSO	and	the	labile	Cl−	groups	
resulting	 in	 the	 deactivation	 of	 the	 drug	 in	 the	 cell	 medium	 [58],	 cisplatin	 was	
prepared	 in	RPMI-1640	(typical	stock	concentration	2−4	mM)	and	serially	diluted	 in	
RPMI-1640.	 	The	 96-well	 plate	 was	 incubated	 (37	°C)	 for	 24	h,	 after	 which	 the	
treatment	 medium	was	 removed	 and	 the	 cells	 were	 washed	 twice	 with	 sterile	 PBS	
solution.		Fresh	RPMI-1640	(100	μL)	was	added	to	each	well,	followed	by	the	addition	
of	MTT	solution	(50	μL,	2	mg/mL	in	PBS).		The	96-well	plate	was	incubated	(37	°C)	for	
4	h,	after	which	the	medium	was	removed	and	DMSO	(200	μL)	was	added	to	each	well.		
The	96-well	plate	was	agitated	for	25	s	and	the	absorbance	of	each	well	was	recorded	
at	 570	 nm	 and	 630	nm	 using	 a	 POLARstar	 Omega	 microplate	 reader	 with	 Omega	
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software	 (Version	1.1.2,	BMG	Labtek	GmbH,	Ortenberg,	Germany).	 	The	results	were	
expressed	as	percent	MTT	conversion,	which	is	proportional	to	the	number	of	healthy	
cells	(Equation	1):	
MTT conversion % = !!"#!!!"# !"#$!#% !"##$
!!"#!!!"# !"#$%&#%' !"##$
 × 100														(1)	
The	calculated	cell	viability	was	plotted	against	the	treatment	concentrations	using	
Microsoft	 EXCEL™	 (Version	 12	 for	 Windows	 2007,	 Microsoft,	 Redmond,	 USA)	 to	
determine	 the	 IC50	 value	 of	 each	 compound.	 	 The	 MTT	 assays	 were	 performed	 in	
triplicate	for	each	compound.	
	
2.2.5 Cell	death	assays	
2.2.5.1 Morphological	analysis	by	phase	contrast	microscopy	
HCT-8	 cells	 were	 plated	 in	 60-mm	 cell	 culture	 dishes	 (2	 ×	 106	 cells,	 5	mL)	 in	
growth	medium	and	maintained	at	37	°C,	5%	CO2	overnight.	 	The	cells	were	washed	
twice	with	 PBS	 solution	 and	 the	 treatment	 solutions	 (3	mL)	were	 then	 added.	 	 The	
treatment	concentrations	were	the	approximate	IC50	doses	of	each	BiNSAID	dissolved	
in	treatment	medium	(2%	DMSO	v/v)	as	determined	by	MTT	assays	(Section	2.3.2),	or	
the	 equimolar	 concentration	 of	 the	 corresponding	 free	 NSAID,	 as	 denoted	 in	 the	
figures	and	 text.	 	A	minimum	of	 three	 fields	of	view	were	examined	 for	each	sample	
using	a	Motic	Binocular	AE20	Inverted	light	microscope	equipped	with	a	20×	objective	
lens.	 	 Images	were	 recorded	 using	 a	Moticam	 2000	 2.0	MP	 Live	 Resolution	 camera	
with	Motic	Images	Plus	Version	2.0	for	Windows	(Motic	China	Group	Co.,	Ltd.,	Xiamen,	
China). 
	
2.2.5.2 Measurement	of	cell	death	by	cytofluorometric	assay	
HCT-8	 cells	 were	 plated	 in	 60-mm	 cell	 culture	 dishes	 (1	 ×	 106	 cells,	 5	mL)	 in	
growth	medium	and	maintained	at	37	°C,	5%	CO2	overnight.	 	The	cells	were	washed	
twice	 with	 PBS	 solution	 and	 treatment	 solutions	 were	 added	 (3	 mL	 RPMI-1640,	
2%	DMSO	 v/v).	 	 Cells	were	 treated	with	 the	 approximate	 IC50	 doses	 of	 the	BiNSAID	
(Bi(tolf)3,	 Bi(mef)3	 or	 Bi(difl)3)	 as	 determined	 by	 MTT	 assays	 (Section	 2.3.2),	 or	
equimolar	 concentrations	 of	 the	 corresponding	 free	 NSAID	 (tolfH,	 mefH	 or	 diflH).		
Following	 incubation	(37	°C,	24	h),	 the	 treatment	solutions	and	PBS	solution	washes	
were	 collected	 and	 the	 remaining	 cells	 were	 detached	 using	 trypsin	 (0.25%	 in	 PBS	
solution).	 	The	detached	cells	were	combined	with	the	cells	in	the	treatment	solution	
washings	 and	 the	 resultant	 suspension	 was	 centrifuged	 (300	g,	 5	min)	 to	 ensure	
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collection	 of	 all	 cells	 (live	 and	 dead).	 	Cell	 death	 was	 determined	 by	 quantitative	
measurement	 using	 flow	 cytometry.		 The	 collected	 HCT-8	 cells	 were	 washed	 twice	
with	HEPES-buffered	saline	solution	(145	mM	NaCl,	5	mM	KCl,	10	mM	HEPES,	pH	7.4,	
1	mL),	followed	by	Annexin	V	binding	medium	(1	mL).		The	cells	were	incubated	with	
AnnV	 (5	µL)	 and	 7AAD	 (1	mg/mL	 in	 PBS	 solution,	 1	µL)	 at	 room	 temperature	
protected	 from	 light	 for	15	min.		 Following	 staining,	AnnV	binding	medium	 (400	µL)	
was	added	to	each	tube	and	events	(20,000	per	sample)	were	collected	using	a	LSR	II	
flow	 cytometer	 (BD	 Biosciences,	 San	 Diego,	 CA)	 using	 an	 excitation	 wavelength	 of	
488	nm	 and	 emission	 collected	with	 515/20	 and	 695/40	 band	pass	 filters	 for	AnnV	
and	7AAD,	respectively.		The	mean	fluorescent	intensity	(MFI)	of	AnnV	and	7AAD	was	
determined	 using	 FloJo	 software	 (Tree	 Star,	 Ashland,	 OR).	 	Quadrant	markers	 were	
used	 to	 determine	 the	 percentage	 of	 AnnV‒/7AAD‒	 (viable),	 AnnV+/7AAD‒	 (early	
apoptotic),	 AnnV+/7AAD+	 (late	 apoptotic/late	 necrotic),	 and	 AnnV‒/7AAD+	 (early	
necrotic)	cells.	
2.2.6 COX	inhibition:	Prostaglandin	assays	
HCT-8	cells	(1	×	106	cells,	5	mL)	were	seeded	into	60-mm	cell	culture	dishes	and	
were	 incubated	 for	24	h,	after	which	the	growth	medium	was	removed	and	the	cells	
were	washed	twice	with	PBS	solution.	 	The	BiNSAID	(Bi(difl)3,	Bi(mef)3,	or	Bi(tolf)3),	
NSAID	(diflH,	mefH	or	 tolfH),	aspH	or	BSS	 treatments	 in	DMSO	(5	µM	to	50,000	µM)	
were	 added	 to	 each	 dish	 as	 a	 solution	 in	 RPMI-1640	 (2mL,	 2%	 DMSO	 v/v;	 final	
concentration	 of	 drug	 0.1−1000	 µM),	while	 the	 control	 cells	were	 incubated	 (37	°C)	
with	 the	 vehicle	 (2	mL	 RPMI-1640,	 2%	 DMSO	 v/v)	 for	 4	h.	 	 AspH	 was	 chosen	 as	 a	
positive	control	as	it	is	a	well-established	COX	inhibitor,	and	clinical	evidence	suggests	
that	 aspH	may	 possess	 chemopreventive	 properties	 (as	 discussed	 in	 Section	 1.2.2).		
BSS	 was	 chosen	 to	 represent	 a	 marketed	 anti-ulcer	 Bi	 medication.		 Following	 the	
incubation	 period,	 the	 treatment	 medium	 was	 removed	 and	 the	 cells	 were	 washed	
twice	with	PBS	 solution.		 Fresh	arachidonic	 acid	 solution	was	prepared	according	 to	
the	 manufacturer’s	 instructions.	 	Arachidonic	 acid	 (0.1	 M	 in	 ethanol,	 20	 µL)	 was	
diluted	 by	 the	 addition	 of	 potassium	 hydroxide	 (0.1	M,	 20	 µL)	 and	 the	 resultant	
solution	was	added	to	RPMI-1640	(960	µL).		Fresh	RPMI-1640	medium	(1980	µL)	and	
arachidonic	 acid	 solution	 (20	 µL;	 final	 concentration	 20	 µM)	was	 added	 to	 the	 cells	
and	 the	 60-mm	 dishes	 were	 incubated	 (37	°C)	 for	 30	min.	 	The	 cell	 medium	 was	
collected	and	centrifuged	(11	000	g,	30	sec)	 to	remove	any	cellular	material,	and	the	
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supernatant	was	stored	at	−80	°C	until	the	assay	was	performed.		PGE2	production	was	
assayed	 using	 a	 Prostaglandin	 E2	 EIA	 Kit	 in	 accordance	 with	 the	 manufacturer’s	
instructions.	 	 Briefly,	 the	 absorbance	 of	 each	 well	 was	 recorded	 at	 420	 nm	 using	 a	
POLARstar	 Omega	 microplate	 reader	 with	 Omega	 software	 (Version	 1.1.2,	
BMG	Labtek).		 The	 PGE2	 concentration	(pg/mL)	 of	 each	 sample	was	 calculated	 using	
GraphPad	 Prism	 Version	 5.04	 for	Windows	 (GraphPad	 Software,	 La	 Jolla,	 USA),	 and	
PGE2	 release	 was	 expressed	 as	 a	 percentage	 of	 control	 PGE2	 production.	 The	
sensitivity	of	the	assay,	as	reported	by	the	manufacturer,	was	15.6	pg	PGE2/mL.	
	
2.2.7 Statistical	analysis	
Statistical	 analysis	 of	 the	 results	 of	 the	 AnnV/7AAD	 assays	 was	 performed	 by	
one-way	 ANOVA,	 followed	 by	 the	 Tukey-Kramer	 Multiple	 Comparison	 Test,	 using	
GraphPad	 Prism,	 Version	 5.04	 for	 Windows	 (GraphPad	 Software,	 La	 Jolla,	 USA).		
The	results	were	analysed	as	vehicle	versus	BiNSAID	versus	the	corresponding	NSAID,	
in	order	to	draw	a	statistical	comparison	at	the	same	NSAID	concentration.	A	value	of	
P	≤	0.05	was	considered	statistically	significant.	 	
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2.3 Results	
2.3.1 Stability	of	BiNSAIDs	in	cell	medium	
Features	of	the	1H	NMR	spectra	(aromatic	region	only,	presented	for	clarity;	Figure	
2.2a–d)	of	tolfH	and	Bi(tolf)3	as	obtained	in	DMSO-d6	prior	to	and	after	incubation	in	
cell	medium	are	summarised	in	Table	2.1.		It	is	apparent	that	there	is	no	proton	signal	
corresponding	 to	 the	 –COOH	 in	 the	 Bi(tolf)3	 spectrum,	 which	 is	 consistent	 with	
previous	 studies	 [8],	 and	 corresponds	 to	 the	 expected	 absence	 of	 the	 proton	
subsequent	 to	 coordination	 to	 Bi.	 	 As	 shown	 in	 Table	 2.1,	 the	 13C	 NMR	 spectra	 of	
Bi(tolf)3	 also	 confirm	 the	 complexation	 to	 Bi,	 with	 downfield	 shifts	 observed	 from	
170.1	ppm	to	174.0	ppm	for	the	resonance	corresponding	to	the	carboxylate	carbon,	
C14	(C–OOBi),	in	comparison	with	uncomplexed	tolfH;	additionally,	a	substantial	shift	
in	 the	 resonance	 of	 the	 quaternary	 carbon	 C1	 (C–COOBi)	 was	 observed	 from	
112.3	ppm	to	118.6	ppm.		The	majority	of	the	signal	shifts	relating	to	the	introduction	
of	 the	d6-DMSO	solution	of	 tolfH	and	Bi(tolf)3	 to	 cell	medium	were	observed	 for	 the	
aromatic	protons,	as	shown	in	Figure	2.2b	and	d.		Small	downfield	shifts	in	the	1H	NMR	
signals	of	 tolfH	 incubated	 in	cell	medium	occurred	 for	H5,	and	H8	which	overlapped	
with	 the	 signal	 of	 H4	 (Fig.	 2.2b),	 indicating	 that	 there	 were	 some	 changes	 in	 the	
chemical	environment	surrounding	these	atoms	following	incubation	of	the	NSAID	in	
cell	medium	compared	to	the	original	NSAID	(Fig.	2.2a).		In	addition,	the	proton	signal	
at	 13.11	 ppm	 related	 to	 –COOH	 disappeared	 and	 there	 was	 broadening	 and	 a	
downfield	shift	of	the	signal	associated	with	–NH	in	the	1H	NMR	spectra	obtained	from	
the	 precipitated	 tolfH	 (and	 Bi(tolf)3).	 These	 observations	 are	 attributed	 to	 the	
presence	of	a	small	amount	of	water	in	the	sample	and	subsequent	exchange	with	H2O	
protons.			Following	 incubation	 in	 cell	 medium,	 the	 1H	 NMR	 spectrum	 of	
Bi(tolf)3	(Fig.	2.2d)	 showed	 some	 differences	 from	 the	 initial	 spectrum	 of	
Bi(tolf)3	(Fig.	2.2c),	 most	 substantially	 for	 the	 1H	 signals	 of	 H4,	 H8,	 H9	 and	 H10.		
However,	the	13C	NMR	spectrum	(Table	2.1)	obtained	for	Bi(tolf)3	after	 incubation	in	
cell	medium	showed	minimal	shift	 in	 the	C14	(C–OOBi)	signal	 (174.0	 to	173.8	ppm).		
Additionally,	 there	 was	 minimal	 shift	 in	 the	 C1	 signal	 (Table	 2.1)	 suggesting	 that	
following	 incubation	 of	 the	 complex	 in	 cell	 medium,	 the	 interaction	 between	 the	
carboxylate	group	and	Bi	remains	intact.	
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Figure	 2.2:	 1H	 NMR	 spectra	 of	 the	 aromatic	 region	 (6.6–8.0	 ppm)	 of:	 (a)	 tolfH;	 (b)	 tolfH	
collected	after	incubation	in	cell	medium	(24	h,	37	°C);	(c)	Bi(tolf)3	and,	(d)	Bi(tolf)3	collected	
after	incubation	in	cell	medium	(24	h,	37	°C).		All	samples	were	analysed	in	d6-DMSO	at	25	°C	
(referenced	to	DMSO,	2.49	ppm).	
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The	 1H	 NMR	 spectra	 of	 mefH	 and	 Bi(mef)3	 (aromatic	 region	 only	 presented	 for	
clarity,	 Figure	 2.3a–d),	 as	 obtained	 in	 d6-DMSO	 prior	 to	 and	 after	 incubation	 in	 cell	
medium,	 are	 summarised	 in	 Table	 2.2.		 Prior	 to	 incubation	 in	 cell	 medium	 it	 is	
apparent	that	there	is	no	signal	corresponding	to	the	proton	of	–COOH	in	the	Bi(mef)3	
spectrum,	which	is	consistent	with	the	absence	of	coordination	of	the	NSAID	to	Bi	[8].		
As	shown	in	Table	2.2,	the	13C	NMR	spectra	of	Bi(mef)3	also	confirm	the	complexation	
to	Bi,	with	downfield	shifts	observed	from	170.2	ppm	to	175.5	ppm	for	the	resonance	
corresponding	 to	 the	 carboxylate	 carbon,	 C15	 (C–OOBi),	 in	 comparison	 with	
uncomplexed	mefH.	 	The	1H	NMR	signals	of	Bi(mef)3	(Table	2.2)	were	shifted	upfield	
in	 comparison	 to	 free	mefH	 (with	 the	 exception	 of	 H3	 and	 NH).	 	 The	most	 obvious	
difference	between	the	1H	NMR	spectra	of	mefH	and	Bi(mef)3	 is	the	chemical	shift	of	
H5	 (Fig.	 2.3	 a	 and	 c).	 	 After	 incubation	 in	 cell	 medium,	 there	 appeared	 to	 be	 little	
change	to	the	1H	NMR	spectrum	of	mefH	(Fig.	2.3b,	Table	2.3).		Comparatively,	Figure	
2.3d	shows	that	the	H5	signal	overlaps	with	the	H3	signal	after	incubation	of	Bi(mef)3	
in	cell	medium	which	was	accompanied	by	additional	downfield	shifts	in	the	majority	
of	 the	other	 1H	NMR	signals	 (Table	2.3).	 	Furthermore,	 the	 13C	NMR	signals	revealed	
that	after	the	incubation	of	Bi(mef)3	in	cell	medium,	the	C–OOBi	signal	shifted	upfield	
to	 170.8	 ppm	 (Table	 2.3).	Overall,	 these	 results	 suggest	 that	 following	 incubation	 of	
Bi(mef)3	in	cell	medium	there	is	liberation	of	mef	from	the	Bi	complex.		
The	 1H	 NMR	 spectra	 of	 diflH	 and	 Bi(difl)3	 (aromatic	 region	 only,	 presented	 for	
clarity;	 Fig.	 2.4a–d),	 as	 obtained	 in	 d6-DMSO	 prior	 to	 and	 after	 incubation	 in	 cell	
medium,	 are	 summarised	 in	 Table	 2.3.	 	 Interestingly,	 reference	 to	 the	 spectrum	 of	
diflH	prior	to	incubation	in	cell	medium	indicates	the	absence	of	the	proton	signal	of	
the	 –COOH	 (of	 C13)	 and	 –OH	 (of	 C10);	 however,	 solid	 IR	 analysis	 (data	 not	 shown)	
confirmed	the	presence	of	–OH	in	the	diflH	structure.	 	Additionally,	the	C10,	C11	and	
C13	 (–COOH)	 signals	 of	 Bi(difl)3	 were	 not	 observed	 (Table	 2.3,	 Fig.	 2.4a).	 	This	
phenomenon	 is	most	 likely	 a	 result	 of	 the	 slower	 tumbling	of	 a	 larger	molecule	 and	
hence	the	broadening	of	some	of	the	13C	signals,	thereby	decreasing	their	detectability;	
this	is	further	evidenced	by	the	broadening	of	the	H8,	H9	and	H12	signals	observed	in	
the	 1H	 NMR	 spectrum	 of	 Bi(difl)3	 (Fig.	 2.4c).		 The	 24-h	 incubation	 of	 diflH	 in	 cell	
medium	resulted	in	upfield	shifts	of	the	proton	signals	associated	with	the	phenyl	ring	
containing			the			–COOH			moiety			(Fig.	2.4d).			Following			the			incubation			of			Bi(difl)3		
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Figure	 2.3:	 1H	 NMR	 spectra	 of	 the	 aromatic	 region	 (6.6–8.0	 ppm)	 of:	 (a)	 mefH;	 (b)	 mefH	
collected	after	incubation	in	cell	medium	(24	h,	37	°C);	(c)	Bi(mef)3,	and	(d)	Bi(mef)3	collected	
after	incubation	in	cell	medium	(24	h,	37	°C).	All	samples	were	analysed	in	d6-DMSO	at	25	°C	
(referenced	to	DMSO,	2.49	ppm). 
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in	cell	medium,	a	pronounced	upfield		shift		in		the		H8,		H9		and		H12		1H		NMR		signals		
was	 	observed	 	 (Fig.	2.4d),	 	 in	 comparison	 to	 free	diflH	 (Fig.	2.4b).	 	Additionally,	 the	
carbon	signals	 for	C10,	C11	and	the	–COOH	were	observed	(Table	2.4)	suggesting	an	
alteration	in	structure.		However,	the	C11	signal	of	the	Bi(difl)3	differs	substantially	to	
that	of	diflH	after	incubation	(120.4	ppm	and	115.9	ppm)	which	suggests	that	difl	may	
remain	coordinated	to	Bi.	
Interestingly,	 weak	 yet	 observable	 signals	 were	 detected	 in	 the	 1H	 NMR	 from	
another	molecule(s)	 present	 in	 the	 Bi(difl)3	 sample	 after	 incubation	 in	 cell	medium	
which	 were	 not	 detected	 in	 any	 other	 sample	 studied.	 	Complete	 characterisation	
could	not	be	achieved	due	to	the	 low	concentration	of	 the	molecule(s).	 	Nonetheless,	
the	 appearance	of	weak	 1H	NMR	signals	 of	 the	unknown	molecule(s)	 suggested	 that	
only	molecules	with	concentration	comparable	to	the	concentration	of	Bi(difl)3	in	the	
cell	medium	would	be	detected,	in	particular	D-glucose	or	HEPES.		Reference	to	the	1H	
NMR	spectra	of	D-glucose	or	HEPES	(alone)	in	d6-DMSO,	suggested	that	the	potential	
identity	 of	 the	 molecule(s)	 in	 the	 incubated	 Bi(difl)3	 sample	 consisted	 of	
D-glucose	(Fig.	2.5).	 	Overall,	 the	 changes	observed	 in	 the	 1H	and	 13C	NMR	signals	of	
the	incubated	Bi(difl)3	complex	compared	to	the	original	compound	may	suggest	that	
the	coordination	of	Bi	to	the	difl	ligands	is	altered	following	incubation	in	cell	medium	
due,	possibly,	to	subsequent	interactions	with	D-glucose.		
As	well	as	the	DMSO-soluble	species	described	above	(Fig.	2.2–2.5,	Table	2.1–2.3),	
it	 was	 noted	 that	 a	 DMSO-insoluble	 species	 was	 present	 upon	 preparation	 of	 the	
samples	 for	 NMR	 analysis	 (after	 collection	 and	 drying	 following	 incubation	 in	 cell	
medium).		The	formation	of	the	white	precipitate	was	not	observed	upon	incubation	of	
the	 free	 NSAID	 in	 cell	 medium	 and	 consequently	 implied	 that	 at	 least	 some	 of	 the	
BiNSAID	 must	 be	 interacting	 with	 other	 species	 present	 in	 the	 solution.	 High	
concentrations	 of	 anions	 such	 as	 phosphate,	 chloride,	 sulphate	 and	 carbonate	 are	
present	in	the	inorganic	salts	found	in	RPMI-1640.		Given	that	Bi(III)	has	a	particularly	
high	 affinity	 for	 phosphate	 ions,	 it	 is	 envisaged	 that	 the	 precipitation	 could	 be	
insoluble	 Bi(III)	 phosphate.	 	 Identification	 of	 the	 species	 was	 attempted	 using	 IR	
spectroscopy;	however,	the	dominating	signals	in	the	spectrum	originated	from	DMSO	
that	proved	difficult	to	remove	due	to	its	non-volatile	nature.		Attempts	to	repeatedly	
wash	 the	 precipitate	 with	 MilliQ	 water	 were	 performed;	 however,	 due	 to	 the	
low			quantity			of			the			solid			produced,		isolation			of			a			sufficient			quantity		of			dried		
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Figure	 2.4:	 1H	 NMR	 spectra	 of	 the	 aromatic	 region	 (6.6–8.0	 ppm)	 of:	 (a)	 diflH;	 (c)	 diflH	
collected	after	incubation	in	cell	medium	(24	h,	37	°C);	(d)	Bi(difl)3,	and	(f)	Bi(difl)3	collected	
after	incubation	in	cell	medium	(24	h,	37	°C).	All	samples	were	analysed	in	d6-DMSO	at	25	°C	
(referenced	to	DMSO,	2.49	ppm).  
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Figure	 2.5:	 1H	 NMR	 spectra	 of:	 (a)	 unknown	 molecule	 present	 in	 the	 sample	 containing	
Bi(difl)3	 collected	 after	 incubation	 in	 cell	 medium	 (24	 h,	 37	 °C)	 (l	 indicates	 signals	
corresponding	 to	 D-glucose,	 ×	 indicates	 unassigned	 signals);	 and	 (b)	 D-glucose.	 All	 samples	
were	analysed	in	d6-DMSO,	25	°C,	referenced	to	DMSO	(2.49	ppm).	
compound	to	produce	good	quality	 IR	spectra	was	not	possible.	 	Whether	phosphate	
(or	any	other	ion)	has	an	effect	on	the	BiNSAIDs	at	low	concentrations	in	cell	medium	
(i.e.	biologically	relevant	concentrations)	will	need	to	be	confirmed	in	further	studies.	
2.3.2 In	vitro	cytotoxicity	towards	cancer	cells		
To	 evaluate	 the	 effects	 of	 the	BiNSAIDs	 and	NSAIDs	 on	 cell	 viability,	HCT-8	 cells	
were	 exposed	 to	 the	 compounds	 for	 4	 h	 or	 24	h,	 following	which	 the	 conversion	 of	
MTT	 by	 functioning	 mitochondria	 was	 measured.	 	As	 DMSO	 was	 necessary	 to	
solubilise	the	BiNSAIDs	and	NSAIDs,	 the	MTT	assay	was	performed	to	determine	the	
tolerance	 of	 HCT-8	 cells	 to	 increasing	 concentrations	 of	 DMSO	 in	 the	 cell	 medium.		
A	representative	 concentration-response	 curve	 is	 shown	 in	Appendix	 1.1.	 	Following	
24-h	exposure	to	DMSO,	the	viability	of	the	HCT-8	cells	decreased	in	a	concentration-
dependent	 manner.		 At	 DMSO	 concentration	 of	 1%	 v/v	 approximately	 95%	 of	
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mitochondrial	activity	was	maintained	compared	to	the	control	cells	(treated	with	cell	
medium	 in	 the	 absence	of	DMSO).	 	 Increasing	 the	 concentration	of	DMSO	 to	2%	v/v	
resulted	 in	 a	 decrease	 in	 viability	 to	 approximately	 78%	 of	 mitochondrial	 activity	
compared	to	the	control	cells;	 further	increasing	the	concentration	of	DMSO	resulted	
in	 a	 further	 reduction	 in	 mitochondrial	 activity.	 	Despite	 a	 minor	 impact	 on	
mitochondrial	 activity,	 a	 concentration	 of	 2%	v/v	 DMSO	 was	 chosen	 for	 compound	
delivery	in	order	to	maximize	the	dissolution	of	the	highly	water-insoluble	BiNSAIDs	
and	NSAIDs	in	the	cell	medium.		
The	 concentration-response	 curves	 shown	 in	 Appendix	 1.2	 and	 Figure	 2.6	 are	
graphed	for	the	NSAID	concentration	(acknowledging	that	there	are	3	mole	of	NSAID	
present	 in	 each	 BiNSAID	 complex)	 following	 4-h	 or	 24-h	 treatment,	 respectively.		
As	shown	in	Appendix	1.2,	no	appreciable	loss	of	mitochondrial	activity	was	observed	
in	HCT-8	cells	following	4-h	treatment	with	any	of	the	BiNSAIDs	or	NSAIDs	up	to	the	
highest	 tested	 concentrations	 (300	 µM	 or	 1000	µM).	 	However,	 following	 24-h	
exposure	 to	 BiNSAIDs	 the	 viability	 of	 HCT-8	 cells	 decreased	 in	 a	 concentration-
dependent	manner	 (Figure	 2.6).	 	 The	 IC50	 values	 determined	 after	 24-h	 exposure	 to	
the	 BiNSAID	 complexes	 and	 reference	 compounds	 (cisplatin,	 BiCl3,	 and	 BSS)	 are	
summarised	 in	 Table	 2.4.		 Notably,	 the	 compounds,	 Bi(tolf)3,	 Bi(mef)3,	 and	 tolfH	
(Table	2.4,	Fig.	2.6),	were	more	toxic	to	HCT-8	cells	than	the	anti-cancer	drug,	cisplatin	
(Table	2.4,	Appendix	1.3).		Bismuth	salicylate,	which	was	used	to	mimic	the	anti-ulcer	
drug,	BSS,	showed	little	effect	on	the	viability	of	the	HCT-8	cells	up	to	2000	µM	(Table	
2.4,	 Appendix	 1.3).		 However,	 the	 Bi	 compound,	 BiCl3,	 showed	 moderate	 toxicity	
(IC50	=	383	μM)	towards	the	HCT-8	cells	 	 (Table	2.4,	Appendix	1.3).	 	 	Following	close	
inspection	 of	 the	 results	 obtained	 from	 the	 BiNSAIDs	 it	 is	 apparent	 that	 their	
IC50	values	 are	 lower	 than	 the	 respective	 free	 NSAIDs	 (Table	 2.4),	 ranging	 from									
16–81	μM	(BiNSAIDs)	 to	 37–403	μM	 (NSAIDs).		 Importantly,	 the	 toxicity	 of	 the	
BiNSAIDs	 increased	 in	 the	 order:	 Bi(difl)3	 <	 Bi(mef)3	 <	 Bi(tolf)3	 paralleling	 the	
response	exhibited	by	the	free	NSAIDs	(diflH	<	mefH	<	tolfH).		Figure	2.6	demonstrates	
that	 the	 toxicity	 profiles	 of	 the	BiNSAIDs,	 Bi(tolf)3	 and	Bi(mef)3,	were	 similar	 to	 the	
respective	 free	NSAIDs	(tolfH	and	mefH)	whereby	 the	BiNSAIDs	were	approximately	
three	 times	more	 toxic	 than	 the	 respective	 free	NSAIDs	 (representative	of	 the	molar	
ratio	 of	 NSAID	 contained	 in	 the	 BiNSAID	 complexes).	 	 The	 results	 of	 the	 assay	 for	
Bi(difl)3	differ,	however,	whereby	the	binding	of	difl	to	bismuth	enhanced	the	toxicity	
of	the	NSAID	(Fig.	2.6).	
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Figure	 2.6:	 Concentration-response	 curves	 obtained	 from	 the	 MTT	 assays	 of	 HCT-8	 cells	
treated	(24	h)	with	tolfH,	Bi(tolf)3,	mefH,	Bi(mef)3,	diflH,	or	Bi(difl)3.		Error	bars	represent	the	
standard	 deviation	 from	 the	 mean	 (n	 =	 6).	 	 One	 representative	 of	 three	 independent	
experiments	is	shown.	
Table	2.4:	IC50	values	determined	by	MTT	toxicity	assays	following	the	24-h	treatment	of	
HCT-8	colon	cancer	cells	with	the	specified	compounds.	
	
	
IC50	(µM)a	
								Ligand	(LH)																	Complex	[Bi(L)3]	
IC50	ratio	
LH:Bi(L)3	
tolf	 		37	±	2	 16	±	1	 2.3	
mef	 118	±	2	 44	±	5	 2.7	
difl	 403	±	6	 81	±	6	 5.0	
cisplatin	 		50	±	5	 	
BiCl3	 		383	±	38	 	
BSS	 >	2000	 	
a	IC50	value	was	determined	using	at	least	three	independent	MTT	assays.		
2.3.3 Cell	death	assays	
2.3.3.1 Phase	contrast	microscopy	
In	 order	 to	 determine	 whether	 the	mode	 of	 cell	 death	 of	 the	 BiNSAIDs	 was	 the	
same	as	the	respective	NSAIDs,	phase	contrast	microscopy	was	initially	performed	to	
assess	the	morphological	changes	of	the	HCT-8	cells.	 	As	observed	in	Figure	2.7a,	the	
vehicle-treated	cells	maintain	their	normal	fibroblastic	intact	shape	and	close	contact	
with	neighboring	cells.	 	Following	24-h	treatment	with	the	approximate	IC50	doses	of	
the	BiNSAIDs,	or	the	equivalent	molar	concentration	of	the	NSAIDs	(as	determined	by	
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MTT	assays,	Section	2.3.2),	an	increased	proportion	of	HCT-8	cells	had	detached	from	
the	 dish	 surfaces	 and	 were	 observed	 floating	 in	 the	 medium	 of	 all	 drug-treated	
samples.		The	floating	debris	could	be	identified	as	intact	cells	and	apoptotic	bodies	as	
indicated	 by	 the	 variation	 in	 size	 of	 the	material.		 As	 observed	 in	 Figure	 2.7b–g,	 an	
increased	proportion	of	BiNSAID-	and	NSAID-treated	cell	populations	appeared	to	be	
rounded	 and	 smaller	 in	 size,	 in	 contrast	 to	 the	 cells	 treated	 with	 vehicle	 alone	
(Fig.	2.7a).		Morphological	changes	of	the	cell	membrane	are	consistent	with	apoptosis	
and	 include	 the	 formation	 of	 blebs,	 which	were	 clearly	 evident	 in	 HCT-8	 cells	 after	
treatment	with	BiNSAIDs	or	NSAIDs	(Fig.	2.7b–g).		These	were	seldom	observed	in	the	
vehicle-treated	 dishes	 (Fig.	2.7a).	 	The	 diflH-treated	 (Fig.	2.7g)	 cells	 showed	 less	
evidence	of	cell	membrane	blebbing	compared	to	the	other	compounds	tested,	which	
is	 reflective	 of	 the	 lower	 toxicity	 of	 diflH	 towards	 the	HCT-8	 cells	 determined	 using	
MTT	 assays.	 Furthermore,	 a	 proportion	 of	 the	 diflH-treated	 cell	 population,	
maintained	their	fibroblastic	shape	(Fig.	2.7g),	an	expected	observation	given	that	the	
diflH-treated	 cells	 were	 treated	 at	 a	 concentration	 lower	 than	 the	 IC50	value	
determined	by	MTT	assay	(225	μM	and	401	μM,	respectively).	
2.3.3.2 AnnV/7AAD	assays	
Flow	 cytometric	 analysis	 employing	 the	 use	 of	 the	 fluorescent	 probes	 AnnV	 and	
7AAD	was	used	to	determine	whether	BiNSAIDs	and	NSAIDs	induce	the	same	mode	of	
cell	 death	 in	 HCT-8	 cells.		 As	 demonstrated	 in	 Figure	 2.8a,	 24-h	 treatment	 with	
Bi(tolf)3,	 Bi(mef)3,	 Bi(difl)3	 or	 the	 respective	 free	 NSAIDs	 resulted	 in	 a	 substantial	
increase	 in	 the	 proportion	 of	 cells	 in	 the	 AnnV+/7AAD−	 population	 (bottom	 right	
quadrant),	 and	 AnnV+/7AAD+	 population	 (top	 right	 quadrant),	 but	 no	 appreciable	
increase	in	AnnV-/7AAD+	population	(top	left	quadrant).		As	an	appreciable	increase	in	
the	 population	 of	 AnnV+/7AAD−	 cells	 was	 observed,	 with	 little	 increase	 in	 the	
AnnV−/7AAD+	population,	it	appeared	that	cells	were	proceeding	through	an	apoptotic	
pathway	and	 thus	AnnV+/7AAD+	 could	be	defined	as	 late	apoptotic	 (rather	 than	 late	
apoptotic/necrotic).		 The	 overall	 proportions	 of	 dying	 cells	 (encompassing	 early	
apoptotic,	late	apoptotic	and	early	necrotic	cell	populations)	were	significantly	higher	
(P	 ≤	 0.001)	 in	 all	 BiNSAID-	 or	 NSAID-treated	 cells	 compared	 to	 the	 control	
cells	(Fig.	2.8b).		 When	 the	 total	 population	 of	 dying	 cells	 induced	 by	 each	 BiNSAID	
was	compared	to	that	for	the	respective	free	NSAID,	only	Bi(difl)3-treated	cells	showed	
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Figure	2.7:	Morphological	effects	following	24-h	treatment	with:	(a)	vehicle	(DMSO	2%	v/v);	
(b)	Bi(tolf)3	(15	μM);	(c)	tolfH	(45	μM);	(d)	Bi(mef)3	(40	μM);	(e)	mefH	(120	μM);	(f)	Bi(difl)3	
(75	μM);	and	(g)	diflH	(225	μM).		Images	were	viewed	using	the	20×	objective	lens	on	a	light	
microscope	equipped	with	a	Moticam	2000,	2.0MP	Live	Resolution	camera	system.		
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a	significantly	higher	proportion	of	cell	death	(P	≤	0.01)	compared	to	the	diflH-treated	
cells.		Following	24-h	treatment	with	the	vehicle,	the	majority	of	the	HCT-8	cells	were	
viable	(Fig.	2.8b	and	Table	2.5).		In	comparison,	treatment	with	Bi(tolf)3	(15	μM,	24	h)	
resulted	 in	 significant	 increases	 in	 the	 populations	 of	 early	 apoptotic,	 and	 late	
apoptotic	 cells	 (P	 ≤	 0.001	 and	P	 ≤	 0.05	 respectively,	 Table	 2.5).		 TolfH-treated	 cells	
showed	 a	 significant	 increase	 in	 early	 apoptotic	 and	 late	 apoptotic	 populations	
compared	 to	 vehicle-treated	 cells	 (P	≤	 0.001	 and	 P	 ≤	 0.01,	 respectively,	 Table	 2.5).		
While	 no	 statistical	 difference	was	 found	 between	 the	 proportion	 of	 early	 apoptotic	
cells	induced	in	Bi(tolf)3-treated	cells	compared	to	tolfH-treated	cells	(Table	2.5),	tolfH	
treatment	induced	a	significantly	greater	number	of	late	apoptotic	cells	(P	≤	0.05).		The	
total	 percentage	 of	 dying	 cells	 following	 treatment	 with	 Bi(mef)3	 and	 mefH	 were	
similar	(Fig.	2.8b,	Table	2.5,	P	>	0.05).		A	significant	increase	in	the	proportion	of	early	
apoptotic	 cells	 was	 observed	 in	 the	 Bi(mef)3-	 and	 mefH-treated	 cells	 compared	 to	
vehicle-treated	cells	(both	P	≤	0.01,	Table	2.5)	,	although	mefH-treated	cells	induced	a	
higher	proportion	of	 early	 apoptotic	 cells	 compared	 to	Bi(mef)3	 (P	≤	0.01).	 	Notably,	
there	was	 a	 3-fold	 increase	 in	 the	percentage	 of	 late	 apoptotic	 cells	 in	 the	Bi(mef)3-
treated	 cell	 population	 compared	 to	 the	 mefH-treated	 cell	 population	 (P	 ≤	 0.01,	
Table	2.5).	 	While	 both	 treatments	 increased	 the	 proportion	 of	 late	 apoptotic	 cells,	
only	the	Bi(mef)3-treated	cell	population	was	found	to	be	significant	compared	to	the	
control	 (P	≤	 0.001,	 Table	 2.5).		 Following	 24-h	 treatment	 with	 Bi(difl)3	 or	 diflH,	
significant	 increases	 in	 the	percentage	of	 early	 apoptotic	 cells	 (both	P	≤	0.001)	were	
observed	(Table	2.5);	however,	treatment	with	Bi(difl)3	induced	a	2.4-fold	increase	in	
the	 proportion	 of	 late	 apoptotic	 cells	 (P	 ≤	 0.001	 compared	 to	 the	 control;	 Fig.	2.8b)	
compared	 to	 treatment	 with	 diflH	 (P	 ≤	 0.001	 compared	 to	 Bi(difl)3;	 Fig.	2.8b).		
Importantly,	 no	 significant	 increase	 in	 the	 proportion	 of	 early	 necrotic	 cells	 was	
observed	in	any	of	the	BiNSAID-	or	NSAID-treated	cell	populations	(Table	2.5).		Overall	
these	results	indicate	that	Bi(tolf)3,	Bi(mef)3,	Bi(difl)3,	and	the	respective	free	NSAIDs,	
induce	cell	death	via	apoptosis.	
Chapter	2.	Stability,	toxicity	and	PGE2	inhibition	of	BiNSAIDs	
90	
	
	
Figure	 2.8:	 Flow	 cytometric	 analysis	 of	 cell	 death	 in	 HCT-8	 cells	 treated	 for	 24	 h	 with	
vehicle	(RPMI-1640,	2%	v/v	DMSO;	Control),	BiNSAIDs	(Bi(tolf)3	(15	µM),	Bi(mef)3	(40	µM)	or	
Bi(difl)3	(75	µM));	or	the	respective	equimolar	free	NSAIDs.	(a)	Bivariate	flow	cytometric	plots	
of	 AnnV	 fluorescence	 versus	 7AAD	 fluorescence.	 Bottom	 left	 quadrant	 represents	 viable	
cells	(AnnV−/7AAD−);	bottom	right	quadrant	represents	early	apoptotic	cells	(AnnV+/7AAD−);	
top	 right	 quadrant	 represents	 late	 apoptotic/late	 necrotic	 cells	 (AnnV+/7AAD+);	 top	 left	
quadrant	 represents	 early	 necrotic	 cells	 (AnnV−/7AAD+).		 Data	 are	 representative	 of	 n	 =	 3	
replicates.		(b)	Percentage	of	early	apoptotic	and	late	apoptotic	cells	based	on	flow	cytometry	
analysis.	 	 Each	 segment	 represents	 the	mean	 ±	 s.d.	 (n	 =	 3	 replicates	 from	 one	 experiment).		
Statistical	 significance	 of	 the	 population	 of	 dying	 cells	 (encompassing	 early	 apoptotic,	 late	
apoptotic	 and	 necrotic	 cell	 populations)	 compared	 to	 the	 control	 is	 indicated	 by	
***	=	P	≤	0.001.	 Statistical	 significance	 of	 the	 BiNSAID-treated	 samples	 compared	 to	 the	
respective	NSAID-treated	samples	is	indicated	by	‡	=	P	≤	0.001.		The	viable	(AnnV−/7AAD−)	and	
early	necrotic	(AnnV−/7AAD+)	cell	populations	have	been	omitted	from	the	graph	for	clarity.	
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Table	2.5:	Cell	populations	determined	by	flow	cytometric	analysis	of	HCT-8	cells	treated	
for	 24	 h	 with:	 vehicle	 (RPMI-1640,	 2%	 v/v	 DMSO),	 BiNSAIDs	 (Bi(tolf)3	 (15	 µM),	
Bi(mef)3	(40	µM),	or	Bi(difl)3	(75	µM)),	or	the	respective	equimolar	free	NSAIDs.	
	 	 Percentage	of	cells	(%)	 	
	
Treatment	
Viable	
AnnV–/7AAD–	
Early	apoptotic	
AnnV+/7AAD–	
Late	apoptotic	
AnnV+/7AAD+	
Early	necrotic	
AnnV–/7AAD+	
Vehicle	 86.7	±	1.0	 								7.8	±	0.5	 4.8	±	0.8	 0.7	±	0.2	
Bi(tolf)3,	15	µM	 		46.4	±	12.2	 41.0	±	6.9***	 12.3	±	5.8*	 0.3	±	0.2	
tolfH,	45	µM	 29.5	±	3.1	 48.7	±	2.2***		 				21.5	±	1.4**	† 	 0.3	±	0.2	
Bi(mef)3,	40	µM	 40.9	±	3.8	 39.6	±	4.6***	 			18.8	±	0.8***	 0.8	±	0.4	
mefH,	120	µM	 41.9	±	7.0	 			51.5	±	6.1***	† 	 6.15	±	1.4	‡	 0.6	±	0.3	
Bi(difl)3,	75	µM	 53.2	±	3.1	 26.2	±	2.0***	 			19.5	±	1.7***	 1.2	±	0.3	
diflH,	225	µM	 63.3	±	2.8	 27.5	±	1.5***	 8.20	±	2.4	‡	 1.1	±	0.7	
Each	value	represents	mean	±	s.d.	(n	=	3	replicates	from	one	experiment).	
Statistical	significance	compared	to	the	control	is	indicated	by	*	=	P	≤	0.05,	**	=	P	≤	0.01,	***	=	P	≤	0.001.	
Statistical	 significance	 of	 the	 BiNSAID	 compared	 to	 the	 corresponding	 free	 NSAID	 is	 indicated	 by	
† 	=	P	≤	0.05,	or	‡	=	P	≤	0.001.			
2.3.4 The	effect	of	BiNSAIDs	on	PGE2	production	by	HCT-8	cells	
The	 production	 of	 PGE2	 by	 HCT-8	 cells	 was	 determined	 in	 order	 to	 establish	
whether	BiNSAIDs	were	able	to	inhibit	arachidonic	acid	conversion	to	PGE2	by	COX	at	
a	 similar	 extent	 to	 the	 respective	 free	 NSAIDs.		 As	 shown	 in	 Figure	 2.9,	 the	
concentration-response	 curves	 are	 presented	 for	 the	 NSAID	 concentration	
(recognising	that	there	are	3	mole	of	NSAID	per	mole	of	BiNSAID).		Figure	2.9a	shows	
that	 the	 Bi(tolf)3	 and	 Bi(mef)3	 complexes	 inhibited	 PGE2	 production	 in	 a	
concentration-dependent	manner,	which	paralleled	 the	 inhibition	displayed	by	 tolfH	
and	 mefH	 alone,	 respectively.	 	The	 concentration-response	 curve	 of	 Bi(difl)3	 also	
mirrored	 the	 inhibition	 of	 diflH	 (Fig.	 2.9b).	 	 However,	 PGE2	 production	 increased	
comparative	 to	 control	 cells	 at	 treatment	 concentrations	 of	 1–100	 µM	 difl,	 but	
decreased	at	higher	concentrations	(300–1000	µM	difl).	 	Although	the	concentration-
response	curve	obtained	for	Bi(difl)3	mirrored	the	effect	of	diflH,	PGE2	production	was	
less	 effectively	 inhibited	 at	 higher	 concentrations	 of	 Bi(difl)3	 compared	 to	
diflH	(Fig.	2.9b).		The	concentration-response	curve	of	aspH	exhibited	a	concentration-
dependent	decrease	in	PGE2	production	(Fig.	2.9b)	similar	to	tolfH	and	mefH.	
Inspection	of	the	IC50	values	(50%	reduction	of	PGE2	production	compared	to	the	
control)	determined	from	the	PGE2	assays	(Table	2.6)	showed	that	the	COX	inhibition	
of	the	BiNSAIDs/NSAIDs	in	HCT-8	cells	increased	in	the	order:	difl	<	mef	<	tolf,	which	
paralleled	 the	 toxicity	 response	 determined	 by	 the	 MTT	 assays	 (Section	2.3.2).		
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The	PGE2	 production	 IC50	 values	 for	 tolfH	 and	 Bi(tolf)3	 were	 lower	 than	 that	 of	
aspH	(Table	2.6),	 while	 mefH	 and	 Bi(mef)3	 showed	 comparable	 inhibitory	 activity	
to	aspH	(Table	2.6).	 	Substantially	higher	PGE2	production	IC50	values	were	observed	
for	diflH	and	Bi(difl)3	compared	to	aspH	(Table	2.6).		Treatment	with	BSS	(1–300	µM)	
caused	 no	 significant	 reduction	 in	 PGE2	 production	 compared	 to	 control	
cells	(Appendix	1.4).			
	
	
	
Figure	 2.9:	 Concentration-response	 curve	 obtained	 from	 the	 PGE2	 assays	 of	 HCT-8	 cells	
treated	 (4	 h)	 with:	 (a)	 tolfH,	 Bi(tolf)3,	 mefH,	 Bi(mef)3;	 and	 (b)	 diflH,	 Bi(difl)3,	 and	 aspH,	
followed	by	arachidonic	acid	(20	µM,	30	min).		Results	are	expressed	as	the	mean	±	s.d.	(n	=	3	
from	three	independent	experiments,	with	the	exception	of	aspH,	n	=	2	from	two	independent	
experiments).		
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Table	2.6:	 IC50	values	determined	by	PGE2	assays	following	4-h	treatment	of	HCT-8	cells	
with	the	specified	compounds.	
	
Treatment	
IC50	(µM)a	
									Ligand	(LH)																		Complex	[Bi(L)3]	
IC50	ratio	
LH:Bi(L)3	
tolf	 1.3	±	0.7	 		0.5	±	0.3	 2.6	
mef	 23	±	16	 10	±	8	 2.3	
difl	 340	±	180	 203	±	32	 1.7	
asp	 														13	±	4	 	 	
BSS	 n.d.	 	 	
aIC50	value	was	determined	from	three	independent	experiments	(with	the	exception	of	aspH,	which	was	
determined	from	two	independent	experiments).	n.d.	=	not	determined.	 	
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2.4 Discussion	
2.4.1 NMR	stability	studies	
NMR	spectroscopy	was	used	 to	 investigate	 the	structural	 stability	of	BiNSAIDs	 in	
RPMI-1640	 cell	medium	 to	 gain	 an	 understanding	 of	 the	 possible	 biologically	 active	
species	 and	 interactions	 that	 give	 rise	 to	 the	 observed	 toxicity	 (examined	 in	
Section	2.3.2),	 cell	 uptake	 and	 localisation	 of	 the	 Bi	 (discussed	 in	 Chapter	 3).		 The	
sparing	solubility	of	BiNSAIDs	in	aqueous	solutions	and	a	number	of	common	organic	
solvents	 (such	 as	 methanol,	 acetonitrile	 and	 chloroform)	 limited	 the	 analytical	
techniques	which	could	be	used	for	the	stability	studies;	however,	the	high	solubility	
of	 the	 compounds	 in	 DMSO	 meant	 that	 NMR	 spectroscopy	 was	 suitable.		
Unfortunately,	 the	 low	 sensitivity	 of	 1H	NMR	 spectroscopy	 for	 the	 complexes	 at	 the	
low	concentrations	employed	in	cell	assays	(40	μM)	meant	that	it	was	necessary	to	use	
higher	concentrations	of	the	BiNSAIDs.		It	should	be	noted	that	little	to	no	precipitate	
was	observed	 in	 the	 cell	medium	at	 the	BiNSAID	concentrations	used	 for	 cell	 assays	
and	as	such	the	NMR	study	(~	600	μM	Bi)	represents	the	most	extreme	case	scenario	
performed	in	order	to	explore	what	potential	products	might	form.		
The	 NMR	 studies	 were	 limited	 to	 studying	 the	 chemical	 shifts	 of	 the	 1H	 and	
13C	signals.		Theoretically,	the	209Bi	signal	(chemical	shift	range	of	~	5000	ppm)	could	
be	used	to	study	the	environmental	symmetry	of	the	Bi	nuclei,	and	hence	any	changes	
in	 the	 complexation	 of	 the	 NSAIDs.		 Bi	 has	 ideal	 properties	 for	 NMR	 studies	 due	 to	
100%	 natural	 abundance	 of	 209Bi	 and	 its	 high	 receptivity	 (0.144	 relative	 to	 1H,	 and	
8.48	×	102	relative	to	13C)	[59,	60].		An	attempt	was	made	to	study	the	209Bi	nuclei	in	
the	present	study;	however,	 this	proved	unsuccessful	due	to	difficulties	tuning	to	
209Bi	 nuclear	 resonance	 frequency	 with	 the	 broadband	 probe	 of	 the	 NMR	
spectrometer	used	 for	 the	NMR	studies	 (Dr	Wilford	Lie,	 personal	 communication).		
In	 the	absence	of	 instrument	 limitations,	a	recent	review	[60]	commented	on	the	
difficult	nature	of	recording	209Bi	spectra	due	to	the	broad	signal	that	it	produces,	
and	as	a	result	there	are	few	Bi	NMR	studies	reported	in	the	literature.	
The	NMR	results	(Section	2.3.1)	indicated	that	the	stability	of	the	BiNSAIDs	in	cell	
medium	might	 be	 influenced	 directly	 by	 the	 structure	 of	 the	 NSAID	 ligands,	 since	 a	
marked	 effect	 in	 the	 stability	 of	 the	 BiNSAIDs	 was	 observed	 by	 the	 substitution	 of									
–Cl	(tolfH)	for	–CH3	(mefH).	 	The	difference	in	the	stability	of	Bi(tolf)3	and	Bi(mef)3	is	
unlikely	 to	 be	 related	 to	 physicochemical	 properties	 of	 the	 free	 NSAIDs	 because	
similar	 values	 are	 reported	 for	 both	 the	 pKa	 [61-63]	 and	 logP	 [64]	 values	 of	 tolfH	
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and	mefH.		It	is	notable	that	the	tolfH	and	mefH	molecules	differ	only	by	the	presence	
of	 an	 electron-withdrawing	 group	 (–Cl)	 and	 an	 electron-donating	 group	 (–CH3).		
However,	these	groups	are	located	on	the	opposite	phenyl	ring	of	molecule	to	the	Bi–
carboxylate	bond;	as	such	the	atomic	distance	is	likely	to	be	too	far	away	to	have	any	
through-bond	 influence	 that	 affects	 the	 stability	 of	 the	 Bi–carboxylate	 bond.		
Ultimately,	 further	 studies	 would	 be	 required	 to	 determine	 the	 exact	 nature	 of	 the	
interaction	of	Bi(tolf)3	and	Bi(mef)3	in	cell	medium.	
The	NMR	 studies	 suggested	 that	 following	 incubation	of	Bi(difl)3	 in	 cell	medium,	
ligand	exchange	reactions	may	be	 facilitated	by	 the	high	concentrations	of	D-glucose	
present	 in	 RPMI-1640	(~11	 mM	 [65]).	 	 It	 is	 postulated	 that	 partial	 substitution	 by	
glucosyl	on	to	the	Bi	complex	could	potentially	result	in	the	formation	of	Bi(difl)2glu	or	
Bi(difl)glu2	 (where	 glu	 =	 glucosyl)	 complexes;	 however,	 further	 studies	 would	 be	
required	 to	 confirm	 this.	 The	 involvement	 of	 glucose	 should	 be	 further	 studied	 to	
explore	 the	 likelihood	 of	 this	 occurring	 in	 blood	wherein	 the	 normal	 blood	 glucose	
concentration	is	approximately	5	mM	[66].	
While	 the	 NMR	 studies	 performed	 in	 the	 current	 study	 provide	 some	 useful	
insights	 into	 the	stability	of	 the	BiNSAIDs	 in	cell	medium,	 it	has	been	suggested	 that	
the	use	of	solid-state	NMR	could	be	another	suitable	technique	to	study	the	stability	of	
the	 BiNSAIDs	 following	 incubation	 of	 the	 complexes	 in	 various	 biological	
media	(Professor	Philip	Andrews,	personal	communication).		One	of	the	disadvantages	
of	solid-state	NMR	is	that	it	can	take	up	to	three	days	to	run	one	some	sample,	and	3-h	
warm-up	 time	 is	 required	 prior	 to	 replacing	 the	 cryo-probe	 with	 an	 ambient	
temperature	 solid-state	 probe	 (Dr	 Wilford	 Lie,	 personal	 communication).		
Additionally,	given	that	inorganic	samples	typically	require	100–200	mg	of	compound	
for	each	measurement	[67]	and	the	limited	quantities	of	BiNSAIDs	synthesised	for	the	
studies	described	in	this	Thesis,	the	use	of	solid	state	NMR	was	unfeasible.		
2.4.2 In	vitro	cytotoxicity	towards	cancer	cells	
In	order	to	determine	 if	a	 lead	compound	has	any	potential	 for	development	as	a	
chemotherapeutic	 drug,	 the	 in	 vitro	 toxicity	 towards	 tumour	 cell	 lines	 needs	 to	 be	
determined	 first	 [68].	 	 As	 discussed	 in	 Section	 2.1.2,	 the	 BiNSAIDs	 exhibit	 limited	
solubility	 in	 aqueous	 solutions	 (including	 biological	 medium)	 and	 some	 organic	
solvents.		Following	range	finding	studies	to	determine	feasible	DMSO	concentrations,	
the	 BiNSAIDs	were	 solubilised	 in	 DMSO	 (final	 concentration	 2%	 v/v)	 prior	 to	 their	
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addition	to	cell	medium	for	 in	vitro	 testing	against	 the	HCT-8	cells.	 	While	 the	use	of	
DMSO	 should	 be	 revisited	 for	 in	 vivo	 testing,	 the	 solubility	 of	 the	 BiNSAIDs	 was	
substantially	improved	in	order	to	introduce	the	complexes	into	the	cell	medium	for	in	
vitro	 testing.	 	In	 addition,	 the	 range	 finding	 ensured	 the	 optimal	 balance	 between	
minimal	 DMSO	 toxicity	 and	 maximal	 solubilisation	 of	 the	 BiNSAIDs	 and	 NSAIDs,	
allowing	for	the	successful	determination	of	IC50	values	(Table	2.4)	and	comparison	of	
the	toxicity	of	the	BiNSAIDs	to	each	other	and	the	respective	NSAIDs.	
The	MTT	assays	(Section	2.3.2)	showed	that	the	order	of	toxicity	of	the	BiNSAIDs	
paralleled	the	response	exhibited	by	the	free	NSAIDs	(tolfH	>	mefH	>	diflH),	suggesting	
that	NSAIDs	are	primarily	responsible	for	the	toxicity	of	the	BiNSAIDs.		Additionally,	if	
the	 IC50	 ratio	 LH:BiL3	 was	 close	 to	 3,	 it	 may	 be	 assumed	 that	 the	 NSAIDs	 are	
predominantly	responsible	for	the	toxicity	of	the	BiNSAIDs	(acknowledging	there	are	
3	mole	of	NSAID	per	mole	of	Bi).	 	The	IC50	ratios	of	tolfH:Bi(tolf)3	and	mefH:Bi(mef)3	
were	 found	 to	be	2.3	 and	2.7,	 respectively	 (Table	2.4).	 	While	Bi(tolf)3	 exhibited	 the	
highest	IC50	value	of	the	three	BiNSAIDs	tested,	the	IC50	ratio	tolfH:Bi(tolf)3	potentially	
indicated	 that	 tolf	 is	 slightly	 less	 toxic	 to	 HCT-8	 cells	 when	 complexed	 to	 Bi.	
Alternatively,	 the	 IC50	 ratio	 of	 mefH:Bi(mef)3	 was	 closer	 to	 3,	 potentially	 indicating	
that	 complexation	 of	 mef	 to	 Bi	 had	 little	 effect	 on	 the	 toxicity	 of	 mefH.		 Although	
Bi(difl)3	was	the	least	toxic	of	the	three	BiNSAIDs	when	the	ratio	of	the	IC50	values	was	
considered	 (diflH:Bi(difl)3	 =	 5.0,	 Table	 2.4),	 	 Bi(difl)3	 showed	 substantially	 higher	
toxicity	 than	 that	 expected	 for	 diflH,	 indicating	 that	 difl	 was	 more	 toxic	 when	
complexed	to	Bi.		There	are	a	number	of	factors	that	may	influence	the	toxicity	of	the	
BiNSAIDs	 towards	 the	 HCT-8	 colon	 cancer	 cells	 and	 the	 observed	
differences/similarities	 to	 the	 NSAIDs:	 (i)	 stability	 in	 cell	 medium	 (Sections	2.3.1.1	
and	2.4.1),	 (ii)	intrinsic	 physicochemical	 properties,	 and	 (iii)	 cellular	 uptake	 (to	 be	
discussed	in	Chapter	3).	
The	NMR	stability	studies	suggested	that	Bi(tolf)3	displayed	greater	stability	than	
Bi(mef)3	 following	 incubation	 in	 cell	medium	 (Section	 2.3.1.1);	 however,	 the	 overall	
coordination	(or	lack	thereof)	of	Bi	to	the	NSAID	appeared	to	have	little	 influence	on	
the	 toxicity	 of	 Bi(tolf)3	 and	 Bi(mef)3	 compared	 to	 the	 corresponding	 free	 NSAIDs.		
As	the	toxicity	of	Bi(tolf)3	was	slightly	lower	than	the	corresponding	concentration	of	
tolfH,	 it	 is	 plausible	 that	 the	 increased	 stability	 of	 Bi(tolf)3	 may	 be	 influencing	 the	
toxicity	of	the	tolf	ligands.			
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In	contrast,	Bi(difl)3	was	substantially	more	toxic	than	the	analogous	diflH.	 	There	
are	two	possible	reasons	for	this;	the	first	explanation	is	the	contributing	toxicity	of	Bi.	
Reference	 to	 Table	 2.4	 shows	 that	 diflH	 exhibits	 an	 IC50	 value	 of	 403	 µM.	 	When	
considering	BiCl3,	which	possesses	a	conceivably	non-toxic	anion	(Cl−),	it	is	noted	the	
IC50	value	(IC50	=	383	µM)	is	comparable	to	diflH	that	indicates	that	an	additive	effect	
would	be	more	noticeable.		The	second	possible	explanation	for	the	increased	toxicity	
of	Bi(difl)3	(versus	diflH)	towards	HCT-8	cells	 is	the	NMR	evidence	for	glucose	in	the	
sample	 obtained	 from	 the	 incubation	 of	 Bi(difl)3	 in	 cell	 medium.	 	This	 raises	 the	
question	of	whether	 glucose	 is	potentially	 coordinating	with	Bi(difl)3	 and	 increasing	
its	 toxicity	 compared	 to	 free	 diflH.		 For	 instance,	 it	 might	 be	 possible	 that	 the	
coordination	 of	 glucosyl	 ligands	 to	 Bi	 assists	 the	 uptake	 of	 the	 complex	 via	 glucose	
uptake	mediated	 transporters.	 	This	would	be	 expected	 to	be	greater	 in	 cancer	 cells	
since	they	have	a	high	affinity	for	glucose	[69,	70].		In	other	studies	by	Dillon	and	co-
workers	[71],	Bi(difl)3	showed	1.2-fold	lower	toxicity	against	HepG2	liver	cancer	cells	
compared	 to	 HCT-8	 cells,	 as	 assessed	 by	 the	MTT	 assay.	 	 Additionally,	 proportional	
enhancement	of	toxicity	(Bi:NSAID	IC50	ratio	3.6)	was	observed	[71].	 	One	hypothesis	
put	 forth	 to	 rationalise	 this	 observation	 was	 the	 content	 of	 glucose	 in	 the	 cell	
medium	[71].		Interestingly,	the	culture	medium	that	was	used	to	maintain	the	HepG2	
during	the	MTT	assays	contained	a	lower	concentration	of	D-glucose	than	RPMI-1640	
used	 in	 the	 present	 study	 (5.5	mM	and	11.1	mM,	 respectively).	 Therefore	 it	may	be	
possible	 that	 the	 increased	 concentration	 of	 D-glucose	 in	 RPMI-1640	 increases	 the	
propensity	 of	 Bi(difl)3	 to	 undergo	 ligand	 exchange	 reactions	 with	 glucose	[71].	
In		future	 experiments,	NMR	 studies	 could	 be	 performed	 to	 validate	 this	 hypothesis.		
This	would	involve	studies	of	Bi(difl)3	in	DMEM	for	comparison	to	the	result	obtained	
in	this	Thesis.		
The	order	of	toxicity	of	tolfH	>	mefH	>	diflH,	may	be	related	to	the	physicochemical	
properties	 of	 the	molecules.	 	The	 reported	 logP	 values	 of	 tolfH,	 mefH	 and	 diflH	 are	
very	 similar	 (4.94,	 4.79	 and	5.20,	 respectively)	 [64].	 	These	minor	 variations	 in	 logP	
and	the	lack	of	correlation	with	the	toxicity	suggest	the	logP	is	not	accountable	for	the	
observed	 differences	 in	 toxicity	 or	 cellular	 uptake.			Additionally,	 the	 NSAIDs	 have	
reported	 pKa	 values	 in	 a	 similar	 range	 (3.5–4.3)	[61],	 all	 of	 which	 lie	 well	 below	
pH	7.4	(the	pH	of	RPMI-1640).	 	The	main	differences	in	the	NSAID	structures	include	
the	 structural	 incorporation	 of	 the	 diphenylamine	 (tolfH	 and	mefH)	 or	 the	 diphenyl	
(diflH)	 [72-74].		 Diphenylamine	 NSAIDs	 (such	 as	 tolfH	 and	 mefH)	 were	 shown	 to	
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induce	 lactate	 dehydrogenase	 leakage	 in	 primary	 cells	 obtained	 from	 isolated	 rat	
hepatocytes,	 more	 significantly	 than	 diflH,	 at	 the	 same	 concentration	 [72].	 	The	
absence	of	 an	 amine	 in	 the	 structure	of	 diflH	might,	 therefore,	 result	 in	 the	 reduced	
toxicity	 observed	 in	 this	 study.	 	 The	 current	 study	 showed	 that	 the	 substitution	 of									
–CH3	(mef)	for	–Cl	(tolf)	resulted	in	almost	a	3-fold	increase	in	toxicity	associated	with	
both	the	free	NSAID	and	BiNSAIDs.	 	This	result	parallels	other	studies	whereby	tolfH	
reportedly	 exhibited	 higher	 activity	 than	 mefH	 against	 BT474	 and	 SKBR3	 breast	
cancer	cells	[52].	 
The	 toxicity	 of	 the	 BiNSAIDs	was	 substantially	 higher	 than	 the	 two	 reference	 Bi	
compounds,	 BiCl3	 and	 BSS.	 	Notably,	 the	 IC50	 values	 obtained	 for	 the	 BiNSAIDs	 are	
comparable	to	that	of	the	range	of	the	anti-cancer	drug,	cisplatin,	although	it	should	be	
recognised	that	cisplatin	has	achieved	greatest	clinical	effectiveness	against	testicular	
and	 ovarian	 cancers	 [75].	 	 Although	nanomolar	 toxicity	 is	 desirable	when	 screening	
for	lead	compounds	for	anti-cancer	drug	development,	the	moderate	toxicity	displayed	
by	 the	 BiNSAIDs	 and	 the	 similar	 toxicity	 compared	 to	 cisplatin	 is	 an	 encouraging	
result.	 	Ultimately,	 the	 BiNSAIDs	 will	 need	 to	 be	 evaluated	 for	 chemotherapeutic,	
chemopreventive	and	gastroprotective	activity	in	animal	models	in	order	to	determine	
whether	they	have	any	potential	use	as	chemotherapeutic	or	chemopreventive	drugs	
in	humans.		However,	the	in	vitro	cytotoxicity	of	the	BiNSAIDs	determined	in	this	study	
suggests	 that	 further	 study	 is	 warranted	 into	 the	 interactions	 of	 the	 BiNSAIDs	 in	
biological	systems.	
2.4.3 Cell	death	assays	
The	 results	 from	 the	 phase	 contrast	 microscopy	 and	 the	 AnnV/7AAD	 assays	
indicated	 that	 apoptosis	 is	 the	 primary	 mode	 of	 cell	 death	 induced	 by	 exposure	 of	
HCT-8	 cells	 to	Bi(tolf)3,	Bi(mef)3,	 or	Bi(difl)3,	 and	 the	 respective	 free	NSAIDs.	 	These	
results	are	 important	as	 they	show	that	all	 three	BiNSAIDs	 induce	the	same	mode	of	
cell	 death	 as	 the	 respective	 uncomplexed	 NSAIDs.	 These	 results	 were	 also	 in	
agreement	with	 a	 number	 of	 published	 studies	 that	 have	 reported	 apoptosis	 as	 the	
mode	 of	 cell	 death	 induced	 by	 NSAIDs,	 including	 tolfH	 [42,	 44,	 45,	 48,	 50,	 76-79],	
mefH	[51,	 80]	 and	 diflH	[80,	 81]	 in	 other	 cancer	 cell	 lines	 in	 vitro.	 	 Additionally,	 a	
number	of	Bi	 compounds	have	been	reported	 to	 induce	cell	death	via	apoptosis	 in	a	
number	of	cancer	cell	lines	in	vitro	[82-86].	 	The	results	from	the	AnnV/7AAD	assays	
were	 in	 agreement	 with	 the	 toxicity	 determined	 by	 the	 MTT	 assays,	 whereby	 the	
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Bi(tolf)3	 or	 tolfH,	 Bi(mef)3	 or	 mefH,	 and	 Bi(difl)3	 treatments	 induced	 apoptosis	 in	
approximately	 47–70%	 of	 the	 HCT-8	 cell	 populations	 when	 treated	 with	 the	
approximate	IC50	concentration	(as	determined	from	the	MTT	assay).		Additionally,	the	
diflH	 treatment	 resulted	 in	 a	 smaller	 increase	 in	 the	 proportion	 of	 apoptotic	 cells	
(approximately	 37%	of	 the	 cell	 population),	which	 is	 also	 consistent	with	 the	 lower	
toxicity	as	the	concentration	of	diflH	applied	in	the	assay	(225	μM)	was	lower	than	its	
IC50	value	(403	μM),	and	the	healthier	physical	appearance	of	the	cells	observed	using	
phase	contrast	microscopy	(presented	in	Section	2.3.3.1).	
The	present	 study	confirmed	 that	apoptosis	 is	 the	mode	of	 cell	death	 induced	by	
BiNSAID	 and	 NSAID	 treatment	 in	 HCT-8	 cells.	 	As	 discussed	 in	 Section	 2.1.3.2,	
apoptosis	is	often	described	as	a	‘programmed’	form	of	cell	death.		Apoptosis	can	occur	
via	two	distinct	pathways	termed	‘extrinsic’	and	‘intrinsic’.		Apoptosis	via	an	extrinsic	
signaling	 pathway	 results	 from	 transmembrane	 receptor-mediated	 interactions	
involving	death	receptors	that	are	members	of	the	tumor	necrosis	factor	receptor	gene	
superfamily	 [32].	 	Alternatively,	 apoptosis	 initiated	 via	 the	 intrinsic	 signaling	
pathways	are	mitochondrial-initiated	events	involving	non-receptor-mediated	stimuli	
that	produce	 intracellular	 signals	 that	 act	directly	on	 targets	within	 the	 cell	 (further	
details	 on	 these	 mechanisms	 are	 reviewed	 in	 [32]).		 The	 MTT	 assay	 is	 a	 useful	
indicator	of	toxicity,	which	relies	on	functioning	mitochondria	in	metabolically	active	
cells	to	convert	MTT	to	formazan	(discussed	in	Section	1.2.3.1).		When	considered	with	
the	 results	 from	 the	 cell	 death	 studies,	 the	 reduction	 in	 mitochondria	 function	
observed	 in	 the	 MTT	 assays	 may	 suggest	 that	 the	 mitochondria	 are	 involved	 in	
BiNSAID-	 and	NSAID-induced	apoptosis,	 and	 thus	 the	BiNSAIDs/NSAIDs	may	 trigger	
cell	death	through	the	intrinsic	apoptotic	pathway.	 	While	it	is	recognised	that	COX-2	
contributes	 to	 the	 anti-apoptotic	 effects	 and	 proliferation	 of	 cancer	 cells,	 there	 are	
reports	 that	 suggest	 that	 NSAID-induced	 cell	 death	 is	 also	 mediated	 via	 non-COX-2	
regulated	pathways	 (discussed	 in	Section	1.2.4).	 	 In	 the	present	 study,	 the	BiNSAIDs	
and	NSAIDs	 inhibited	 the	 production	 of	 PGE2,	 suggesting	 the	 compounds	 inhibit	 the	
COX	 enzymes	 (discussed	 further	 in	 the	 next	 Section	 2.4.4).		 However,	 it	 cannot	 be	
ignored	 that	 numerous	 studies	 have	 reported	 that	 diphenylamine	 NSAIDs	 (such	 as	
tolfH	 and	 mefH)	 can	 also	 cause	 uncoupling	 of	 oxidative	 phosphorylation	 in	
mitochondria	[73,	74,	87-89].		Furthermore,	mefH	and	diflH	showed	uncoupling	effects	
on	oxidative	phosphorylation	in	isolated	rat	mitochondria	[90],	and	primary	cells	from	
isolated	 rat	 hepatocytes	 [72]	 resulting	 in	 depletion	 of	 ATP.	 Overall,	 the	 exact	
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mechanisms	by	which	the	NSAIDs	and	BiNSAIDs	induce	apoptosis	and	why	the	three	
NSAIDs	in	this	study	show	variation	in	toxicity	cannot	be	drawn	conclusively	without	
further	 investigation.		 Further	 investigation	 could	 be	 performed	 in	 the	 future	 to	
determine	 the	 detailed	 molecular	 pathway	 involved	 in	 BiNSAID/NSAID	 induced	
cell	death.		
2.4.4 PGE2	production	
As	 discussed	 in	 Section	 2.1.4, the	 increased	 expression	 of	 COX-2	 has	 been	
established	 in	 many	 cancer	 cell	 types	 and	 the	 subsequent	 production	 of	
prostaglandins,	 including	 PGE2,	 is	 advantageous	 for	 neoplastic	 cell	 survival	 and	
proliferation.		As	such,	studying	the	ability	of	the	BiNSAIDs	to	inhibit	PGE2	production	
is	important	for	determining	the	chemopreventive	potential	of	the	complexes.	
The	PGE2	concentration-response	curves	showed	that	 the	BiNSAIDs	mirrored	 the	
effects	of	the	free	NSAIDs	after	4	h	exposure	to	the	HCT-8	cells.	 	This	is	an	important	
result	as	it	demonstrates	that	administration	of	the	BiNSAID	(wherein	the	NSAID	does	
not	 initially	 posses	 a	 free	 carboxylate)	 does	 not	 hinder	 the	 ability	 of	 the	 NSAID	 to	
target	 the	 COX	 enzymes.	 As	 no	 appreciable	 loss	 of	 cell	 viability	 was	
observed	(Appendix	 1.2a–c),	 it	 could	 be	 concluded	 that	 the	 reduction	 of	 PGE2	
production	 at	 increasing	 concentrations	 of	 BiNSAIDs/NSAIDs	 was	 not	 due	 to	 cell	
toxicity.	 	Additionally,	no	appreciable	decrease	in	the	viability	of	the	HCT-8	cells	was	
observed	following	24-h	treatment	with	aspH	(Appendix	1.5);	as	such	no	decrease	in	
viability	was	expected	 following	only	4-h	 treatment,	 confirming	 toxicity	of	aspH	was	
not	associated	with	reduced	PGE2	production.	
When	 the	 PGE2	 production	 concentration-response	 curves	 (Fig.	 2.9a)	 are	
compared	 to	 the	MTT	 assay	 concentration-response	 curves	 (Fig	 2.6),	 it	 is	 clear	 that	
Bi(tolf)3	 and	 Bi(mef)3	 paralleled	 the	 respective	 free	 NSAIDs	 whereby	 the	 BiNSAIDs	
were	 approximately	 three	 times	 more	 toxic	 than	 the	 respective	 free	 NSAIDs	
(representative	 of	 the	molar	 ratio	 of	 NSAID	 per	 BiNSAID).	 	 The	 results	 of	 the	 PGE2	
production	concentration-response	curves	of	Bi(difl)3	differed	(Figure	2.9b),	however,	
whereby	 diflH	 appeared	 to	 have	 slightly	 enhanced	 PGE2	 inhibition	 compared	 to	
Bi(difl)3	 (at	 higher	 concentrations	 of	 NSAID).	 Additionally,	 the	 potency	 of	 the	
reduction	 in	PGE2	 occurred	 in	 the	 same	order	 as	 the	 toxicity	 of	 the	NSAIDs	 (tolfH	<	
mefH	 <	 diflH),	 which	 may	 suggest	 a	 correlation	 between	 PGE2	 production	 and	 cell	
health.	 It	 was	 observed	 that	 the	 IC50	 values	 associated	 with	 the	 PGE2	
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inhibition	(Table	2.6),	were	 lower	 than	 the	 IC50	 values	 required	 to	 induce	 toxicity	 in	
the	HCT-8	cells	(Table	2.5).	
The	time	frame	of	the	PGE2	assays	compared	to	the	MTT	assays	used	to	determine	
the	 IC50	 values	 of	 the	 compounds	 (4	 h	 versus	 24	 h)	 reveals	 some	 insight	 into	 the	
intracellular	stability	of	the	complexes.		It	has	been	established	that	NSAIDs	must	have	
a	 free	carboxylate	 in	order	 to	 interact	with	 the	COX-1/-2	active	site	 [91].	 	Given	that	
the	 BiNSAIDs	 decreased	 PGE2	 production	 in	 a	 similar	 manner	 compared	 to	 the	
analogous	NSAIDs,	it	is	reasonable	to	assume	that	the	NSAID	ligand	must	be	liberated	
from	the	BiNSAID	complex,	allowing	a	free	carboxylate	to	interact	with	the	COX.		This	
is	 particularly	 significant	 in	 the	 case	 of	 Bi(tolf)3	 and	 Bi(difl)3	 as	 the	 stability	 results	
described	in	Section	2.3.1	suggest	that	these	complexes	remain	intact	in	the	medium;	
however,	 they	 can	 undergo	 hydrolysis/dissociation	 once	 inside	 the	 cells	 following	
interaction	with	 enzymes	 and	 competing	 ligands.	 	 Subsequently,	 it	 seems	 likely	 that	
the	 Bi(tolf)3	 and	 Bi(difl)3	 complexes	 are	 metabolised	 by	 intracellular	 processes	
relatively	quickly	(i.e.	<	4	h).		
The	ability	of	the	BiNSAIDs	and	NSAIDs	to	inhibit	PGE2	in	the	HCT-8	cell	 line	was	
studied	in	order	to	ensure	that	BiNSAIDs	showed	comparable	activity	within	a	cancer	
cell	line,	and	thus	provide	information	on	the	ability	to	reduce	PGE2	in	a	malignant	cell	
for	 chemopreventive	 potential.		 It	 is	 important	 to	 note	 that	 HCT-8	 cells	 have	 been	
shown	to	express	higher	levels	of	COX-1	than	COX-2	[55,	56,	92];	hence	the	preference	
for	BiNSAIDs	or	NSAIDs	for	COX-2	over	COX-1	in	HCT-8	cells	cannot	be	evaluated	from	
the	present	study.	 	Further	work	needs	to	be	performed	to	determine	the	expression	
of	 COX-1	 and	 COX-2	 in	 the	 HCT-8	 cells	 used	 in	 this	 study,	 especially	 as	 the	 level	 of	
expression	 of	 COX-1/-2	 by	 HCT-8	 cells	 varies	 between	 reports	 [55-57,	 92,	 93].		
It	would	also	be	of	value	to	study	the	inhibitory	activity	of	the	BiNSAIDs	compared	to	
the	NSAIDs	with	purified	COX	enzymes	in	an	acellular	environment	to	determine	if	the	
selectivity	for	COX-1/-2	is	affected	by	the	complexation	of	the	NSAID	to	Bi.		However,	
this	assay	would	not	take	into	account	the	conditions	experienced	by	the	BiNSAIDs	in	
the	cell	environment.	 	For	instance,	the	stability	of	the	complexes	in	cell	medium	and	
the	 intracellular	 fluids,	 cell	 uptake	 and	 any	 alterations	 in	 structure	 following	 cell	
uptake	and	subsequent	intracellular	metabolism	are	important	factors	that	affect	COX	
inhibition.	 	 As	 such,	 the	 cell-based	 assay	 as	 performed	 in	 the	 present	 study,	 and	 an	
enzyme-based	assay	utilizing	purified	COX-1/-2	would	provide	complementary	results	
and	should	be	evaluated	 in	conjunction.	 	The	results	 from	the	present	study	utilising	
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the	HCT-8	cell	model	should	be	compared	to	other	cell	lines	that	display	high	levels	of	
COX-2,	and	cells	with	essentially	no	COX-2	expression	(currently	being	performed	by	
Brown,	Dillon	and	Ranson,	personal	communication).		
Of	final	note	was	the	finding	that	diflH	increased	the	amount	of	PGE2	production	by	
HCT-8	 cells	 at	 low	 concentrations	 ranging	 from	1−100	 μM	 (Fig.	 2.9).	 	The	 increased	
production	 may	 be	 related	 to	 the	 gastroprotective	 activity	 reported	 by	 other	
authors	[53,	54].		This	result	may	indicate	that	the	concentration	of	Bi(difl)3	needs	to	
be	 considered	 carefully	 if	 the	 complex	 is	 tested	 in	 vivo	 for	 cancer	 prevention	 as	
treatment	with	 a	 dose	 that	 increases	 the	production	of	 PGE2	may	have	 the	 opposite	
result	 to	 the	 intended	 therapeutic	 effect.		 This	 is	 clearly	 an	 observation	 that	 will	
require	further	investigation.	
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2.5 Chapter	summary	
The	main	aim	of	this	chapter	was	to	use	 in	vitro	assays	to	determine	whether	the	
BiNSAIDs,	 Bi(tolf)3,	 Bi(mef)3,	 and	 Bi(difl)3,	 possess	 any	 chemotherapeutic	 or	
chemopreventive	 potential	 in	 a	 colon	 cancer	 (HCT-8)	 cell	 line.	 To	 this	 end,	 the	
following	studies	were	performed	with	the	subsequent	outcomes:		
i. NMR	 spectroscopic	 determination	 of	 the	 BiNSAID	 stability	 in	 RPMI-1640	
cell	medium	showed	that	Bi(tolf)3	is	relatively	stable,	whilst	mef	appeared	
to	 dissociate	 from	 Bi.	 	The	 1H	 NMR	 spectrum	 of	 Bi(difl)3	 suggested	 that	
D-glucose	in	the	cell	medium	may	interact	with	the	complex	resulting	in	the	
formation	of	a	new	species.		
ii. Examination	of	 in	 vitro	 toxicity	 towards	 cancer	 cells	 using	 the	MTT	assay	
demonstrated	 the	 ability	 of	 the	 complexes	 to	 eradicate	 transformed	 cells.		
Specifically,	the	BiNSAIDs	displayed	moderate	toxicity	towards	HCT-8	cells	
with	the	IC50	values	ranging	between	16–81	µM.		The	order	of	toxicity	of	the	
BiNSAIDs	was	Bi(difl)3	<	Bi(mef)3	<	Bi(tolf)3,	which	paralleled	the	order	of	
toxicity	 of	 the	 free	 NSAIDs.		 When	 considering	 the	 molar	 ratio	 of	 NSAID	
contained	in	the	BiNSAID	complexes,	Bi(tolf)3	and	Bi(mef)3	showed	similar	
activity	 to	 the	 free	 NSAIDs;	 the	 activity	 of	 diflH	 was	 improved	 when	
complexed	to	Bi.		
iii. The	mode	 of	 cell	 death	was	 determined	using	 phase	 contract	microscopy	
and	flow	cytometric	experiments.		Phase	contrast	microscopy	showed	that	
the	morphological	changes	in	HCT-8	cells	indicative	of	apoptosis	(including	
cell	 rounding,	 shrinking	 and	 membrane	 blebbing)	 were	 induced	 by	 the	
BiNSAIDs	 and	 the	 respective	 uncomplexed	 NSAIDs.		 Flow	 cytometric	
analysis	of	co-stained	(AnnV	and	7AAD)	cells	confirmed	that	both	BiNSAIDs	
and	 their	 respective	 NSAIDs	 induced	 cell	 death	 through	 apoptosis	 rather	
than	necrosis.	
iv. The	 ability	 of	 BiNSAIDs	 to	 inhibit	 COX	 and	 reduce	 PGE2	 production	 in	
HCT-8	 cells	 was	 determined.	 	 The	 BiNSAIDs	 inhibited	 the	 production	 of	
PGE2	by	the	HCT-8	cells	at	treatment	concentrations	comparable	to	the	free	
NSAIDs.		The	order	of	PGE2	inhibition	was	Bi(difl)3/diflH	<	Bi(mef)3/mefH	<	
Bi(tolf)3/tolfH.	
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Although	the	results	from	the	NMR	studies	suggest	that	the	BiNSAIDs	have	limited	
stability	 in	RPMI-1640	 cell	 culture	medium,	 the	BiNSAIDs	 (or	 the	 biologically	 active	
forms	 of	 these	 complexes)	 elicited	 micromolar	 toxicity	 towards	 HCT-8	 cells	 (as	
demonstrated	in	the	MTT	assays)	that	were	comparable	or	better	than	the	respective	
NSAIDs.	 	 Importantly,	 the	 presence	 of	 Bi	 did	 not	 adversely	 affect	 the	 toxicity	 or	 the	
ability	 of	 the	 NSAIDs	 to	 induce	 apoptosis	 or	 inhibit	 PGE2	 production.		 The	 superior	
stability	 in	 cell	 medium,	 increased	 toxicity,	 and	 highest	 PGE2	 inhibition	 of	 Bi(tolf)3	
compared	 to	 the	 Bi(mef)3	 and	 Bi(difl)3,	 suggests	 that	 Bi(tolf)3	 might	 be	 the	 best	
candidate	 for	 further	 testing	 using	 in	 vivo	 systems.		 However,	 the	 diversity	 in	 the	
results	warrants	 further	 investigation	 into	how	the	 three	BiNSAIDs	 interact	with	 the	
HCT-8	 cells.	 	Further	 work	 will	 be	 required	 to	 determine	 whether	 the	 molecular	
mechanisms	 involved	 in	 apoptosis	 are	 analogous	 between	 each	 BiNSAID	 and	
respective	free	NSAID.	
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HCT-8	cells	
	
	
	
Having	established	the	stability	of	the	BiNSAIDs	in	cell	medium	and	the	toxicity	of	the	
BiNSAIDs	towards	HCT-8	cells	in	Chapter	2,	it	was	of	interest	to	investigate	the	uptake	
of	 the	 complexes.	 	 The	 focus	 of	 this	 work	 was	 to	 quantify	 the	 cellular	 Bi	 following	
treatment	 with	 BiNSAIDs	 to	 determine	 if	 there	 were	 any	 correlations	 between	 Bi	
uptake	 and	 BiNSAID	 stability	 or	 toxicity.	 	 Additionally,	 studies	 of	 the	 subcellular	
distribution	of	Bi	were	performed	on	HCT-8	cells	and	the	results	were	discussed	with	
respect	 to	 the	 stability	 results	 (Chapter	 2)	 and	 potential	 intracellular	 targets	 of	 the	
BiNSAIDs.	
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3.1 Introduction	
As	 introduced	 in	 Section	 2.1,	 there	 are	 a	 number	 of	 factors	 that	 need	 to	 be	
addressed	 in	 order	 to	 determine	 the	 suitability	 of	 BiNSAIDs	 as	 potential	
chemotherapeutic	 or	 chemopreventive	 candidates.	 The	 cellular	 uptake	 and	
intracellular	distribution	of	a	drug	is	an	important	criteria	that	requires	examination,	
particularly	 in	 the	 context	of	 chemoprevention	as	 it	 is	 important	 to	establish:	 (i)	the	
quantity	 of	 the	drug	 that	 can	 enter	 the	 cell	 (i.e.	 how	much	 is	 required	 to	 induce	 the	
desired	 therapeutic	 effect);	 and	 (ii)	 where	 the	 drug	 distributes	 in	 the	 cell	 (i.e.	 if	 it	
localises	at	the	desired	biological	target	or	indiscriminately	throughout	the	cell).			
Having	investigated	the	stability	of	the	BiNSAIDs	in	cell	medium,	and	the	toxicity	of	
the	BiNSAIDs	and	PGE2	inhibition	towards	HCT-8	cells	in	Chapter	2,	it	was	of	interest	
to	 quantify	 the	 uptake	 of	 the	 BiNSAIDs	 to	 determine	 if	 there	were	 any	 correlations	
between	uptake	and	the	stability	and	toxicity	of	the	BiNSAIDs.		Additionally,	assessing	
the	 intracellular	distribution	of	Bi	 in	HCT-8	 cells	was	of	 interest	 in	order	 to	provide	
insight	into	the	intracellular	targets	of	Bi	and	potentially	the	BiNSAIDs	(in	the	instance	
of	the	complex	remaining	intact).			
Beneficially,	BiNSAIDs	contain	two	components	that	can	be	used	to	determine	drug	
uptake	 and	 intracellular	 distribution,	 the	 inorganic	 Bi	 atom	 and	 the	 organic	 NSAID	
molecule.	 	The	studies	described	herein	 focused	on	 the	uptake	and	distribution	of	Bi	
within	the	HCT-8	cells	following	treatment	with	BiNSAIDs.		While	it	will	be	important	
in	future	work	to	focus	on	the	uptake	and	distribution	of	the	NSAIDs,	there	were	a	few	
reasons	why	it	was	initially	important	to	study	the	uptake	and	intracellular	fate	of	Bi.		
Firstly,	 given	 the	 potential	 for	 Bi	 accumulation	 within	 mammalian	 cells	 and	 the	
potential	 for	Bi	 toxicity	 (discussed	 in	Section	1.4.2),	 it	 is	 important	 to	determine	 the	
quantity	 of	 Bi	 that	 enters	 cells	 at	 the	 BiNSAID	 concentration	 required	 to	 cause	
cytotoxicity.		Secondly,	organic	molecules	(including	NSAIDs)	are	generally	comprised	
of	endogenous	elements	that	are	found	within	cells	(C,	H,	O,	N)	that	make	it	difficult	to	
detect	 drug	 molecules	 inside	 cells	 without	 using	 labeling	 techniques.	 Radioactive	
labeling	 (e.g.	 3H)	 overcomes	 this	 issue,	 but	 is	more	 advantageous	 for	whole	body	or	
tissue	imaging	rather	than	the	micron	resolution	required	for	intracellular	imaging	[1].	
Thirdly,	 chemical	 labeling,	 such	 as	 the	 use	 of	 fluorophores,	 involves	 altering	 the	
chemical	structure	and	often	 increasing	 the	molecular	weight	of	 the	molecule,	which	
can	 potentially	 alter	 the	 uptake	 and	 distribution	 of	 the	 drug	 [2].		 In	 contrast,	
metal/metalloid	 complexes	 offer	 an	 advantage	 in	 this	 instance,	 as	 many	metals	 are	
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often	 found	 endogenously	 within	 cells	 in	 trace	 quantities.	 	The	 presence	 of	 a	
metal/metalloid	in	the	compound,	therefore,	negates	the	need	to	label	the	drug.	 	The	
limitation	of	this	approach	is	that	it	is	not	possible	to	tell	whether	the	metal/metalloid	
is	still	attached	to	the	organic	ligands.	
There	 are	 a	 number	 of	 analytical	 techniques	 that	 can	 be	 used	 to	 detect	 trace	
quantities	 of	 metals/metalloids	 in	 cell	 samples	 including	 atomic	 absorption	
spectroscopy	(AAS;	discussed	in	Section	3.1.1.)	and	microprobe	synchrotron	radiation	
X-ray	fluorescence	(SRXRF)	spectroscopy	(discussed	in	Section	3.1.2).		
3.1.1 Atomic	absorption	spectroscopy	for	studying	cellular	uptake	of	inorganic	
complexes/drugs	
Establishing	 the	 uptake	 of	 drugs	 entering	 cancer	 cells	 is	 important	 to	 determine	
their	effectiveness,	whereby	the	focus	of	bowel	cancer	chemopreventives	is	to	provide	
insight	into	their	toxicity	towards	bowel	cancer	cells	(Section	2.3.2)	and	their	ability	to	
inhibit	 PG	 production	 through	 the	 inhibition	 of	 COX-2	 (Section	 2.3.4).	 	 The	 cellular	
uptake	 of	 inorganic	 complexes/drugs	 containing	 non-endogenous	 elements	 (such	 as	
As,	Bi,	Co,	Cr,	Ni,	Pd,	Pt,	Rd,	Ru	and	Rh)	can	be	monitored	by	a	number	of	analytical	
techniques.			
A	common	choice	 is	AAS,	which	uses	either	a	 flame	(FAAS),	or	an	electrothermal	
source,	 also	 known	 as	 graphite	 furnace	 atomic	 absorption	 spectroscopy	 (GFAAS),	 to	
analyse	 metals/metalloids	 [3].	 The	 sample	 is	 atomised	 using	 high	 temperatures	
(2,000−3,000	K)	 to	produce	ground	 state	 free	atoms	 in	 the	vapour	 state	 [3].		A	 light	
source	 (generally	 a	 hollow	 cathode	 lamp),	 which	 produces	 the	 characteristic	
wavelengths	 of	 light	 specific	 to	 the	 analyte,	 is	 used	 to	 quantify	 the	 element	 in	 the	
sample	 [3].	 	 The	 techniques	 known	 as	 inductively	 coupled	 plasma-atomic	 emission	
spectroscopy	(ICP-AES)	and	inductively	coupled	plasma-mass	spectrometry	(ICP-MS),	
employ	 a	 plasma	 source	 as	 the	 sample	 atomiser.	 	A	 plasma	 source	 reaches	
temperatures	 that	 exceed	 twice	 the	 temperature	 of	 a	 combustion	 flame	
(6,000−10,000	K)	[3].				
A	 number	 of	 factors	 are	 important	 when	 determining	 the	 suitability	 of	 these	
techniques	for	analysing	metals	in	cell	samples,	including;	sensitivity,	sample	volumes	
and	chemical	matrix/interference.		The	typical	detection	limits	of	the	aforementioned	
techniques	 vary	 depending	 on	 the	 element	 of	 interest,	 and	 the	 particular	 brand	 of	
instrument	 employed	 for	 the	 analysis	 [4].	 	The	 typical	 detection	 limits	 of	 Bi	 are	
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50	parts	 per	 billion	 (ppb),	 0.3	 ppb,	 18	 ppb,	 and	 0.01-0.1	parts	 per	 trillion	 (ppt)	 for	
FAAS,	GFAAS,	ICP-AES,	and	ICP-MS,	respectively	[4].		GFAAS	has	a	detection	limit	up	to	
1000	 times	 greater	 than	 FAAS	 [4].	 	 The	 greater	 density	 of	 atoms	 generated	 by	 the	
graphite	tube	and	improved	residency	time	of	the	analyte	in	the	optical	path	(<	1	s	in	
FAAS	versus	 several	 seconds	 in	GFAAS)	 contribute	 to	 the	 superior	detection	 limit	of	
GFAAS	[3,	 4].	 	 As	 such,	 GFAAS	 [3-9]	 and	multi-element	 GFAAS	 [10]	 have	 been	 used	
successfully	to	determine	the	concentration	of	Bi	in	biological	samples	with	adequate	
detection	limits	(≤	1	μg/L).	
Additionally,	GFAAS	only	requires	small	sample	volumes	(approximately	20	μL	per	
detection)	for	accurate	elemental	detection,	whereas	1−2	mL	of	sample	is	required	for	
FAAS	[3].		As	atomisation	of	the	sample	occurs	 in	discrete	steps,	selective	removal	of	
matrix	components	can	be	performed	with	the	aid	of	chemical	modifiers.	 	The	use	of	
chemical	 modifiers	 reduces	 the	 effect	 of	 chemical	 interferences	 arising	 from	
components	 of	 the	 sample	 matrix,	 which	 would	 otherwise	 cause	 issues	 with	
determining	the	concentration	of	the	element	of	interest	[4].	
The	main	disadvantages	of	GFAAS	are	 its	 low	dynamic	 range	 (102),	which	means	
that	 the	 concentrations	 of	 the	 analyte	must	 be	 kept	within	 a	 narrow	 range,	 and	 the	
amount	 of	 time	 that	 it	 takes	 to	 analyse	 the	 samples	 (>	 5	 min	 per	 sample)	 [4];	 the	
length	of	 time	 taken	 to	analyse	one	sample	 is	a	particular	disadvantage	 if	more	 than	
one	 element	 is	 to	 be	 studied.	 	 ICP-MS	 has	 the	 advantage,	 over	 GFAAS,	 of	 greater	
sensitivity	(parts	per	trillion	for	some	elements),	a	greater	dynamic	range,	and	rapid	
multi-element	detection;	however,	 there	are	a	number	of	 limitations	associated	with	
ICP-MS.	 	These	 include	high	 instrument	cost,	 spectral	 interferences,	and	high	sample	
volume;	 the	 latter	 being	 a	 crucial	 determining	 factor	 for	 the	 analysis	 of	 cell	
samples.		With	these	advantages	and	disadvantags	in	mind,	GFAAS	was	selected	as	the	
most	appropriate	method	by	which	to	examine	the	uptake	of	Bi	by	HCT-8	cells	in	the	
present	study.	
3.1.2 Microprobe	 synchrotron	 radiation	 X-ray	 fluorescence	 imaging	 for	
studying	intracellular	metal	localisation	
While	Section	3.1.1	described	highly	sensitive	techniques	for	the	quantification	of	
metal/metalloids	within	biological	samples,	the	aforementioned	techniques	cannot	be	
used	 to	 determine	 the	 cellular	 localisation	 and	 consequently	 potential	 intracellular	
targets	 of	 the	 metal/metalloid.	 	Microprobe	 SRXRF	 spectroscopy	 (also	 known	 as	
Chapter	3.	Uptake	and	localisation	of	BiNSAIDs	
115	
microprobe	 synchrotron	 radiation-induced	 X-ray	 emission	 (SRIXE)	 spectroscopy)	 is	
an	analytical	technique	that	can	provide	images	of	intracellular	metal	localisation	and	
colocalisation	 information	 with	 respect	 to	 other	 elements.	 	 Techniques	 such	 as	
microprobe	 SRXRF	 spectroscopy	 remove	 the	 need	 for	 labeling	 the	 drug,	 due	 to	 the	
direct	 analysis	 of	 the	 element	 of	 interest	 [5-8].	 	 A	 number	 of	 studies	 have	 used	
traditional	 staining	 and	 microscopy	 techniques	 such	 as	 autometallography	 (which	
involves	 silver	 enhancement	 of	 bismuth	 sulfide/selenide	 clusters)	 to	 determine	 the	
subcellular	 location	 of	 Bi	 following	 the	 treatment	 of	 various	 cell	 lines	 [9,	 10],	
animal	[11-15]	 and	 human	 tissues	 [16].	 	 However,	 microprobe	 SRXRF	 offers	 the	
advantage	of	multi-element	detection	mapping	and	quantification	 [5-8].	 	This	 allows	
researchers	 to	 study	 the	 changes	 in	 distribution	 and	 semi-quantitatively	 determine	
fluctuations	 in	 concentrations	 of	 endogenous	 elements	 (such	 as	 Ca,	 Fe,	 P,	 S	 and	 Zn)	
that	are	involved	in	important	cellular	processes,	and	hence	the	effects	of	the	drug	on	
the	distribution	of	these	elements	[5-8].	
Figure	 3.1	 illustrates	 the	 basic	 principle	 of	 XRF	 with	 respect	 to	 the	 Bohr	 atom	
model	[17].		Ejection	of	a	core	shell	electron	(generally	a	K	or	L	shell	electron)	from	an	
atom	occurs	when	photons	of	an	X-ray	beam	possess	a	high	enough	energy	(i.e.	greater	
than	the	binding	energy	[18];	in	the	hard	X-ray	region,	>	1	keV)	to	excite	the	electron.		
The	ejection	of	 the	electron	 leaves	a	vacancy	 in	 the	shell.	 	An	electron	 from	an	outer	
orbital	can	then	fill	the	vacancy	and	restore	stability	to	the	atom.					The	process	results	
	
Figure	 3.1:	 Bohr	 atom	 model	 illustrating	 the	 basic	 principle	 of	 X-ray	 fluorescence.		
(a)		An		X-ray	 possessing	 energy	 that	 is	 equal	 to	 or	 greater	 than	 the	 binding	 energy	 of	 the	
electron	results	in	ejection	of	that	electron	into	the	continuum.		(b)	An	electron	from	an	outer	
shell	 fills	 the	 vacancy	 left	 by	 the	 ejected	 electron	 resulting	 in	 the	 emission	of	 a	 fluorescence	
photon	with	an	energy	that	is	equal	to	the	difference	in	the	energy	of	the	two	shells	associated	
with	the	transition.		Adapted	from	Fahrni	[17].		
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in	the	emission	of	a	photon	with	energy	equal	to	the	difference	in	binding	energies	of	
the	 two	 shells	 involved	 in	 the	 transition.	 	 The	 binding	 energy	 of	 each	 electron	 is	
proportional	 to	 the	 squared	nuclear	 charge;	 for	 example,	 the	 analysis	 of	 Bi	 requires	
energy	 of	 10.7	keV	 (the	 binding	 of	 the	 Lα2	 electrons).		 In	 addition,	 every	 element	
possesses	unique	binding	energies	and	characteristic	photon	emissions	(fluorescence)	
enabling	detection	of	 the	relevant	elements	 in	the	sample.	 	Furthermore,	 the	relative	
quantities	 of	 the	 elements	 can	 be	 determined	 since	 the	 fluorescence	 emission	 is	
directly	proportional	to	the	amount	of	an	element	present	in	a	sample.		
The	use	of	X-rays	produced	at	a	synchrotron	offers	a	number	of	advantages	over	
conventional	 bench-top	 X-ray	 sources.	 	 These	 include	 the	 capability	 of	 generating	
X-rays	up	 to	12	orders	of	magnitude	brighter	 than	a	 conventional	X-ray	source	 [19],	
and	following	the	advances	in	modern	X-ray	optics,	the	ability	to	focus	the	X-rays	to	a	
submicron	spot	on	a	sample	with	the	use	of	devices	such	as	a	Kirkpatrick-Baez	mirror	
[20]	or	Fresnel	zone	plate	[21].		Both	of	these	factors	have	facilitated	the	development	
of	microprobe	 SRXRF	 spectroscopy.	 	 Detection	 sensitivities	 in	 the	 ppb	 range	 can	 be	
routinely	 obtained	 from	 using	 microprobe	 SRXRF,	 in	 comparison	 to	 the	 ppm	
sensitivities	 of	 alternative	 microprobe	 (particle	 induced	 X-ray	 emission)	 and	
nanoprobe	(electron	dispersive	X-ray	analysis)	techniques.	 	The	improved	sensitivity	
of	microprobe	 XRF	 stems	 from	 the	 absence	 of	 the	 continuum	 background	 radiation	
that	 is	a	 feature	of	 the	spectra	obtained	 from	the	use	of	charged	particle	beams,	and	
the	 increased	 X-ray	 flux	 on	 the	 sample	 associated	 with	 the	 use	 of	 third	 generation	
synchrotron	facilities	([22]	and	references	within).		
The	achievement	of	submicron	resolution	with	microprobe	SRXRF	combined	with	
the	high	sensitivity	and	penetration	depth	of	hard	X-rays	makes	the	technique	highly	
amenable	 to	 the	 study	 of	 single	 mammalian	 cells	 [22].	 	Raster	 scanning	 produces	
quantitative	 information	 from	an	 entire	 scanned	 area	 of	 a	 specimen	 resulting	 in	 the	
generation	 of	 elemental	 maps.	 	Depending	 on	 the	 particular	 element,	 detection	
sensitivities	 have	 been	 reported	 in	 the	 range	 of	 10−17−10−14	 g	 for	 mammalian	 cell	
studies	([22]	and	references	within).		Microprobe	SRXRF	has	been	applied	to	the	study	
of	the	intracellular	fate	of	both	marketed	and	potential	metal-based	drugs	containing												
Pt	 [6,	23,	24],	Cr	 [5],	Ru	 [8,	25],	 Se	 [26,	27],	Gd	 [28,	29],	 and	As	[30]	 in	a	number	of	
cancer	 cell	 lines.	 	 However,	 to	 date	 there	 are	 few,	 if	 any,	 reports	 assessing	 the	
distribution	 of	 Bi-based	 drugs	 in	 human	 cells	 using	 microprobe	 SRXRF	
microspectroscopy.	
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3.1.3 Chapter	aims	
Having	established	the	stability	of	the	BiNSAIDs,	Bi(difl)3,	Bi(mef)3	and	Bi(tolf)3,	in	
cell	medium,	and	the	toxicity	of	the	BiNSAIDs	towards	HCT-8	cells,	it	was	of	interest	to	
quantify	 the	 cellular	 Bi	 content	 following	 treatment	 with	 BiNSAIDs	 to	 determine	 if	
there	were	any	correlations	between	cellular	uptake	versus	stability	and/or	 toxicity.		
Assessing	the	subcellular	distribution	of	Bi	was	of	interest	in	order	to	provide	insight	
into	the	intracellular	targets	of	the	BiNSAIDs,	Bi(difl)3,	Bi(mef)3	and	Bi(tolf)3,	in	HCT-8	
cells.		The	specific	aims	of	this	Chapter	were	to:	
1. Quantify	 Bi	 uptake	 by	 the	 HCT-8	 cells	 using	 GFAAS	 in	 order	 to	 determine	
whether	Bi	uptake	correlates	with	BiNSAID	stability	and	toxicity.	
2. Ascertain	 the	 subcellular	 location	 of	 Bi	 in	 HCT-8	 cells	 following	 treatment	
with	 BiNSAIDs	 using	 microprobe	 SRXRF	 imaging	 to	 assess	 how	 this	 might	
influence	toxicity	towards	the	cancer	cells	and	how	this	might	 influence	the	
targeting	of	COX.	
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3.2 Materials	and	methods	
3.2.1 Materials	
The	materials	used	for	the	cell	culture	experiments	described	in	this	Chapter	have	
been	 previously	 described	 in	 Section	 2.2.1.	 	The	 chemicals,	 ammonium	 acetate	
(≥98%),	sodium	chloride	(99.999%	trace	metal	basis),	and	trypan	blue	(0.5%	in	PBS)	
were	purchased	from	Sigma-Aldrich	(St	Louis,	USA).	 	Pyroneg	detergent	was	sourced	
from	DiverseyLever	Australia	Pty	Ltd	(Smithfield,	Australia).		Analytical	grade	ethanol	
(absolute,	 ≥99.5%)	 and	 nitric	 acid	 (68−70%)	 were	 sourced	 from	 Ajax	
Finechem	(Seven	 Hills,	 Australia).	 A	certified	 Bi	 standard	 solution	 (1004	±	3	mg/mL,	
2%	 HNO3	 v/v)	 was	 acquired	 from	 PerkinElmer	 Instruments	 (Massachusetts,	 USA),	
while	the	magnesium	(Mg(NO3)2,	10	mg/mL)	and	palladium	matrix	modifier	solutions	
(Pd(NO3)2,	 5	mg/mL)	were	 procured	 from	 Astral	 Scientific	 (Taren	 Point,	 Australia).	
Analytical	 volumetric	 flasks	 (Class	 A)	 were	 purchased	 from	 GlassCo	 (Dandenong	
South,	 Australia).	 	 Tracepur	 nitric	 acid	 (69%)	was	 sourced	 from	Merck	 (Darmstadt,	
Germany).	 	 A	 Bi	 hollow	 cathode	 lamp	 and	 standard	 transversely	 heated	 graphite	
atomizer	 tubes	(inserted	pyrolytic	L’vov	platform)	were	obtained	 from	Perkin	Elmer	
Instruments	 (Victoria,	 Australia).	 	 Glutaraldehyde	 (25%	 solution),	 Spurr's	 low	
viscosity	embedding	resin	and	toluidine	blue	were	sourced	from	Proscitech	(Kirwan,	
Australia).	 Silicon	nitride	 (Si3N4)	membranes	 (frame	 size,	 5	×	5	mm2;	 sample	 surface	
area,	1.5	×	1.5	mm2;	membrane	thickness,	500	nm;	and	frame	thickness,	200	nm)	were	
manufactured	by	Silson	Ltd	(Northampton,	England).	
3.2.2 Cell	culture	procedures	
HCT-8	cells	were	sourced	and	employed	as	described	in	Section	2.2.3.	
3.2.3 GFAAS	uptake	studies	
3.2.3.1 Preparation	of	cell	digests	
Cell	 digests	were	 prepared	 for	 GFAAS	 analysis	 using	 a	 similar	 procedure	 to	 that	
documented	previously	 [23].	 	 Briefly,	HCT-8	 cells	 (2	 ×	 106	 cells,	 5	mL)	were	 seeded	
into	60-mm	cell	culture	dishes	and	incubated	for	24	h,	after	which	the	growth	medium	
was	 removed	 and	 the	 cells	 were	 washed	 twice	 with	 PBS.	 	 The	 control	 cells	 were	
incubated	with	 vehicle	 (5	mL	RPMI-1640,	 2%	DMSO	 v/v)	 for	 24	 h,	while	 treatment	
solutions	of	Bi(difl)3,	Bi(mef)3,	Bi(tolf)3	or	BSS	were	added	to	the	other	dishes	(15	µM	
or	 40	 µM	 Bi	 in	 5	mL	 RPMI-1640,	 2%	 DMSO	 v/v)	 for	 24	 h.	 	The	 two	 treatment	
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concentrations	were	approximately	equal	to	the	two	lowest	IC50	values	obtained	from	
the	 toxicity	 studies	 (Section	 2.2.4).	 	 Triplicate	 dishes	were	 prepared	 for	 the	 control	
and	each	treatment.		Following	the	treatment	period,	the	solutions	were	removed	and	
the	cells	were	washed	 twice	with	PBS	(2	mL),	harvested	with	 trypsin	(0.25%,	2	mL)	
and	centrifuged	(300	g,	5	min).		The	cells	were	resuspended	in	RPMI-1640	(1	mL)	and	
trypan	 blue	 exclusion	 assays	 were	 performed	 by	 removing	 the	 resultant	 cell	
solution	(50	µL)	 from	each	sample	and	mixing	with	 trypan	blue	(50	µL,	0.5%	w/v	 in	
PBS).	 	The	 populations	 of	 intact	 cells	 and	 disrupted	 cells	 were	 scored	 using	 a	
haemocytometer	(100×	magnification),	whereby	cells	that	appeared	blue	represented	
uptake	 of	 trypan	 blue	 and	 loss	 of	membrane	 integrity	 (dead	 cells)	 while	 those	 that	
were	colourless	represented	cells	with	an	intact	membrane	(healthy	cells).	 	The	cells	
in	the	main	suspensions	were	washed	twice	with	sterile	PBS	solution	(2	mL),	followed	
by	 two	washes	 with	 sterile	 saline	 solution	 (0.9%,	 2	mL).	 	 The	 final	 saline	 solutions	
were	 drained	 from	 the	 pellets	 and	 the	 cells	 were	 freeze-dried	 for	 2	h.	 	 Nitric	 acid	
(Tracepur,	69%	v/v)	was	added	to	each	Eppendorf	tube	(43	µL)	and	the	pellets	were	
digested	 overnight.	 	 The	 digested	 pellets	 were	 transferred	 to	 volumetric	 flasks	
(prewashed	with	a	solution	of	Pyroneg	detergent	(72	h),	followed	by	nitric	acid	(72	h),	
and	MilliQ	 water	(72	 h)	 and	 rinsed	 5	times	 with	MilliQ	 water)	 and	 the	 volume	was	
adjusted	 to	5.00	mL	 (using	MilliQ	water)	or	25.00	mL	 (using	MilliQ	water	and	nitric	
acid	(177	µL,	Tracepur,	69%	v/v)),	to	obtain	a	final	HNO3	concentration	of	0.6%	v/v.	
3.2.3.2 			Preparation	of	fixed/dehydrated	cell	digests	
It	 has	 been	 previously	 reported	 that	 formalin	 fixation	 can	 cause	metal	 and	 trace	
element	 leaching	 from	 tissues	 [31].	 	In	 this	 study,	 the	 integrity/effect	 of	 the	
glutaraldehyde	 fixation	 and	 ethanol	 dehydration	 process	 used	 for	 preparation	 of	
thin-sectioned	 cell	 samples	 for	 microprobe	 SRXRF	 analysis	 was	 investigated	 to	
determine	 if	 there	 was	 any	 change	 in	 Bi	 uptake.	 	 As	 such,	 the	 cell	 samples	 were	
prepared	as	outlined	in	the	previous	section	but	with	the	following	changes.		After	the	
final	 PBS	 wash	 of	 the	 treated	 cells,	 the	 cells	 were	 resuspended	 in	 glutaraldehyde	
(1	mL,	2%	v/v	in	PBS)	and	fixed	for	2	h	at	room	temperature.		Dehydration	of	the	cells	
was	 performed	 incrementally	 using	 increasing	 ethanol	 concentrations	 (in	 MilliQ	
water;	 30%	 ×2,	 50%	 ×2,	 70%	 ×2,	 80%	 ×2,	 90%	 ×2,	 95%	×2,	 100%	 ×4)	 with	
centrifugation,	and	removal	of	the	supernatant	and	cell	resuspension	after	each	step.		
The	 pellets	 were	 then	 freeze-dried	 after	 the	 final	 ethanol	 wash	 and	 digested	 as	
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described	in	Section	3.2.3.1.	
3.2.3.3 			Graphite	furnace	atomic	absorption	spectroscopy	
Digested	 cell	 solutions	 were	 analysed	 for	 Bi	 using	 a	 PerkinElmer	 AAnalyst	 600	
atomic	 absorption	 spectrometer	 equipped	with	 the	Winlab	 32	 AA	 Furnace	 program	
incorporating	 Zeeman-effect	 background	 correction,	 an	 AS-800	 autosampler	 and	 an	
AA	Accessory	 cooling	 system.	 	A	Bi	hollow	cathode	 lamp	 (PerkinElmer)	was	used	at	
223	nm,	 using	 a	 slit	 width	 of	 0.7	nm,	 to	 give	 an	 instrument	 energy	 reading	 of	
approximately	 35	W.	 	 A	 certified	 Bi	 standard	 solution	was	 employed	 to	 prepare	 the	
stock	 Bi	 standard	 (100	µg/L,	 0.6%	 HNO3	v/v)	 for	 the	 calibration	 curve	 (correlation	
coefficients:	 0.993−0.997).	 	The	 autosampler	 volumes	 consisted	 of	 the	 chemical	
modifier	(5	µL,	0.005	mg/mL	Pd(NO3)2	and	0.003	mg/mL	Mg(NO3)2),	 followed	by	the	
standard	 or	 sample	 (20	µL).	 	 Bi	 was	 atomised	 from	 the	 surface	 of	 the	 pyrolytic	
graphite-coated	 tubes	 using	 the	 furnace	 operating	 conditions	 described	 in	
Appendix	2.1.	 	The	analyte	reading	was	performed	during	atomisation	(1700	°C)	and	
Ar	gas	was	supplied	to	the	instrument	during	analysis.		After	analysis	of	each	digested	
cell	 sample,	 a	 blank	 (containing	 0.6%	 HNO3	v/v)	 was	 analysed	 to	 minimise	
interference	 from	 previous	 samples	 and	 ensure	 that	 Bi	 detection	 returned	 to	
background	levels.	
3.2.4 Microprobe	SRXRF	analysis	of	Bi-treated	cells	
3.2.4.1 			Preparation	of	thin-sectioned	cell	samples	
Thin-sectioned	 cells	 were	 prepared	 for	 microprobe	 SRXRF	 analysis	 using	
procedures	 documented	 previously	 [5,	 6,	 32,	 33].	 	 Briefly,	 cells	 were	 seeded	 in	 cell	
culture	flasks	(75	cm2)	and	grown	to	80%	confluence.		Treatment	solutions	of	Bi(difl)3,	
Bi(mef)3,	Bi(tolf)3	or	BSS	(40	µM	Bi,	10	mL	RPMI-1640,	2%	DMSO	v/v)	were	applied	to	
the	 cell	 culture	 flasks,	 while	 control	 cells	 were	 incubated	 with	 vehicle	 (10	mL	
RPMI-1640,	 2%	DMSO	 v/v)	 for	 4	 h	 or	 24	 h.	 	 The	 treatment	 concentration	 of	 the	
complexes	 was	 chosen	 based	 on	 the	 uptake	 results	 obtained	 from	 the	 toxicity	 and	
GFAAS	experiments	(Sections	2.3.2	and	3.3.1)	to	ensure	that	detectable	concentrations	
of	 Bi	 (suitable	 for	 microprobe	 SRXRF	 imaging)	 were	 present	 in	 the	 cells	 following	
treatment.		The	cells	were	washed	twice	with	PBS	and	harvested	using	trypsin	(0.25%	
in	PBS).	The	harvested	cells	were	washed	twice	with	sterile	PBS	using	centrifugation	
and	the	 final	cell	pellet	was	 fixed	 in	glutaraldehyde	(1	mL,	2%	v/v	 in	PBS)	 for	2	h	at	
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room	 temperature;	 and	 dehydrated	 in	 ethanol	 (30%	 ×2,	 50%	 ×2,	 70%	×2,	 80%	 ×2,	
90%	 ×2,	 95%	 ×2,	 100%	 ×4).	 	 Infiltration	 was	 achieved	 by	 rocking	 the	 cells	 in	
50%	ethanol/50%	 Spurr’s	 resin	 overnight	 and	 then	 replacing	 with	 100%	 Spurr’s	
resin	(×2	over	2	days)	to	ensure	the	removal	of	all	 traces	of	water.	 	On	the	 final	day,	
the	cells	were	embedded	in	100%	Spurr’s	resin,	centrifuged	(8000	g,	1	h)	and	cured	at	
60	 °C	overnight	 in	 a	Beem	capsule.	 	 Thin	 sections	 (1	µm)	of	 the	 cell	 pellet	were	 cut	
using	 an	 ultramicrotome	 (Leica	 EM	 UC7).	 	 The	 thin-sections	 were	 stained	 with	
toluidine	blue	before	mounting	on	silicon	nitride	membranes.	
3.2.4.2 			Microprobe	SRXRF	analysis	of	thin-sectioned	cells	
Silicon	nitride	membranes	were	attached	to	kinematic	mounts	designed	to	fit	both	
the	light	microscope	(Leica	DMXRE	Epi-fluorescence/visual	microscope)	and	the	X-ray	
microprobe	(2-ID-D).		Optical	micrographs	and	XY	coordinates	were	obtained	in	order	
to	locate	suitable	cells	for	analysis.		Those	cells	that	exhibited	an	intact	appearance,	a	
clearly	 defined	 nucleus	 and	 were	 located	 away	 from	 other	 cells	 and	 cellular	 debris	
were	chosen	for	analysis.	
Microprobe	 SRXRF	 was	 performed	 at	 beamline	 2-ID-D	 at	 the	 Advanced	 Photon	
Source,	Argonne	National	 Laboratory	 (Lemont,	 IL,	USA).	 	 The	13.45	keV	X-ray	beam	
was	focused	to	a	spot	size	of	0.3	×	0.3	µm2	using	two	zone	plates.	 	The	samples	were	
housed	in	a	helium	atmosphere	and	the	distributions	of	the	elements	from	P	(2.1	keV)	
to	Bi	(13.45	keV)	were	mapped	by	raster	scanning	the	sample	in	0.3	µm	steps,	with	the	
aid	of	a	XYZ	motorised	stage.		Fluorescent	X-rays	were	detected	using	a	dwell	time	of	
2.5	s/pt	 and	 an	 energy	 dispersive	 Vortex	 EM	 (Hitachi	 High-Technologies	 Science	
America,	 Northridge,	 CA)	 silicon	 drift	 detector.	 	 Elemental	 distribution	 maps	 were	
processed	using	MAPS	Version	1.7.3.02	software	package	provided	by	Dr	Stefan	Vogt	
(Advanced	Photon	Source)	 [34].	 	Conversion	of	 elemental	 fluorescence	 intensities	 to	
absolute	 densities	 in	 microgram	 per	 square	 centimetre	(µg/cm2)	 was	 performed	 by	
comparing	 X-ray	 fluorescence	 intensities	 with	 those	 from	 thin	 film	 standards,	
NBS-1832	and	NBS-1833	(NIST,	Gaithersburg,	MD,	USA).		The	elemental	quantification	
of	specific	regions	of	the	elemental	distribution	maps	(i.e.	the	nucleus	and	cytoplasm)	
was	 performed	 by	 selecting	 the	 region	 of	 interest	 (ROI)	 and	 extracting	 the	
quantification	information	for	the	ROI	using	MAPS	Version	1.7.3.11	software	package	
provided	by	Dr	Stefan	Vogt	(Advanced	Photon	Source)	[34].	
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3.2.5 Statistical	analysis	
Statistical	 analysis	 of	 the	 results	 of	 the	 trypan	 blue	 exclusion	 assays,	 the	 GFAAS	
assays	 and	 the	 microprobe	 SRXRF	 elemental	 quantification	 were	 performed	 using	
one-way	 ANOVA,	 followed	 by	 the	 Tukey-Kramer	 Multiple	 Comparison	 Test,	 using	
GraphPad	Prism,	Version	5.04	 for	Windows	(GraphPad	Software,	La	 Jolla,	USA).	 	The	
trypan	 blue	 exclusion	 assay	 and	 GFAAS	 results	 were	 analysed	 as	 two	 treatment	
sets	(i.e.	control	and	15	µM,	or	control	and	40	µM	treatment	samples)	in	order	to	draw	
a	statistical	comparison	at	the	same	Bi	treatment	concentration.		Results	are	presented	
as	mean	±	 standard	deviation	 (s.d.).	 	 A	 value	of	P	≤	0.05	was	 considered	 statistically	
significant.	 	
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3.3 Results	
3.3.1 GFAAS	analysis	of	cellular	Bi	
Figure	 3.2	 shows	 the	 results	 of	 the	 trypan	 blue	 assay	 and	 the	 corresponding	 Bi	
detected	 in	 cells	 treated	 with	 the	 vehicle,	 BiNSAIDs	 or	 BSS	 (15	 µM	 and	 40	 µM	 Bi).	
The	trypan	blue	positive	cells	(Fig.	3.2a)	formed	a	relatively	low	proportion	(<1%)	of	
the	 total	number	of	control	and	BiNSAID-treated	cells,	 indicating	 that	 the	membrane	
integrity	of	the	majority	of	the	cells	was	uncompromised.		This	is	an	important	result	
because	it	establishes	that	any	cellular	Bi	detected	(Fig.	3.2b)	is	not	the	result	of	rapid	
uptake	due	to	loss	of	cell	membrane	integrity.		Notably,	significant	decreases	in	the	cell	
populations	were	observed	following	treatment	with	Bi(mef)3	(40	µM	Bi,	P	≤	0.01)	and	
Bi(tolf)3	 (15	 µM	 Bi,	 P	 ≤	 0.01;	 40	 µM	 Bi,	 P	 ≤	 0.001,	 Fig.	 3.2a).	 	The	 number	 of	
Bi(tolf)3-treated	 cells	 (15	 µM	 Bi)	 was	 approximately	 45%	 of	 the	 number	 of	 control	
cells	 and	 further	 decreased	 to	 approximately	 20%	 with	 increased	 Bi	 treatment	
concentration	(40	µM	Bi,	Fig.	3.2a).		The	cell	population	observed	following	treatment	
with	 Bi(mef)3	 (40	 µM	 Bi,	 24	 h)	 was	 approximately	 43%	 of	 the	 population	 of	
vehicle-treated	cells	(Fig.	3.2a).		The	lower	cell	populations	observed	for	Bi(mef)3-	and	
Bi(tolf)3-treated	cells	(40	µM,	Figure	3.2a)	were	consistent	with	the	results	of	the	MTT	
assay	(Fig.	2.6,	Table	2.4)	that	showed	that	Bi(mef)3	and	Bi(tolf)3	were	the	more	toxic	
complexes.	
In	 the	 treatment	group	exposed	 to	15-µM	Bi,	 the	cellular	Bi	 (Fig.	3.2b)	was	more	
than	 three	 times	 higher	 in	 Bi(tolf)3-treated	 cells	 than	 in	 the	 Bi(difl)3-	 and	
Bi(mef)3-treated	cells.	Interestingly,	BSS-treated	cells	exhibited	the	highest	amount	of	
cellular	 Bi	 (three	 times	 higher	 than	 Bi(tolf)3),	 and	 displayed	 the	 only	 statistically	
significant	 (P	≤	 0.001)	 increase	 above	 the	 control	 for	 the	 15-µM	 treatment	 group.		
Increasing	the	treatment	concentration	from	15	µM	to	40	µM	resulted	in	an	increase	in	
cellular	 Bi	 content	 in	 all	 Bi-treated	 cells	 (Fig.	 3.2b).	 	 Treatment	with	 the	most	 toxic	
BiNSAID,	 Bi(tolf)3	 (40	 µM,	 24	 h),	 showed	 the	 highest	 Bi	 concentration	 per	 cell	
(P	≤	0.001	 compared	 to	 the	 control,	 and	 the	 other	 Bi	 treatments),	 which	 was	
approximately	 70	 times	 higher	 than	 the	 cellular	 Bi	 associated	 with	 Bi(difl)3-	 and	
Bi(mef)3-treated	 cells	 (40	 µM,	 24	 h)	 and	 approximately	 340	 times	 higher	 than	 the	
cellular	 uptake	 of	 Bi(tolf)3-treated	 cells	 at	 15	µM.	 	 The	 cellular	 uptake	 of	 Bi(difl)3-,	
Bi(mef)3-,	 and	 BSS-treated	 cells	 increased	 only	 approximately	 9,	 18	 and	 5	 times,	
respectively,	 in	comparison	to	cells	treated	with	15-µM	of	the	compounds	(P	>	0.05).		
Interestingly,	 despite	 the	 differences	 in	 the	 toxicities	 of	 the	 40-µM	 treatments	 with	
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Bi(difl)3	or	Bi(mef)3	(whereby	40-µM	represents	a	sub-toxic	concentration	and	the	IC50	
value,	respectively;	Fig.	2.6,	Table	2.4),	Bi(mef)3-treated	cells	only	exhibited	1.5	times	
the	cellular	Bi	concentration	of	the	Bi(difl)3-treated	cells.	
	
	
Figure	 3.2:	 Trypan	 blue	 exclusion	 assay	 and	 GFAAS	 analysis	 of	 HCT-8	 cells	 treated	with	 Bi	
compounds.	 	(a)	Cell	populations	obtained	 from	trypan	blue	exclusion	assays	of	vehicle-	and	
Bi-treated	cells	(15	and	40	µM,	24	h).	 	Results	are	expressed	as	mean	±	 s.d.	 (n	=	3	replicates	
from	 one	 experiment).	 	 Error	 bars	 represent	 the	 standard	 deviation	 from	 the	 mean	 of	 the	
negative	 and	 positive	 trypan	 blue	 cells.	 (b)	 GFAAS	 detection	 of	 Bi	 in	 HCT-8	 cells	 following	
exposure	 to	 vehicle	 (2%	DMSO	v/v)	 and	 specified	 Bi	 compounds	 (15	 μM	 and	 40	 µM)	 for	
24	h.			Results	are	expressed	as	mean	±	s.d.	(n	=	3	replicates	from	one	experiment).		Statistical	
significance	with	respect	to	the	control	is	indicated	by	**	P	≤	0.01	or	***	P	≤	0.001.		 	
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3.3.2 The	dependence	of	cell	preparation	on	the	cellular	uptake	of	Bi	
Figure	3.3	shows	 the	results	of	 the	Bi	cell	uptake	studies	performed	on	cells	 that	
were	prepared	using	the	fixation	and	dehydration	protocol	employed	for	preparation	
of	thin-sectioned	cells	for	the	microprobe	SRXRF	analyses	compared	with	the	protocol	
typically	used	for	GFAAS	analysis.	 	There	were	no	significant	differences	(P	>	0.05)	in	
the	 amount	 of	 cellular	 Bi	 detected	 after	 fixation	 and	 dehydration	 compared	 to	 the	
analogous	 non-fixed	 and	 non-dehydrated	 cells.	 	 This	 is	 an	 important	 result	 as	 it	
establishes	 that	 there	 is	 no	 loss	 of	 intracellular	 Bi	 due	 to	 leaching	 following	
preparation	 of	 thin-sectioned	 cells	 for	 microprobe	 SRXRF	 analysis.	 Conversely,	
samples	 treated	with	BSS	 showed	a	decrease	 in	 the	 amount	 of	Bi	 contained	per	 cell	
compared	 to	 the	 normally	 washed	 cells;	 however,	 this	 result	 was	 not	 statistically	
significant	(P	>	0.05).	
	
Figure	 3.3:	 GFAAS	 detection	 of	 Bi	 in	 HCT-8	 cells	 following	 exposure	 to	 the	 specified	 Bi	
compounds	(40	μM,	24	h)	prepared	by	normal	washing	method	or	prepared	following	fixation	
with	glutaraldehyde	(2%	in	PBS,	2	h)	and	dehydration	with	ethanol.		Results	are	expressed	as	
mean	±	s.d.	(n	=	3	replicates	from	one	experiment).	  
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3.3.3 Microprobe	SRXRF	spectroscopy	
Figure	 3.4a	 shows	 the	 elemental	 maps	 for	 P,	 S,	 Zn,	 Ca,	 and	 Bi	 generated	 from	
microprobe	SRXRF	 imaging	of	 a	 thin-section	prepared	 from	a	 typical	 vehicle-treated	
HCT-8	 cell.	 	 The	 concentration	 range	 of	 each	 element	 detected	 within	 the	 scanned	
region	 is	 specified	 above	 each	 elemental	 map	 (Fig.	 3.4	 and	 Appendix	 2.2).	 	High	
concentrations	 of	 the	 endogenous	 elements,	 P,	 S,	 Zn,	 and	 Ca,	 were	 detected	 in	 the	
vehicle-treated	 cells	 (Fig.	3.4a).	 	 Inspection	 of	 the	 micrograph	 (top	 panel,	 Fig.	 3.4a)	
reveals	 the	overall	size	and	shape	of	 the	cell,	which	correlates	well	with	endogenous	
elements	S,	P,	Zn	and	Ca.		Proteins	found	in	both	the	nucleus	and	cytoplasm	contain	S;	
additionally,	 S	 is	 also	 associated	 with	 the	 toluidine	 blue	 stain	 (which	 targets	 DNA),	
which	was	necessary	to	locate	the	cells	for	the	microprobe	SRXRF	imaging	due	to	their	
translucent	 appearance.	 	 The	 position	 of	 the	 nucleus	 is	 also	 defined	 by	 the	 high	
presence	of	P	and	Zn;	P	is	a	fundamental	element	in	the	backbone	of	DNA	[35],	while	
Zn	plays	an	 important	role	 in	DNA	binding	proteins	(known	as	zinc	 fingers)	 that	are	
localised	in	the	nucleus	[36].		Distinctly	dense	areas	of	P	(observed	as	the	dense	region	
of	 green/red/yellow	 pixels)	 inside	 the	 nuclear	 membrane	 can	 be	 attributed	 to	 the	
densely	 packed	 DNA	 regions	 known	 as	 the	 heterochromatin	 [37].	 	In	 addition,	 the	
dense	 spherical	 structure	 in	 the	 top	 left	 of	 the	 nucleus	 (Fig.	 3.4a)	 is	 the	 nucleolus	
(observable	 in	 the	 S	 and	Zn	maps	 as	 yellow/red	pixels).	 	 Both,	 the	 heterochromatin	
and	the	nucleolus	correlate	with	the	dark	stained	regions	in	the	micrograph	image	that	
represent	dense	DNA	material.		As	observed	in	the	vehicle-treated	cells,	Ca	appears	to	
be	evenly	distributed	throughout	the	cytoplasm	and	the	nucleus	(Fig.	3.4a).		Only	very	
low	concentrations	of	Bi	were	present	within	the	scanned	region	of	the	vehicle-treated	
cells	 (maximum	 Bi	 0.00431	μg/cm2,	 Fig.	 3.4a,	 and	 0.00469	μg/cm2,	 Appendix	 2.2a),	
and	are	not	distinctly	associated	with	the	cells	against	the	background	regions.	
Figure	 3.4b	 shows	 the	 elemental	 map	 of	 typical	 Bi(difl)3-treated	 cells	 following			
24-h	 treatment.	 	The	 Bi(difl)3-treated	 cell	 samples	 showed	 evidence	 of	 intracellular	
accumulation	 of	 Bi	 in	 ‘hot	 spots’	 (areas	 of	 high	 Bi	 concentration)	 distributed	
throughout	 the	 cytoplasm	 (Fig.	 3.4b,	 bottom	 panel).	 	 The	 Bi(difl)3-treated	 cells	
(Fig.	3.4b	and	Appendix	2.2b)	contained	several	hot	spots	ranging	from	approximately	
0.3−1.5	μm2	in	size.		The	maximum	cellular	Bi	detection	was	0.0578	μg/cm2	(Fig.	3.4b)	
and	0.106	μg/cm2	(Appendix	2.2b).	
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Figure	3.4:	Microprobe	SRXRF	elemental	maps	for	thin-sectioned	HCT-8	cells	 following	24-h	
treatment	with:	(a)	vehicle	only	(DMSO	2%	v/v);	(b)	Bi(difl)3	(40	μM);	(c)	Bi(mef)3	(40	μM);	
(d)	Bi(tolf)3	(40	μM);	and	(e)	BSS	(40	μM).	 	The	detected	elements	are	specified	to	the	left	of	
each	row.		Operating	conditions	include:	beam	energy	=	13.45	keV;	beam	size	=	0.3	×	0.3	μm2;	
step	 size	 =	 0.3	 μm;	 dwell	 time	 =	 2.5	 s/pt;	 and	 scan	 dimensions	 (H	 ×	 V)	 =	 (a)	 20	 ×	 17μm2;	
(b)	19	×	16	μm2;	(c)	22	×	15	μm2;	(d)	31	×	21	μm2	and	(e)	14	×	12	μm2.	 	
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Figure	 3.4c	 shows	 the	 elemental	 map	 of	 typical	 Bi(mef)3-treated	 cells	 following	
24-h	treatment.	 	 	There	were	substantial	differences	observed	in	the	distribution	and	
maximum	Bi	detected	between	Cell	A	and	Cell	B	(Fig.	3.4c).		The	maximum	Bi	detected	
in	 Cell	A	 was	 0.128	μg/cm2,	 twice	 the	 amount	 detected	 in	 Cell	B	 (maximum	
0.06136	μg/cm2).		Additionally,	Bi	was	distributed	throughout	Cell	A,	with	the	highest	
concentration	 of	 Bi	 localised	 in	 the	 nucleus	 and	 considerable	 Bi	 also	 present	 in	 the	
cytoplasm	(Fig.	3.4c).	 	 It	 should	be	noted	that	 this	was	 the	only	BiNSAID-treated	cell	
where	 the	Bi	 localisation	was	observed	 in	both	 the	nuclear	and	cytoplasmic	 regions.		
The	majority	of	the	Bi	present	in	the	cytoplasm	of	Cell	B	appears	to	be	concentrated	in	
one	 large	 hot	 spot,	 approximately	 5.8	μm2	 in	 size	 (Fig.	 3.4c).	 	 A	 similar	 result	 was	
observed	 in	 a	 third	 Bi(mef)3-treated	 cell	 (24	h),	 whereby	 one	 large	 hot	 spot	 was	
observed	 in	 the	cytoplasm	(Appendix	2.2c).	 	 	Notably,	 there	was	 little	evidence	of	Bi	
accumulation	within	the	Bi(mef)3-treated	cells	 following	4-h	treatment	(maximum	Bi	
0.0065	μg/cm2	and	0.0134	μg/cm2,	Appendix	2.3).	
The	 24-h	 Bi(tolf)3-treated	 cell	 samples	 also	 showed	 evidence	 of	 intracellular	
accumulation	of	Bi	in	hot	spots	distributed	throughout	the	cytoplasm.		The	maximum	
Bi	 detected	 in	 Bi(tolf)3-treated	 cells	 (Fig.	 3.4d)	 was	 0.0496	μg/cm2	 (Cell	 A)	 and	
0.0408	μg/cm2	 (Cell	 B),	 10	times	 greater	 than	 the	 amount	 of	 Bi	 detected	 in	 vehicle-
treated	 cells	 (Fig.	 3.4a).	 	A	 third	 Bi(tolf)3-treated	 cell	 (Appendix	 2.2d)	 contained	 the	
largest	 amount	 of	 Bi	 of	 all	 the	 BiNSAID-treated	 cells	 analysed	 (1.01	 μg/cm2),	which	
appeared	to	be	localised	in	one	cytoplasmic	hot	spot.	The	Bi	hot	spots	ranged	in	size	
from	approximately	0.7	μm2	to	2.8	μm2	in	the	Bi(tolf)3-treated	cells.		
Figure	3.4e	shows	that	there	was	no	evidence	of	accumulation	of	Bi	in	cells	treated	
with	BSS	(24	h).		The	maximum	Bi	counts	detected	were	0.005	μg/cm2	(Fig.	3.4e)	and	
0.006	μg/cm2	 (Appendix	 2.2e),	 similar	 to	 the	 Bi	 content	 of	 the	 vehicle-treated	 cells	
(Fig.	3.4a	and	Appendix	2.2a).		
Across	all	BiNSAID-treated	cells,	many	of	the	Bi	hot	spots	showed	close	proximity	
to	 the	 nucleus;	 the	 colocalisation	 maps	 with	 P	 and	 Zn,	 confirmed	 the	 spots	 were	
located	 close	 to	 the	nuclear	membrane	 in	 a	 number	of	 cells	 (Appendix	2.4	 a(i),	 b(i),	
b(ii)	and	c(i)).	 	Analysis	of	 the	microprobe	SRXRF	elemental	maps	also	revealed	that	
the	Ca	distribution	of	all	the	Bi-treated	HCT-8	cells	(Fig.	3.4b-e	and	Appendix	2.2b-e)	
differed	 compared	 to	 the	 vehicle-treated	 cells	 (Fig.	3.4a	 and	 Appendix	 2.2a).	
For	instance,	 in	 the	 case	 of	 all	 Bi-treated	 cells	 (Fig.	 3.4b-e	 and	 Appendix	 2.2b-e),	
cellular	Ca	concentration	appeared	higher	than	the	vehicle-treated	cells	(Fig.	3.4a	and	
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Appendix	 2.2a)	 as	 evident	 in	 the	 Ca	 range	 (maximum	 quantity	 detected	 in	 vehicle-
treated	 cells	 ranged	 from	 0.027−0.0344	 μg/cm2,	 Bi-treated	 cells	 0.0507−0.371	
μg/cm2)	and	the	higher	definition	in	the	Ca	maps.	
The	elemental	quantifications	of	 the	cytoplasmic	and	nuclear	 regions	of	 the	 thin-
sections	obtained	from	vehicle-,	BiNSAID-	and	BSS-treated	HCT-8	cells	are	presented	
in	Figure	3.5.		Since	quantification	of	the	entire	cellular	contents	is	not	possible	from	a	
thin-section,	 the	 quantifications	 are	 represented	 per	 unit	 area	 (μm2).	 Statistical	
analysis	shows	that	there	were	no	significant	differences	in	the	cytoplasmic	or	nuclear	
P	 concentrations	 in	 the	 vehicle-treated	 cells	 compared	 to	 the	 Bi-treated	 cells	
(Fig.	3.5a).		The	concentration	of	Zn	was	significantly	elevated	in	the	cytoplasm	of	the	
Bi(difl)3-treated	 cells,	 and	 the	 nucleus	 of	 the	 Bi(mef)3-treated	 cells	 compared	 to	 the	
vehicle-treated	 cells	 (P	 ≤	 0.05	 and	 P	≤	0.01,	 respectively);	 however,	 no	 significant	
changes	were	observed	in	the	Zn	content	of	the	Bi(tolf)3-treated	cells	compared	to	the	
vehicle-treated	cells	(Fig.	3.5b).			
The	concentration	of	Ca	was	significantly	 increased	 in	 the	cytoplasm	and	nucleus	
of	 the	 Bi(mef)3-treated	 cells	 (both	 P	 ≤	 0.001)	 compared	 to	 the	 vehicle-treated	 cells	
(Fig.	3.5c).		There	were	no	significant	fluctuations	in	Ca	in	the	cytoplasm	of	any	of	the	
other	Bi-treated	cells	(Fig.	3.5c).		An	increase	in	Ca	(1.4–1.8	fold)	was	observed	in	the	
nucleus	of	the	other	Bi-treated	cell	groups	(Fig.	3.5c),	although	this	increase	was	only	
significant	in	the	Bi(difl)3-treated	cells	(P	≤	0.05).	 	Negligible	levels	of	intracellular	Bi	
were	detected	in	the	cytoplasm	and	nucleus	of	the	vehicle-	and	BSS-treated	cells	(Fig.	
3.5d);	 however,	 the	 BiNSAID-treated	 cells	 showed	 large	 fluctuations	 in	 the	
intracellular	levels	of	Bi	in	both	the	cytoplasm	and	the	nucleus.	
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Figure	3.5:	Quantifications	of:	(a)	P;	(b)	Zn;	(c)	Ca;	and	(d)	Bi,	in	the	cytoplasmic	and	nuclear	
regions	 of	 the	 HCT-8	 thin-sectioned	 cells	 following	 24-h	 treatment	 with	 vehicle	
(2%	DMSO	v/v),	or	the	specified	Bi	compounds	(40	μM).		All	data	were	collected	using	a	0.3	μm	
stepsize	and	a	2.5	s	dwell	time.		Data	are	presented	as	mean	±	s.d.	where	n	=	3	(except	Bi(tolf)3,	
n	=	4,	and	BSS,	n	=	2).	 	Significance	with	respect	to	the	vehicle-treated	sample	is	indicated	by	
*	P	≤	0.05,	 **	P	 ≤	0.01,	 ***	P	 ≤	0.001.	 	The	 cytoplasm	and	nucleus	were	analysed	as	 separate	
groups.		
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3.4 Discussion	
3.4.1 GFAAS	uptake	studies	
Quantitative	studies	of	the	cellular	uptake	of	Bi	resulting	from	treatment	of	HCT-8	
cells	with	BiNSAIDs	were	performed	to	determine	whether	there	was	any	correlation	
between	 Bi	 uptake,	 and	 the	 stability	 and/or	 toxicity	 of	 the	 BiNSAIDs	 (results	
presented	in	Chapter	2).		It	is	important	to	note	that	the	trypan	blue	exclusion	assays	
(Fig.	3.2a)	showed	that	the	membrane	integrity	remained	intact	in	the	majority	of	the	
cells;	therefore,	uptake	of	the	BiNSAIDs	most	likely	occurs	through	an	uncompromised	
cell	membrane.	 	 In	order	 to	 rationalise	how	 the	BiNSAIDs	enter	 the	HCT-8	 cells,	 the	
documented	mechanisms	 by	which	 Bi(III)	 complexes	 and	 NSAIDs	 enter	mammalian	
cells	must	also	be	considered	in	the	following	discussion.	
	The	 results	 from	 the	 GFAAS	 studies	 showed	 that	 24-h	 treatment	 of	 HCT-8	 cells	
with	 15-μM	 or	 40-μM	 Bi(tolf)3	 resulted	 in	 substantially	 higher	 Bi	 uptake	 compared	
with	the	analogous	concentrations	of	the	other	Bi	complexes	(Fig.	3.2b).		Importantly,	
the	 results	 from	 the	 NMR	 stability	 studies	 (Section	 2.3.1)	 of	 Bi(tolf)3	 also	 indicated	
that		Bi	 remains	 coordinated	 to	 tolf	 in	 the	 cell	medium	 for	 the	 duration	 of	 the	 24-h	
treatment.	 	 Accordingly,	 the	 Bi	 uptake	 associated	 with	 Bi(tolf)3	 treatment	 must	 be	
facilitated	by	the	NSAID	or	the	overall	lipophilicity	of	the	complex.		There	are	at	least	
two	known	mechanisms	of	NSAID	diffusion	across	 the	membranes	of	 the	cells	 in	 the	
upper	 and	 lower	 intestines.	 	 The	 first	 is	 the	 monocarboxylate/H+	 transporters	 [38]	
while	 the	 second	 is	 a	 pH-dependent,	 but	 non-carrier	 mediated	 absorption	 of	
NSAIDs	[39].	 	The	first	mechanism	is	highly	unlikely	for	the	intact	Bi(tolf)3	as	the	tolf	
carboxylate	 necessary	 for	 interaction	 with	 monocarboxylate/H+	 transporters	 is	
unavailable	due	to	the	coordination	to	Bi.		Given	that	the	complex	likely	remains	intact	
in	the	cell	medium,	it	is	more	likely	that	the	lipophilicity	of	the	complex,	imparted	by	
the	 coordinated	 tolf,	 is	 facilitating	 interaction	 and	 diffusion	 through	 the	 cell	
membrane.		 A	passive	 transport	mechanism	 for	Bi	 compounds	has	been	observed	 in	
recent	studies	performed	by	other	researchers.		Hong	et	al.	[40]	have	shown	that	HK-2	
human	proximal	tubular	cells	treated	with	CBS	(0.5	mM)	over	24	h,	exhibited	a	pattern	
of	 Bi	 saturation	 that	 was	 consistent	 with	 the	 profile	 of	 passive	 transport.	 	 More	
recently,	 neutron	 reflectometry	 experiments	 performed	 by	 Brown	 and	 Dillon	 ([41]	
and	unpublished	work)	showed	that	Bi(tolf)3	interacted	with	the	head	groups	of	lipid	
bilayer	 membrane	 mimics	 and	 partitioned	 into	 the	 tail	 region	 of	 the	 membranes	
(comprised	 of	 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine	 (POPC)	 molecules).	
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While	 these	 experiments	 were	 performed	 in	 a	 non-cell	 system,	 they	 showed	 that	
Bi(tolf)3	 was	 able	 to	 displace	 lipid	 molecules,	 which	 provides	 credence	 to	 the	
hypothesis	 that	 passive	 diffusion	 is	 a	 potential	 uptake	 mechanism	 employed	 by	
Bi(tolf)3	to	pass	through	the	cell	membrane	and	accumulate	in	HCT-8	cells.	
The	 much	 lower	 Bi	 uptake	 associated	 with	 the	 Bi(mef)3-	 and	 Bi(difl)3-treated	
cells	(Fig.	3.2)	can	probably	be	attributed	to	the	differing	stability	and	reactions	of	the	
complexes	 in	 the	 cell	 medium	 as	 observed	 by	 NMR	 spectroscopic	
investigations	(Section	2.3.1).		Given	the	structural	similarities	in	the	tolf	and	mef,	one	
would	 expect	 that	 Bi	 uptake	 would	 be	 similar	 for	 both	 Bi(tolf)3	 and	 Bi(mef)3	
treatment.		However,	the	lower	Bi	uptake	is	consistent	with	the	Bi(mef)3	NMR	stability	
studies	 (Section	 2.3.1)	 that	 indicated	 that	 mef	 dissociates	 from	 Bi.	 	 As	 such,	 the	 Bi	
uptake	would	not	be	facilitated	by	the	lipophilicity	that	would	be	imparted	by	mef	and	
its	subsequent	interactions	with	the	membrane.			
Interestingly,	 Bi(mef)3-treated	 cells	 only	 exhibited	 1.5	 times	 greater	 Bi	 uptake	
compared	 with	 the	 Bi(difl)3-treated	 cells	 despite	 the	 more	 substantial	 difference	 in	
toxicity	of	 	40-μM	Bi(mef)3-	and	Bi(difl)3-	(approximately	50%	versus	20%	reduction	
of	 MTT	 conversion,	 respectively	 (Section	 2.3.2).	 	 The	 NMR	 results	 indicated	 that	
glucose	may	interact	with	the	Bi(difl)3	complex.		It	might	be	possible	that	glucose	may	
facilitate	 uptake	 of	 any	 Bi(difl)2(glu)	 or	 Bi(difl)(glu)2	 species	 that	 are	 formed.		
Unfortunately,	given	that	the	glucosyl	1H	NMR	signals	only	represented	approximately	
1/6	 that	 of	 the	 difl	 signals,	 one	 would	 not	 expect	 a	 significant	 increase	 in	 the	
detectable	Bi	found	in	the	cells.		
Another	observation	from	this	study	was	the	high	Bi	detected	for	the	BSS-treated	
cells.	 	 For	 instance,	 the	 cellular	 Bi	 was	 approximately	 4−10	 times	 higher	 than	 all	
BiNSAID-treated	cells	for	the	15	μM	treatment,	and	approximately	4	times	higher	than	
Bi(mef)3	 and	 Bi(difl)3	 for	 the	 40	 μM	 treatment.	 	 It	 is	 proposed	 that	 the	 increased	
cellular	Bi	associated	with	the	BSS-treated	cells	(as	compared	to	the	BiNSAID-treated	
cells)	 was	 due	 to	 extracellular	 bound	 Bi	 that	 could	 not	 be	 completely	 removed	 by	
washing	 the	 cells	 using	 the	 protocol	 employed	 for	 GFAAS	 cell	 sample	 preparation	
(Section	 3.2.3.1).		 Inspection	 of	 the	 treatment	 dishes	 revealed	 that	 BSS	was	 far	 less	
soluble	than	the	BiNSAIDs	as	noted	by	the	precipitation	in	the	treatment	medium.		The	
adherence	of	metal	complexes	to	the	exterior	of	the	cell	membrane	has	been	observed	
in	 other	 studies	 [42].	 	 Specifically,	 it	 was	 observed	 that	 during	 the	 preparation	 of	
Cr(NO3)3.9H2O-treated	 A549	 lung	 cancer	 cell	 samples	 for	 GFAAS	 analysis,	 the	 cell	
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pellets	 appeared	 blue	 in	 colour	 after	 several	 washes	 with	 PBS,	 followed	 by	 sterile	
saline	[42].		When	GFAAS	analysis	was	performed	on	only	the	intracellular	contents	of	
the	A549	cells,	 the	Cr	 content	of	 the	Cr(NO3)3.9H2O-treated	 cells	was	 reduced	 to	 the	
same	quantity	as	the	other	Cr(III)	complexes	tested	[42],	 indicating	that	the	majority	
of	the	Cr	was	associated	with	the	cell	membrane.		Unfortunately,	BSS	is	white	such	that	
its	appearance	in	the	cell	pellet	is	not	as	easily	discerned.	 	It	is	noteworthy,	however,	
that	 the	 GFAAS	 analysis	 of	 the	 BSS-treated	 cells	 differed	 when	 the	 more	 extensive	
washing,	 fixation	and	dehydration	protocol	used	 for	microprobe	SRXRF	analysis	was	
employed	 (Fig.	3.3).	 In	 contrast,	 no	 change	was	observed	 in	 the	 cellular	Bi	 following	
treatment	with	 the	 soluble	BiNSAIDs	 (Fig.	3.3).	 	 In	 addition,	 the	maximum	Bi	 counts	
detected	 in	 BSS-treated	 thin-sectioned	 cells	 were	 similar	 to	 the	 Bi	 content	 of	 the	
vehicle-treated	cells	(Fig.	3.4)	indicating	there	was	negligible	intracellular	Bi.		
It	 is	 important	to	note	that	the	GFAAS	analyses	do	not	provide	information	about	
the	 mechanisms	 by	 which	 “unbound”	 Bi	 enters	 and	 accumulates	 in	 cells.	 	 While	
beyond	the	scope	of	this	study,	some	assumptions	can	be	made	based	on	the	literature.		
Importantly,	 the	 mechanisms	 of	 uptake,	 accumulation	 and	 metabolism	 of	 Bi	 by	
mammalian	cells	are	poorly	understood.		There	is	evidence	that	suggests	that	Bi	binds	
strongly	to	the	enzyme	transferrin	(discussed	in	Section	1.4.1.1),	which	cycles	 in	and	
out	 of	 cells	 as	 a	 method	 of	 iron	 transport	 [43].	 	 Acknowledging	 that	 transferrin	
receptors	 are	 overexpressed	 in	 cancer	 cells	 [44-46]	 it	 is	 feasible	 that	 in	 the	 serum-
deficient	 (and	 Fe-deficient)	 cell	 medium	 used	 during	 treatment	 that	 Bi	 may	 be	
substituted	into	transferrin	for	uptake	into	the	cells.		Additionally,	it	has	been	reported	
that	 Bi	 has	 a	 high	 affinity	 for	 glutathione,	 a	 tripeptide	 that	 is	 present	 in	 cells	 in	
relatively	high	concentrations	(0.5–7	mM)	and	is	believed	to	play	a	role	in	Bi	transport	
in	cells	and	biofluids	 [47].	 	Recently,	 the	 importance	of	 the	 role	of	glutathione	 in	 the	
intracellular	transport	of	Bi	was	examined	in	HK-2	cells	treated	with	CBS,	whereby	it	
was	 apparent	 that	 glutathione	 depletion	 adversely	 affected	 the	 ability	 of	 the	 cell	 to	
detoxify	 itself	of	Bi	 [40].	 	As	such,	 it	 is	plausible	 that	glutathione	present	 in	 the	cells	
may	 assist	 in	 transporting	 unbound	 Bi	 (in	 the	 case	 of	 Bi(mef)3)	 in	 the	 HCT-8	 cells.		
Furthermore,	 if	 Bi(tolf)3	 enters	 the	 cell	 intact,	 as	 indicated	 by	 the	 NMR	 stability	
studies,	it	could	be	postulated	that	cellular	processes	result	in	the	release	of	tolf	from	
Bi,	whereby	the	mechanism	of	Bi	release	may	be	a	result	of	the	strong	affinity	of	Bi	for	
other	 more	 abundant	 intracellular	 ligands	 such	 as	 glutathione,	 metallothionein,	 	 or	
other	 metal-binding	 proteins	 that	 are	 responsible	 for	 intracellular	 transport	 of	
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endogenous	metal	ions	(such	as	Zn(II)	and	Fe(III)).			The	exact	uptake	and	metabolism	
pathways	of	the	BiNSAIDs	will	need	to	be	examined	in	future	studies.	
One	final	consideration	stemming	from	the	GFAAS	analysis	of	the	Bi-treated	cells	is	
the	 impact	 resulting	 from	 the	 Bi	 accumulation	 in	 the	 cells.	 	 At	 the	 lower	 treatment	
concentration	 (15	 μM	 Bi,	 which	 reflects	 the	 IC50	 value	 of	 Bi(tolf)3),	 the	 Bi	 uptake	
following	Bi(tolf)3	 treatment	was	only	 three	 times	higher	 than	 that	observed	 for	 the	
other	 BiNSAID	 treatments.	 	 Treatment	 with	 the	 higher	 concentration	 (40	 μM),	
however,	resulted	in	substantial	Bi	accumulation	in	the	cells	in	high	quantities.		These	
results	highlight	the	question	as	to	where	the	Bi	is	localising	in	the	cells	with	respect	to	
the	mechanisms	of	action	of	the	BiNSAIDs,	as	addressed	in	Section	3.4.2.	
3.4.2 Microprobe	SRXRF	spectroscopy	of	thin-sectioned	cells	
Microprobe	SRXRF	was	utilised	as	a	 sensitive	 technique	 to	determine	subcellular	
location	 of	 Bi	 in	 thin-sectioned	 HCT-8	 cells	 to	 glean	 some	 information	 regarding	
mechanisms	 of	 action	 of	 the	BiNSAIDs.	 	 The	 results	 from	 the	GFAAS	 cellular	 uptake	
studies	(Section	3.3.2)	demonstrated	that	the	total	cellular	Bi	concentration	remained	
essentially	 the	same	 following	a	comparison	of	 the	cell	preparation	procedures	used	
for	 thin-sectioning	 versus	 normal	 washing	 procedures	 (with	 the	 exception	 of	 BSS-
treated	 samples;	 Section	 3.2.3.1	 and	 3.4.1),	 suggesting	 that	 there	was	 no	 significant	
difference	 in	 Bi	 leaching	 from	 the	 cells	 using	 the	 fixation	 procedures	 employed	 for	
sample	preparation	for	the	microprobe	SRXRF	imaging.	 	However,	it	should	be	noted	
that	 it	 can	 be	 assumed	 that	 under	 those	 conditions	 Bi	 does	 not	 leach	 into	 any	 of	
solutions	 used	 during	 the	 washing	 steps	 in	 the	 normal	 GFAAS	 sample	 preparation	
method	(Section	3.2.3.1).			
The	 consistent	 trend	 observed	 from	 the	 microprobe	 SRXRF	 imaging	 of	 thin-
sectioned	cells	was	that	the	intracellular	fate	of	Bi	was	essentially	the	same,	regardless	
of	the	BiNSAID	administered.		In	the	majority	of	BiNSAID-treated	cells	discrete	Bi	hot	
spots	 were	 detected	 in	 the	 cytoplasm;	 however,	 there	 was	 some	 evidence	 that	 Bi	
might	accumulate	 in	 (or	around)	 the	nucleus.	 	These	 findings	need	 to	be	 considered	
with	 respect	 to	 a	 number	 of	 potential	 chemotherapeutic	 targets	 including	 (i)	 the	
nucleus,	(ii)	COX,	and	(iii)	mitochondria,	and	potential	detoxification	mechanisms	via	
accumulation	in	(iv)	lysosomes.	
The	first	potential	target	for	discussion	is	the	cell	nucleus,	which	is	relevant	due	to	
the	fact	that	it	is	a	common	target	for	anti-cancer	agents.		It	was	noted	that	there	was	
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disperse	 distribution	 of	 Bi	 throughout	 the	 cell	 nucleus	 in	 one	 BiNSAID-treated	 cell,	
(Bi(mef)3-treated	 Cell	 A,	 Fig.	 3.4c).	 	 Of	 the	 approximately	 twenty	 cells	 studied,	
however,	 this	result	was	atypical	and	raises	 the	question	of	whether	 this	occurs	 in	a	
greater	 number	 of	 cells	 (if	 a	 larger	 sample	 size	 was	 studied).	 In	 other	 microprobe	
SRXRF	 studies	 of	 the	 clinically-used	 drugs,	 arsenite	 [30]	 and	 cisplatin	 [23],	
colocalisation	 of	 As	 and	 Pt	 (respectively)	 was	 evident	 in	 the	 nucleus	 of	 a	 high	
proportion	of	the	drug-treated	cells,	which	is	consistent	with	the	main	mechanism	of	
anti-cancer	action	of	these	compounds,	whereby	DNA	is	the	relevant	target.		Given	that	
there	is	little	evidence	of	Bi	accumulation	in	the	nucleus	of	the	other	BiNSAID-treated	
cells	 (very	 low	 proportion	 of	 Bi-treated	 cells	 compared	 to	 every	 cell	 analysed	
following	treatment	with	Pt	drugs	[23]	and	As	compounds	[30]),	it	appeared	unlikely	
that	the	main	target	of	BiNSAIDs	was	DNA	in	HCT-8	cells.		
As	 described	 in	 Sections	 1.2.3	 and	1.2.4,	 the	 chemopreventive/chemotherapeutic	
nature	of	NSAIDs	 is	perceived	 from	their	ability	 to	 inhibit	COX-2.	 	The	COX	enzymes	
are	 membrane-bound	 enzymes,	 specifically	 located	 on	 the	 endoplasmic	 reticulum	
(COX-1	and	COX-2),	plasma	membrane	(COX-1	and	COX-2)	or	 the	nuclear	membrane	
(COX-2	only)	 [48,	49].	 	The	 colocalisation	maps	 (Appendix	2.4)	 indicated	 that	Bi	hot	
spots	 were	 not	 located	 in	 close	 proximity	 to	 the	 plasma	 membrane.	 	 However,	 a	
number	of	Bi	hot	spots	were	located	in	close	proximity	to	the	nucleus	as	shown	in	the	
colocalisation	maps	(Appendix	2.4	a(i),	a(ii),	b(i),	b(ii),	and	c(i)).	 	While	this	does	not	
provide	 indisputable	 evidence	 of	 BiNSAID	 localisation	 at	 the	 site	 of	 COX,	 it	 does	
provide	 evidence	 that	 places	 Bi	 in	 the	 vicinity	 of	 COX-2.	 	In	 the	 instance	 that	 the	
BiNSAID	remains	 intact,	 this	suggests	that	the	mobility	 is	such	that	there	 is	potential	
for	the	interaction	with	COX.	 	It	 is	important	to	note	that	it	 is	 likely	that	the	BiNSAID	
also	dissociates	inside	the	cell	as	implied	by	the	PGE2	production	assays	(Section	2.3.4)	
as	a	free	carboxylate	is	required	to	interact	with	the	COX-2	active	site.		Consequently,	it	
would	be	beneficial	to	study	the	location	of	the	NSAID.		Unfortunately,	direct	probing	
of	the	NSAID	using	microprobe	SRXRF	is	not	feasible	as	the	chemical	elements	of	the	
NSAIDs	 are	 endogenous	 to	 the	 cell	 and	 cannot	 be	 discerned.	 	 An	 alternative	 study	
worth	 considering	might	 be	 the	 substitution	 of	 an	 element	 such	 as	 Br	 for	 Cl	 (in	 the	
instance	of	tolf).		Additionally,	the	use	of	COX-2-specific	antibody	with	Au	nanoparticle	
labelling	 and	 microprobe	 SRXRF	 could	 be	 used	 to	 image	 Au	 and	 Bi	 and	 determine	
colocalisation	akin	to	an	experiment	reported	by	Yuan	et	al.	[50].		
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Due	to	beam	time	restrictions,	the	amount	of	samples	that	could	be	analysed	was	
limited.	 	 Samples	 for	 microprobe	 SRXRF	 were	 prepared	 following	 4-h	 or	 24-h	
treatment	with	 the	Bi	 compounds,	however,	only	4-h	Bi(mef)3-treated	samples	were	
analysed	(Appendix	2.3).		Negligible	Bi	was	observed	 in	 the	4-h	Bi(mef)3-treated	 cell	
microprobe	SRXRF	elemental	maps	(Appendix	2.3),	indicating	that	any	Bi	taken	up	by	
the	cells	 is	 lower	 than	 the	detection	 limit.	 	There	are	 two	notable	observations	 from	
these	 results.	 Firstly,	 given	 that	 the	 NMR	 studies	 (Section	 2.3.1)	 suggested	 that	
Bi(mef)3	 is	unstable	 in	the	cell	medium,	the	uptake	and	 localisation	of	Bi	may	not	be	
indicative	of	COX.	 	Secondly,	 it	would	appear	that	a	 longer	 incubation	time	(>	4	h)	 is	
required	for	significant	uptake	of	Bi	(Fig.	3.5	and	Appendix	2.2)	if	it	is	not	bound	to	an	
NSAID.	 	Further	beam	time	would	be	required	 to	study	 the	elemental	distribution	of	
the	 4-h	 Bi(tolf)3-	 and	 Bi(difl)3-treated	 cells	 in	 order	 to	 determine	 the	 concentration	
and	location	of	Bi	of	the	stable	complexes.	
The	 third	potential	mechanism	of	 action	of	BiNSAIDs	 that	 is	worth	 addressing	 is	
targeting	 the	 mitochondria.	 The	 validity	 of	 this	 mechanism	 stems	 from	 results	
reported	 in	Chapter	 2	 (toxicity	 and	 cell	 death	 assays)	 since	 the	 intrinsic	 pathway	of	
apoptosis	 is	 inextricably	 linked	with	mitochondrial	 health	 [51].	 	 The	 size	of	 some	of	
the	 hot	 spots	 detected	 in	 the	 microprobe	 SRXRF	 studies	 are	 similar	 to	 the	 size	
reported	 for	mitochondria	 (0.5−10	μm)	 [52,	 53].	 A	means	 for	 determining	 if	 Bi	was	
located	 in	 the	mitochondria	 is	 to	examine	whether	 it	 is	colocalised	with	Fe	since	 the	
mitochondria	primarily	consume	Fe	for	the	synthesis	of	heme	and	Fe–S	clusters	and	as	
such	 serve	 as	 the	 centre	 for	 cellular	 Fe	 homeostasis	 [54].	 A	 study	 by	
Morrison	et	al.	[28]	 showed	 that	 Gd(III)	 from	 several	 Gd(III)	 complexes	 colocalised	
with	 Fe	 that	 was	 contained	 in	 the	 mitochondria	 of	 T98G	 human	 glioblastoma	
multiforme	 cells.	 Unfortunately,	 examination	 of	 the	 thin-sectioned	 cell	 maps	 in	 the	
current	 study	 failed	 to	 discriminate	 Fe	 from	 the	 background	 (data	 not	 shown),	 thus	
the	 colocalisation	 of	 Fe	 with	 other	 elements	 (such	 as	 Bi)	 could	 not	 be	 definitively	
established.	 	 Alternatively,	 Ca	 has	 been	 shown	 to	 localise	 in	 the	 euchromatin	 and	
mitochondria	[55].	 	Mitochondria	are	vital	for	maintaining	Ca2+	homeostasis	and	play	
an	important	role	in	Ca2+	storage	in	the	cell	[56].		However,	there	was	little	evidence	to	
show	colocalisation	of	Ca	and	Bi	in	the	cytoplasm	where	mitochondria	would	be	found.		
For	 example,	 only	 one	 Bi(mef)3-treated	 cell	 showed	 any	 colocalisation	 with	 Ca	
(Appendix	 2.4,	 Fig.	 3.4,	 Cell	A).	 	 Coincidentally,	 this	was	 the	 only	Bi-treated	 cell	 that	
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displayed	 nuclear	 Bi	 localisation,	 which	 was	 an	 exception	 compared	 to	 the	 other	
BiNSAID-treated	cells.	
The	final	site	of	possible	Bi	intracellular	localisation	that	needs	to	be	considered	is	
the	 lysosomes.	 	 Lysosomes	 are	 membrane-bound,	 acidic	 organelles	 that	 play	 an	
important	role	in	removing	cellular	waste.		Lysosomes	contain	acid	hydrolases,	which	
are	responsible	for	the	degradation	of	unwanted	cellular	biomolecules	[57].		Previous	
reports	 following	 autometallography	 studies	 have	 shown	 that	 Bi	 accumulates	 in	
lysosomes	of	various	cell	 types,	 including	kidney	cells,	macrophages,	motor	neurons,	
ganglion,	Leydig	and	Sertoli	cells	in	rats	as	part	of	a	detoxification	process	[10-12,	16].		
More	recently,	Hong	et	al.	[40]	have	performed	fluorescence	microscopy	experiments	
that	 showed	 that	Bi	 colocalised	 in	 lysosomes	of	CBS-treated	 (0.5	mM)	HK-2	 (human	
proximal	 tubular)	 cells.	 	 The	 microprobe	 SRXRF	 results	 are	 consistent	 with	 these	
observations	since	the	small	hot	spots	of	the	Bi	are	similar	 in	size	to	 lysosomes	(50–
500	nm	diameter)	 [58,	59].	 	There	are	 two	possible	explanations	 for	 the	diversity	 in	
the	 size	 and	 number	 of	 the	Bi	 hot	 spots	 that	were	 observed	 in	 the	BiNSAID-treated	
cells	 in	 this	 study;	 firstly,	 since	 the	 thin-section	 represents	 a	 1-μm	 slice	 of	 the	 cell,	
there	may	be	heterogeneous	distribution	throughout	the	cell.	 	Secondly,	the	variation	
in	 the	 size	 of	 lysosomes	 could	 be	 the	 result	 of	 certain	 cellular	 events;	 for	 instance	
events	 leading	to	the	 fusion	of	multiple	 lysosomes	with	autophagosomes	resulting	 in	
autolysosomes	with	increased	size	and	reduced	lysosome	number	[60].		It	is	unknown	
whether	 these	 lysosomes	 are	 excreted	 from	 the	 cells	 over	 time,	 which	 may	 also	
account	for	the	diversity	in	the	distribution	and	the	number	of	the	lysosomes	present.		
Unfortunately,	 due	 to	 the	 limitation	 in	 spatial	 resolution	 (beam	 dimensions	 (0.3	 ×	
0.3	μm2)	and	step	size	(0.3	μm)	associated	with	this	technique,	any	lysosomes	smaller	
than	300	nm	would	not	 be	 easily	 detected.	 Given	 the	 evidence	 in	 the	 literature	 that	
shows	that	Bi	localises	in	lysosomes	of	many	other	cell	types,	and	without	evidence	of	
colocalisation	 with	 mitochondrion-related	 elements	 (Fe	 &	 Ca),	 it	 is	 rational	 to	
conclude	 that	 the	 Bi	 hot	 spots	 observed	 in	 the	 present	 study	 are	 indicative	 of	
lysosomes	 rather	 than	 mitochondria.	 Further	 experiments	 such	 as	 transmission	
electron	microscopy	could	be	performed	to	unequivocally	confirm	this	is	the	case.		
There	were	a	few	interesting	observations	emanating	from	the	microprobe	SRXRF	
imaging	with	respect	to	the	distribution	and	changes	in	Ca	concentration	that	warrant	
discussion.	 	 The	 first	 observation	was	 the	 increase	 in	 nuclear	 Ca	 localisation	 of	 the	
Bi-treated	cells	(Fig.	3.5).	 	This	observation	has	been	reported	by	Lui	and	Huang	[61]	
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and	Munro	et	al.	[30]	in	arsenite-treated	CHO-K1	and	Hep-G2	cells,	respectively.		Both	
studies	 [30,	 61]	 concluded	 that	 the	mechanism	 of	 toxicity	 of	 arsenite	might	 involve	
disturbances	in	intracellular	Ca	homeostasis,	a	known	indicator	of	apoptosis	[62].		The	
results	obtained	from	the	toxicity	assays	in	Chapter	2	indicated	that	the	health	of	the	
cells	 was	 affected	 in	 all	 BiNSAID	 treatments	 at	 the	 treatment	 concentration	 and	
treatment	time	chosen	for	the	microprobe	SRXRF	cell	sample	treatment	(40	μM,	24	h).		
Additionally,	 the	 redistribution	 of	 Ca	 as	 indicated	 by	 the	microprobe	 SRXRF	 studies	
reported	 herein,	 coupled	 with	 the	 cell	 death	 studies	 in	 Chapter	 2,	 suggests	 that	
BiNSAID-induced	apoptosis	is	associated	with	a	disruption	of	Ca	homeostasis.		Similar	
to	 the	 conclusions	 drawn	 by	Munro	 et	 al.	 [30],	 it	 is	 unclear	 from	 the	 present	 study	
whether	 the	 redistribution	 of	 nuclear	 Ca	 is	 related	 to	 drug-induced	 mitochondrial	
damage	 or	 another	 intracellular	 source	 of	 Ca	 such	 as	 disruption	 to	 the	 endoplasmic	
reticulum	leading	to	the	release	of	Ca	into	the	cytosol	[63].			
The	 increase	 in	 Ca	 concentration	 in	 the	 nucleus	 of	 the	 BSS-treated	 cells	was	 the	
second	 interesting	observation,	 since	 low	 toxic	 effects	were	observed	 in	HCT-8	 cells	
following	treatment	with	BSS	(40	μM,	24	h)	in	the	toxicity	assays	reported	in	Chapter	
2.	 	It	 has	 been	 observed	 in	 normal	 human	 gastric	 mucous	 epithelial	 cells	 that	
treatment	with	BSS	increased	intracellular	Ca2+	[64].	 	The	increased	concentration	of	
Ca2+	promoted	p44/p42	and	p38	MAP-kinase	activation,	and	subsequently	stimulated	
the	 growth	 of	 the	 gastric	mucous	 epithelial	 cells	 [64]. Given	 that	 the	metabolism	 of	
normal	 cells	 differs	 to	 that	 of	 cancer	 cells	 [65],	 further	 studies	would	 be	 needed	 to	
determine	 the	 significance	 of	 intracellular	 Ca2+	 flux	 in	 BSS-treated	 HCT-8	 cells.		
Additionally,	 it	 cannot	 be	 ruled	 out	 that	 the	 Ca	 redistribution	 within	 BSS-treated	
HCT-8	cells	may	alternatively	be	due	to	salicylate	rather	than	Bi.			
Thirdly,	 elemental	quantification	of	 the	 thin-sectioned	cells	 showed	 that	Bi(mef)3	
significantly	 increased	 cytosolic	 and	 nuclear	 levels	 of	 Ca	 compared	 to	 the	
vehicle-treated	cells.		As	such,	this	might	suggest	that	Bi(mef)3	induces	apoptosis	via	a	
pathway	which	is	attenuated	to	the	effects	of	Ca2+	compared	to	Bi(tolf)3	and	Bi(difl)3.		
Given	that	Bi(mef)3	caused	such	a	significant	increase	in	[Ca2+]i	compared	to	the	other	
Bi	 compounds	 at	 the	 same	 treatment	 concentration,	 it	 seems	 unlikely	 that	 Bi	 alone	
would	be	the	cause	of	the	increase.		This	raises	the	question	as	to	whether	the	effect	on	
[Ca2+]i	is	due	to	the	ligand	alone	or	the	combination	of	Bi	and	ligand.		As	such,	further	
experiments	 could	 be	 performed	 to	 shed	 more	 light	 on	 the	 effects	 of	 Bi-	 and	
NSAID-induced	 toxicity	 on	 intracellular	 Ca	 concentration	 and	 distribution.	 One	
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approach	 could	be	 the	preparation	of	NSAID-treated	 samples	 for	microprobe	SRXRF	
analysis	 to	 compare	 to	 the	 BiNSAID-treated	 samples	 (Fig.	 3.4	 and	 Appendix	 2.2).		
Alternatively,	 bulk	 cell	 assays	 (with	 the	 advantage	 of	 increased	 statistical	 power)	
could	be	performed	to	quantify	[Ca2+]i	levels	using	a	technique	such	as	flow	cytometry	
and	 a	 Ca	 fluorescent	 probe	 such	 as	 Fluo-4-AM	 [63].	 	 Additionally,	 co-stained	 cells	
containing	a	calcium	fluorescent	probe	and	a	nuclear	dye	such	as	Hoechst	33342	could	
be	analysed	using	fluorescence	microscopy	[66].	
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3.5 Chapter	summary	
The	aim	of	 this	Chapter	was	 to	quantify	Bi	 cellular	uptake	and	 the	 localisation	 in	
HCT-8	 cells	 following	 treatment	 with	 BiNSAIDs	 to	 further	 examine	 potential	
mechanisms	of	cell	toxicity.		Specifically:	
i. The	 most	 striking	 result	 from	 the	 GFAAS	 study	 was	 that	 Bi	 uptake	 was	
influenced	 by	 the	 treatment	 concentration,	 whereby	 a	 higher	 treatment	
concentration	(40	µM)	resulted	in	increased	Bi	uptake	by	BiNSAID-treated	cells	
(ranging	 from	5	 to	340	times)	compared	 to	 the	 lower	concentration	(15	µM).	
The	most	toxic	BiNSAID,	Bi(tolf)3,	showed	the	highest	concentration	of	cellular	
Bi	 at	 both	 treatment	 concentrations	 15	 µM	 and	 40	µM	 (24	h),	 while	 the	
Bi(mef)3-	and	Bi(difl)3-treated	cells	showed	similar	quantities	of	cellular	Bi	at	
both	treatment	concentrations	tested.	 	The	uptake	of	Bi	may	be	influenced	by	
stability,	whereby	Bi(tolf)3	showed	substantially	greater	Bi	uptake	and	was	the	
most	stable	of	the	BiNSAIDs	as	determined	by	NMR	spectroscopy	(Chapter	2).		
ii. The	 microprobe	 SRXRF	 imaging	 of	 thin-sectioned	 cells	 showed	 that	 Bi	
generally	accumulates	in	discrete	hot	spots	found	in	the	cytoplasm.		The	size	of	
the	hot	spots	is	consistent	with	two	possible	intracellular	fates.		The	first	is	the	
accumulation	of	Bi	within	that	of	the	cells	detoxification	organelles,	lysosomes.		
Additionally,	 the	close	proximity	of	 the	Bi	hot	spots	to	the	nuclear	membrane	
(and	 location	 of	 COX-2),	 may	 suggest	 that	 intracellular	 movement	 of	 Bi	 can	
occur.		However,	this	second	proposition	requires	further	investigation.	
While	 the	 GFAAS	 results	 indicated	 substantially	 greater	 Bi	 uptake	 for	 Bi(tolf)3	
(versus	 Bi(mef)3	 and	 Bi(difl)3),	 which	 paralleled	 the	 greater	 toxicity	 and	 greater	
inhibition	 of	 PGE2	 production	 of	 the	 former	 complex,	 the	microprobe	 SRXRF	 results	
showed	 less	 compelling	 differences	with	 respect	 to	 the	 toxicities.	 	 Of	 course	 greater	
insight	 into	 the	 disparity	 between	 the	 cellular	 quantities	 of	 Bi	 associated	 with	 the	
different	 BiNSAID	 treatments	 could	 be	 obtained	 following	 studies	 of	 NSAID	 uptake,	
which	is	challenging	work	and	has	been	commenced	by	Spremo	and	Dillon	([67]	and	
unpublished	 results)	 and	 is	 continued	 Brown	 and	 Dillon	 ([41],	 and	 unpublished	
results).		 	
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Chapter	4. 		
Synchrotron	radiation	infrared	microspectroscopy	
studies	of	live	HCT-8	cells	treated	with	BiNSAIDs	
and	NSAIDs	
	
	
	
	
In	 the	 last	 decade	 there	 has	 been	 an	 increase	 in	 the	 use	 of	 synchrotron	 radiation	
infrared	 microspectroscopy	 (SR-IRMS)	 for	 the	 study	 of	 single	 mammalian	 cells	 to	
discern	biomolecular	changes	that	are	associated	with	disease	and	disease	treatment.	
This	 Chapter	 describes	 live	 cell	 SR-IRMS	 experiments	 performed	 at	 the	 Australian	
Synchrotron	(Clayton,	Australia)	for	the	analysis	of	HCT-8	cells	following	exposure	to	
BiNSAIDs	 or	 NSAIDs	 in	 order	 to:	 (i)	 study	 global	 biomolecular	 variations,	
(ii)	determine	whether	any	changes	are	reflective	of	the	mechanisms	of	cell	death,	and	
(iii)	 identify	 whether	 the	 coordination	 of	 NSAIDs	 to	 Bi	 results	 in	 alterations	 in	 the	
biomolecular	 effects	 of	 NSAIDs.	 	 A	 multivariate	 approach,	 Principal	 Component	
Analysis	 (PCA),	was	 applied	 to	 discriminate	 the	 spectral	 differences	 associated	with	
the	different	cell	treatments.	
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4.1 Introduction	
Identifying	 cellular	 events	 that	 occur	 as	 a	 result	 of	 exposure	 to	 a	
chemotherapeutic	agent	is	necessary	to	understand	how	the	drug	affects	a	cancer	cell.	
Specific	 biological	 assays	 can	 be	 used	 to	 probe	mechanisms	 of	 action,	 a	 selection	 of	
which	 are	 discussed	 in	 Chapter	 2.	 	 Alternatively,	 Fourier	 transform	 infrared	(FTIR)	
spectroscopy,	which	probes	chemical	changes,	is	being	increasingly	utilised	as	a	rapid,	
non-destructive,	 label-free	 technique	 for	 studying	 the	 biochemistry	 of	 biological	
materials	 [1].	 	 The	 coupling	 of	 FTIR	 spectroscopy	with	microscopy	 and	 synchrotron	
light	 has	 allowed	 researchers	 to	 simultaneously	 probe	 a	 large	 number	 of	
macromolecules	 present	 within	 a	 single	 cell	 [1].	 	Importantly,	 detection	 of	
simultaneous	 changes	 in	 the	molecular	 composition	 of	 single	 cells	 can	 assist	 in	 the	
identification	 of	 biological	 processes	 that	 can	 then	 be	 probed	 further	 using	
complementary	techniques.		
4.1.1 FTIR	spectroscopy	of	biological	molecules	
FTIR	 spectroscopy	 is	 a	 technique	 traditionally	 employed	 by	 chemists	 and	
materials	scientists	for	the	identification	and	molecular	analysis	of	chemicals.		Selected	
frequencies	(energies)	of	IR	radiation	are	absorbed	by	molecules	at	energies	required	
to	 cause	 vibrational	 excitation	 of	 bonds	 within	 a	 molecule	 [2].	 	 The	 characteristic	
vibrations	of	each	chemical	group	give	rise	 to	a	spectrum	that	enables	elucidation	of	
the	 identity	 of	 a	 molecule	 [2].	 	 As	 demonstrated	 in	 Figure	 4.1,	 IR	 active	 molecules	
display	 two	 fundamental	modes	 of	 vibration	which	 include:	 (i)	 stretching	 vibrations	
(symmetric	 or	 asymmetric	motion	 of	 two	or	more	 atoms	bonded	 to	 a	 central	 atom)	
resulting	from	a	change	in	bond	lengths,	and	(ii)	bending	vibrations	(including	out	of	
plane	motions,	 twisting	 and	wagging,	 and	 in	 plane	motions,	 rocking	 and	 scissoring)	
resulting	from	a	change	in	bond	angles	[2].			
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Figure	4.1:	Fundamental	modes	of	vibration	of	IR	active	molecules.	
	
	
The	 IR	 spectrum	 can	 be	 subdivided	 into	 three	 regions,	 the	 near-IR,	mid-IR	 and	
far-IR	 regions,	 encompassing	 the	 red	 end	 of	 the	 visible	 spectrum	 at	 769	 nm	
(13000	cm−1)	to	the	beginning	of	the	microwave	region	at	0.1	mm	(100	cm−1)	[2].		The	
mid-IR	range	(4000–400	cm−1)	encompasses	the	molecular	‘fingerprint’	region	that	is	
frequently	used	to	study	structural	and	chemical	information	of	organic	molecules	and	
biological	samples	alike	[2].		
Eukaryotic	 cells	 are	 comprised	of	 protein,	DNA,	RNA,	 carbohydrates,	 and	 lipids.	
Each	 of	 these	 biomolecules	 produces	 a	 unique,	 yet	 complex	 IR	 spectrum	 due	 to	 the	
distinctive	molecular	bonds	present	in	their	structures,	as	demonstrated	in	Figure	4.2.	
As	 such,	 the	 IR	 spectrum	 of	 a	mammalian	 cell	 exhibits	 a	 superposition	 of	 all	 of	 the	
biomolecules	 contained	 in	 the	 cell	 (Fig.	 4.2).		 Generalised	 assignments	 for	
characteristic	IR	bands	associated	with	biological	materials,	including	eukaryotic	cells,	
are	presented	in	Table	4.1.		
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Figure	4.2:	Typical	IR	signatures	of	biological	materials.		Adapted	from	Miller	et	al.	[3].		
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Table	4.1:	Generalised	assignments	of	characteristic	IR	bands	of	biological	and	eukaryotic	
cell	spectra	[2,	4].	
Wavenumber		
(cm−1)	
Assignment	 Associated	
biomolecule	
2955	 νas(C−H)	of	CH3	 Lipid/phospholipid	
2930	 νas(C−H)	of	CH2	 Lipid/phospholipid	
2898	 ν(C−H)	of	methine	 Lipid/phospholipid	
2870	 νs(C−H)	of	CH3	 Lipid/phospholipid	
2850	 νs(C−H)	of	CH2	 Lipid/phospholipid	
1740	 ν(C=O)	ester	 Lipid/phospholipid	
1720	 ν(C=O)	ester	 DNA	
1680–1715	 ν(C=O)	 Nucleic	acids	
1653	 ν(C=O)/ν(C−N)/δ(N−H),	amide	I	 Protein	
1567–1520	 ν(C−N)/δ(N−H),	amide	II	 Protein	
1515	 Tyrosine	band	 Protein	
1470	 δas(C−H)	of	CH2	 Lipid/phospholipid	
1420	 νs(COO−)	 Protein	
1310–1240	 ν(C−N)/δ(N−H)/ν(C=O)/ν(O=C−N),	amide	III	 Protein	
1232	 νas(PO2−)	 Nucleic	acids	
1170	 νas(CO−O−C)	 Lipid	
1080	 ν(C−O−P),	νs(PO2−)	 Nucleic	acids	
1050	 ν(C−O)	 Carbohydrate	
Key:	ν	=	stretching	vibrations,	δ	=	bending	vibrations,	s	=	symmetric,	as	=	asymmetric.	
4.1.2 FTIR	microscopy	and	synchrotron	sources	
The	coupling	of	modern	FTIR	spectrometers	with	purpose	built	 IR	microscopes,	
has	 allowed	 researchers	 to	 study	 samples	 on	 a	microscopic	 scale	 [1,	 5].	 	 One	 of	 the	
limitations	 of	 conventional	 lab-based	 FTIR	 microspectroscopy	 is	 the	 low	 intrinsic	
brightness	 which	 limits	 the	 smallest	 practical	 spot	 size	 (defined	 by	 the	 microscope	
masking	 aperture)	 to	 approximately	 20–40	 μm	 at	 the	 expense	 of	 signal-to-								
noise	[1,	 5].	 	This	 represents	 a	 major	 limitation	 when	 examining	 cells	 and	 cell	
organelles	 [1,	 5].	 	 Conversely,	 a	 synchrotron	 light	 source	 produces	 light	with	 higher	
brilliance	 (increased	 photon	 flux)	 which	 when	 focused	 to	 narrow	 range	 emission	
angles	 [5]	with	microscope	apertures	(5–20	μm)	results	 in	 the	 inherently	bright	and	
highly	 focused	 synchrotron	 light	 that	 facilitates	 the	 analysis	 of	micrometre	 samples	
with	 high	 signal-to-noise	 [1].	 	 The	 main	 restrictions,	 however,	 stem	 from	 the	
diffraction	 limit	 [1].	 For	 instance,	 the	 diffraction	 limit	 in	 the	 mid-IR	 region	 (3500–
650	cm−1)	is	approximately	1.4–7.7	μm	for	a	conventional	confocal	microscope	which	
approaches	λ/2	[1].	 	
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4.1.3 Infrared	microspectroscopy	studies	of	drug	effects	on	cancer	cells	
More	recent	developments	of	infrared	microspectroscopy	(IRMS)	in	conventional	
lab-based	 settings,	 and	 the	 increasing	 utilisation	 of	 synchrotron	 radiation	 (SR)	 light	
sources	has	allowed	a	number	of	researchers	to	study	the	effects	of	clinically-used	(or	
potential)	 anti-cancer	 drugs	 on	 cancer	 tissue	 or	 cells,	 at	 single-cell	 (and	 even	
subcellular)	resolution	[6-14].		The	study	of	drug	effects	on	cancer	cells	using	the	IRMS	
approach	has	a	number	of	perceived	advantages	in	a	clinical	setting.	 	For	instance,	in	
cancer	 treatments	 where	 multiple	 drug	 combinations	 are	 recommended	 for	 the	
treatment	of	specific	types	of	cancer	(such	as	non-small	cell	 lung	cancer),	 it	has	been	
proposed	 that	 IRMS	 could	 potentially	 be	 employed	 to	 determine	 the	most	 effective	
combination	of	drugs	to	administer	to	each	individual	patient	[6].		Additionally,	IRMS	
could	 provide	 information	 on	 early	 cellular	 events	 to	 varied	 doses	 of	
chemotherapeutics	which	could	allow	clinicians	 to	determine	 the	minimum	effective	
dose	to	administer,	reducing	the	severity	of	chemotherapeutic	side	effects	[9].		In	this	
context,	IRMS	conceivably	provides	a	rapid,	sensitive	and	effective	means	to	improve	
the	treatment	of	cancer	with	long-term	beneficial	outcomes	for	patients	[6].	
As	IRMS	can	provide	a	global	view	of	the	effects	of	drug	treatment	on	all	cellular	
biomolecules	 (i.e.	 proteins,	 lipids,	 nucleic	 acids,	 carbohydrates),	 it	 is	 considered	 that	
the	 technique	 could	 potentially	 be	 used	 to	 identify	 possible	 modes	 of	 action	 of	 the	
drug,	 as	 changes	 to	 IRMS	 spectra	 may	 be	 correlated	 to	 alterations	 in	 biological	
function	specific	to	the	mode	of	action	[8].		A	recent	review	discusses	the	potential	use	
of	 IRMS	 as	 a	 fast	 and	 easy	 technique	 to	 determine	 the	 mechanisms	 of	 action	 of	
prospective	 candidate	 compounds	 in	 drug	 discovery	 programs	 [15],	 whereby	 the	
authors	 propose	 that	 IRMS	 this	 could	 help	 widen	 the	 screening	 process	 beyond	
conventional	toxicity	screening	methods.		In	order	to	develop	IRMS	for	clinical	use,	the	
characterisation	and	interpretation	of	the	spectral	changes	induced	by	drug	treatment	
on	cancer	cells	needs	to	be	fully	developed.		To	this	end,	a	number	of	research	groups	
have	used	IRMS	or	SR-IRMS	to	study	the	effects	of	various	chemotherapeutic	agents	on	
cancer	cells	in	vitro	[6-14].		A	selection	of	these	studies	is	summarised	in	Table	4.2.		On	
the	 cellular	 level,	 IRMS	 has	 been	 used	 to	 study	 events	 which	 are	 important	 for	 the	
fundamental	understanding	of	 cellular	processes	 such	as	 apoptosis/necrosis	 [16-21]	
and	stages	of	 cell	 cycle	 [16,	22],	 the	differences	between	proliferating	and	quiescent	
cells	[23],	differentiation	of	stem	cells	[24,	25]	and	blood	cells	[17],	and	the	effects	of	
ultraviolet	B	radiation	on	cells	[26,	27].		
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Table	 4.2:	 Summary	 of	 some	 IRMS	 or	 SR-IRMS	 studies	 that	 examined	 the	 effects	 of	
chemotherapeutic	agents	(either	potentially	or	clinically-used)	on	cancer	cells.	
Author	 Drug	(mechanism	of	
action)	and	
Cell	line	(cancer	type)	
Key	observations	
Bellisola	
et	al.	
[14]	
• Imatinib	mesylate	
(inhibits	ABL	tyrosine	
kinase	activity)	
• K562	(human	
erythroleukemic)	
• Hierarchical	Cluster	Analysis	showed	clustering	of	
the	spectra	of	single	K562	cells	treated	with	the	drug	
into	two	distinct	groups	corresponding	to	living	and	
to	apoptotic	cells	
• The	amide	I	peak	was	shifted	to	a	lower	wavenumber	
and	there	was	a	difference	in	the	absorbance	
associated	with	the	ν(C=O)	mode	of	phospholipids	at	
1736 cm−1	in	the	apoptotic	cell	population	
Chio-
Srichan	
et	al.	[7]	
• Hypocrellin	A	(HA,	lipid-
soluble	peryloquinone	
derivative,	isolated	from	
Hypocrella	bambusae)	
• HeLa	(human	cervical	
cancer)	
• Principal	component	analysis	(PCA)	showed	spectra	
collected	in	the	nucleus	differed	to	those	of	the	
cytoplasm	(nucleus	=	Ó	β-type	protein	structure)	
• Irradiated,	HA-treated	(6	h)	nuclear	spectra	
separated	from	non-irradiated	control,	and	HA-
treated	(30	min,	6	h	and	24	h)	spectra.		The	loadings	
plot	indicated	irradiation	caused	a	change	in	protein	
secondary	structure	(Ó	β-type	structure)	
Derenne	
et	al.	
[10]	
• Methotrexate	(MTX,	
antimetabolite	–	inhibits	
folic	acid	metabolism)	
• PC-3	(human	prostate	
cancer)	
• Student	t-tests	indicated	that	the	most	significant	
differences	caused	by	MTX	over	24	h	were	located	
between	1300–1000	cm−1	
• MTX	treatment	for	48	h	caused	significant	change	in	
the	protein	region	with	limited	changes	in	the	nucleic	
acid	region	compared	to	24	h	MTX-treated	spectra	
• The	results	suggested	that	MTX	metabolic	
perturbations	occur	in	two	steps	over	48	h	
Draux		
et	al.	
2009	[9]	
• Gemcitabine	(GMB,	
pyrimidine	
antimetabolite	–	inhibits	
DNA	replication	and	
repair)	
• Calu-1	(non-small	cell	
lung	cancer)	
• Spectral	effects	of	GMB	were	detectable,	and	
classifiable	(using	cluster	analysis)	at	sub-lethal	
doses	that	induced	weak-moderate	growth	inhibition	
(0.1–1	nM,	48–72	h,	but	not	24	h)	and	high	growth	
inhibition	(10–100	nM,	24–72	h)	
• Effects	observed	on	cell	populations	were	similar	to	
those	observed	on	single	cells	
Flower	
et	al.	
[12]	
• 	KF0101	(cytotoxic	gold	
complex),	cisplatin,	MTX,	
paclitaxel	(inhibits	
tubulin	destabilisation)	
and	5-fluorouracil	
(irreversible	inhibitor	of	
thymidylate	synthase)	
• A2780	(human	ovarian	
cancer)	
• Several	hundred	single	control	cell	spectra	were	
required	due	to	cell	cycle	heterogeneity	among	cells	
• PCA	showed	that	drug-treated	cell	spectra	clustered	
in	well-defined	areas	indicating	a	cell	cycle	specific	
response.		This	overlapped	with	a	small	region	of	
control	cells	with	some	spectra	appearing	outside	the	
control	cell	cluster,	deemed	to	be	“cell	cycle	plus”	
behaviour,	i.e.	due	to	drug	response	not	cell	cycle	
Gasper	
et	al.	[8]	
• Ouabain	(inhibits	
sodium	pump	activity)	
• PC-3	(human	prostate	
cancer)	
• Early	ouabain	treatment	(6	h)	induced	limited	
changes,	mainly	to	amide	I	and	fingerprint	region	
(1500–1200	cm−1)	compared	to	0	h	spectra	
• Extended	ouabain	treatment	(24	h)	caused	obvious	
changes	to	lipid-related	bands,	and	a	shift	in	the	
amide	I	band	compared	to	6-h	ouabain-treated	
spectra.		However,	few	further	effects	were	observed	
between	36	h	vs.	24	h	ouabain-treated	spectra	
Sulé-
Suso		
et	al.	[6]	
• GMB	(pyrimidine	anti-
metabolite)	
• A549	and	Calu-1	(non-
small	cell	lung	cancers)	
• Increased	intensity	of	1080	cm−1	following	GMB	
treatment	in	both	cell	lines	
• Increased	1080/1050	cm−1	band	ratio	up	to	LD50	
doses,	plateaued	at	higher	doses	in	both	cell	lines	
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Notably,	the	studies	presented	in	Table	4.2	were	performed	on	fixed	or	dried	cell	
samples.	 	Traditionally,	 IRMS	 sample	 preparation	 of	 mammalian	 cells	 involves	
chemical	fixation	(with	chemicals	such	as	formalin	or	ethanol)	onto	an	IR-transparent	
substrate	 (such	 as	MirrR	 Low-E	 coated	 slides,	 zinc	 selenide	 (ZnSe),	 barium	 fluoride	
(BaF2),	 or	 calcium	 fluoride	 (CaF2)	windows)	 [28].	 	While	 a	 general	 consensus	 in	 the	
literature	supports	the	validity	of	results	obtained	from	fixed	samples,	interest	in	the	
use	 of	 FTIR	 microspectroscopy	 studies	 employing	 live	 cells	 has	 grown	 in	 the	 last	
decade	 [29-40].	 	The	advantages	and	 limitations	of	SR-IRMS	studies	of	hydrated	 live	
cell	samples	will	be	discussed	in	the	following	section.	
	
4.1.4 SR-IRMS	of	live	cells:	advantages	and	disadvantages	
The	IRMS	analysis	of	living	cells	versus	fixed	cells	has	gained	attention	in	the	last	
decade	for	several	reasons.		These	include:	(i)	the	elimination	of	artefacts	arising	from	
chemical	 fixation,	 (ii)	 the	 minimisation	 of	 physical	 artefacts	 such	 as	 resonant	 Mie	
scatter	 (RMieS)	 in	 the	 spectra,	 and	 (iii)	 the	analysis	of	 cells	 in	 real-time,	providing	a	
means	 to	 monitor	 the	 biomolecular	 effects	 of	 cell	 events	 or	 drug	 treatment	 in													
situ	[41-43].		It	is	generally	recognised	that	a	bright	light	source	of	IR	photons,	such	as	
a	synchrotron,	 is	required	to	obtain	good	signal-to-noise	 from	single	 live	cell	spectra	
due	to	attenuation	of	the	IR	signal	caused	by	the	IR	beam	as	it	passes	through	two	IR	
transparent	windows,	cell	medium	and	the	hydrated	cell	[28].	 	However,	it	should	be	
noted	that	the	collection	of	live	cell	spectra	has	also	been	successfully	performed	using	
conventional	bench-top	IR	light	sources	[33,	35].		
In	 the	 past	 decade,	 live	 cell	 experiments	 have	 been	 made	 possible	 by	 the	
development	 and	 fabrication	 of	 purpose-built	 chambers	 for	 the	maintenance	 of	 cell	
hydration	 during	 data	 collection.	 	The	 simplest	 designs	 involve	 placing	 the	 cells	
between	 two	 IR	 transparent	 windows	 (e.g.	 CaF2,	 ZnSe,	 or	 diamond)	 separated	 by	 a	
spacer	 (<	12	 μm)	 in	 a	 demountable	 holder.		 These	 setups	 have	 been	 utilised	 in	 a	
number	 of	 studies	 [16,	 32,	 44-49]	 wherein	 these	 devices	 have	 been	 employed	
successfully	 for	 short-term	 analyses	 of	 live	 cells.	 	 The	 holders	 are	 not	 generally	
suitable	for	 long-term	(>	2	h)	measurements	due	to	the	 loss	of	cell	medium	[50].	 	To	
this	 end,	 more	 elaborately	 designed	 micro-machined	 thin-reservoirs	 have	 been	
employed	for	live	cell	studies	[23,	33],	while	a	multi-faceted,	fully	sealed	fluidic	device	
was	 designed	 and	 employed	 in	 studies	 reported	 by	Vaccari	 et	 al.	 [34].	 	 In	 the	 latter	
system,	 the	 cells	 are	 introduced	 into	 the	 device	 via	 a	 syringe	 pump.	 	 Additionally,	
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lithographed	biocompatible	materials	were	used	to	create	separate	chambers	for	the	
cells,	 fresh	cell	medium	and	air	background	measurements	 [34].	 	Other	groups	have	
developed	more	complex	flow	chambers	with	an	open-channel	geometry	[51,	52].		
One	of	the	reasons	that	significant	effort	has	focused	on	maintaining	hydration	is	
to	simulate	the	biochemistry	of	mammalian	cells,	and	their	biomolecules,	in	particular	
nucleic	acid	bands.		For	instance,	Whelan	et	al.	[42]	reported	that	dehydration	causes	a	
B-like	to	A-like	transition	 in	 the	DNA	of	several	eukaryotic	cells	and	that	 the	reverse	
A-like	to	B-like	transition	occurs	upon	rehydration.		This	work	also	showed	that	upon	
rehydration	 of	 the	 cells,	 sharp	 DNA-specific	 bands	 were	 observed;	 however,	 these	
bands	 were	 previously	 broader	 and	 less	 intense	 when	 dehydrated.	 	Furthermore,	
Vaccari	 and	 co-workers	 [34]	 performed	 a	 study	 to	 investigate	 the	 effects	 of	 cell	
fixation	methods	(air	drying,	ethanol,	and	 formalin)	on	 the	SR-IRMS	spectra	of	U937	
monocytes	compared	to	the	SR-IRMS	spectra	of	the	living	U937	cells.		Importantly,	this	
study	 showed	 that	 while	 formalin	 fixation	 produced	 spectra	 that	 were	 the	 most	
similar	 to	 those	 from	 live	 cells	 (particularly	 in	 the	 lipid	and	protein	 regions),	 effects	
were	observed	in	the	DNA	absorptions.	 	For	instance,	the	band	centred	at	1717	cm−1	
(reflective	of	base	pairing	of	nucleic	acids	 in	 the	B-form)	was	pronounced	 in	 the	 live	
cell	spectra,	but	absent	in	the	chemical-fixed	and	dried	cell	spectra.	
The	second	advantage	of	performing	SR-IRMS	studies	of	live,	hydrated	cells	is	the	
minimisation	 of	 dispersion	 effects,	 which	 is	 an	 issue	 that	 affects	 fixed	 cell	 studies.		
Dispersion	artefacts	 such	as	RMieS	can	arise	 in	 the	 spectra	of	 single	 cells,	which	are	
typically	8–30	μm	in	diameter	(and	spherical)	and	occurs	when	there	is	a	difference	in	
the	 refractive	 index	 between	 the	 cells	 and	 the	 surrounding	 environment	 [53].	 	 This	
occurs	when	the	IR	wavelength	(typically	3–10	μm,	or	3333–1000	cm−1)	 is	similar	 in	
size	to	the	diameter	of	the	cell	such	that	the	incident	IR	beam	is	scattered	as	it	contacts	
the	outer	edges	of	the	cell	resulting	in	the	distortion	of	the	collected	IR	spectrum	[53].		
Consequently,	RMieS	 can	be	observed	 in	 a	 single	 cell	 spectrum	as	 a	highly	distorted	
baseline	 (particularly,	 between	 2800–1700	 cm−1)	 and	 derivative-like	 peak	 shapes	
arising	from	predominant	bands	[54,	55].		Such	distortion	can	lead	to	alterations	in	the	
position	and	intensity	of	spectral	features,	in	particular	the	amide	I	band,	which	is	an	
important	 biomarker	 for	 diagnostics	 and	 an	 indicator	 of	 therapeutic	 response	 [53].		
The	recent	development	of	an	algorithm	to	correct	for	the	effects	of	RMieS	has	allowed	
researchers	to	remove	the	effects	of	RMieS	from	single	cell	spectra	[53,	56].		However,	
dispersion	effects	such	as	RMieS	are	generally	minimised	in	live	cell	studies	since	the	
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refractive	 index	 of	 the	 aqueous	 background	 closely	 matches	 that	 of	 the	 cell	 [28].		
Therefore,	there	is	no	need	to	apply	any	RMieS	compensation	methods,	saving	analysis	
time.	
Traditional	IRMS	studies	of	fixed	cells	only	allow	for	static	measurements	and	do	
not	allow	the	same	cells	 to	be	studied	at	 continuous	 time	points.	 	 In	contrast,	 in	 situ	
measurements	 associated	 with	 live	 cell	 studies	 are	 ideal	 for	 tracking	 drug-induced	
changes	in	the	same	cell	over	the	course	of	a	treatment	period.		For	instance,	the	effect	
of	 arsenite	 treatment	 (100	 μM)	 on	 K562	 leukaemia	 cells	 has	 been	 analysed	 in	
real-time	 in	 a	 purpose-built	 micro-fabricated	 chamber	 [32]	 at	 the	 Australian	
Synchrotron	[31].		The	authors	were	able	to	track	spectral	changes	consistent	with	the	
biochemistry	 of	 apoptosis	 induced	 by	 arsenite	 treatment.	 	Specifically,	 following	
40	min	of	exposure,	a	decrease	in	the	ν(C=O)	band	at	1742	cm−1	in	the	arsenite-treated	
cell	 spectra	was	 consistent	with	 lipid	membrane	 changes,	while	 the	 decrease	 in	 the	
intensities	of	the	νs(PO2−)	and	νas(PO2−)	was	attributed	to	the	IR	opaqueness	of	DNA	in	
an	 increasingly	 condensed	 state.	 	 Following	 100	 min	 incubation	 with	 arsenite,	 the	
intensity	of	the	νs(PO2−)	and	νas(PO2−)	was	attributed	to	DNA	fragmentation,	an	event	
in	later	stages	of	apoptosis.		A	significant	shift	in	the	amide	I	band	from	1642	cm−1	to	
1650	 cm−1	 in	 the	 arsenite-treated	 cell	 spectra	 was	 observed	 suggesting	 arsenate	
induces	changes	 in	the	composition	of	proteins	 in	the	cell	 (from	primarily	β-sheet	to	
α-helix/random	coil).	
The	 IRMS	analysis	of	 live	cells	 is	not	without	 its	disadvantages;	one	particularly	
difficult	challenge	to	overcome	is	 the	strong	IR	absorptivity	of	 the	water	molecule	 in	
aqueous	media.		The	normal	modes	of	liquid	water	include	the	asymmetric	stretching	
mode,	 the	 symmetric	 stretching	 mode,	 and	 the	 deformation	 (bending)	 mode	 that	
appear	at	~3600	cm−1,	~3450	cm−1,	and	~1643	cm−1,	respectively	[41].		A	broad	band	
centred	at	~2125	cm−1,	which	 is	 comprised	of	 a	 combination	of	 a	bending	band	and	
the	 librational	modes	of	water,	 can	also	be	visualised	 in	 cell	 spectra	between	2500–
1800	cm−1	[57].	 	The	water	band	of	particular	concern	for	IRMS	spectra	is	the	strong	
deformation	band	at	1640	cm−1	which	completely	overlaps	with	the	amide	I	band	and	
partially	with	the	amide	II	band	of	proteins	(Fig.	3.3a),	resulting	in	the	distortion	of	the	
intensity	 ratio	 of	 the	 amide	 I/amide	 II	 bands	 (Fig.	 4.3b)	 [33].	 	 There	 is	 currently	no	
general	 consensus	on	 the	approach	 to	 take	 to	 correct	 the	effects	of	water	 saturation	
from	 the	 spectrum	 of	 a	 cell,	 although	 a	 number	 of	 groups	 have	 developed	MATLAB	
algorithms	to	correct	for	the	absorption	of	water	[33,	34];	other	groups	have	opted	to	
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omit	 the	 amide	 region	 from	 chemometric	 analysis	 altogether	 due	 to	 the	 uncertainty	
surrounding	 the	 influence	 of	 water	 on	 this	 region	 of	 the	 spectrum	 and	 a	 lack	 of	 a	
reliable	compensation	method	[43].	 	Studies	assessing	the	use	of	non-aqueous	media	
have	also	been	performed	as	an	alternative	 to	address	 the	problems	associated	with	
water	contribution.		For	instance,	Soh	et	al.	[58]	have	tested	the	effects	of	incubation	of	
MGH-U1	 urothelial	 cancer	 cells	 and	 Caco-2	 cells	 with	 paraffin	 mineral	 oil	 or	
Fluorolube	 for	up	 to	120	min.	 	The	 results	 showed	 that	 cell	 viability	was	unaffected	
following	 2-h	 incubation	 in	 Fluorolube,	 and	 differential	 uptake	 of	 drugs	was	 similar	
between	 cells	 incubated	 with	 or	 without	 Fluorolube	 [58].	 	 FTIR	 mapping	 of	 cells	
incubated	 in	 Fluorolube	 was	 performed	 in	 reflectance	 and	 transmission	 modes,	
whereby	 the	 authors	 claimed	 that	 the	 latter	 proved	 best	 for	 spectroscopy	 [58].	
However,	a	comparison	between	the	spectral	differences	between	Fluorolube	and	cell	
medium	was	not	performed	or	commented	on	[58].	 	While	oil-based	materials	could	
potentially	be	employed	for	the	analysis	of	some	clinical	samples,	ideally	cell	medium	
would	be	best	employed	for	cell	studies	measuring	time-dependent	effects	of	drugs	in	
order	 to	maintain	 an	 environment	 that	 closely	matches	 the	 conditions	 employed	 in	
other	cell	based	assays,	particularly	in	the	case	of	longer	treatment	periods	(>	4	h).	
 
	
Figure	 4.3:	 (a)	 A	 single	 fixed	 HCT-8	 cell	 spectrum	 (—)	 superimposed	 with	 a	 spectrum	
collected	 from	cell	medium	(—).	 	The	overlap	of	 the	bending	mode	of	H2O	with	 the	amide	 I	
band	 of	 the	 cell	 spectrum	 can	 be	 visualised	 around	 1620	 cm−1.	 	 (b)	 The	 distortion	 of	 the	
amide	I	 to	 amide	 II	 band	 intensity	 ratio	 of	 an	 uncorrected,	 single	 live	 HCT-8	 cell	 spectrum	
collected	 in	 cell	 medium	 (cell	 medium	 was	 used	 for	 background	 reference	 during	 spectral	
acquisition).	
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4.1.5 Chapter	aims	
The	 work	 in	 the	 previous	 Chapter	 suggests	 that	 the	 BiNSAIDs,	 Bi(tolf)3	 and	
Bi(mef)3,	 cause	 toxicity	 towards	HCT-8	 cells	 that	 is	 approximately	 equivalent	 to	 the	
respective	 free	 NSAIDs,	 tolfH	 and	 mefH,	 while	 Bi(difl)3	 induced	 a	 greater	 toxic	
response	compared	to	diflH.		However,	the	exact	mechanisms	by	which	the	BiNSAIDs	
cause	toxicity	to	the	HCT-8	cells	are	currently	unknown.		It	is,	therefore,	important	to	
determine	 whether	 BiNSAIDs	 elicit	 toxicity	 through	 similar	 or	 new	 mechanisms	 of	
action	compared	to	the	uncomplexed	NSAIDs.	
While	 several	 groups	 have	 recently	 reported	 the	 results	 from	 SR-IRMS	 studies	
that	 employ	 live	 cells,	 and	 specifically	 the	 effects	 of	 drug	 compounds	 on	 cancer	 cell	
lines,	 there	are	currently	no	studies	that	have	examined	Bi(III)	complexes	or	NSAIDs	
on	 live	cancer	cells	using	this	 technique.	 	Additionally,	 there	 is	no	current	consensus	
on	 the	 pre-processing	 approach	 required	 to	 reduce	 the	 influence	 of	 strong	
absorptivity	 of	 water	 bands	 arising	 from	 the	 aqueous	 environment.	 	 As	 the	 use	 of	
SR-IRMS	 for	 studying	 the	 global	 biomolecular	 effects	 of	 drug-treated	 cells	 is	 still	 in	
relative	 infancy,	 the	 current	 study	 was	 performed	 to	 determine	 the	 usefulness	 of	
SR-IRMS	for	the	investigation	of	dominant	biomolecular	changes	that	occur	following	
drug	 administration,	 with	 the	 focus	 on	 the	 BiNSAIDs	 and	 NSAIDs	 relevant	 to	 this	
Thesis.	
Thus	the	specific	aims	of	this	Chapter	are:	
1. To	 discern	 any	 differences	 in	 the	 results	 of	 principal	 component	 analysis	
(PCA)	 performed	 on	 SR-IRMS	 spectra	 of	 HCT-8	 cells	 using	 two	 different	
approaches	 aimed	 to	 minimise	 the	 effects	 of	 background	 water:	 (i)	 pre-
processing	 using	 a	 water	 band	 subtraction	method,	 or	 (ii)	 omission	 of	 the	
amide	region	from	the	analysis.	
2. To	establish	 spectroscopically	 if	 the	biomolecular	 responses	of	BiNSAIDs	 in	
HCT-8	 cells	 can	 be	 differentiated	 from	 those	 of	 the	 corresponding	 free	
NSAIDs	following	short	(4	h)	and	prolonged	(24	h)	periods	of	drug	exposure.	
3. To	determine	whether	any	observed	changes	induced	by	BiNSAID/NSAID	are	
consistent	with	known	mechanisms	of	cell	death.	
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4.2 Materials	and	Methods	
4.2.1 Materials	
The	 materials	 employed	 for	 these	 studies	 are	 described	 in	 Sections	 2.2.1	 and	
3.2.1.	 	 Additional	 materials	 (specific	 to	 the	 experiments	 in	 this	 Chapter)	 include	
CELLSTAR®	 24-well	 tissue	 culture	 plates	 sourced	 from	 Greiner	 Bio-One	
(Kremsmünster,	 Austria)	 and	 polished	 CaF2	 windows	 (12	mm	 diameter,	 0.5	mm	
thickness)	manufactured	by	Crystran	Limited	(Poole,	England).	
	
4.2.2 General	cell	culture		
Live	 HCT-8	 cells	 were	 transported	 to	 the	 Australian	 Synchrotron	 (Clayton,	
Australia)	 and	 cultured	 onsite	 using	 the	 cell	 culture	 procedures	 described	 in	
Section	2.2.3.	
	
4.2.3 SR-IRMS	studies	
4.2.3.1 Preparation	of	cell	samples	
HCT-8	cells	(2.5	×	105	cells,	1	mL	growth	medium)	were	grown	directly	onto	CaF2	
windows	 (12	mm	 diameter,	 0.5	mm	 thickness)	 that	 were	 located	 in	 24-well	 cell	
culture	plates.		Since	the	cells	did	not	adhere	to	the	windows	rapidly,	a	stainless	steel	
spacer	with	a	5	mm	diameter	hole	was	placed	on	top	of	each	CaF2	window	to	create	a	
confined	area	 for	 the	 cells	 to	 attach.	 	Once	 the	HCT-8	 cells	had	adhered,	 the	 spacers	
were	 removed	 and	 the	 cells	 were	 incubated	 for	 a	 further	 period	 of	 time.	 	 No	
differences	 in	 cell	 morphology	 were	 noted	 between	 the	 method	 employed	 in	 this	
Chapter	 and	 the	 traditional	 cell	 culture	 method.	 	 Prior	 to	 treatment,	 the	 growth	
medium	was	removed	and	the	compounds	(initially	dissolved	in	DMSO,	and	added	to	
1	mL	RPMI-1640	medium	to	produce	a	final	DMSO	concentration	of	2%	v/v)	or	vehicle	
(1	mL	RPMI-1640,	2%	v/v	DMSO)	were	added	to	 the	well.	 	HCT-8	cells	were	 treated	
with	each	BiNSAID	at	a	concentration	equal	to	the	approximate	IC50	(as	determined	by	
MTT	assays,	 Section	2.3.2),	 or	 an	equimolar	 concentration	of	 the	 corresponding	 free	
NSAID.	 	 At	 the	 end	 of	 the	 4-	 or	 24-h	 period,	 the	 cells	 were	 washed	 once	 with	 PBS	
solution.		
SR-IRMS	spectra	of	 live	HCT-8	cells	were	collected	using	the	demountable	liquid	
cell	 shown	 in	 Figure	 4.4,	 details	 of	 which	 (design	 and	 specification)	 have	 been	
described	elsewhere	[32].		Firstly,	the	0.5-mm	thick	CaF2	window	onto	which	the	HCT-
8	cells	were	grown	was	placed	at	the	bottom	of	the	sample	holder	with	the	cell	surface	
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facing	upwards.		A	drop	of	cell	medium	(20	μL)	was	deposited	in	the	centre	of	the	CaF2	
window	directly	above	the	cells.	 	On	top	of	this	was	placed	the	0.5-mm	CaF2	window	
with	 the	 spacer	 that	 had	 been	 patterned	 by	 polymer	 spin	 coating	 and	 UV	
photolithography.	 	 This	 second	 CaF2	 window	was	 orientated	 such	 that	 the	 polymer	
spacer	 was	 in	 contact	 with	 the	 underlying	 CaF2	 window	 (Fig	 4.4a).	 	 Next,	 a	 plastic	
spacer	was	placed	on	top	of	the	CaF2	windows	(Fig.	4.4b),	after	which	was	placed	the	
top	 of	 the	 Thermo	micro-compression	 cell	 (Fig.	 4.4c).	 	 Excess	 liquid	was	 expressed	
through	a	gap	in	the	micro-fabricated	spacer	[32]	as	the	sample	holder	was	tightened	
and	as	the	cells	came	into	contact	with	the	top	window.		It	should	be	noted	that	HCT-8	
cells	are	generally	observed	as	a	mixture	of	individual	cells	or	as	monolayers	of	cells,	
which	is	typical	for	the	growth	pattern	of	the	cell	line.		Cells	that	grew	in	monolayers	
appeared	to	flatten	when	the	sample	holder	was	tightened.		It	was	also	observed	that	
the	monolayers	showed	signs	of	detachment	after	treatment,	which	would	account	for	
this	observation.	 	No	differences	to	the	morphology	of	the	single	cells	were	noted.	 	In	
order	 to	 obtain	 results	 representative	 of	 the	 entire	 population,	 effort	 was	 taken	 to	
collect	cell	spectra	from	both	single	cells	and	cells	that	could	be	defined	as	individual	
cells	in	the	cell	monolayer.		
	
Figure	4.4:	 Construction	 of	 the	 compression	 cell	 holder	 components	 employed	 for	 SR-IRMS	
measurements:	(a)	The	CaF2	window	onto	which	a	spacer	had	been	patterned	by	polymer	spin	
coating	and	UV	photolithography	was	placed	on	top	of	the	window	onto	which	the	HCT-8	cells	
were	grown.		The	cells	were	housed	in	the	centre	of	the	CaF2	window	and	the	channels	etched	
into	the	spacer	enabled	a	fully	aqueous	environment	to	be	maintained;	(b)	A	plastic	spacer	was	
placed	on	top	of	 the	etched	CaF2	window;	(c)	The	top	of	 the	Thermo	micro-compression	cell	
was	placed	on	top	of	 the	CaF2	windows	and	plastic	spacer	and	tightened	until	 the	cells	were	
observed	to	come	into	contact	with	the	top	etched	CaF2	window.	
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The	 live	 cell	 SR-IRMS	analyses	were	 limited	 to	 approximately	 100	min	 for	 each	
sample	 due	 to	 the	 loss	 of	 cell	medium	 from	 the	 demountable	 liquid	 cell	 used	 in	 the	
present	 study.	 	 As	 such,	 the	 cells	were	 treated	 in	 cell	 culture	 plates	 for	 the	 desired	
period	(4	h	or	24	h),	and	the	CaF2	substrate	with	the	droplet	of	fresh	cell	medium	was	
placed	in	the	demountable	cell	for	analysis.	
4.2.3.2 SR-IRMS	data	collection	
All	FTIR	spectroscopy	measurements	were	recorded	in	transmission	mode	at	the	
IRM	beamline	at	the	Australian	Synchrotron	(Clayton,	Australia).		The	setup	employed	
a	 Bruker	 Vertex	 V80v	 spectrometer	 coupled	 to	 a	Hyperion	 2000	microscope	with	 a	
liquid	nitrogen	cooled	narrow-band	mercury	cadmium	telluride	(MCT)	detector.	 	The	
microscope	 XYZ	 stage	 was	 housed	 in	 a	 nitrogen-purged	 atmosphere	 to	 minimise	
interference	 from	 atmospheric	 water	 vapor	 and	 carbon	 dioxide.	 	Spectra	 were	
acquired	 at	 4	cm−1	 resolution	 over	 the	 range	 3800–700	cm−1	 (Blackman–Harris	
3-Term	apodization,	Mertz	phase	correction	and	a	zero	fill	factor	of	2)	using	OPUS	6.5	
software	(Bruker	Optics	GmbH,	Ettlingen,	Germany).		The	knife-edge	aperture	was	set	
to	5	×	5	µm2	and	centred	over	each	cell	to	ensure	only	cell	material	was	analysed.		Each	
cell	spectrum	was	recorded	using	128	co-added	scans.	 	A	background	spectrum	(128	
co-added	scans)	of	cell	medium	was	recorded	after	collecting	every	 two	cell	 spectra.		
Cell	spectra	were	generally	collected	within	20–100	min	after	assembly	of	the	sample	
holder	as	the	cell	medium	began	to	evaporate	from	the	edges	of	the	sandwiched	CaF2	
windows	after	this	period.	
	
4.2.3.3 SR-IRMS	spectral	processing	and	chemometric	analysis	
The	first	stage	of	FTIR	spectral	processing	was	performed	using	OPUS	Version	7.0	
(Bruker	 Optics	 GmbH,	 Ettlingen,	 Germany)	 software.	 	 All	 spectra	were	 restricted	 to	
3020–1000	cm−1.	 	Although	 the	 samples	were	analysed	 in	 a	N2	purged	environment,	
weak	CO2	bands	were	observed	in	a	number	of	the	spectra.	 	As	such	the	atmospheric	
compensation	was	applied	to	minimise	the	appearance	of	CO2.		In	addition,	a	reference	
spectrum	 collected	 from	 the	 cell	 medium	 background	 for	 each	 sample	 (using	 the	
conditions	 described	 in	 Section	 4.2.3.2)	 was	 subtracted	 from	 each	 individual	 cell	
spectrum.		This	was	performed	in	the	interactive	mode	using	iterative	steps	to	ensure	
that	 the	 effects	 of	 the	 water	 spectrum	 were	 minimised	 without	 undue	
overcompensation	of	the	cell	spectrum	(Fig.	4.5);	the	correction	value	generally	varied	
Chapter	4.	Synchrotron	radiation	infrared	microspectroscopy		
	
	160	
from	 0	 to	 −0.09.	 	 Following	 water	 subtraction,	 each	 spectrum	 was	 rubberband	
baseline	 corrected	 using	 64	 baseline	 points.	 	The	 Unscrambler	 X	 software,	
Version	10.2	 (Camo,	 Oslo,	 Norway)	 was	 employed	 for	 chemometric	 analysis.	 	 The	
spectra	were	 analysed	 by	 PCA	 (full	 cross	 validation,	 7	 PCs)	 following	 derivatisation	
(second	 derivative,	 Savitzky-Golay	 algorithm,	 13	 smoothing	 points)	 and	 unit	 vector	
normalisation.	
	
Figure	4.5:	 Individual	 cell	 spectrum	 (—)	before	 (top	panel)	 and	after	 (bottom	panel)	water	
subtraction	to	a	correction	value	of	−0.04	using	OPUS	7.0.		A	reference	spectrum	collected	from	
the	cell	medium	background	is	represented	in	the	top	panel	(—).	 	
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4.3 Results	
4.3.1 Comparison	of	spectral	correction	factors	used	for	data	analysis	
In	 this	 Section	 the	 SR-IRMS	 spectra	 of	 HCT-8	 cells	 treated	 with	 RPMI-1640	
containing	DMSO	 (2%	 v/v,	 referred	 to	 herein	 as	 vehicle)	 and	HCT-8	 cells	 incubated	
with	RPMI-1640	(without	fetal	bovine	serum,	penicillin/streptomycin	or	GlutaMAXTM	
solutions,	referred	to	herein	as	cell	medium)	have	been	used	to:	(i)	describe	and	justify	
the	correction	processes	used	for	the	spectral	data	analyses	presented	in	this	Chapter	
(Sections	4.3.1.1	and	4.3.1.2),	 and	 (ii)	produce	control	data	 to	establish	whether	any	
differences	could	be	detected	in	the	biomolecular	signatures	of	the	treated	HCT-8	cells	
over	 the	 course	 of	 the	 drug	 treatment	 periods	 (4	 h,	 Section	 4.3.2,	 or	 24	 h,	
Section	4.3.3).		
In	 general,	 the	SR-IRMS	spectra	 collected	 from	 the	HCT-8	 cells	 (typical	 example	
shown	in	Fig.	4.6a)	exhibited	water	saturation.		This	was	observed	as	the	νs(OH)	band	
typically	 centred	 around	 3400	 cm−1	 (not	 shown	 in	 Fig.	 4.6a),	 a	 decrease	 in	 the	
intensity	 ratio	 of	 the	 amide	 I/amide	 II	 bands,	 and	 the	 presence	 of	 the	 water	
combination	 band	 between	 2500–1800	 cm−1,	 which	 creates	 a	 characteristic	 broad	
curve	in	the	spectrum	(indicated	by	the	leftmost	arrow	in	Fig.	4.6a).	 	As	explained	in	
Section	4.1.4,	the	presence	of	the	water	band	overlapping	the	amide	I	band	(and	to	a	
lesser	 extent	 the	 amide	 II	 band)	 presents	 one	 of	 the	 biggest	 challenges	 when	
interpreting	SR-IRMS	spectra	of	live	cells.		Two	approaches	were	taken	in	an	effort	to	
extract	and	interpret	the	biomolecular	differences	between	the	SR-IRMS	spectra	of	the	
cell	samples:	(i)	water	band	correction	using	spectral	subtraction,	and	(ii)	omission	of	
the	amide	I	and	amide	II	band	region	(1709–1486	cm−1)	from	PCA.		In	addition	to	the	
presence	 of	 strong	 water	 bands	 in	 the	 SR-IRMS	 spectra,	 high	 noise	 was	 observed	
below	1150	cm−1	as	a	result	of	the	poor	transmission	of	IR	light.		This	was	due	to	the	
combination	 of	 the	 two	 CaF2	windows	 and	 the	 small	 aperture	window	 (5	 ×	 5	 μm2)	
used	 in	 these	experiments.	As	 such,	 spectral	data	at	wavenumbers	below	1150	cm−1	
were	omitted	before	performing	the	PCA	presented	in	this	Chapter.	
4.3.1.1 Water	band	correction	using	a	spectral	subtraction	method	
The	 averaged,	 baseline	 corrected	 and	 vector	 normalised	 SR-IRMS	 spectra	 of				
HCT-8	cells	incubated	with	cell	medium	(4	h),	before	and	after	water	band	subtraction	
are	 shown	 in	Figure	4.6a.	 	As	 indicated	by	 the	 arrows	 in	Fig.	 4.6a,	 the	most	 striking	
difference	observed	between	the	non-subtracted	and	water	band	subtracted	SR-IRMS	
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spectra	 was	 the	 decrease	 in	 the	 absorbance	 of	 the	 amide	 II	 band	 (1548	 cm−1)	 in	
comparison	 to	 the	 amide	 I	 band	 (1653	cm−1),	 and	 the	 flattening	 of	 the	 water	
combination	 band	 between	 2500–1800	cm−1	 (this	 result	 was	 expected	 as	 the	 water	
combination	 band	 was	 used	 to	 determine	 the	 amount	 of	 correction	 to	 apply)	
producing	a	SR-IRMS	spectral	profile	in	the	amide	region	more	representative	of	that	
observed	from	fixed	cell	spectra	(see	Fig.	4.2).	
	
									 	
Figure	 4.6:	 (a)	 Averaged	 (n	 =	 59),	 baseline	 corrected	 (rubberband	 baseline	 corrected,	
64	baseline	 points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 4-h	 incubation	 in	 cell	
medium	 before	 (—),	 and	 after	 (—),	 water	 band	 subtraction.	 	 Black	 arrows	 indicate	 the	
spectral	 feature	 changes	 substantially	 affected	 by	 water	 band	 subtraction.	 	 (b)	 Unit	 vector	
normalised,	 second	 derivative	 of	 the	 spectra	 shown	 in	 (a).	 	 The	 wavenumbers	 in	 black	
represent	 the	non-corrected	band	positions,	while	wavenumbers	 in	 red	 represent	 the	water	
band	 subtracted	 band	 positions.	 The	 black	 arrows	 denote	 bands	 affected	 by	 water	 band	
subtraction.	
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Figure	 4.6b	 shows	 the	 averaged,	 normalised,	 second	 derivative	 spectra	 of	 the	
same	 SR-IRMS	 spectra	 presented	 in	 Figure	 4.6a.	 	The	 second	 derivative	
representations	 of	 the	 averaged	 SR-IRMS	 spectra	 were	 typically	 examined	 as	 they	
resolve	 the	overlapped	absorption	components,	which	provide	clearer	elucidation	of	
band	 positions	 and	 band	 shifts	 [59,	 60].	 	Compared	 to	 the	 non-subtracted	 second	
derivative	 spectrum,	 a	 very	 slight	 reduction	 in	 the	 intensity	 of	 the	 amide	 II	 band	
(1551	cm−1),	 the	 region	between	 the	 amide	 I	 and	 amide	 II	 bands	 (1601–1591	cm−1),	
and	the	ν(C=O)	band	(1714	cm−1)	were	observed	following	water	band	subtraction	(as	
indicated	 by	 the	 arrows	 in	 Fig.	 4.6b).	 	 Importantly,	 however,	 no	 differences	 were	
observed	 in	 the	 band	 positions	 between	 the	 non-subtracted	 and	 water	 band	
subtracted	 spectra	 (Fig.	 4.6b).	 	 Following	 the	 application	 of	water	 band	 subtraction,	
these	 observations	 were	 similarly	 noted	 when	 the	 averaged,	 normalised,	 second	
derivative	 SR-IRMS	 spectrum	 of	 the	 4-h	 vehicle-treated	 cells	 was	 examined	
(Appendix	3.1),	suggesting	that	the	routine	application	of	the	water	band	subtraction	
method	produces	a	consistent	response	across	different	samples.	
When	the	average	SR-IRMS	spectrum	of	HCT-8	cells	treated	with	cell	medium	was	
compared	to	that	of	the	vehicle,	before	water	band	subtraction	(Appendix	3.2),	 there	
was	only	a	slight	difference	 in	 the	 intensities	of	 the	major	bands.	 	Additionally,	band	
shifts	 of	 only	 1–2	 cm−1	 were	 observed	 in	 the	 bands	 in	 the	 CH2/CH3	 stretching	
region	(3000–2800	 cm−1),	 the	 lipid	 ν(C=O)	 band	 (1742	 cm−1)	 and	 the	 amide	 I	 band	
(1653	cm−1),	as	indicated	in	Appendix	3.2a.	 	Given	the	noise	observed	in	the	SR-IRMS	
spectra	below	1150	cm−1,	any	shifts	in	the	νs(PO2−)	band	at	1088	cm−1	are	unlikely	to	
be	 reliable	 and	 these	 observations	 have	 not	 been	 discussed	 further.	 	 Following	 the	
application	 of	water	 band	 subtraction,	 the	 intensities	 of	 the	 SR-IRMS	 spectra	 of	 cell	
medium-	 and	 vehicle-treated	 cells	 showed	 closer	 agreement	 (Appendix	 3.2b),	
particularly	 in	 the	 fingerprint	 region	 (1750–1000	 cm−1);	 however,	 there	 was	 an	
increase	in	the	absorbance	of	the	lipid	bands,	νas(CH3)	and	νas(CH2)	at	2958	cm−1	and	
2926	cm−1,	respectively,	in	the	average	vehicle-treated	spectrum.		It	is	noteworthy	that	
the	ν(C=O)	bands	of	 lipids	and	DNA	at	1742	cm−1	and	1714	cm−1,	 respectively,	were	
less	defined	following	water	band	subtraction	(Appendix	3.2b);	although,	examination	
of	 the	second	derivative	spectra	showed	no	shift	 in	wavenumber	 in	relation	to	 these	
bands	 (Appendix	 3.3a-b).	 	 In	 fact,	 very	 little	 difference	 was	 observed	 between	 the	
averaged	 second	 derivative	 spectra	 of	 cell	 medium-	 and	 vehicle-treated	 cells	 (4	 h)	
before	and	following	water	band	subtraction	(Appendix	3.3a-b).		 	
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4.3.1.2 Statistical	analysis	of	data:	Principal	component	analysis	(PCA)	
The	multivariate	 data	 analysis	 technique,	 PCA,	was	 employed	 in	 this	 study	 as	 a	
means	 to	 distinguish	 any	 biomolecular	 differences	 between	 the	 cell	 populations	
treated	with	BiNSAIDs	or	NSAIDs,	or	within	the	cell	populations	themselves.		As	the	IR	
spectra	contain	thousands	of	wavenumbers	(or	variables)	a	statistical	method	such	as	
PCA	is	employed	to	reduce	the	complexity	of	the	data	set,	by	creating	a	small	number	
of	uncorrelated	artificial	variables,	or	principal	components	(PCs),	that	will	account	for	
most	of	 the	variance	 in	 the	observed	variables	 [60].	 	The	sample	variance	of	 the	PCs	
are	 represented	by	eigenvalues	and	are	 ranked	according	 to	 their	magnitude,	where	
the	 first	 eigenvalues	 account	 for	 a	 large	 portion	 of	 the	 variance	 of	 the	 data	 [60].		
As	such,	 the	 first	 PC	 (PC-1)	 is	 the	 linear	 combination	 with	 maximal	 variance	 (the	
largest	eigenvalue),	and	the	second	PC	(PC-2)	represents	the	next	highest	variance	in	
an	orthogonal	direction	to	PC-1	[60,	61].	 	PCA	displays	the	main	patterns	as	a	scores	
matrix	(or	plot),	where	each	point	(score)	on	the	plot	represents	one	cell	spectrum;	as	
such,	 similar	 spectra	 cluster	 together,	 while	 dissimilar	 spectra	 appear	 further	 away	
from	 each	 other	 [61,	 62].	 	 Additionally,	 PCA	 produces	 loadings	 plots	 that	 provide	
information	 on	 the	 variables	 (spectral	 bands	 arising	 from	 differences	 in	 the	
biomolecular	groups	within	 the	samples	 in	 the	case	of	SR-IRMS	data),	which	are	 the	
determinants	for	the	clustering	visualised	in	the	scores	plots	[62].	 	 In	this	work,	PCA	
was	performed	on	second	derivative	SR-IRMS	spectra.	 	As	such,	positive	loadings	are	
associated	with	scores	in	the	negative	space	of	the	scores	plot,	and	negative	loadings	
are	 associated	 with	 positive	 scores	 [31].	 	Using	 PCA,	 the	 most	 significant	 spectral	
differences	and	trends	can	be	identified	[62].	
The	starting	point	was	 to	use	PCA	as	a	 tool	 to	evaluate	 the	effect	of	water	band	
subtraction.	 	PCA	 scores	 plots	were	 generated	 from	 spectra	without	 and	with	water	
band	subtraction	and	compared.		While	it	would	be	ideal	to	check	each	non-subtracted	
cell	 spectrum	 against	 the	 water	 band	 subtracted	 spectrum	 of	 each	 individually	
corrected	cell,	 this	process	would	be	extremely	time-consuming	given	the	number	of	
spectra	 collected.	 	The	 average	 spectra	 of	 the	 cell	 medium	 and	 vehicle-treated	 cell	
spectra	 (Appendix	 3.2	 and	 Appendix	 3.3)	 represent	 the	 average	 of	 over	 50	
unsynchronised	 living	 HCT-8	 cells;	 as	 such,	 differences	 between	 the	 spectra	 of	 cells	
within	 the	 population	 need	 to	 be	 examined	 in	 order	 to	 determine	 whether	 cells	
subjected	to	different	conditions	represent	biochemically	distinct	populations.	
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Figure	 4.7	 shows	 the	 PCA	 scores	 plot	 and	 corresponding	 loadings	 plots	 (3000–
2800	cm−1,	1790–1150	cm−1)	comparing	cell	medium-	and	vehicle-treated	cell	spectra,	
without	(Fig.	4.7a)	and	with	(Fig.	4.7b)	water	band	subtraction	applied.	 	While	some	
slight	changes	to	the	coordinates	of	several	of	the	scores	can	be	observed	(Fig.	4.7b),	
the	overall	distribution	of	the	scores	appears	very	similar	to	the	scores	plot	obtained	
from	 the	 spectra	without	water	band	 subtraction	 (Fig.	 4.7a).	 	Additionally,	 the	 same	
bands	 in	 the	 loadings	 plots	 of	 both	 the	 non-subtracted	 (Fig.	4.7a),	 and	 water	 band	
subtracted	 cells	 (Fig.	 4.7b)	were	 responsible	 for	 the	 distribution	 of	 the	 scores	 along	
the	PC-1	and	PC-2	axes.	 	Consequently,	 these	 results	 indicate	 that	 there	 is	negligible	
difference	 to	 the	outcome	of	 the	PCA	when	water	band	subtraction	 is	 applied	 to	 the	
SR-IRMS	spectra	of	the	HCT-8	cells	compared	to	non-subtracted	spectra.		
	
Figure	4.7:	PCA	scores	plot	(left)	and	corresponding	PC-1	(—)	and	PC-2	(—)	X-loadings	plots	
(right)	 of	 second	 derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	
SR-IRMS	spectra	obtained	 from	HCT-8	 cells	 treated	 for	4	h	with	 cell	medium	 (n),	 or	 vehicle	
(RPMI-1640,	DMSO	2%	v/v)	(l):	(a)	before	water	band	subtraction,	and	(b)	after	water	band	
subtraction.		PCA	was	performed	on	the	spectra,	encompassing	all	biological	regions	of	interest	
(3000–2800	cm−1,	1790–1150	cm−1).	
Chapter	4.	Synchrotron	radiation	infrared	microspectroscopy		
	
	166	
When	the	amide	bands	were	omitted	(1709–1486	cm−1)	from	the	PCA	(Fig.	4.8)	of	
second	 derivative	 SR-IRMS	 4-h	 cell	 medium-	 or	 vehicle-treated	 spectra,	 without	
(Fig.	4.8a)	 and	with	 (Fig.	 4.8b)	water	 band	 subtraction	 applied,	 there	was	 negligible	
difference	 observed	 between	 the	 scores	 plots	 of	 the	 non-subtracted	 or	 water	 band	
subtracted	 spectra.	 	 Additionally,	 negligible	 difference	was	 observed	 in	 the	 loadings	
plot	of	the	water	band	subtracted	spectra	(Fig.	4.8b)	compared	to	the	non-subtracted	
spectra	 (Fig.	 4.8a).	 Consequently,	 the	 analysis	 presented	 in	 the	 remainder	 of	 this	
Chapter	was	performed	on	non-subtracted	spectra.		
	
Figure	4.8:	PCA	scores	plot	(left)	and	corresponding	PC-1	and	PC-2	X-loadings	plots	(right)	of	
second	 derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	
spectra	 obtained	 from	 HCT-8	 cells	 treated	 for	 4	 h	 with	 cell	 medium	 (n),	 or	 vehicle	
(RPMI-1640,	DMSO	2%	v/v)	(l).		PCA	was	performed	on	the	spectra	(3000–2800	cm−1,	1790–
1710	cm−1,	 and	1485–1150	 cm−1)	with	 the	 omission	of	 the	 amide	 region	 (1709–1486	 cm−1):	
(a)	before	water	band	subtraction,	and	(b)	after	water	band	subtraction.	
	
4.3.1.3 Effects	of	vehicle	on	live	HCT-8	cells	(4-h	study)	
Having	shown	 the	 rationale	 for	 the	data	analysis,	 the	next	 step	was	 to	 interpret	
the	results	with	respect	to	the	cell	treatment.		Figure	4.7a	(Section	4.3.1.1)	shows	the	
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PCA	scores	plot	and	corresponding	loadings	plots	(3000–2800	cm−1,	1790–1150	cm−1)	
that	 compare	4-h	 cell	medium-	 and	 vehicle-treated	 cell	 spectra,	without	water	 band	
subtraction	applied.	 	The	scores	plot	shows	complete	overlap	of	the	cell	medium	and	
vehicle	 scores	 and	 no	 distinct	 clustering	 of	 either	 group.	 	 This	 result	 suggests	 that	
there	 were	 no	 substantial	 biomolecular	 differences	 between	 the	 two	 treatment	
groups,	 and	 that	 heterogeneity	 among	 the	 SR-IRMS	 spectra	 of	 the	 cells	 within	 each	
sample	is	responsible	for	the	distribution	of	the	scores	along	both	the	PC-1	and	PC-2	
axis.	 	 The	PC-1	 loadings	 plot	 indicated	 that	 the	 lipid-related	bands,	 νas(CH2),	 νs(CH2)	
and	ν(C=O)	(2924	cm−1,	2852	cm−1	and	1743	cm−1,	respectively),	and	loadings	related	
to	the	amide	I	band	(1662	cm−1,	1649	cm−1	and	1637	cm−1)	are	the	predominant	bands	
causing	 the	 distribution	 of	 the	 spectra	 along	 the	 PC-1	 axis.	 	 The	 PC-2	 loadings	 plot	
(Fig.	4.7a)	 indicated	 that	 the	 lipid-related	 bands,	 νas(CH2),	 νs(CH2)	 and	 ν(C=O)	
(2926	cm−1,	2854	cm−1	and	1745	cm−1,	respectively),	and	loadings	related	to	the	amide	
I	band	(1662	cm−1	and	1647	cm−1)	and	amide	II	band	(1562	cm−1	and	1539	cm−1)	are	
the	 predominant	 bands	 causing	 the	 distribution	 of	 the	 spectra	 along	 the	 PC-2	 axis.		
These	 results	 suggest	 that	 variations	 in	 cellular	 proteins	 and	 lipids	were	 present	 in	
each	 population.	 	 This	 result	 is	 not	 unexpected	 as	 the	 cells	 were	 not	 cell	 cycle	
synchronised;	 thus	 the	 distribution	 of	 cells	 throughout	 different	 phases	 of	 the	 cell	
cycle	could	be	the	likely	cause	of	heterogeneity	amongst	the	two	populations.		This	is	
also	 consistent	 with	 other	 live	 cell	 studies	 that	 have	 shown	 that	 cells	 have	 distinct	
biomolecular	signatures	at	different	phases	of	the	cell	cycle	[43].	
Figure	4.8a	shows	the	PCA	scores	and	loadings	plots	of	second	derivative	SR-IRMS	
4-h	 cell	medium-	 or	 vehicle-treated	 spectra	 following	 omission	 of	 the	 amide	 region	
(3000–2800	 cm−1,	 1790–1710	 cm−1,	 1485–1150	cm−1),	 without	 water	 band	
subtraction.		Both	the	cell	medium	and	the	vehicle	scores	were	distributed	across	both	
the	 positive	 and	 negative	 PC-1	 space.	 	 Once	 again,	 this	 suggests	 that	 heterogeneity	
exists	 within	 both	 cell	 populations,	 and	 that	 the	 biomolecular	 differences	 that	 exist	
within	 each	 sample	 are	more	 dominant	 than	 the	 biomolecular	 differences	 that	 exist	
between	 the	 two	 samples.	 	 In	 contrast	 to	 Figure	 4.7a	 (amide	 region	 included),	 the	
loadings	 plot	 in	 Figure	 4.8a	 shows	 that	 there	 are	 strong	 lipid-related	 loadings	 at	
2924	cm−1	(νas(CH2)),	2839	cm−1	(νs(CH2)),	and	1745	cm−1	(ν(C=O))	and	a	weak	loading	
at	 1464	cm−1	 (δ(CH2))	 that	 are	 responsible	 for	 the	 distribution	 of	 the	 scores	 along	
PC-1.	 	This	 observation	 suggests	 that	 variation	 in	 cellular	 lipids	 exists	 between	 the	
SR-IRMS	spectra	in	both	the	cell	medium-,	and	vehicle-treated	cell	populations.		Along	
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the	PC-2	space,	there	was	no	clear	delineation	of	the	two	samples,	although,	the	scores	
obtained	 from	 the	 cell	medium-treated	 cells	 appeared	predominantly	 in	 the	positive	
PC-2	space,	while	the	scores	from	vehicle-treated	cells	appeared	predominantly	in	the	
negative	 PC-2	 space.	 	 Figure	 4.8a	 shows	 that	 strong	 loadings	 in	 the	 region	 between	
1250-1150	cm−1	were	 observed,	 which	were	 not	 present	 in	 the	 loadings	 plot	 of	 the	
PCA	performed	with	the	amide	region	included	(Fig.	4.7a);	the	loadings	at	1252	cm−1,	
1238	 cm−1,	 and	 1227	 cm−1	 are	 associated	 with	 the	 νas(PO2−)	 band	 of	 nucleic	 acids.		
Additionally,	 the	derivative-like	bands	 at	2931	 cm−1	 and	2847	 cm−1	 are	 indicative	of	
band	 shifts	 of	 lipids.	 	These	 observations	may	 indicate	 that	 the	 4-h	DMSO	 (2%	 v/v)	
exposure	may	induce	changes	to	lipid	and	nucleic	acid	concentrations	in	HCT-8	cells.	
4.3.1.4 Effect	of	vehicle	on	live	HCT-8	cells	(24-h	study)	
HCT-8	 cells	 were	 incubated	 with	 cell	 medium	 or	 vehicle	 for	 24-h	 in	 order	 to	
correlate	with	the	treatment	period	employed	in	the	toxicity	and	uptake	experiments	
performed	 with	 the	 HCT-8	 cells	 (Chapter	 2	 and	 3,	 respectively).	 	The	 averaged,	
baseline	corrected	and	vector	normalised	SR-IRMS	spectra	of	HCT-8	cells	treated	with	
cell	medium	or	vehicle	(24	h),	before	and	following	water	band	subtraction	are	shown	
in	 Appendix	 3.4.	 	 Similar	 to	 the	 4-h	 samples	 (Appendix	 3.2),	 only	 small	 differences	
could	be	observed	when	comparing	the	24-h	average	cell	medium	and	vehicle-treated	
cell	spectra,	before	or	following	water	band	subtraction	(Appendix	3.4).	Additionally,	
the	effects	of	water	band	subtraction	were	also	consistent	with	the	effects	observed	on	
the	4-h	samples	(Appendix	3.2);	specifically,	the	intensity	ratio	of	the	amide	I/amide	II	
bands	 were	 affected,	 and	 the	 intensity	 of	 the	 ν(C=O)	 bands	 at	 1743	cm−1	 and	
1715	cm−1	were	slightly	reduced	(Appendix	3.4).	 	A	slight	shift	in	the	band	centres	of	
the	 ν(C=O)	 bands	 was	 observed	 following	 water	 band	 subtraction	 (Appendix	 3.4a	
and	b);	however,	no	band	shift	was	noted	in	the	respective	second	derivative	spectra	
(Appendix	3.5a	and	b).		Little	difference	was	observed	in	the	second	derivative	spectra	
when	comparing	the	cell	medium-	and	vehicle-treated	cells	with	the	exception	of	the	
line	 shape	 of	 the	 νas(PO2−)	 centred	 at	 1240	 cm−1	 (and	 shoulder	 at	 1227	 cm−1)	
(Appendix	3.5a	and	b).		This	might	indicate	that	the	presence	of	vehicle	induces	small	
changes	to	the	nucleic	acid	composition	of	the	HCT-8	cells	following	24-h	incubation.		
The	PCA	scores	plot	in	Figure	4.9a,	which	includes	the	amide	region	(3000–2800	cm−1,	
and	1790–1150	cm−1),	showed	there	was	no	delineation	of	the	24-h	cell	medium	and	
vehicle	scores	along	the	PC-1	or	PC-2	axes	between	the	sample	sets	suggesting	that	the	
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biomolecular	 differences	 that	 exist	within	 each	 sample	 are	more	 dominant	 than	 the	
biomolecular	differences	that	exist	between	the	two	samples.		The	PC-1	loadings	(Fig.	
4.9a)	 were	 attributable	 to	 CH2	 stretches	 at	 2924	cm−1	 and	 2852	cm−1	 (νas(CH2)	 and	
νs(CH2),	 respectively),	 and	 the	 ester	 stretch	 at	 1743	 cm−1	 (ν(C=O)),	which	 are	 bands	
associated	with	 lipids,	 amide-related	bands	at	1657	cm−1,	1549	cm−1,	 and	1398	cm−1	
(amide	 I,	amide	 II	and	νs(COO−)),	and	 the	ν(C=O)	band	at	1716	cm−1,	 related	 to	DNA.		
The	 derivative-like	 band	 shapes	 in	 the	 PC-2	 loadings	 plot	
(Fig.			4.9a)		indicated		that		shifts		in		the		positions		of		the		νas(CH2),			ν(C=O),			amide		I,	
amide	II	and	νas(PO2−)	bands	were	contributing	to	the	distribution	of	the	scores	along	
the	 PC-2	 axis.	 These	 observations	 suggest	 that	 intra-sample	 variations	 in	 the	
composition		of		lipid,		protein,		and		the		DNA		exist		within	both	of	the	cell	populations.		
	
Figure	4.9:	PCA	scores	plot	(left)	and	corresponding	PC-1	(—)	and	PC-2	(—)	X-loadings	plots	
(right)	 of	 second	 derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	
SR-IRMS	 spectra	 obtained	 from	HCT-8	 cells	 treated	 for	 24	 h	with	 cell	medium	 alone	(n),	 or	
vehicle	 (RPMI-1640,	 DMSO	 2%	 v/v)	 (l):	 (a)	 including	 the	 amide	 region	 (3000–2800	 cm−1,	
1790–1150	cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	 1790–1710	 cm−1,	
1485–1150	cm−1).		
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Once	 again,	 this	 observation	 could	 potentially	 be	 attributed	 to	 the	 lack	 of	 cell	 cycle	
synchronisation.	
Figure	 4.9b	 shows	 the	 PCA	 scores	 and	 loadings	 plots	 obtained	 using	 the	 cell	
medium-,	or	vehicle-treated	(24	h)	SR-IRMS	spectra	presented	in	Figure	4.9a,	but	with	
the	omission	of	 the	amide	region	(1709–1486	cm−1).	 	As	with	Figure	4.9a,	 the	scores	
plot	 showed	 no	 sign	 of	 delineation	 of	 the	 cell	 medium	 or	 vehicle	 scores	 from	 one	
another	 (Fig.	4.9b);	 again	 intra-sample	 variation	 appeared	 to	 be	 the	 predominant	
source	of	the	biomolecular	differences	in	these	samples.	 	In	the	absence	of	the	amide	
region,	lipid-related	bands	(2924	cm−1	(νas(CH2)),	2854	cm−1	(νs(CH2)),	and	1743	cm−1	
(ν(C=O))	dominated	the	PC-1	 loadings	plot	(Fig.	4.9b).	 	 Interestingly,	omission	of	 the	
amide	 region	 resulted	 in	 tighter	 distribution	 of	 the	 scores	 along	 the	 PC-2	 axis	 as	
shown	in	the	scores	plot	in	Figure	4.9b.		The	results	(Fig.	4.9a	and	b)	indicate	that	the	
strong	amide	I	loadings	may	be	responsible	for	the	wider	distribution	of	scores	along	
the	 PC-2	 axis	 in	 the	 scores	 plot	 when	 the	 amide	 region	 is	 included	 (Fig.	 4.9a).		
As	shown	 in	 Figure	 4.9b,	 the	most	 pronounced	 PC-2	 loadings	were	 the	 νas(CH2)	 and	
νs(CH2)	 bands,	which	 appeared	 as	 a	 derivative-like	 shape,	 indicative	 of	 a	 band	 shift.		
Some	weak	 PC-2	 loadings	 contributions	 from	 the	 νas(PO2−)	 band	 (1259–1217	 cm−1)	
were	also	evident.	 	Overall,	 the	PCA	performed	without	 the	amides	present	 suggests	
that	 intra-sample	 lipid	 variations	 exist	 in	 the	 cell	 spectra	 of	 the	 cell	 medium-	 and	
vehicle-treated	 samples.	As	no	 separation	of	 the	 cell	medium-	or	vehicle-treated	cell	
spectra	 scores	 is	 evident,	 the	 PCA	 results	 suggest	 that	 the	 intra-sample	 spectral	
variation	within	 each	 of	 these	 treatment	 populations	 is	 dominant	 over	 any	 spectral	
variations	occurring	as	a	result	of	the	two	treatments.		
The	PCA	results	appear	 to	 suggest	 that	DMSO	has	 little	observable	effect	on	 the	
SR-IRMS	HCT-8	 cell	 spectra	 following	 24-h	 incubation,	 as	 compared	 to	 the	 SR-IRMS	
spectra	of	HCT-8	cells	incubated	with	cell	medium	alone.	
	
4.3.2 Comparison	of	the	effects	of	BiNSAIDs,	and	the	respective	NSAIDs,	on	SR-
IRMS	spectra	of	live	HCT-8	cells	
4.3.2.1 Bi(tolf)3-	and	tolfH-treated	cells	(4-h	treatment)	
The	 averaged	 SR-IRMS	 spectra	 (29–54	 spectra	 recorded	 for	 each	 treatment)	 of	
vehicle-,	Bi(tolf)3-,	and	tolfH-treated	cells		showed	a	few	notable	distinctions	from	each	
other	 following	4-h	 treatment	as	 shown	 in	Appendix	3.6.	 	Notably,	 the	Bi(tolf)3-	 and	
tolfH-treated	average	cell	spectra	showed	an	increase	in	intensity	of	the	νas(CH2)	and	
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νs(CH2)	 bands	 (2924	 cm−1	 and	 2853	 cm−1,	 respectively)	 compared	 to	 the	 vehicle-
treated	 average	 spectrum	 (Appendix	 3.6a).	 	 In	 addition,	 the	 average	 tolfH-treated	
spectrum	 showed	 a	 distinctive	 shift	 in	 the	 νas(PO2−)	 band	 (from	 1240	 cm−1	 to	
1232	cm−1)	when	compared	to	the	vehicle-treated	average	spectrum	(Appendix	3.6a),	
while	the	Bi(tolf)3-treated	average	spectrum	showed	only	a	slight	shift	 to	1238	cm−1.		
The	 substantial	 shift	 in	 the	 νas(PO2−)	 was	 also	 identifiable	 in	 the	 average	 second	
derivative	spectrum	of	tolfH-treated	cells	(Appendix	3.6b),	with	a	less	substantial	shift	
in	 the	 Bi(tolf)3-treated	 average	 spectrum	 compared	 to	 the	 vehicle	 (Appendix	 3.6b).	
A	change	associated	with	the	nucleic	acids	is	observed	as	a	the	frequency	shift	of	the	
ν(C=O)	 band	 from	 1716	cm−1	 (vehicle)	 to	 1718	 cm−1	 and	 1720	 cm−1,	 in	 the	
Bi(tolf)3-	and	tolfH-treated	average	spectra,	respectively	(Appendix	3.6b).	
A	 comparison	 of	 the	 SR-IRMS	 spectra	 following	 4-h	 treatment	 with	 vehicle,	
Bi(tolf)3,	or	tolfH,	is	shown	in	the	PCA	(3000–2800	cm−1,	1790–1150	cm−1)	scores	and	
loadings	plots	in	Figure	4.10a.		At	first	glance	it	was	observed	that	both	the	Bi(tolf)3	or	
tolfH	scores	overlap	with	 the	vehicle	 scores	and	 that	 there	 is	no	clear	delineation	of	
the	clustering	between	the	three	populations.		However,	on	closer	inspection	the	tolfH	
scores	 appear	 to	 show	an	 increased	proportion	of	positive	PC-1	 scores	 compared	 to	
the	vehicle	(which	appear	to	be	predominantly	negative	PC-1	scores).		There	appears	
to	be	even	distribution	of	Bi(tolf)3	in	both	the	negative	and	positive	PC-1	scores.		The	
PC-1	loadings	plot	in	Figure	4.10a	shows	that	the	positive	PC-1	scores	were	associated	
with	strong	negative	loadings	from	methylene	vibrations	at	2924	cm−1	and	2854	cm−1	
(νas(CH2)	and	νs(CH2),	respectively),	and	moderate	to	weak	negative	loadings	observed	
at	1466	cm−1	(δ(CH2))	and	1745	cm−1	(ν(C=O)).		These	observations	may	indicate	that	
there	was	a	difference	in	lipid	composition	in	subpopulations	of	the	tolfH-treated	cells	
and	Bi(tolf)3-treated	cells,	compared	to	the	majority	of	the	vehicle-treated	cells.	 	Two	
weak	positive	PC-1	loadings	related	to	the	amide	I	band,	at	1693	cm−1	and	1620	cm−1,	
were	associated	with	 the	aforementioned	scores,	which	may	suggest	a	change	 in	 the	
composition	of	cellular	proteins	following	NSAID	treatment.		The	negative	PC-1	scores	
(consisting	of	the	majority	of	the	vehicle	scores,	and	some	of	the	Bi(tolf)3	scores)	were	
correlated	with	moderate	to	weak	positive	loadings	associated	with	proteins	including	
1662	cm−1	and	1639	cm−1	(amide	I),	1549	cm−1	(amide	II),	and	1398	cm−1	(νs(COO−))	
(Fig.	4.10a).		A	weak	positive	loading	at	1248	cm−1	(νas(PO2−)),	associated	with	nucleic	
acids,	 was	 also	 correlated	with	 the	 negative	 PC-1	 scores.	 	Along	 PC-2,	 there	was	 no	
clear	distinction	of	the	three	sample	groups;	in	fact,	the	relatively	even	distribution	of	
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the	 samples	 along	 PC-2	 suggests	 intra-sample	 variation	was	 greater	 for	 each	 of	 the	
three	samples	than	the	inter-sample	variation.		The	PC-2	loadings	showed	derivative-
like	 loadings	(indicative	of	band	shifts)	 in	 the	amide	 I	region	suggesting	 that	cellular	
protein	composition	was	 the	greatest	determinant	of	 intra-sample	variability.	 	Weak	
contributions	from	lipid	loadings	also	contributed	to	intra-sample	variability,	with	no	
contributions	 from	 the	 lower	 wavenumber	 region	 of	 the	 spectrum	 (<	1500	cm−1)	
evident	in	the	loadings	plot	(Fig.	4.10a).		
	
	
Figure	4.10:	 PCA	 scores	plot	 and	 corresponding	PC-1	 and	PC-2	X-loadings	plots	 generated	
from	 the	 second	 derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	
SR-IRMS	spectra	obtained	from	HCT-8	cells	following	4	h	treatment	with	vehicle	(RPMI-1640,	
DMSO	2%	v/v)	(n),	Bi(tolf)3	(l),	or	tolfH	(p)	(45	μM	NSAID);	(a)	including	the	amide	region	
(3000–2800	cm−1,	 1790–1150	 cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	
1790–1710	cm−1,	1485–1150	cm−1).	
Figure	 4.10b	 shows	 the	 results	 of	 PCA	 comparing	 second	 derivative	 spectra	
obtained	 from	 the	4-h	 vehicle-,	Bi(tolf)3-,	 or	 tolfH-treated	 cells,	with	 the	omission	of	
the	amide	region	(1709–1486	cm−1).		As	the	PCA	scores	plot	in	Figure	4.10b	shows,	the	
tolfH	scores	exhibit	some	delineation	from	both	the	vehicle	and	Bi(tolf)3	scores	along	
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PC-2	 following	 removal	 of	 the	 amide	 region.	 	However,	 closer	 inspection	 of	 the	 PCA	
scores	 plot	 in	 Figure	 4.10b	 reveals	 that	 a	 similar	 proportion	 of	 tolfH	 and	 Bi(tolf)3	
scores	appear	on	the	opposite	side	of	the	PC-1	axis	when	compared	to	the	PCA	scores	
plot	in	Figure	4.10a	(albeit	on	the	reverse	side	of	the	PC-1	axis).		Additionally	the	two	
PC-1	loadings	plots	in	Figure	4.10	show	comparable	contributions	from	similar	bands	
(although	 the	 PC-1	 loadings	 plot	 appears	 to	 be	 inverted	 in	 Fig.	4.10b).	 	Thus,	 the	
subpopulations	 of	 Bi(tolf)3	 and	 tolfH	 scores	 were	 associated	 with	 strong	 positive	
loadings	 from	 the	νas(CH2),	 νs(CH2),	 and	moderate	 to	weak	 loadings	 from	 the	ν(C=O)	
and	 δ(CH2)	 bands	 of	 lipids,	 indicating	 a	 change	 in	 the	 lipid	 composition	 of	
subpopulations	of	the	NSAID-treated	cells	compared	to	the	vehicle-treated	cells.	 	The	
obvious	change	in	the	distribution	of	the	tolfH	scores	along	PC-2	was	accompanied	by	
an	 increase	 in	 the	 PC-2	 loadings	 contributions	 from	 bands	 in	 the	 1465–1150	 cm−1	
region	 following	 the	 removal	 of	 the	 amide	 region	 from	 the	 PCA	 (Fig.	4.10b).	 	 The	
positive	PC-2	scores	(vehicle	and	Bi(tolf)3	scores	only)	were	associated	with	the	strong	
ν(C=O)	loading	at	1745	cm−1,	the	νas(PO2−)	band	of	nucleic	acids	at	1246	cm−1;	and	the	
νs(COO−)	 band	 at	 1398	cm−1.	 	 These	 changes	 demonstrate	 that	 lipids,	 proteins,	 and	
nucleic	acids	are	differently	affected	by	tolfH	compared	to	Bi(tolf)3	in	the	HCT-8	cells	
following	4-h	treatment.	
4.3.2.2 Bi(tolf)3-	and	tolfH-treated	cells	(24-h	treatment)	
The	 averaged	 SR-IRMS	 spectra	 of	 vehicle-,	 Bi(tolf)3,	 and	 tolfH-treated	 cells	
(between	 33–100	 spectra	 recorded	 for	 each	 treatment)	 did	 not	 show	 very	 many	
differences	from	each	other	following	24-h	treatment,	as	displayed	in	Appendix	3.7.		It	
was	evident	that	the	average	tolfH-treated	cell	spectrum	showed	reduced	intensity	in	
the	 lipid	 region	 (3000–2800	 cm−1),	 the	 ν(C=O)	 band	 (1740	 cm−1)	 and	 the	 νas(PO2−)	
band,	 indicating	 that	 tolfH	 treatment	 may	 reduce	 cellular	 lipid	 and	 nucleic	 acid	
concentration.	 	In	contrast	to	the	4-h	samples	(Appendix	3.6),	there	were	only	subtle	
differences	 in	 the	 line	 shape	 of	 the	 νas(PO2−)	 band	 in	 the	 24-h	 second	 derivative	
spectra	 of	 the	 average	 tolfH-	 and	 Bi(tolf)3-treated	 cells	 compared	 to	 the	 vehicle-
treated	cells	(Appendix	3.7).	
Figure	4.11	shows	the	PCA	comparison	of	the	SR-IRMS	spectra	of	the	single	HCT-8	
cells	 following	 24-h	 treatment	 with	 vehicle,	 Bi(tolf)3,	 or	 tolfH.	 	The	 scores	 plot	
(Fig.	4.11a)	 shows	 that	 the	 vehicle	 and	Bi(tolf)3	 scores	were	distributed	 across	PC-1	
with	no	delineation	from	each	other;	however,	a	small	Bi(tolf)3	subpopulation	cluster	
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may	be	distinguished	in	the	PC-1/PC-2	negative	spaces	(Fig.	4.11a).	 	While	there	was	
no	obvious	delineation	of	the	tolfH	scores	from	the	other	two	samples,	it	was	observed	
that	 the	 tolfH	 scores	 appeared	 as	 predominantly	 positive	 PC-1	 scores	 in	 a	
comparatively	 tight	 cluster	 (Fig.	 4.11a);	 additionally,	 the	 tolfH	 scores	 appeared	
primarily	 in	 the	 negative	 PC-2	 space.	 	 The	 negative	 PC-1	 scores	 (comprised	 of	
subpopulations	of	vehicle	and	Bi(tolf)3	scores,	Fig.	4.11a)	were	associated	with	strong	
loadings	from	lipid	bands	including	νas(CH2),	νs(CH2),	ν(C=O)	and	δ(CH2).		Conversely,	
negative	PC-1	loadings	indicative	of	proteins	at	1655	cm−1,	1549	cm−1	and	1398	cm−1	
(amide	I,	amide	II,	and	νs(COO−),	respectively)	were	correlated	with	the	positive	PC-1		
	
Figure	 4.11:	 PCA	 scores	 plot	 and	 corresponding	 PC-1	 and	 PC-2	 X-loadings	 plots	 of	 second	
derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	 spectra	
obtained	from	HCT-8	cells	following	24	h	treatment	with	vehicle	(RPMI-1640,	DMSO	2%	v/v)	
(n),	 Bi(tolf)3	 (l),	 or	 tolfH	 (p)	 (45	 μM	NSAID);	 (a)	 including	 the	 amide	 region	 (3000–2800	
cm−1,	 1790–1150	cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	 1790–
1710	cm−1,	1485–1150	cm−1).		
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scores	(comprised	of	a	 large	tolfH	population,	Fig.	4.11a).	 	These	results	suggest	that	
treatment		with		tolfH		results		in		lipid		and		protein		changes.			The		PC-2		loadings		plot	
showed	that	the	majority	of	the	tolfH	scores	and	the	Bi(tolf)3	subpopulation	of	scores	
in	the	negative	PC-2	space	were	associated	with	the	νas(CH2),	νs(CH2)	and	ν(C=O)	lipid-	
related	bands	(Fig.	4.11a).		The	derivative-like	shift	in	the	amide	I	and	amide	II	bands	
of	the	PC-2	loadings	plot	(Fig.	4.11a)	suggests	there	is	a	band	shift	between	the	treated	
populations	in	the	PC-2	negative	space	and	the	vehicle	(and	some	Bi(tolf)3	scores)	in	
the	PC-2	positive	space.	
As	shown	in	the	scores	plot	 in	Figure	4.11b,	 the	relatively	tight	clustering	of	 the	
tolfH	 scores	 was	 still	 apparent	 following	 the	 removal	 of	 the	 amide	 region	 (1709–
1486	cm−1)	from	PCA.		The	Bi(tolf)3	subpopulation	could	also	be	identified	in	the	PC-1	
negative/PC-2	 positive	 space	 (Fig.	 4.11b).	 	 Again,	 strong	 lipid	 loadings	 arising	 from	
νas(CH2),	 νs(CH2),	 ν(C=O),	 and	 δ(CH2)	 bands	 (2924	 cm−1,	 2852	 cm−1,	 1743	 cm−1,	 and	
1466	cm−1,	respectively)	were	observed	and	associated	with	the	PC-1	negative	scores	
(comprised	 of	 subpopulations	 of	 vehicle	 and	 Bi(tolf)3	 scores)	 in	 Figure	 4.11b.	 	 The	
removal	of	 the	amide	region	from	the	PCA	increased	the	 intensity	of	 the	nucleic	acid	
(νas(PO2−))	 PC-2	 loadings	 at	 1239	 cm−1	 and	 1227	 cm−1	 and	 the	 lipid-related	
νas(CO−O−C)	loading	at	1160	cm−1	(Fig.	4.11b).		Derivative-like	loadings	were	observed	
in	the	PC-2	loadings	for	the	νas(CH2)	and	νs(CH2)	lipid-related	bands	when	the	amides	
were	 omitted	 (Fig.	 4.11b),	 in	 contrast	 to	 the	 non-derivative	 bands	 in	 Figure	 4.11a.		
These	 observations	 suggest	 the	 lipid	 and	 nucleic	 acid	 SR-IRMS	 signatures	 of	 these	
BiNSAID-	and	NSAID-treated	subpopulations	differed	from	the	majority	of	the	vehicle-
treated	cell	spectra	following	24-h	treatment.		
4.3.2.3 Bi(mef)3-	and	mefH-treated	cells	(4-h	treatment)	
The	 averaged	 SR-IRMS	 spectra	 of	 vehicle-,	 Bi(mef)3,	 and	 mefH-treated	 cells	
(between	 42–83	 spectra	 recorded	 for	 each	 treatment)	 showed	 some	 differences	
following	 4-h	 treatment	 as	 shown	 in	Appendix	 3.8.	 	When	 compared	 to	 the	 average	
vehicle-treated	 cell	 spectrum,	 the	 average	 Bi(mef)3-treated	 spectrum	 showed	 a	
slightly	 increased	 intensity	 in	 the	 lipid	 region	 (3000–2800	 cm−1)	 and	 the	 νas(PO2−),	
whereas	 the	 average	 mefH-treated	 spectrum	 showed	 the	 opposite	 trend	
(Appendix	3.8a).		However,	the	average	second	derivative	spectra	of	the	Bi(mef)3-	and	
mefH-treated	cells	showed	very	 little	variation	 in	 line	shape	when	compared	to	each	
other	 (Appendix	3.8b);	 additionally,	 both	 the	 mefH	 and	 Bi(mef)3-treated	 average	
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spectra	showed	the	same	variation	in	the	line	shape	of	the	δ(CH2)	and	νas(PO2−)	bands	
when	compared	to	the	average	vehicle-treated	spectrum	(Appendix	3.8b).	
Figure	 4.12a	 shows	 the	 PCA	 scores	 plot	 comparison	 of	 the	 SR-IRMS	 spectra	
(3000–2800	cm−1,	1790–1150	cm−1)	of	single	HCT-8	cells	following	4-h	treatment	with	
vehicle,	 Bi(mef)3,	 or	 mefH.	 	 There	 was	 no	 clear	 delineation	 observed	 between	 the	
vehicle,	Bi(mef)3	 and	mefH	 score	populations;	however,	 the	majority	of	 the	Bi(mef)3	
and	 mefH	 PC-1	 scores	 were	 positive,	 whereas	 the	 vehicle	 PC-1	 scores	 were	
predominantly	negative	(Fig.	4.12a).	The	PC-1	loadings	plot	(Fig.	4.12a)	indicated	that	
the	 majority	 of	 the	 Bi(mef)3	 and	 mefH	 scores	 are	 associated	 with	 strong	 loadings	
arising	 from	 the	 νas(CH2),	 νs(CH2),	 and	 νas(C=O)	 bands	 (2924	 cm−1,	 2852	 cm−1,	 and	
1743	cm−1,	 respectively),	 which	 may	 indicate	 that	 differences	 between	 the	
mefH/Bi(mef)3-treated	cells	and	the	vehicle-treated	cells	were	attributed	to	 the	 lipid	
bands.	 Conversely,	 the	 PC-1	 scores	 primarily	 associated	 with	 vehicle-treated	 cells	
were	 correlated	with	 loadings	 attributed	 to	 amide	 I,	 amide	 II	 and	νs(COO−)	bands	of	
proteins	 at	 1637	cm−1,	 1533	cm−1,	 and	 1396	 cm−1,	 respectively	 (Fig.	 4.12a).	 	 The	
relatively	even	distribution	of	the	scores	of	all	three	samples	across	the	negative	and	
positive	 PC-2	 space	 suggests	 that	 intra-sample	 variation	 was	 dominant	 over	 inter-
sample	 variation.	 	 Moderate	 PC-2	 loadings	 attributable	 to	 lipids	 (2926	 cm−1,	 2854	
cm−1,	 and	 1745	 cm−1)	 and	 strong	 derivative-like	 amide	 I	 loadings	 (1660	 cm−1,	 1647	
cm−1,	and	1635	cm−1)	suggest	variation	in	the	lipid	composition	and	protein	structure	
in	the	populations	of	each	of	the	three	cell	groups.		
As	shown	in	Figure	4.12b,	the	PCA	was	performed	with	the	omission	of	the	amide	
region	 (1709–1486	cm−1)	 on	 the	 same	 SR-IRMS	 spectra	 analysed	 in	 Figure	 4.12a.	
Notably,	 in	Figure	4.12b	the	vehicle	scores	cluster	was	almost	separated	from	that	of	
the	 Bi(mef)3	 and	 mefH	 scores,	 which	 were	 completely	 overlapped.	 	 A	 higher	
proportion	 of	 vehicle	 PC-1	 scores	were	 positive,	 while	 the	 higher	 proportion	 of	 the	
Bi(mef)3	and	mefH	PC-1	scores	were	negative;	however,	some	intra-sample	variation	
was	evident	in	PC-1,	as	indicated	by	the	spread	of	the	three	separate	populations	over	
the	negative	and	positive	sides	of	the	PC-1	space.		As	shown	in	the	PC-1	loadings	plot	
in	 Figure	 4.12b,	 the	majority	 of	 the	Bi(mef)3	 and	mefH	PC-1	 scores	were	 associated	
with	strong	loadings	arising	from	the	νas(CH2),	νs(CH2),	and	ν(C=O)	lipid-related	bands,	
similar	 to	 the	 results	 of	 the	 PCA	 inclusive	 of	 the	 amides	 (Fig.	 4.12a).	 	 In	 the	 PC-2	
loadings	plot	(Fig.	4.12b)	 it	was	observed	that	 the	removal	of	 the	amide	region	 from	
the	PCA	increased	the	intensity	of	the	nucleic	acid	νas(PO2−)	loadings	at	1244	cm−1	and	
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1223	cm−1	 and	 the	 lipid	 νas(CO−O−C)	 loading	 at	 1176	 cm−1.	 	 Derivative-like	 loadings	
were	observed	 in	 the	PC-2	 loadings	 for	 the	 lipid	bands	νas(CH2)	and	νs(CH2),	and	 the	
νas(PO2−)	 nucleic	 acid	 band,	 indicating	 a	 change	 in	 the	 band	 position	 between	 the	
vehicle	scores	and	the	NSAID	scores.		
	
Figure	 4.12:	 PCA	 scores	 plot	 and	 corresponding	 PC-1	 and	 PC-2	 X-loadings	 plots	 of	 second	
derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	 spectra	
obtained	 from	HCT-8	cells	 following	4	h	 treatment	with	vehicle	 (RPMI-1640,	DMSO	2%	v/v)	
(n),	 Bi(mef)3	 (l),	 or	 mefH	 (p)	 (120	 μM	 NSAID);	 (a)	 including	 the	 amide	 region	 (3000–
2800	cm−1,	 1790–1150	 cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	 1790–
1710	cm−1,	1485–1150	cm−1).		
4.3.2.4 Bi(mef)3-	and	mefH-treated	cells	(24-h	treatment)	
The	 averaged	 SR-IRMS	 spectra	 of	 vehicle-,	 Bi(mef)3,	 and	 mefH-treated	 cells	
(between	54–95	spectra	recorded	 for	each	 treatment)	also	showed	some	differences	
from	each	other	 following	24-h	 treatment	as	shown	 in	Appendix	3.9.	 	 It	was	evident	
that	 the	 average	Bi(mef)3-	 and	mef-treated	 cell	 spectra	 showed	 reduced	 intensity	 in	
the	 νas(CH2),	 νs(CH2),	 and	 ν(C=O)	 bands,	 indicating	 that	 Bi(mef)3-treatment	 may	
Chapter	4.	Synchrotron	radiation	infrared	microspectroscopy		
	
	178	
reduce	 cellular	 lipid	 concentrations	 (Appendix	 3.9a).	 	Additionally,	 there	were	 some	
variations	 in	 the	 line	 shape	 of	 the	 νas(PO2−)	 band	 in	 the	 average	 second	 derivative	
spectra	 of	 the	 mefH-	 and	 Bi(mef)3-treated	 cells	 (Appendix	 3.9b)	 compared	 to	 the	
vehicle-treated	cells.	
A	 comparison	 of	 the	 SR-IRMS	 spectra	 of	 the	 single	 HCT-8	 cells	 following	 24-h	
treatment	 with	 vehicle,	 Bi(mef)3,	 or	 mefH,	 is	 shown	 in	 the	 PCA	 scores	 plot	 in	
Figure	4.13a	 (examining	 the	 3000–2800	 cm−1	 and	 1790–1150	 cm−1	 regions).	 The	
majority	 of	 the	 Bi(mef)3	 scores	 appear	 in	 the	 negative	 PC-1	 space	 and	 show	 some	
delineation	 from	 the	 vehicle	 scores;	 however,	 the	 mefH	 scores	 appear	 to	 be	
distributed	 across	 the	 positive	 and	 negative	 PC-1	 space,	 overlapping	 with	 both	 the	
Bi(mef)3	scores,	and	some	of	the	vehicle	scores.			
	
Figure	 4.13:	 PCA	 scores	 plot	 and	 corresponding	 PC-1	 and	 PC-2	 X-loadings	 plots	 of	 second	
derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	 spectra	
obtained	from	HCT-8	cells	following	24	h	treatment	with	vehicle	(RPMI-1640,	DMSO	2%	v/v)	
(n),	 Bi(mef)3	 (l),	 or	 mefH	 (p)	 (120	 μM	 NSAID);	 (a)	 including	 the	 amide	 region	 (3000–
2800	cm−1,	 1790–1150	 cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	 1790–
1710	cm−1,	1485–1150	cm−1).		
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The	 PC-1	 loadings	 plot	 shows	 that	 νas(CH2),	 νs(CH2),	 and	 νas(C=O)	 lipid-related	
loadings	at	2924	cm−1,	2854	cm−1	and	1743	cm−1,	respectively,	are	associated	with	the	
vehicle	and	a	proportion	of	 the	mefH	scores	on	the	positive	PC-1	scores.	 	The	strong	
loading	originated	 from	 the	 amide	 I	 band	 at	 1637	cm−1	 and	was	 associated	with	 the	
Bi(mef)3,	 negative	 PC-1	 scores.	 Intra-sample	 variation	 was	 observed	 along	 PC-2,	
resulting	 from	 moderate	 lipid	 loadings,	 and	 strong	 amide	 I	 and	 amide	 II	 protein	
loadings.	
As	shown	in	Figure	4.13b,	the	PCA	was	performed	with	the	omission	of	the	amide	
region	(1709–1486	cm−1)	on	the	same	SR-IRMS	spectra	analysed	in	Figure	4.13a.		The	
majority	of	the	Bi(mef)3	scores	appear	in	the	positive	PC-1	space	with	a	small	number	
extending	 into	 the	negative	PC-1	space	 that	overlaps	with	 the	vehicle	 scores.	 	Again,	
the	mefH	scores	appear	to	be	distributed	across	the	positive	and	negative	PC-1	space,	
overlapping	with	both	 the	positive	Bi(mef)3	scores,	and	some	of	 the	negative	vehicle	
scores.		Similarly	to	the	amide	inclusive	PCA	(Fig.	4.13b),	the	PC-1	loadings	plot	shows	
that	 lipid	 loadings	 at	 2924	 cm−1,	 2854	 cm−1	 and	 1743	 cm−1	 are	 associated	with	 the	
vehicle	and	the	small	proportion	of	the	Bi(mef)3	and	mefH	scores	on	the	positive	PC-1	
scores.	 	With	 the	 omission	 of	 the	 amide	 region,	 the	 PC-2	 loadings	 plot	 has	 some	
obvious	differences	to	the	amide	inclusive	PC-2	loadings	plot.		Specifically,	the	νas(CH2)	
and	νs(CH2)	bands	are	now	derivative-like	in	shape,	indicating	a	band	shift	within	each	
sample.	 	Additionally,	 the	 intensity	 of	 the	 νas(PO2−)	 loadings	 at	 1240	cm−1	 and	
1228	cm−1,	and	the	νas(CO−O−C)	loadings	at	1184	cm−1	and	1158	cm−1	were	increased.	
4.3.2.5 Bi(difl)3-	and	diflH-treated	cells	(4-h	treatment)	
As	shown	in	Appendix	3.10,	the	averaged	Bi(difl)3-	and	diflH-treated	cell	spectra	
showed	a	decrease	in	the	intensity	of	the	νas(CH2)	and	νs(CH2)	bands	(2624	cm−1	and	
2952	cm−1)	and	lack	of	definition	of	the	ν(C=O)	band	at	1745	cm−1	(particularly	in	the	
case	 of	 diflH).	 	 The	 averaged	 Bi(difl)3-treated	 second	 derivative	 spectrum	 showed	
substantial	differences	in	the	δ(CH2)	and	νas(PO2−)	bands	at	1466	cm−1	and	1248	cm−1,	
respectively,	 compared	 to	 both	 the	 averaged	 vehicle-	 and	 diflH-treated	 second	
derivative	 spectra	 (Appendix	 3.10b).	 	 Also	 evident	 was	 the	 appearance	 of	 a	 slight	
shoulder	 on	 the	 amide	 I	 band	 of	 the	 diflH-treated	 average	 second	 derivative	
spectrum	(Appendix	3.10b).	
Individual	 second	derivative	 spectra	of	vehicle-,	Bi(difl)3-	 and	diflH-treated	cells	
were	examined	using	PCA,	and	the	resulting	scores	and	loadings	plots	(examining	the	
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3000–2800	 cm−1	 and	 1790–1150	 cm−1	 regions)	 are	 presented	 in	 Figure	 4.14a.		
The	diflH	 scores	 were	 spread	 across	 both	 sides	 of	 the	 PC-1	 axis,	 whereas	 both	 the	
vehicle	and	Bi(difl)3	scores	showed	a	higher	degree	of	clustering	relative	to	the	diflH	
scores.		Disparity	among	the	amide	I	bands	appears	to	be	the	major	contributor	to	the	
distribution	of	the	scores	along	PC-1,	particularly	for	the	diflH	scores.		On	the	PC-2	axis	
there	was	no	clear	delineation	observed	between	the	vehicle,	Bi(difl)3	and	diflH	score	
populations;	however,	for	the	majority	of	the	Bi(difl)3	and	diflH	(the	latter	even	more	
so),	 the	 PC-2	 scores	 were	 primarily	 positive	 values,	 whereas	 the	 vehicle	 scores	
appeared	as	predominantly	negative	PC-2	values.			
	
	
Figure	 4.14:	 PCA	 scores	 plot	 and	 corresponding	 PC-1	 and	 PC-2	 X-loadings	 plots	 of	 second	
derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	 spectra	
obtained	 from	HCT-8	cells	 following	4	h	 treatment	with	vehicle	 (RPMI-1640,	DMSO	2%	v/v)	
(n),	 Bi(difl)3	 (l),	 or	 diflH	 (p)	 (225	 μM	 NSAID);	 (a)	 including	 the	 amide	 region	 (3000–
2800	cm−1,	 1790–1150	 cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	 1790–
1710	cm−1,	1485–1150	cm−1).		
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It	 was	 observed	 in	 the	 PC-2	 loadings	 plot	 that	 the	 amide	 I	 and	 amide	 II	 bands	
were	 the	main	 source	 of	 the	 variation,	with	 the	derivative-like	 shape	 of	 the	 amide	 I	
band,	 indicative	 of	 a	 band	 shift.	 	 The	 PC-2	 loadings	 arising	 from	 lipid	 bands	 were	
associated	 with	 the	 positive	 PC-2	 scores,	 primarily	 composed	 of	 Bi(difl)3	 and	 diflH	
scores.	
The	 PCA	 scores	 plot	 following	 the	 omission	 of	 the	 amide	 region	 (1709–
1486	cm−1)	 for	 the	 comparison	 of	 the	 vehicle-,	 Bi(difl)3,	 and	 diflH-treated	 cell	
spectra		(Fig.	 4.14b)	 shows	 a	 substantial	 difference	 in	 the	 distribution	 of	 the	 three	
sample	 populations	 compared	 to	 the	 amide	 inclusive	 PCA	 scores	 plot	 (Fig.	 4.14a).		
As	observed	in	Figure	4.14b,	the	vehicle	and	diflH	scores	appear	to	completely	overlap,	
while	the	Bi(difl)3	scores	are	primarily	distributed	over	negative	PC-1	and	PC-2	values	
and	 only	 partially	 overlap	with	 the	 other	 treatments.	 	 The	 distribution	 of	 the	 three	
samples	across	the	PC-1	axis	suggests	that	intra-sample	variation	is	predominant	over	
any	inter-sample	variations;	the	PC-1	loadings	plot	indicates	that	the	lipid-associated	
bands,	 νas(CH2),	 νs(CH2),	 and	 ν(C=O)	 bands	 (2926	cm−1,	 2854	cm−1,	 and	 1745	cm−1,	
respectively)	 are	 the	 source	 of	 this	 variation	 (Fig.	 4.14b).	 	 Inter-sample	 differences	
could	be	observed	by	 the	minimal	overlap	of	 the	Bi(difl)3	negative	PC-2	 scores	 from	
the	 predominantly	 positive	 PC-2	 vehicle	 and	 diflH	 scores	 (Fig.	 4.14b).	 	The	 PC-2	
loadings	 plot	 indicates	 that	 the	 positive	 loadings	 attributable	 to	 lipids	 (δ(CH)2	 at	
1466	cm−1),	 proteins	 (amide	III	 at	 1321	 cm−1),	 and	 nucleic	 acids	 (νas(C=O)	 at	
1718	cm−1)	 are	 associated	 with	 the	 PC-2	 negative	 Bi(difl)3	 scores	 (Fig.	 4.14b).		
Negative	 PC-2	 loadings	 designated	 to	 lipids	 (νas(CH2)	 at	 2920	 cm−1,	 and	 νs(CH2)	 at	
2850	cm−1),	 proteins	 (νs(COO−)	 at	 1396	cm−1)	 and	 nucleic	 acids	 (νas(PO2−)	 at	
1246	cm−1)	are	associated	with	the	positive	scores,	consisting	primarily	of	vehicle	and	
diflH	scores	(Fig.	4.14b).		
4.3.2.6 Bi(difl)3-	and	diflH-treated	cells	(24-h	treatment)	
As	shown	in	Appendix	3.11a,	a	comparison	of	the	average	SR-IRM	spectra	of	24-h	
vehicle-,	Bi(difl)3-	or	diflH-treated	cells	revealed	that	the	diflH-treated	sample	showed	
a	strong	increase	in	the	bands	associated	with	lipids	(3000–2800	cm−1	and	1740	cm−1).	
Additionally,	 the	 averaged	 diflH-treated	 second	 derivative	 spectrum	 showed	
substantial	 differences	 in	 the	 δ(CH2)	 band	 at	 1466	cm−1	 compared	 to	 both	 the	
averaged	vehicle-	and	Bi(difl)3-treated	second	derivative	spectra	(Appendix	3.11b).							
Figure	4.15a	shows	the	scores	and	loadings	plots	(examining	the	3000–2800	cm−1	
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and	 1790–1150	 cm−1	 regions)	 obtained	 following	 PCA	 of	 the	 individual	 second	
derivative	 spectra	 obtained	 from	 the	 vehicle-,	 Bi(difl)3-	 and	 diflH-treated	 cells.	
Although	there	was	substantial	overlap	of	the	clusters	between	the	three	samples	on	
the	scores	plot,	 the	diflH	scores	appeared	almost	exclusively	as	negative	PC-1	scores		
(Fig.	 4.15a).	 	 These	 scores	were	 associated	with	 strong	 νas(CH2),	 νs(CH2)	 and	 ν(C=O)	
loadings	of	 lipids.	 	The	positive	PC-1	scores	composed	of	vehicle	and	Bi(difl)3	 scores	
were	 associated	 with	 moderate	 loadings	 from	 the	 amide	 I	 and	 amide	 II	 bands	 of	
proteins.		All	three	samples	showed	scores	distribution	along	the	PC-2	axis	suggesting	
intra-sample	variation	appeared	to	be	the	predominant	factor	in	the	PC-2	distribution	
of	 the	samples.	The	 loadings	plot	suggests	 that	variations	within	 the	positions	of	 the	
νas(CH2),	νs(CH2),	and	amide	I	bands	existed	within	these	populations.	
	
	
Figure	 4.15:	 PCA	 scores	 plot	 and	 corresponding	 PC-1	 and	 PC-2	 X-loadings	 plots	 of	 second	
derivative	 (Savitzky	 Golay,	 13	 smoothing	 points),	 unit	 vector	 normalised	 SR-IRMS	 spectra	
obtained	 from	 HCT-8	 cells	 following	 24	 h	 treatment	 with	 vehicle	 (RPMI-1640,	 DMSO	
2%	v/v)	 	(n),	 Bi(difl)3	 (l),	 or	 diflH	 (p)	 (120	 μM	 NSAID);	 (a)	 including	 the	 amide	 region	
(3000–2800	cm−1,	 1790–1150	 cm−1),	 and	 (b)	 excluding	 the	 amide	 region	 (3000–2800	 cm−1,	
1790–1710	cm−1,	1485–1150	cm−1).		
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The	 PCA	 results	 obtained	 following	 omission	 of	 the	 amide	 region	 (1709–
1486	cm−1)	 from	 the	 vehicle,	 Bi(difl)3	 and	 diflH	 SR-IRMS	 spectra	 are	 presented	 in	
Figure	4.15b.		Similar	to	Figure	4.15a,	the	diflH	scores	appeared	almost	exclusively	as	
PC-1	 negative	 scores	 and	 remained	 associated	with	 strong	 positive	 loadings	 arising	
from	 lipids	 (νas(CH2),	 νs(CH2)	 and	 ν(C=O)).	 	 As	 was	 also	 observed	 in	 Figure	 4.15a,	
intra-sample	variation	appeared	to	be	the	predominant	factor	in	the	distribution	of	the	
samples	 across	 PC-2;	 the	 loadings	 plot	 (Fig.	 4.15b)	 indicated	 that	 this	 resulted	 from	
variations	 within	 the	 positions	 of	 νas(CH2),	 νs(CH2)	 and	 ν(C=O)	 bands	 within	 the	
samples.		Relatively	little	change	was	observed	from	the	loadings	contributions	in	the	
1485–1150	cm−1	region	when	comparing	 the	amide	 inclusive	or	amide	omitted	PC-1	
and	 PC-2	 loadings	 plots	 (Fig.	 4.15a	 and	 Fig.	 4.15b,	 respectively).	 	 The	 scores	 plots	
indicate	that	24-h	incubation	with	diflH	produces	biomolecular	effects	 in	HCT-8	cells	
which	 are	 relatively	 distinct	 from	 Bi(difl)3-	 and	 vehicle-treated	 cells	 and	 appear	 to	
result	 from	 lipid-related	 differences.	 However,	 no	 significant	 differences	 were	
observed	 for	 the	 Bi(difl)3-treated	 SR-IRM	 spectra	 when	 compared	 to	 the	 vehicle-
treated	SR-IRM	spectra.	
4.3.2.7 Summary	 of	 the	 IR	 spectral	 and	 PCA	 differences	 following	 BiNSAID	 and	
NSAID	treatment	
The	 results	 described	 in	 Sections	 4.3.2.1–4.3.2.6	 have	 been	 summarised	 in	
Table	4.3	 for	 ease	 of	 reference	 in	 the	 Discussion	 (Section	 4.4).	 Briefly,	 the	 key	
observations	emanating	from	the	analysis	of	the	SR-IRMS	studies	include:	
(i)	 TolfH	 treatment	 (4	 h	 and	 24	 h)	 of	 HCT-8	 cells	 predominantly	 resulted	 in	
changes	to	the	lipid	bands	and	possibly	the	amide	bands.	
(ii)	Bi(tolf)3	treatment	(4	h)	caused	some	change	in	lipids;	however,	the	effect	was	
less	 pronounced	 compared	 to	 tolfH.	 Additionally,	 the	 tolfH	 spectra	 were	
distinguishable	 from	Bi(tolf)3	 and	 vehicle	 scores	 due	 to	 a	 change	 in	 lipids.	 	 The	
24-h	treatment	resulted	in	Bi(tolf)3	scores	that	were	widely	scattered	(compared	
to	the	vehicle	and	tolfH	scores)	and	populated	areas	of	vehicle	and	tolfH	scores.	
(iii)	 MefH	 and	 Bi(mef)3	 treatment	 (4	 h	 and	 24	 h)	 induced	 variation	 in	 the	
spectrum	of	HCT-8	 cells	 compared	 to	 vehicle-treated	 cells,	which	was	primarily	
attributed	to	an	effect	on	lipids.	The	response	between	mefH	and	Bi(mef)3	could	
not	be	distinguished	as	the	scores	were	overlapped.	
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(iv)	 DiflH	 treatment	 (4	 h)	 induced	 a	 difference	 in	 the	 spectrum	 of	 HCT-8	 cells	
compared	to	vehicle,	which	was	primarily	attributed	to	an	effect	on	amides	in	the	
amide	 inclusive	 PCA.	 When	 the	 amide	 bands	 were	 omitted	 from	 the	 PCA,	 no	
distinction	was	observed	between	the	diflH-	and	vehicle-treated	cells.	 	Following	
24-h	 treatment,	 diflH	 induced	 a	 difference	 in	 the	 spectrum	 of	 HCT-8	 cells	
compared	to	vehicle	that	was	due	to	an	increase	in	the	intensity	of	the	lipid	bands.	
(v)	PCA	of	the	amide	inclusive	spectra	suggested	there	was	no	difference	between	
vehicle	and	Bi(difl)3	scores	(4	h).		However,	when	the	amides	were	omitted	from	
the	 PCA,	 4-h	 Bi(difl)3	 treatment	 induced	 a	 difference	 in	 the	 spectrum	 of	 HCT-8	
cells	 compared	 to	 vehicle/diflH,	 which	was	 primarily	 attributed	 to	 an	 effect	 on	
lipids.	 	 PCA	 suggests	 there	 was	 no	 difference	 between	 the	 24-h	 vehicle	 and	
Bi(difl)3	scores,	and	indicated	Bi(difl)3	had	a	different	effect	to	diflH	at	the	chosen	
treatment	concentrations.	
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4.4 Discussion	
Previous	in	vitro	studies	have	shown	that	NSAIDs	can	exert	anti-neoplastic	effects	
through	a	number	of	biochemical	pathways	(discussed	in	Section	1.2.4).		In	this	work	
SR-IRMS	 has	 been	 employed	 to	 determine	 whether	 gross	 biomolecular	 changes	
induced	by	NSAIDs/BiNSAIDs	can	be	distinguished.		This	approach	has	been	explored	
based	 on	 previous	 studies	 by	 other	 researchers	 who	 have	 correlated	 biomolecular	
effects	observed	by	SR-IRMS	with	specific	drug	treatments	(Table	4.2).	 	SR-IRMS	was	
specifically	employed	in	this	study	to	determine	whether	the	technique	could	be	used	
to:	(i)	observe	global	molecular	changes	in	the	live	HCT-8	cells	that	have	been	exposed	
to	 the	NSAIDs	or	 the	 corresponding	BiNSAIDs,	 (ii)	 determine	whether	 any	observed	
changes	 induced	 by	 the	 BiNSAID/NSAID	 are	 consistent	 with	 known	mechanisms	 of	
cell	death,	 and	 (iii)	determine	whether	BiNSAIDs/NSAIDs	 induce	similar	or	different	
biomolecular	responses.		
Live	cell	studies	were	performed	in	order	to	examine	the	cells	in	a	state	that	most	
closely	mimicked	that	used	for	the	other	biochemical	assays	performed	as	part	of	this	
Thesis,	without	 any	 potential	 confounding	 IR	 effects	 from	 a	 fixation/drying	 process.		
It	was	clear	from	the	SR-IRMS	study	of	live	cells	that	a	number	of	factors	needed	to	be	
considered	 when	 determining	 the	 usefulness	 of	 SR-IRMS	 for	 the	 abovementioned	
purposes.	 	These	 include:	(i)	 the	data	analysis,	specifically	the	water	band	correction	
strategies	 (discussed	 in	 Section	 4.4.1)	 and	 (ii)	 the	 significance	 of	 the	 biomolecular	
changes	 induced	 by	 vehicle,	 and	 BiNSAID/NSAID	 treatments,	 with	 respect	 to	
intra-sample	 variation	 (discussed	 in	 Section	 4.4.2).	 Finally,	 the	 experimental	
approach/design	and	improvements	for	future	experiments	with	respect	to	the	results	
are	discussed	in	Section	4.4.3.	
4.4.1 Data	analysis:	Water	absorption	correction	strategy		
As	previously	highlighted	in	Section	4.1.4,	the	effects	of	the	aqueous	background	
can	create	problems	when	analysing	the	SR-IRMS	spectra	of	live	cells	in	cell	medium.	
In	particular,	the	water	deformation	band	centred	at	1620	cm−1,	which	overlaps	with	
the	 amide	 I	 absorbance	band	needs	 to	be	 addressed.	 	Many	 researchers	 [33,	 43,	 57]	
have	 highlighted	 the	 issue	 of	 water	 absorption	 in	 the	 collection	 and	 processing	 of	
SR-IRMS	 spectra	 obtained	 from	 living	 single	 cells.	 	Conflicting	 approaches	 in	 the	
literature	led	to	the	use	of	the	two	analytical	strategies	presented	in	this	Thesis.		
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In	 the	 present	 study	 it	 was	 observed	 that	 when	 comparing	 the	 average	 cell	
spectra	 of	 a	 sample	 corrected	 for	 water	 band	 absorption	 to	 the	 same	 sample	 set	
without	water	band	 correction,	 little	 to	no	differences	 in	 the	position	of	 the	 amide	 I	
and	 amide	 II	 bands	 were	 observed	 in	 the	 second	 derivative	 spectra.	 	 This	 result	 is	
similar	 to	that	reported	by	Marcsisin	et	al.	[33],	whereby	the	authors	concluded	that	
the	 spectral	 integrity	 of	 the	 data	 was	 maintained;	 consequently,	 they	 employed	
spectra	 without	 any	 water	 band	 correction	 in	 PCA.	 	 In	 the	 present	 study	 (Section	
4.3.1),	 PCA	 was	 performed	 on	 spectra	 uncorrected,	 and	 corrected	 for	 the	 water	
absorption,	 in	order	 to	 further	determine	whether	 there	were	any	differences	 in	 the	
PCA	 scores	 and	 loadings	 plots	 following	 correction	 for	 the	water	 absorption.	 	 Some	
subtle	differences	were	observed	in	the	coordinates	of	some	of	the	individual	scores	in	
the	 PCA	 scores	 plot	 following	 correction	 for	water	 absorption;	 however,	 the	 overall	
trends	remained	the	same	regardless	of	whether	water	band	correction	was	applied	in	
all	 of	 the	 sample	 sets	 tested.	 	 The	 results	 from	 the	 present	 study	 suggest	 that	 the	
biomolecular	information	in	the	amide	region	contributed	by	cell	SR-IRMS	may	remain	
extractable	 using	 PCA,	 despite	 the	 contributions	 from	 the	 water	 band	 centred	 at	
1620	cm−1.	
Water	 correction	 strategies	 have	 been	 debated	 in	 a	 number	 of	 studies.	 	 For	
instance,	Whelan	et	 al.	 [43]	 argue	 that	 any	water	 band	 ratioing	 is	 unreliable	 as	 it	 is	
unconventional.	 	 Given	 that	 the	 water	 band	 influences	 the	 amide	 region,	 the	
researchers	 excluded	 the	 amide	 region	 from	 PCA	 obtained	 from	 their	 live	 cell	 cycle	
study	[43].	 	Consequently,	 in	 the	present	study	PCA	was	also	performed	on	SR-IRMS	
that	excluded	the	amide	region,	and	compared	to	the	PCA	performed	on	spectra	that	
included	the	amide	region.		In	most	cases,	the	scores	plot	was	altered	markedly	when	
the	 amide	 region	 was	 excluded,	 which	 can	 be	 expected	 as	 the	 amide	 I	 band	 is	 the	
strongest	band	in	the	spectrum	and	the	strongest	measure	of	proteins	in	the	spectrum.		
However,	 in	 all	 cases	 the	 explained	 variance	 of	 PC-1	 (observed	 on	 the	 x-axis	 of	 the	
scores	plots	in	Fig.	4.7−4.15)	was	substantially	increased	following	the	omission	of	the	
amide	region,	which	may	indicate	that	the	amide	I	region	was	contributing	more	noise	
than	 information.	 	 Additionally,	with	 the	 omission	 of	 the	 amide	 region,	 the	 loadings	
plots	showed	predominant	contributions	 from	lipid-related	bands,	and	 in	most	cases	
increased	the	strength	of	the	contributions	from	bands	between	1485–1150	cm−1.	
There	are	two	outcomes	that	require	further	examination.		Firstly,	the	omission	of	
the	amide	bands	appears	to	have	a	substantial	effect	on	the	outcome	of	PCA;	thus	the	
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omission	of	the	amide	bands	may	in	fact	result	in	the	oversight	of	useful	data	from	PCA	
producing	 results	 less	 representative	 of	 the	 true	 biomolecular	 differences	 between	
samples.	 	Secondly,	 the	 effectiveness	 of	 the	 water	 band	 correction	 is	 difficult	 to	
evaluate	and	may	still	not	provide	a	true	biochemical	representation.		
In	 conclusion,	 the	 water	 band	 correction	 using	 spectral	 subtraction	 strategy	
employed	 in	 the	present	 study	appears	 to	have	 subtle	 effects	on	 the	outcome	of	 the	
PCA	 results	 when	 compared	 to	 the	 respective	 non-corrected	 spectra.	 	If	 a	 suitable	
water	 compensation	 strategy	 can	 be	 determined	 in	 the	 future,	 and	 employed	
universally	 by	 researchers	 who	 perform	 SR-IRMS	 studies	 of	 live	 cells,	 the	 results	
obtained	in	the	present	study	should	be	reanalysed	with	this	strategy.		For	the	present	
study,	 however,	 it	 was	 opted	 to	 perform	 PCA	 on	 SR-IRMS	 spectra	 that	 were	 not	
corrected	for	the	water	band	as	the	results	in	Section	4.3.1	revealed	little	difference	in	
the	resultant	PCA.	
4.4.2 The	biomolecular	effects	of	treatment	on	live	HCT-8	cells	
4.4.2.1 Vehicle-treated	cells	
One	 of	 the	 notable	 results	 of	 the	 PCA	 of	 the	 SR-IRMS	 cell	 spectra,	 evident	 even	
within	 control	 cell	 populations	 was	 intra-sample	 variation.	 	 There	 are	 a	 number	 of	
reasons	that	can	contribute	to	intrinsic	variations	within	a	cell	population	subjected	to	
the	same	treatment.		Two	well-studied	causes	are:	(i)	cell	cycle,	and	(ii)	biomolecular	
changes	due	to	cell	death.	
	At	 any	 given	 time	 in	 an	 unsynchronised	 population	 of	 mammalian	 cells,	
subpopulations	of	 cells	will	 be	 found	 in	one	of	 the	different	phases	of	 the	 cell	 cycle:	
gap	1	 (G1),	 synthesis	 (S),	 gap	 2	 (G2),	 mitosis	 (M)	 or	 quiescence	 (G0)	 [43].		
FTIR	demonstrated	that	mammalian	cells	undergoing	cell	division	show	differences	in	
each	different	phase	of	 the	cell	 cycle	 [16,	22].	 	Furthermore,	Whelan	et	al.	 [43]	have	
shown	 through	 live	 cell	 studies	 that	 biomolecular	 changes	 could	 be	 distinguished	
within	 each	 specific	 phase	 by	 examining	 the	 SR-IRMS	 spectra	 of	 the	 cells	 every	 two	
hours	post-mitosis.		In	the	present	study	no	attempt	was	made	to	synchronise	the	cells	
in	any	particular	phase	of	 the	 cell	 cycle,	but	 instead	 the	 cells	were	prepared	using	a	
similar	procedure	to	that	employed	for	all	other	assays	performed	in	this	Thesis.		It	is	
reasonable	 to	 suggest	 that	 lipid,	 protein	 and	 nucleic	 acid	 content	 of	 the	HCT-8	 cells	
will	be	influenced	by	the	cell	cycle	phase	and	will	therefore	result	in	variations	in	the	
SR-IRMS	spectra	of	each	individual	cell	within	the	population.	
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Cell	death	is	another	factor	that	may	influence	the	SR-IRMS	spectra	of	individual	
cells.		 For	 instance,	 studies	 have	 shown	 that	 apoptosis	 and	 necrosis	 can	 be	
distinguished	 in	 the	 IRMS	 spectra	 of	 single	 cells	 [18,	 20,	 21].	 	 Importantly,	 in	 the	
present	study,	it	was	established	from	flow	cytometry	assays	(presented	in	Chapter	2)	
that	late	apoptotic/dead	HCT-8	cells	detached	from	the	cell	substrate.		In	the	SR-IRMS	
study	reported	 in	 this	Chapter	any	dead	cells	would	have	been	removed	by	washing	
steps	performed	prior	 to	 insertion	 into	 the	 cell	 chamber	 for	 analysis.	 	 Thus,	 the	 cell	
population	that	remains	adhered	to	the	substrate	primarily	contains	cells	of	relatively	
good	 health	 or	 in	 the	 early	 stages	 of	 apoptotic	 cell	 death	 as	 confirmed	 by	 flow	
cytometry	analysis	of	the	adherent	cell	population	(Appendix	4.12).		
While	there	are	variations	in	the	biochemistry	of	the	cells	due	to	cell	cycle	and	cell	
death	(which	correlates	in	variations	in	the	SRIRMS	spectra),	the	control	cell	samples	
that	were	 incubated	with	 cell	medium,	 in	 the	 absence	 of	 vehicle	 or	 drugs,	would	 be	
considered	to	be	the	‘normal’	distribution	of	a	culture	of	HCT-8	cells.		Flower	et	al.	[12]	
also	reported	a	similar	heterogeneity	in	the	scores	plots	of	spectra	associated	with	the	
control	cells.		Encouragingly,	the	results	from	the	PCA	loadings	plots	generated	in	this	
study	 (Fig.	4.9)	 indicate	 that	 the	 main	 source	 of	 variation	 of	 the	 cell	 medium	 and	
vehicle	 cells	 is	 the	 lipid	 bands	 which	 causes	 the	 dominant	 variance	 across	 the	
PC-1	axis.	 	This	 is	consistent	with	the	PCA	results	of	Whelan	et	al.	 [43]	who	reported	
the	same	observation	when	they	performed	a	PCA	of	G1,	S,	and	G2	cells.		It	is,	therefore,	
likely	 that	 the	 distribution	 of	 the	 vehicle	 scores	 is	 indicative	 of	 cell	 cycle	 variation	
within	the	population.	
It	 was	 essential	 to	 prepare	 non-treated	 (cell	 medium	 only)	 cells	 and	 vehicle-
treated	(DMSO	2%	v/v	in	RPMI-1640)	cells	in	order	to	determine	if	any	biomolecular	
changes	 occurred	 in	 response	 to	 DMSO	 exposure.	 	 It	 should	 be	 noted	 that	 all	 cell	
experiments	performed	 in	 this	Thesis	 included	a	vehicle-treated	 ‘control’	 in	order	 to	
directly	compare	with	the	BiNSAID/NSAID	treatments	(prepared	as	DMSO	solutions	in	
cell	medium	 to	achieve	dissolution	of	 the	drug).	 	A	 shorter	4-h	 treatment	 timeframe	
(as	well	as	the	typical	24-h	treatment)	was	evaluated	in	order	to	determine	whether	
any	 spectral	 changes	 indicative	 of	 biomolecular	 changes	 could	 be	 detected	 in	 the	
absence	 of	 cytotoxic	 effects	 (as	 indicated	 by	 MTT	 assays,	 Appendix	 1.2).	 	Vehicle	
treatment	 appeared	 to	 effect	 the	 SR-IRMS	 spectra	 of	 the	 HCT-8	 cells	 after	 4-h	 as	
evidenced	 by	 the	 PCA	 scores	 plots	 (Fig.	 4.8);	 however,	 the	 delineation	 identified	
between	 cell	medium-	 and	 vehicle-treated	 cells	was	 only	 observed	when	 the	 strong	
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loadings	 from	 the	 amide	 region	 (Fig.	 4.7)	 were	 omitted	 from	 the	 PCA	 (Fig.	4.8).	
Following	omission	of	the	amide	region,	the	PC-2	loadings	plots	(Fig.	4.8)	showed	that	
the	 νas(CH2),	 νs(CH2),	 νas(C=O),	 and	νas(CO−O−C)	bands,	 and	 the	 νas(PO2−)	band,	were	
the	primary	contributors	to	the	variance	between	the	cell	medium	and	vehicle	scores.		
DMSO	is	a	water-miscible,	polar	solvent,	which	has	often	been	used	in	cell	biology	
for	 the	 dissolution	 of	 hydrophobic	 compounds,	 cryoprotection,	 inducing	 cell	
differentiation,	 free	 radical	 scavenging,	 membrane	 penetration,	 and	 as	 a	 cell	
fusogen	[63].	 	The	 effect	 of	 DMSO	 on	 lipids,	 and	 in	 particular,	 membrane	
phospholipids,	 has	 been	 investigated	 in	 a	 number	 of	 studies	 [64-68].	 	 Molecular	
dynamic	simulations	performed	using	dioleoylphosphatidylcholine	membranes	mixed	
with	20	mol%	of	cholesterol	and	low	DMSO	fractions	(≤	10	mol%)	resulted	in	sporadic	
and	 very	 transient	 hydrophobic	 pores	 which	 were	 arranged	 in	 the	 form	 of	 single-
molecule	 water	 columns	 that	 cross	 the	 membrane	 and	 disappear	 [67].	
In	complimentary	microscopy	experiments,	small	undulations	of	the	cell	membrane	of	
DC-3F	 cells	 treated	 with	 10	 vol%	 (2.74	 mol%)	 DMSO	 were	 identified	 following	
1-h	[67].	 	Gurtovenko	 et	 al.	 [69]	 report	 that	 atomic-scale	 molecular	 dynamic	
simulations	performed	on	lipid	bilayers	comprising	dipalmitoylphosphatidylcholine	in	
aqueous	 solution	 with	 DMSO	 at	 low	 concentrations	 showed	 decreased	 membrane	
thickness	 and	 increased	 membrane	 fluidity	 (2.5−7.5	 mol%),	 while	 moderate	
concentrations	 (10−20	mol%)	 induced	 formation	 of	 transient	water	 pores,	 and	 high	
concentrations	 (25−100	 mol%)	 destroyed	 the	 bilayer	 structure	 of	 membranes.		
More	recently,	neutron	reflectometry	studies	assessing	the	effect	of	DMSO	(2%	v/v)	on	
lipid	 membrane	 mimetic	 bilayers	 comprised	 of	 POPC	 have	 been	 performed	 [68].		
Interestingly,	 scattering	 length	 density	 profiles	 indicated	 that	 DMSO	 (2%	v/v)	 in	
D2O/PBS	caused	no	structural	changes	to	the	bilayer.		However,	a	substantial	decrease	
in	 the	 scattering	 length	 density	 profile	 of	 the	 hydrophobic	 tail	 region	 indicated	 that	
DMSO	enters	 the	 tail	 region	of	 the	POPC	bilayer	and	subsequently	displaces	 the	D2O	
molecules	 [68].	 	Given	 that	 the	 formation	of	 transient	hydrophobic	pores	 across	 cell	
membranes	reportedly	occurs	at	higher	concentrations	of	DMSO	(>	10	vol%)	[69]	than	
that	 utilised	 in	 the	 present	 study,	 it	 is	 conceivable	 that	 variation	 in	 the	 SR-IRMS	
spectra	 was	 potentially	 due	 to	 the	 occupation	 of	 DMSO	 below	 the	 head	 groups	 of	
membrane	 phospholipids	 and	 the	 displacement	 of	 water	 molecules	 resulting	 in	 a	
difference	 in	 the	SR-IRMS	signature	observed	 in	 the	 lipid-related	bands	between	 the	
4-h	cell	medium-	and	vehicle-treated	PCA	scores.	
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Interestingly,	no	delineation	between	the	cell	medium-treated	or	vehicle-treated	
scores	 was	 observed	 following	 24-h	 treatment	 with	 or	 without	 the	 amide	 bands	
included	in	the	PCA	(Fig.	4.9).		Plasma	membrane	disruption	is	often	accompanied	by	
rapid	 resealing	 of	 the	 cell	 membrane	 in	 order	 to	 ensure	 cell	 survival	 [70].	 	Work	
performed	 by	 Togo	 et	 al.	 [71,	 72]	 suggests	 that	 cells	 are	 able	 to	 reseal	 wounded	
membranes	more	 rapidly	 following	 repeated	 disruption	 to	 the	 cell	membrane	when	
compared	 to	 the	 rate	 of	 repair	 following	 the	 initial	 wound	 due	 to	 an	 increase	 in	
exocytosis.	 	 It	 is	plausible	that	 following	an	extended	period	of	treatment	(>	4	h)	the	
HCT-8	 cells	 could	 become	 tolerant	 to	 DMSO	 exposure	 and	 the	 cell	 membrane	 may	
‘recover’	to	an	extent.	 	Perhaps	the	lack	of	biomolecular	distinction	as	determined	by	
PCA	between	 the	spectra	of	 cells	 treated	with	cell	medium	or	vehicle	 following	24-h	
may	 be	 due	 to	 gradual	 displacement	 of	 DMSO	 from	 the	 cell	 membrane.	 	 A	 recent	
report	[73]	suggests	that	experimental	quantification	of	the	properties	of	DMSO–water	
bonds	at	the	lipid	membrane	surface	remains	poorly	understood.	 	Thus	further	work	
is	needed	to	explicitly	confirm	the	present	findings.	
There	are	a	number	of	reports	[65,	74,	75]	that	discuss	the	varying	tolerance	and	
biochemical	 effects	 exhibited	 by	 different	 cell	 lines	 when	 exposed	 to	 DMSO.	 	For	
instance,	 the	 effect	 of	 DMSO	 (2%)	 on	 the	 membrane	 dynamics	 and	 phospholipid	
composition	 of	 the	 two	 different	 cell	 lines,	 FLC	 (Friend	 leukemia	 cells)	 and	 Raji	
(lymphoblastoid)	 cells	 has	 been	 investigated	 [65].	 	 Following	 5-day	 incubation	with	
DMSO	 only	 the	 phospholipid	 composition	 of	 FLC	 cells,	 but	 not	 the	 Raji	 cells	 was	
affected.		The	colon	cancer	cells,	Caco-2/TC7,	have	been	shown	to	be	tolerant	to	DMSO	
for	 concentrations	 up	 to	 10%	v/v	without	 the	 induction	 of	membrane	 leakage	 [74].		
In	another	study,	prolonged	DMSO	(2%	v/v)	treatment	has	been	reported	to	induce	a	
number	 of	 biochemical	 changes	 in	 SW480	 and	 SW620	 cell	 lines	 (primary	 colonic	
tumor	and	lymph	node	metastasis,	respectively,	isolated	from	the	same	patient)	[75];	
however,	 cell	 viability	 was	 not	 affected	 for	 up	 to	 four	 days	 following	 incubation	 in	
DMSO	 [75].	 	Clearly	previous	 research	 shows	 that	 the	 cell	 response	 to	DMSO	can	be	
variable,	 not	only	dependent	on	DMSO	concentration	and	 time	of	 exposure,	 but	 also	
dependent	 on	 the	 specific	 cell	 line.	 	 The	 results	 of	 the	 present	 study	 show	 that	 the	
viability	of	DMSO-treated	HCT-8	cells	is	slightly	affected	following	24-h	treatment	(as	
shown	 by	 MTT	 assay,	 Chapter	 2);	 however,	 no	 significant	 biomolecular	 differences	
could	 be	 detected	 by	 PCA	 of	 the	 SR-IRMS	 spectra.	 	 For	 the	 purpose	 of	 the	 current	
SR-IRMS	 study,	 the	 lack	 of	 distinction	 between	 cell	medium	 and	DMSO	 scores	 is	 an	
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important	result	as	it	suggests	that	DMSO	exposure	of	24-h	does	not	significantly	alter	
the	SR-IRMS	spectra	and	the	biomolecular	integrity	of	the	HCT-8	cells	using	this	tool.		
This	 indicates	 that	 any	 biomolecular	 changes	 observed	 when	 comparing	 the	
DMSO-treated	 cells	 to	 the	 BiNSAID	 or	 NSAID-treated	 cells	 are	 not	 dominated	 by	
presence	of	DMSO.	
4.4.2.2 BiNSAID/NSAID-treated	cells	
A	 few	 key	 observations	 resulted	 from	 the	 PCA	 analysis	 of	 vehicle-treated	 cell	
spectra	 compared	 to	 BiNSAID/NSAID-treated	 spectra.	 	 These	 included	 the	 findings	
that:	 (i)	 in	most	cases	 the	removal	of	 the	amide	region	resulted	 in	subtle	changes	 to	
the	distribution	of	the	scores	plots,	(ii)	in	most	cases	4-h	drug	treatment	caused	subtle	
biomolecular	changes	despite	no	obvious	physical	changes	to	the	cells	or	viability	loss	
(described	 in	 Chapter	 2),	 (iii)	 the	 changes	 observed	 following	 24-h	 drug	 treatment	
differed	 from	 the	 changes	 observed	 at	 4-h,	 and	 (iv)	 differences	 could	 be	 observed	
when	comparing	the	BiNSAID	scores	to	the	respective	NSAID	scores.		
It	 should	 be	 noted	 that	 the	 cell	 medium	 containing	 the	 drugs	 was	 removed	
following	the	defined	incubation	periods	(4	h	or	24	h)	and	the	cells	were	washed	prior	
to	placement	in	the	cell	holder	for	SR-IRMS	analysis.	 	This	was	performed	in	order	to	
prevent	 any	 SR-IRMS	 detection	 of	 drug	 in	 the	 cell	medium.	 	 Other	 researchers	 [35]	
have	reported	that	the	detection	limit	of	FTIR	instrumentation	is	not	sensitive	enough	
to	detect	the	extremely	low	concentrations	of	drug	that	would	reside	in	the	individual	
cell.		This	is	an	important	point	as	it	indicates	that	any	significant	changes	detected	in	
the	cell	spectra	were	the	result	of	the	actions	of	the	drugs	within	the	cells	and	not	due	
to	the	detection	of	the	drug	itself.	
When	 the	 spectral	 analyses	 were	 performed	 for	 the	 full	 spectral	 range	
(3000−2800	 cm−1,	 1790−1150	 cm−1)	 differences	 were	 commonly	 observed	 in	 the	
amide	 bands	 following	 treatment	 with	 BiNSAID/NSAID	 versus	 vehicle.	 	These	
differences	were	most	 obvious	 for	 cells	 treated	with	 Bi(tolf)3	 (subtle	 for	 4	 h),	 tolfH	
(subtle	for	4	h	and	moderate	for	24	h),	Bi(mef)3	(moderate	for	4	h),	mefH	(moderate	
for	 4	 h),	 and	 diflH	 (strong	 for	 4	 h),	 and	 less	 so	 for	 Bi(difl)3,	while	 no	 changes	were	
observed	 in	 Bi(tolf)3	 (24	h).	 	 The	 most	 significant	 changes	 were	 observed	 as	 band	
shifts	in	the	amide	I	band	from	1655	to	1653	cm−1	(tolfH	and	mefH	(4	h),	and	Bi(mef)3	
and	diflH	(24	h))	or	were	associated	with	the	development	of	shoulders	at	~1635	cm−1	
in	samples	treated	for	24-h	with	tolfH,	Bi(mef)3	and	mefH	(24	h).		The	frequency	of	the	
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amide	I	band	has	been	reported	to	represent	the	dominant	protein	structures	within	
in	a	cell.		For	instance,	common	protein	secondary	structures	and	their	corresponding	
vibrational	frequency	ranges	include:		α-helix	(1660−1649	cm−1),	β-sheet	(1637−1615	
cm−1),	 random	 coil	 (1648−1638	 cm−1),	 turn	 (1680−1660	 cm−1),	 and	 β-antiparallel	
(1692−1680	 cm−1)	 [76].	 	 Thus	 the	 development	 of	 a	 shoulder	 at	~1635	 cm−1	 in	 the	
24-h	 tolfH-,	 Bi(mef)3-,	 and	 mefH-treated	 cell	 spectra	 is	 potentially	 indicative	 of	 an	
increase	 in	 β-secondary	 structures.	 	An	 increase	 in	 the	 proportion	 of	 β-sheet	
structures	has	been	identified	in	the	early	stages	of	apoptosis	in	A549	[77],	HeLa	[17]	
and	 U-87	 MG	 cells	 [78].	 	This	 is	 in	 agreement	 with	 the	 present	 study	 where	 a	
substantial	proportion	of	BiNSAID/NSAID-treated	(at	IC50	doses	for	24	h)	HCT-8	cells	
were	 identified	 as	 early	 apoptotic	 in	 flow	 cytometry	 experiments	 (discussed	 in	
Chapter	2).		Unfortunately,	however,	as	has	been	established	by	Vaccari	et	al.	[34]	and	
Whelan	et	al.	[43]	in	Section	4.1.4	the	water	band	also	effects	the	amide	I	and	amide	II	
bands;	as	such,	whilst	it	appeared	that	correction	for	the	water	band	showed	no	effect	
on	 these	 bands,	 it	 cannot	 be	 definitively	 proven	 that	 these	 changes	 are	 solely	
attributed	to	molecular	changes	associated	with	amide	bands.		
In	 most	 cases	 the	 other	 biomolecular	 changes	 associated	 with	 BiNSAID/NSAID	
treatment	of	cells	were	consistent	regardless	of	whether	the	analysis	was	performed	
for	spectra	which	included	or	omitted	the	amide	regions.		The	most	significant	changes	
observed	 in	 both	 of	 these	 analyses	 were	 associated	 with	 CH2/CH3	 region	 (3000−	
2800	cm−1),	 ν(C=O)	 (1745	 cm−1)	 and	 νas(PO2−)	 (1245	 cm−1)	 that	 can	be	 attributed	 to	
lipids.		There	was	only	one	instance	where	the	lipid	changes	were	not	observed	in	both	
data	set	analyses	and	this	was	the	amide	inclusive	analyses	of	the	4-h	Bi(difl)3/diflH-
treated	cell	spectra	(Fig.	4.14a).		Instances	where	lipid	changes	were	observed	include:	
tolfH	(4	h	and	24	h),	Bi(tolf)3	(4	h),	mefH	(4	h	and	24	h),	Bi(mef)3	(4	h	and	24	h),	and	
diflH	(24	h).		
Interestingly,	the	4-h	Bi(tolf)3/tolfH	(Fig.	4.10)	and	4-h	Bi(mef)3/mefH	(Fig.	4.12)	
PCA	 results	 showed	 that	 the	 loadings	 bands	 associated	 with	 the	 lipids	 were	 also	
strongly	associated	with	the	BiNSAID/NSAID-treated	scores	(as	opposed	to	the	vehicle	
scores).	 	Furthermore,	 it	 was	 observed	 in	 the	 average	 Bi(tolf)3-,	 tolfH	 and	 Bi(mef)3-
treated	 (Appendix	 3.6	 and	 Appendix	 3.7)	 spectra	 that	 there	 was	 an	 increase	 in	 the	
intensity	 of	 the	 νas(CH2)	 and	 νs(CH2)	 bands,	 a	 possible	 indication	 that	 lipid	
concentration	 is	 increased	 in	 the	 BiNSAID/NSAID-treated	 cell	 populations.	 	 The	 4-h	
Bi(difl)3	 (Fig.	 4.14),	 showed	 the	 opposite	 trend	 whereby	 the	 lipid	 bands	 were	
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associated	 with	 the	 vehicle	 spectra.	 	This	 is	 not	 surprising	 given	 that	 the	 diflH	
structure	 differs	 significantly	 from	 the	 structures	 of	 mefH/tolfH	 (Fig.	 1.2).		
Importantly,	 as	no	 changes	 to	 the	 viability	 of	 the	BiNSAID/NSAID-treated	 cells	were	
observed	 after	 4-h	 treatment	 (as	 determined	 by	MTT	 assays,	 Chapter	 2),	 it	 is	 likely	
that	 the	 biomolecular	 changes	 observed	 at	 this	 time-point	 are	 associated	 with	
molecular	events	that	precede	apoptosis.		Factors	that	effect	lipids	include:	(i)	changes	
to	 the	 lipid	 membrane	 due	 to	 interaction/uptake	 of	 the	 drug	 molecules,	 or	 (ii)	 a	
downstream	metabolic	effect	once	the	drug	is	inside	the	cell	(e.g.	lipid	synthesis).			
The	SR-IRMS	spectral	changes	observed	in	the	lipid	bands	detected	in	response	to	
NSAID	treatment	are	consistent	with	reports	[79-81]	that	NSAIDs	are	able	to	interact	
with	lipids,	and	in	particular,	phospholipids,	which	constitute	a	large	proportion	of	the	
lipids	 comprising	 the	 cell	membrane.	 	 Experimental	 evidence	 [79]	 suggests	 that	 the	
deleterious	effects	of	NSAIDs	on	the	GI	tissue	could	be	due	to	mechanisms	that	involve	
direct	 disruption	 to	 the	 surface-active	 properties	 of	 phospholipids	 of	 the	 gastric	
mucosa,	 in	 addition	 to	 COX-1	 inhibition.	 	Studies	 by	 Lichtenberger	 et	 al.	 [80]	 have	
shown	 that	 30-min	 exposure	 of	 AGS	 human	 gastric	 carcinoma	 cells	 to	 aspirin	 or	
ibuprofen	 (both	 0.5	 mM),	 or	 naproxen	 (1.5	mM)	 altered	 the	 fluidity	 and	 packing	
density	of	the	cell	membrane	in	a	heterogeneous	manner	resulting	in	portions	of	the	
membrane	 becoming	 hydrophilic.				While	 the	 exposure	 time	 and	 treatment	
concentrations	varied	from	the	present	study	there	is	clear	evidence	that	NSAIDs	can	
directly	 disrupt	 the	 mammalian	 cell	 membrane.	 	 Suwalsky	 et	 al.	 [81]	 used	 X-ray	
diffraction	 to	 show	 that	 mefH	 perturbed	 lipid	 membrane	 mimetics	 consisting	 of	
dimyristoylphosphatidylcholine	 or	 dimyristoylphosphatidylethanolamine	
bilayers.		 Additionally,	 the	 researchers	 used	 fluorescence	 resonance	 energy	 transfer	
measurements	to	show	that	mefH	was	able	to	increase	fluidity	of	the	hydrophobic	core	
of	dimyristoylphosphatidylcholine	liposomes.		It	was	determined	that	this	occurred	as	
a	 result	 of	 intercalation	 of	 mefH	 into	 the	 hydrophobic	 acyl	 chains	 of	 the	
dimyristoylphosphatidylcholine	liposome	[81].			
Interestingly,	the	opposite	trend	(from	that	of	the	4-h	treatments)	was	observed	
when	 examining	 the	 24-h	 Bi(tolf)3/tolfH	 (Fig.	 4.11)	 and	 24-h	 Bi(mef)3/mefH	
(Fig.	4.13)	 PCA	 results	 whereby	 the	 loadings	 bands	 associated	 with	 the	 lipids	 were	
also	 strongly	 associated	 with	 the	 vehicle-treated	 scores	 (as	 opposed	 to	 the	
BiNSAID/NSAID-treated	scores).		As	such,	the	tolfH-,	Bi(mef)3-	and	mefH-treated	cells	
appear	to	be	associated	with	a	lower	lipid	concentration	than	the	vehicle-treated	cells.		
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This	was	 supported	 by	 the	 reduction	 in	 the	 absorbance	 of	 the	 νas(CH2),	 νs(CH2)	 and	
ν(C=O)	 bands	 in	 the	 SR-IRMS	 spectra	 (Appendix	 3.7	 and	 Appendix	 3.9).	 	 Flow	
cytometry	 assays	 (Appendix	 3.12)	 showed	 that	 following	 24	 h	 treatment	 with	 the	
same	 BiNSAID/NSAID	 concentrations,	 there	 was	 an	 increase	 in	 the	 proportion	 of	
apoptotic	 cells	 (~16−40%	 within	 the	 adherent	 cell	 population).	 	 Phase	 contrast	
microscopy	 also	 revealed	 morphological	 changes	 such	 as	 cell	 shrinkage	 and	 the	
formation	 of	 membrane	 blebs	 (Fig.	 2.7).	 	 Thus,	 in	 addition	 to	 changes	 to	 the	 lipid	
membrane	 due	 to	 the	 interaction/uptake	 of	 the	 drug	 molecules,	 or	 effects	 on	 lipid	
metabolism	caused	by	drug	uptake,	it	is	feasible	that	the	lipid	bands	will	additionally	
be	 altered	 as	 a	 result	 of	 apoptosis.	 	 The	 classic	 example	 of	 an	 alteration	 in	 lipid	
distribution	 associated	 with	 cell	 apoptosis	 is	 the	 ‘flipping’	 of	 phosphatidylserine	
species	 from	 the	 interior	 cell	 membrane	 to	 the	 exterior	 leaflet	 of	 the	 cell	
membrane	[82].	 	Additionally,	changes	in	membrane	fluidity	commonly	occur	in	cells	
undergoing	apoptosis	[83].		As	such,	the	observed	decrease	in	lipid	absorbance	may	be	
a	result	of	apoptosis;	however,	this	observation	is	in	contrast	to	a	number	of	fixed	cell	
studies	 that	 have	 demonstrated	 that	 the	 intensity	 of	 the	 lipid	 band	 increases	 in	
apoptotic	cells	[17,	20,	84,	85].		Live	cell	studies	performed	by	Birarda	et	al.	[39]	have	
shown	that	serum	starvation	or	carbonyl cyanide	m-chlorophenylhydrazone	exposure	
induced	 apoptosis	 in	 U937	 monocytes	 and	 caused	 an	 increase	 in	 cellular	 lipid	
concentration.		The	authors	speculated	that	the	increase	in	the	lipid	content	observed	
by	 spectroscopic	measurements	was	 due	 to	 the	 accumulation	 of	 lipid	 droplets.	 	 The	
decrease	(rather	than	increase)	in	lipid	absorbance	in	the	present	study	may	suggest	
that	lipid	droplet	accumulation	is	generally	not	an	event	associated	with	cell	death	in	
the	HCT-8	cell	line.	
Given	 the	 similarity	 in	 the	 structures	 of	 tolfH	 and	 mefH	 (Fig.	 1.2),	 it	 is	
unsurprising	 that	 tolfH	 and	 mefH	 would	 result	 in	 a	 similar	 biomolecular	 effect	 on	
HCT-8	 cells.	 	 Additionally,	 the	 overlap	 of	 the	 scores	 clusters	 in	 the	 Bi(mef)3/mefH	
series	 is	 perhaps	 not	 surprising	 given	 the	 instability	 of	 the	 Bi(mef)3	 complex	
(concluded	 by	 the	 NMR	 data	 presented	 in	 Chapter	 2)	 resulting	 in	 free	 mef	 in	 the	
treatment	medium.	 	However,	 one	of	 the	most	 surprising	 results	were	 those	 for	 the	
24-h	 diflH	 treatment	where	 it	was	 observed	 that	 there	was	 an	 increase	 in	 the	 lipid	
intensity	 associated	 with	 diflH	 treatment,	 but	 no	 change	 associated	 with	 Bi(difl)3	
treatment	 compared	 to	 the	 vehicle	 (Fig.	 4.15	 and	 Appendix	 3.11).	 	 It	 was	 apparent	
from	the	analyses	that	the	diflH-treated	HCT-8	cells	showed	differences	from	vehicle-
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treated	 cells	 but	 this	 was	 not	 the	 case	 for	 Bi(difl)3-treated	 cells.	 	The	 SR-IRMS	
differences	observed	for	diflH-	versus	tolfH/mefH-treated	cells	cannot	be	explained	by	
the	proportion	of	dying	cells	based	on	decreased	toxicity	since	in	all	cases	the	IC50	was	
applied.		 However,	 these	 differences	 might	 be	 explained	 by	 variations	 in	 the	
mechanism	of	action	of	diflH	compared	to	mefH	and	tolfH.		This	is	not	surprising	given	
the	diflH	structure	differs	significantly	from	the	structures	of	mefH	and	tolfH	(Fig.	1.2).			
It	 is	not	clear	why	 the	24-h	diflH-treated	cells	showed	such	a	strong	 increase	 in	
the	intensity	of	the	CH2/CH3	band	region.		A	live	cell	cycle	study	performed	by	Whelan	
et	 al.	 showed	 that	 an	 increase	 in	 lipid	 band	 intensity	 in	 the	 SR-IRMS	 spectra	 of	
synchronised	 cells	 appeared	 17-h	 post-mitosis,	 i.e.	 in	 the	 late-S	 phase	 of	 the	 cell	
cycle	[43].	 	As	such,	 it	 is	plausible	 that	 the	 increase	 in	 the	 lipid	band	 intensity	of	 the	
24-h	diflH-treated	cell	spectra	might	be	due	to	the	accumulation	of	HCT-8	cells	in	the	
S-phase	of	the	cell	cycle.		However,	NSAIDs	with	a	similar	chemical	structure,	including	
aspirin	 and	 salicylate,	 have	 been	 reported	 to	 arrest	 the	 cell	 cycle	 in	 the	 G0/G1	
phase	[86-88].	 	The	 increased	 intensity	of	 the	CH2/CH3	band	region,	 indicative	of	 the	
lipid	band,	was	consistent	with	Birarda	et	al.	[39]	whereby	the	authors	speculate	that	
the	increase	in	the	lipid	content	observed	by	spectroscopic	measurements	was	due	to	
the	accumulation	of	lipid	droplets.  Further	experiments	employing	fluorescent	probes	
could	be	performed	in	the	future	to	study	cell	cycle	arrest	and	the	possible	formation	
of	 lipid	 droplets	 in	 diflH-treated	 HCT-8	 cells,	 in	 order	 to	 better	 understand	 this	
SR-IRMS	observation. 
	
4.4.3 Limitations	of	the	experimental	approach	and	future	improvements	
The	 experimental	 design	 is	 an	 important	 factor	 that	 must	 be	 considered	 when	
undertaking	 any	 scientific	 investigation.	 	 Mignolet	 et	 al.	 have	 recently	 commented	
upon	 the	 variation	 in	 experimental	 design	 (and	 analysis	 procedures),	 cell	 handling,	
and	 spectroscopy,	 in	 relation	 to	 the	 evaluation	 of	 data	 published	 in	 the	 field	 of	
biospectroscopy	[15].		The	preparation	of	live	cells	for	SR-IRMS	analysis	in	the	present	
experiment	was	particularly	challenging	for	a	number	of	reasons.	
Each	treatment	sample	was	prepared	with	a	control	that	was	prepared	from	the	
same	 subculture,	 thus	 the	 passage	 number	 was	 kept	 consistent.	 	 However,	 the	
application	of	treatments	had	to	be	staggered	by	2−3	hours	given	the	time	required	to	
assemble	 the	 cell	 holder	 (typically	 15−20	min),	 set	 up	 the	 holder	 in	 the	microscope	
and	collect	 the	SR-IRMS	spectra	of	 the	cells	 (typically	60−90	min).	 	The	cell	 samples	
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prepared	 following	 2−3	hours	 may,	 therefore,	 experience	 some	 changes	 in	 the	 cell	
cycle	progression	and	the	concentration	of	metabolites	in	the	cell	medium.		While	the	
experiments	 in	 Chapter	 4	 were	 designed	 to	 mimic	 those	 of	 Chapters	 2	 and	 3	 in	
hindsight,	 one	 important	 consideration	 for	 future	 experiments	 might	 also	 be	 the	
preparation	of	synchronised	cell	samples	to	try	to	reduce	intra-sample	variation.			This	
was	not	possible	for	the	current	study,	however,	due	to	beamtime	limitations.	
Vaccari	 and	 co-workers	 [89]	 have	 commented	 on	 the	 issues	 with	 demountable	
liquid	 holders	 in	 recent	 publications.	 	Essentially,	 the	 perfect	 closure	 of	 the	
demountable	device	is	not	guaranteed,	which	can	potentially	result	in	variation	in	the	
optical	 path	 length	 throughout	 the	 device.	 	 Importantly,	water	 subtraction	 accuracy	
can	be	 affected	by	 changes	 in	 path	 length	between	 samples	 and	buffer	 spectra	 [34].		
Additionally,	with	the	demountable	design	(such	as	the	one	used	in	the	present	study)	
it	 is	 difficult	 to	 standardise	 ‘tightening’	 when	 the	 device	 was	 assembled	 with	 a	 cell	
sample	 contained	 inside	 [89].	 	Whelan	 et	 al.	 [43]	 performed	 live	 cell	 studies	 at	 the	
Australian	Synchrotron	that	employed	the	same	device	as	the	one	in	the	present	study	
at	the	and	have	commented	that	 its	assembly	could	be	a	cause	for	variation	between	
replicate	 samples.	 	Birarda	 et	 al.	 [89]	 have	 previously	 demonstrated	 that	 the	
compression	of	U937	monocyte	cells	in	a	device	that	contained	a	chamber	height	less	
than	half	that	of	the	diameter	of	the	cell	(causing	strong	deformation	of	the	cells)	led	to	
changes	in	AmI/AmII,	AmII/lipid	and	νas(PO2−)/νs(PO2−)	ratios;	thus	mechanical	stress	
can	 induce	 cellular	 deformation	 and	 consequent	 biomolecular	 alterations	 that	 are	
detectable	using	SR-IRMS.		If	future	experiments	were	to	be	performed,	the	use	of	a	a	
multi-faceted,	 fully	 sealed	 fluidic	 device,	 such	 as	 that	 reported	 by	Vaccari	 et	 al.	 [34]	
may	be	more	suitable.	
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4.5 Chapter	summary	
SR-IRMS	was	employed	for	the	analysis	of	live	HCT-8	cells	following	exposure	to	
BiNSAIDs	 or	 NSAIDs	 in	 order	 to	 determine	 if	 it	 could	 be	 used	 to	 study	 global	
biomolecular	 changes	 and	 allude	 to	 potential	 mechanisms	 of	 action	 of	 these	
compounds.	 	A	 multivariate	 approach,	 PCA,	 was	 applied	 to	 discern	 the	 spectral	
differences	 associated	 with	 the	 analysis	 of	 the	 data	 and	 different	 cell	 treatments.		
Specific	observations	regarding	the	analytical	approach	included	the	findings	that	the:	
(i) Subtraction	 of	 a	 water	 band	 spectrum	 from	 the	 cell	 spectrum	 of	 each	
individual	cell	only	subtly	affected	the	PCA	results.	
(ii) Omission	 of	 the	 amide	 region	 of	 the	 HCT-8	 cell	 spectra	 from	 PCA	 caused	
substantial	 changes	 to	 the	distribution	of	 the	 sample	 scores	plot.	 	 In	many	
cases,	 weak	 loadings	 bands	 became	 more	 prominent	 in	 the	 loadings	 plot	
upon	omission	of	the	amide	bands.	
The	 subsequent	 PCA	 showed	 that	 there	 was	 significant	 intra-sample	 variation,	
although	some	delineation	could	be	discerned	in	the	following	treatment	groups:	
(i) The	 comparison	 of	 cell	medium-only	 or	 vehicle-treated	HCT-8	 cell	 spectra	
indicated	 there	 were	 subtle	 effects,	 attributable	 to	 the	 vehicle	 (2%	 v/v	
DMSO	in	cell	medium),	on	the	spectra	following	4-h	treatment,	but	not	24-h	
treatment.	
(ii) Following	4-h	treatments:	
a. Bi(tolf)3	 and	 tolfH	 induced	 similar	 biomolecular	 effects	 on	 the	 HCT-8	
cells	 in	 comparison	 to	 the	 vehicle,	which	were	primarily	 attributed	 to	
effects	 on	 the	 lipids	with	 some	 contribution	 from	proteins.	 	However,	
following	removal	of	the	amide	region,	discrimination	between	the	two	
compounds	 was	 apparent	 and	 attributable	 to	 ν(C=O)	 and	 νas(PO2−),	
suggestive	 of	 difference	 in	 the	 effect	 of	 the	 two	 compounds	 on	
phospholipids.	
b. Bi(mef)3	or	mefH	induced	similar	effects	on	the	HCT-8	cells,	which	were	
primarily	attributed	to	lipids.		
c. DiflH	 induced	 biomolecular	 effects	 on	 the	 HCT-8	 cells,	 which	 were	
primarily	 attributed	 to	 proteins.	 	However,	 following	 amide	 removal	
from	 PCA	 analysis,	 diflH	 no	 longer	 showed	 any	 changes	 from	 the	
vehicle.		Treatment	with	Bi(difl)3	was	distinguishable	from	diflH	and	the	
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vehicle	 following	 amide	 removal,	 which	 was	 primarily	 attributed	 to	
lipids.	
(iii) Following	24-h	treatments:	
a. TolfH	 induced	 biomolecular	 effects	 on	 the	 HCT-8	 cells,	 which	 were	
primarily	 attributed	 to	 lipids	 with	 some	 contribution	 from	
proteins.	 	Treatment	 of	 the	 cells	 with	 Bi(tolf)3	 induced	 a	 varied	
response	within	the	Bi(tolf)3-treated	population.	
b. Treatment	with	Bi(mef)3	and	mefH	induced	similar	biomolecular	effects	
on	the	HCT-8	cells,	which	were	primarily	attributed	to	lipids.		
c. Treatment	with	Bi(difl)3	resulted	in	no	distinguishable	difference	from	
the	 vehicle-treated	 cells.	 	However,	 treatment	 with	 diflH	 was	
distinguishable	 from	Bi(difl)3	 and	 vehicle	 scores,	which	was	 primarily	
attributed	to	lipids.	
The	 ambiguity	 surrounding	 the	 inclusion	 or	 omission	 of	 amide	 bands	 from	
SR-IRMS	spectra	obtained	from	live	mammalian	cells	was	investigated	in	the	present	
study	 using	 two	 methods	 reported	 in	 the	 literature.	 	While	 this	 study	 may	 not	
necessarily	be	used	to	provide	further	advice	on	the	 inclusion	of	amide	bands	 in	 live	
cell	 studies,	 and	 the	validity	of	 the	biomolecular	 results	 they	provide,	 this	 study	has	
provided	a	direct	comparison	adding	credence	to	both	procedures	reported	by	other	
investigators.	
The	 SR-IRMS	 results	 obtained	 in	 the	 present	 study	 are	 preliminary	 in	 nature	
showing	 intra-	 and	 inter-sample	 variations	 reflective	 of	 biomolecular	 differences	 in	
the	 cell	 treatment	 groups.	 	 On	 the	 whole,	 the	 PCA	 results	 from	 the	 SR-IRMS	 study	
suggest	 that	 treatment	with	 BiNSAIDs	 or	 NSAIDs	 affect	 the	 lipids	 following	 4-h	 and	
24-h	 treatment.	 	As	SR-IRMS	provided	a	global	overview	of	all	biomolecular	changes	
that	 occurred	 in	 the	 HCT-8	 cells	 following	 treatment	 with	 vehicle,	 BiNSAIDs	 or	
NSAIDs	(including	 cell	 cycle,	 cell	 death	 and	 drug-induced	 biomolecular	 changes),	
additional	experimental	 techniques	 should	potentially	be	employed	 to	 confirm	 these	
observations.		For	instance,	a	study	to	compare	the	effects	of	the	BiNSAIDs/NSAIDs	on	
lipids	in	isolated	systems	(e.g.	cell-free	lipid	bilayers)	is	being	conducted	by	Dillon	and	
Brown	([68]	and	unpublished	results),	and	an	additional	 in	vitro	 lipidomic	study	has	
been	performed	on	isolated	lipids	from	drug-treated	cells	(see	Chapter	5).		 	
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Chapter	5. 	
Lipidomic	 profiling	 of	 glycerophospholipids	 using	
ESI-MS/MS	 of	 HCT-8	 cells	 treated	 with	 BiNSAIDs	
and	NSAIDs		
	
	
This	 Chapter	 describes	 shotgun	 lipidomic	 profiling	 of	 the	 organic	 extracts	 of	 HCT-8	
cells	 using	 electrospray	 ionisation	 tandem	 mass	 spectrometry	 (ESI-MS/MS).	 	This	
study	 was	 undertaken	 to	 compliment	 SR-IRMS	 studies	 reported	 in	 Chapter	 4	 that	
showed	 that	 the	 most	 prominent	 biomolecular	 changes	 in	 BiNSAID/NSAID-treated	
cells	 was	 that	 associated	 with	 lipids.	 	The	 purpose	 of	 the	 lipidomic	 study	 was	 to	
determine	 how	 treatment	with	 BiNSAIDs	 or	 NSAIDs	 affects	 the	 spectral	 profile	 and	
cellular	 concentration	 of	 the	 common	 phospholipids,	 phosphatidylcholine	 (PC),	
phosphatidylethanolamine	(PE)	and	phosphatidylserine	(PS).		
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5.1 Introduction	
Phospholipids	 are	 one	 of	 the	 major	 structural	 lipids	 found	 in	 eukaryotic	 cell	
membranes	 and	 are	 essential	 for	 maintaining	 the	 biochemical	 and	 biophysical	
properties	of	the	cell	membrane	[1].		The	eukaryotic	cell	membrane	is	comprised	of	a	
phospholipid	 bilayer,	 embedded	 with	 other	 lipid	 molecules	 (namely	 sterols	 and	
glycolipids)	 and	 membrane-embedded	 proteins	 [1].	 	The	 lipid	 bilayer	 provides	
individual	 cells	 with	 a	 selective	 barrier	 from	 the	 extracellular	 environment	 and	 a	
communication	 point	 between	 the	 intracellular	 and	 extracellular	 environments	 [1].	
Additionally,	 lipid	 bilayers	 form	 discrete	 organelles	 within	 the	 intracellular	 space.	
They	are	essential	for	compartmentalisation	of	specific	chemical	reactions,	increasing	
the	 biochemical	 efficiency	within	 the	 cell	 [1].	 	 As	well	 as	 their	 structural	 role,	many	
phospholipids	are	the	precursors	for	secondary	messengers,	which	play	an	important	
role	 in	 cellular	 functions	 including	 cell	 proliferation,	 apoptosis,	 signal	 transduction	
pathways	and	the	regulation	of	membrane	trafficking	[2].	 
Given	the	 importance	of	phospholipids	 in	maintaining	 the	physical	 integrity	and	
homeostasis	 of	 cells,	 changes	 to	 the	 composition	 of	 phospholipids	 associated	 with	
apoptosis,	 in	 particular	 drug-induced	 apoptosis,	 have	 been	 increasingly	 investigated	
[3-5].	 	The	 apoptotic	process	 causes	 changes	 to	 the	phospholipid	 composition	of	 the	
outer	surface	of	the	cell	membrane	and	the	phospholipid	distribution	within	the	lipid	
bilayer	 (most	 notably	 the	 externalisation	 of	 negatively-charged	 PS)	 [6].	 	 Recently,	
attention	 has	 focused	 on	 the	 importance	 of	 phospholipid	 composition	 in	 diseases,	
including	cancer	and	their	associated	treatment	[7-9].	 	For	 instance,	cancer	cells	that	
have	 a	 higher	 abundance	 of	 saturated	 phospholipids	[10],	 exhibit	 changes	 in	 lipid	
membrane	 dynamics	 and	 protein	 signal	 transduction,	 which	 can	 protect	 the	 cancer	
cell	 from	oxidative	 stress	by	 lowering	 the	 risk	of	 lipid	peroxidation.	 	Additionally,	 as	
lipids	mediate	a	number	of	cellular	processes	through	signaling	pathways,	alterations	
in	 lipid	 composition	 and	 signaling	 can	 result	 in	 changes	 to	 the	way	 the	 cancer	 cells	
respond	to	certain	chemotherapies	[11].			
The	results	 from	the	SR-IRMS	study	(Chapter	4)	 implied	 that	 there	was	a	global	
effect	 on	 cellular	 lipids	 following	HCT-8	 cell	 treatment	with	BiNSAIDs/NSAIDs.	 	 The	
anti-inflammatory	effects	of	NSAIDs	arise	through	the	interaction	with	lipid	mediators	
resulting	 in	 downstream	 consequences	 for	 arachidonic	 acid,	 which	 is	 derived	 from	
phospholipids	in	the	plasma	membrane	via	phospholipase	A2	[12].		Additionally,	there	
are	 several	 studies	 [13-16]	 suggesting	 that	 NSAIDs	 are	 capable	 of	 interaction	 with	
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phospholipids.		These	include	their	effect	on	hydrophobicity,	fluidity	and	permeability	
properties	 of	 membrane	 phospholipids;	 as	 such	 these	 effects	 could	 ultimately	
contribute	 to	 the	 cell	 injury/toxicity	 observed	 following	 NSAID	 exposure.	
Consequently,	 investigating	 changes	 to	 the	 cellular	 composition	 of	 common	
phospholipids	 is	 a	 logical	 place	 to	 begin	 examining	 lipid-related	 effects	 of	 BiNSAIDs	
and	the	respective	free	NSAIDs	on	the	lipidome	of	HCT-8	cells.	
Recently,	 lipidomics	 (or	 lipid	 profiling)	 has	 been	 increasingly	 utilised	 to	 study	
various	 tissue	 and	 cellular	 lipidomes	 [17].		 This	 has	 been	 aided	 by	 recent	
advancements	in	mass	spectrometry	(MS)	techniques,	which	have	enabled	researchers	
to	 study	 lipids	 with	 high	 sensitivity,	 allowing	 for	 the	 accurate	 characterisation,	
identification,	 and	 quantification	 of	 thousands	 of	 lipid	 species	 in	 biological	
samples	[17].	
	
5.1.1 Shotgun	 lipidomics:	Electrospray	 ionisation	mass	spectrometry	(ESI-MS)	
and	tandem	MS	for	the	examination	of	phospholipids	
	
While	 several	 MS	 approaches	 exist	 for	 the	 analysis	 of	 lipids,	 electrospray	
ionisation	 tandem	 mass	 spectrometry	 (ESI-MS/MS)	 represents	 one	 of	 the	 most	
commonly	 utilised	 techniques	 for	 achieving	 detailed	 structural	 analysis	 of	
phospholipids	 in	 biological	 samples	 [18].	 	 Two	 common	 approaches	 applied	 for	
ESI-MS/MS	analysis	of	lipids	are:	(i)	the	partial	separation	of	the	crude	lipid	extract	via	
high-performance	 liquid	 chromatography	 followed	 by	 infusion	 of	 the	 mobile	 phase	
into	 the	ESI	 source	 [18];	or	 (ii)	 the	direct	 infusion	of	 the	 sample	 into	 the	ESI	 source	
[19].		The	latter	approach,	known	as	shotgun	lipidomics	[19],	was	the	chosen	approach	
in	the	study	described	in	this	Chapter.		
The	 general	 protocol	 for	 the	 preparation	 of	 the	 lipid	 extracts	 from	 biological	
materials	for	shotgun	lipidomic	analysis	using	ESI-MS/MS	is	summarised	in	Figure	5.1	
where	 the	 subsequent	 phospholipid	 analysis	 is	 performed	using	 a	 triple	 quadrupole	
(QqQ)	instrument	with	an	ESI	source.		An	ESI	mass	spectrum	from	a	crude	lipid	extract	
provides	a	profile	of	the	lipids	that	ionise	in	the	chosen	mode	(i.e.	positive	or	negative).	
However,	since	the	mass	accuracy	of	some	MS	instrument	used	for	these	experiments	
may	 be	 low	 and	 the	 crude	 lipid	 extract	 (with	 potentially	 thousands	 of	 lipids)	 is	
complicated,	 the	complementary	 technique	ESI-MS/MS	 is	often	employed	 to	 confirm	
molecular	 identification	[20].	 	ESI-MS/MS	 can	 be	 achieved	 through	 the	 use	 of	 a	QqQ	
mass	spectrometer,	shown	in	Figure	5.1.	 	In	a	traditional	ESI-MS/MS	experiment	in	a	
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QqQ,	 the	 ion	 of	 interest	 (parent	 ion)	 is	 isolated	 in	Q1,	 followed	by	 collision-induced	
dissociation	 (CID)	 in	q2	 (collision	cell)	 (Fig.	5.1).	 	This	 involves	 fragmentation	of	 the	
[M	+	H]+	 or	 [M	−	H]−	 ions	 by	 collision	with	 an	 inert	 gas	 (such	 as	 argon)	 in	 q2,	with	
mass	analysis	 of	 the	 resulting	 ionic	 fragments	 occurring	 in	 Q3.	 	 Specifically,	 CID	 of	
phospholipids	 in	 positive	 ion	mode	 causes	 cleavage	 of	 the	 phosphate-glycerol	 bond	
resulting	 in	elimination	of	the	polar	head	group	as	a	charged	or	neutral	species	[21].		
The	 polar	 head	 group	 fragments	 (or	 product	 ions)	 are	 characteristic	 of	 each	
phospholipid;	therefore,	targeted	scans	(known	as	precursor	ion	or	neutral	loss	scans)	
enable	the	detection	and	structural	elucidation	of	each	of	the	precursor	phospholipid	
molecules	 contained	 in	 a	 sample	while	 excluding	 other	 (sometimes	more	 abundant)	
ions	[17].	
	
Figure	 5.1:	 Schematic	 representation	 of	 the	 shotgun	 lipidomic	 profiling	method	 by	 tandem	
mass	spectrometry	using	a	triple	quadrupole	(QqQ)	MS	instrument.		 	
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5.1.2 The	structure	of	glycerophospholipids	
The	 general	 chemical	 structures	 of	 several	 common	 glycerophospholipids	 are	
shown	in	Figure	5.2a.		Glycerophospholipids	are	amphipathic	molecules	that	contain	a	
polar	head	group	linked	to	a	3-carbon	glycerol	backbone	in	the	sn-3	position,	and	two	
fatty	acyl	molecules	attached	to	the	sn-1	and	sn-2	positions	of	the	glycerol	backbone.		
The	 fatty	 acyl	 molecules	 are	 bonded	 at	 the	 sn-1	 position	 via	 an	 ester	 (diacyl	
glycerophospholipids),	 alkyl	 ether	 (1-O-alkyl)	 or	 alkenyl	 ether	 (1-O-alkenyl)	
linkage	(Fig.	 5.2a).	 	 The	 chemical	 structures	 of	 the	 PC,	 PE	 and	 PS	 head	 groups	 are	
shown	 in	 Figure	 5.2b.	 	 The	 head	 groups	 provide	 the	 glycerophospholipid	 with	 a	
hydrophilic	 region.	 	 The	 final	 components	 of	 phospholipids	 are	 the	 fatty	 acyl	
molecules,	 which	 comprise	 the	 hydrophobic	 region	 of	 the	 glycerophospholipid	
molecule	(Fig.	5.2c).		Fatty	acyl	molecules	are	classified	by	their	chain	length	(number	
of	 carbons,	 typically	 4−30).	 	 The	 number	 and	 position	 of	 double	 bonds,	 including	
saturated	 (no	 double	 bonds),	 monounsaturated	 (one	 double	 bond)	 and	
polyunsaturated	(more	 than	one	double	bond),	are	 further	used	 to	classify	 fatty	acyl	
chains.	 	The	 number	 of	 glycerophospholipid	 head	 groups,	 and	 the	 varying	 carbon	
chain	 lengths	and	number/position	of	double	bonds	of	 fatty	acids,	 essentially	means	
that	over	10,000	unique	molecular	species	of	glycerophospholipids	could	exist. 
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Figure	5.2:	Chemical	structure	of:	(a)	Glycerophospholipids,	where	the	glycerol	backbone	is	in	
black,	 the	hydrophilic	region	 is	highlighted	 in	blue	and	the	hydrophobic	 fatty	acyl	chains	are	
highlighted	 in	 red.	 	(b)	 Common	 glycerophospholipid	 head	 groups.	 	(c)	 A	 fatty	 acid	 (18	
carbons	 in	 length)	 containing	 no	 double	 bonds	 (saturated),	 a	 single	 double	 bond	
(monounsaturated),	and	two	double	bonds	(polyunsaturated).		 	
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5.1.3 Nomenclature	of	glycerophospholipids	
The	glycerophospholipid	nomenclature	used	 in	 this	 thesis	 is	 in	accordance	with	
Fahy	et	al.	[22].		Glycerophospholipids	are	named	firstly	by	their	head	group	and	then	
by	their	fatty	acyl	chains;	for	instance,	a	molecule	with	a	phosphocholine	head	group	
and	two	fatty	acyl	chains	comprised	of	16	carbons	(sn-1	position)	and	18	carbons	with	
one	 double	 bond	 (sn-2	 position)	 would	 be	 referred	 to	 as	 PC	 (16:0/18:1).	 	The	
experiments	 reported	 in	 this	 Chapter	were	used	 to	 identify	 the	 total	 composition	 of	
the	glycerophospholipid	molecule,	but	do	not	identify	the	individual	fatty	acyl	chains.		
In	 this	 instance,	 the sum	 composition	 (i.e.	 total	 quantity	 of	 carbons	 and	 number	 of	
double	bonds)	is	presented	in	the	name.		For	example,	a	PC	molecule	containing	a	total	
of	 34	carbons	 in	 the	 fatty	 acyl	 chains	 and	 one	 double	 bond	 will	 be	 presented	 as	
PC	34:1.		
It	 must	 be	 noted	 that	 one	 of	 the	 limitations	 of	 the	 commonly	 employed	 MS	
techniques	(as	in	this	study)	is	the	inability	to	distinguish	isobaric	species	with	either	
odd-chain	or	ether-linked	fatty	acyl	groups.		In	addition,	the	MS	method	used	does	not	
allow	 for	 definitively	 distinguishing	 between	 glycerophospholipids	 containing	 an	
1-O-alkenyl	ether	versus	glycerophospholipids	with	a	1-O-alkyl	ether-linked	fatty	acyl	
group	containing	a	double	bond,	as	it	 is	not	possible	to	determine	the	position	of	the	
double	 bond	 along	 the	 fatty	 acyl	 chain.	 	 Therefore,	 it	 can	 only	 be	 determined	 that	 a	
double	bond	is	present	in	an	ether-linked	fatty	acyl	chain.	 	This	means	a	PC	molecule	
with	m/z	746	 can	be	 assigned	 to	 three	different	molecules;	 PC	33:1	 (odd-chain),	 PC	
P-34:0	 (1-O-alkenyl	 ether),	 or	 PC	O-34:1	 (1-O-alkyl	 ether).	 	 Odd-chain	 fatty	 acids	
constitute	 very	minor	 components	 in	mammals	 [23]	 and	have	been	 reported	 at	 low	
concentrations	in	human	cancer	cell	lines	[3].		As	such,	molecules	with	isobaric	species	
will	 be	designated	as	 ether-linked,	 by	 the	 “O-”	prefix,	 for	 the	 alkyl	 ether	 linked	 fatty	
acid,	 and	 the	 “P-”	 prefix	 for	 the	 1-O-alkenyl	 ether,	 or	 plasmalogen	 (e.g.	 PC	 O-34:1/	
PC	P-34:0).	
	
5.1.4 Biological	importance	of	glycerophospholipids	
In	eukaryotic	cells	the	glycerophospholipids	account	for	approximately	60	mol%	
of	lipid	mass	[19].		The	most	common	phospholipid	classes	found	in	mammalian	cells	
are	PC	and	PE,	while	PS,	phosphatidylglycerol,	diphosphatidylglycerol	(or	cardiolipin),	
phosphatidylinositol	 and	 phosphatidic	 acid	 comprise	 less	 abundant	 phospholipid	
species	in	mammalian	cells	[1].		In	most	eukaryotic	membranes,	PC	and	PE	collectively	
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comprise	 approximately	 75	mol%	of	 total	 phospholipid	mass,	 and	 are	 present	 in	 an	
approximately	3:2	(PC:PE)	molar	ratio	[19].		Given	the	abundance	of	PC	and	PE	within	
the	cell,	these	two	glycerophospholipids	were	chosen	for	lipidomic	examination	in	the	
present	study.	
As	 phospholipids	 are	 the	 major	 structural	 lipids	 found	 in	 eukaryotic	 cell	
membranes,	 the	variation	 in	 the	molecular	 structures	of	phospholipid	molecules	has	
implications	 for	 cellular	membrane	 properties	 including	membrane	 fluidity	 and	 the	
modulation	of	membrane-bound	protein	activity	[1].		Phospholipids	usually	distribute	
asymmetrically	in	the	cell	membranes	where	PC	can	be	dominantly	found	in	the	outer	
monolayer,	 whilst	 PE	 and	 PS	 are	 mainly	 present	 in	 the	 inner	 monolayer	 of	 plasma	
membranes	 [19].		 The	 composition	 of	 the	 phospholipids	 contained	 in	 the	 lipid	
membranes	 surrounding	 individual	 types	 of	 organelles	 can	 also	 differ	 [1].		 For	
instance,	PE	is	particularly	enriched	in	inner	membranes	of	mitochondria	(∼35–40%	
of	 total	phospholipids)	compared	with	other	organelles	(∼17–25%)	[24].	 	Due	to	the	
relative	size	of	the	PC	head	group,	PC	molecules	are	typically	cylindrical	in	shape	[25].		
Alternatively,	PE	molecules	contain	a	smaller	head	group,	resulting	in	a	typically	cone	
shaped	 molecule	 [26].	 	PE	 molecules	 alone	 cannot	 form	 membranes,	 rather	 their	
insertion	 into	 the	 membrane	 is	 essential	 for	 important	 cellular	 processes	 such	 as	
membrane	fusion	and	fission	and	the	embedding	of	membrane	proteins	[26].		PE	is	the	
most	abundant	 lipid	on	the	cytoplasmic	 layer	of	cellular	membranes,	with	significant	
roles	 in	 cellular	 processes	 such	 as	 membrane	 fusion,	 cell	 cycle,	 autophagy,	 and	
apoptosis	 [27].	 	PE	 molecules,	 similarly	 to	 PS,	 are	 translocated	 to	 the	 outer	 cell	
membrane	during	apoptosis	 [27-29].	 	Phospholipids	also	play	a	 role	 in	cell	 signaling	
pathways.	 	 For	 instance,	 the	 formation	 of	 the	 lipid	 mediators,	 prostaglandins	 and	
leukotrienes,	 are	 derived	 from	 arachidonic	 acid	 sourced	 from	 the	 lipid	
membrane	[30].	
As	 shown	 in	 Figure	 5.2,	 there	 are	 two	 types	 of	 ether-containing	
glycerophospholipids,	 1-O-alkyl	 and	 1-O-alkenyl.	 	The	 ether-linked	 phospholipids	
predominantly	 contain	 either	 a	 phosphocholine	 or	 a	 phosphoethanolamine	 head	
group.	 	Up	to	50%	of	glycerophospholipids	contain	ether-linked	fatty	acyl	chains,	but	
their	 functions	remain	 largely	unknown	[31].	 	Ether-containing	PC	molecules	 tend	to	
contain	the	1-O-alkyl	bond	and	are	typified	by	platelet	activating	factor	[32,	33].	 	The	
1-O-alkenyl	glycerophospholipids	contain	a	fatty	acyl	group	that	has	a	vinyl	ether	bond	
(i.e.	 a	 double	 bond	 on	 the	 first	 carbon	 from	 the	 ether	 end,	 Fig.	 5.2a)	 and	 are	 often	
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termed	 plasmalogens.	 	 Plasmalogens	 are	 particularly	 susceptible	 to	 oxidative	 attack	
due	 to	 the	 presence	 of	 the	 vinyl-ether	 bond;	 as	 such,	 plasmalogens	 have	 a	 reported	
antioxidant	 effect	 towards	 reactive	 species	 including	 ROS	 and	 iron-induced	
peroxidation	[33].		In	certain	cell	types	(e.g.,	inflammatory	cells,	neurons,	and	tumour	
cells),	 up	 to	 70%	 of	 PE	 molecules	 contain	 an	 ether-linkage,	 rather	 than	 an	 acyl-
linkage	[34].		
	
5.1.5 Chapter	Aims	
The	mechanism(s)	of	NSAID-induced	apoptosis	in	cancer	cells	in	vitro	and	in	vivo	
has	yet	 to	be	 fully	determined,	particularly	 in	 the	case	of	COX-2	deficient	cancer	cell	
lines	(discussed	in	Section	1.2.4).		It	has	been	shown	that	a	number	of	NSAIDs	interact	
directly	with	glycerophospholipids,	resulting	in	changes	to	the	hydrophobicity,	fluidity	
and	permeability	properties	of	membrane	phospholipids	[13-16].		Given	that	BiNSAID-	
and	NSAID-induced	apoptosis	in	the	HCT-8	cells	was	identified	in	Chapter	2,	and	that	
lipid	variation	was	prominent	in	the	SR-IRMS	results	(Chapter	4)	it	was	of	interest	to	
determine	 whether	 BiNSAID-	 and	 NSAID-induced	 apoptosis	 caused	 changes	 to	 the	
glycerophospholipid	composition	of	the	most	abundant	cellular	glycerophospholipids,	
PC,	PE	and	PS,	in	HCT-8	cells.		
In	 this	 study,	 the	analysis	of	 cellular	glycerophospholipids	was	performed	using	
shotgun	 lipidomics.	 	 The	 effect	 of	 two	 BiNSAIDs	 and	 their	 respective	 NSAIDs	 were	
chosen	for	examination	using	lipid	extraction.		Bi(tolf)3	was	assessed	due	to	the	fact	it	
exhibited	highest	toxicity	against	the	HCT-8	cells,	and	Bi(difl)3	was	chosen	as	the	diflH	
represented	a	salicylate	acid	structure	versus	the	fenamate	structural	group	of	 tolfH.		
Additionally,	Bi(difl)3	 exhibited	unusual	 toxicity	with	 respect	 to	 the	molar	 IC50	 ratio,	
BiNSAID:NSAID	(as	per	the	MTT	assay	results	presented	in	Chapter	2).	
The	specific	aims	of	this	Chapter	were	to:	
1. Determine	whether	BiNSAID	treatment	affected	the	composition	and	relative	
quantity	 of	 abundant	 glycerophospholipid	 (PC,	 PE	 and	 PS)	molecules	 in	 the	
HCT-8	 colon	 cancer	 cell	 line,	 and	 compare	 the	 effects	 to	 the	 corresponding	
NSAID	treatment.	
2. Compare	whether	the	effects	on	PC,	PE	and	PS	composition	and	their	relative	
quantities	differed	between	BiNSAID	treatment	(Bi(tolf)3	and	Bi(difl)3).	
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5.2 Materials	and	Methods	
5.2.1 Materials	
All	of	 the	chemicals	and	materials	used	 for	 the	cell	 culture	and	 treatment	of	 the	
cell	 samples	 in	 this	 Chapter	 have	 been	 previously	 described	 in	 Section	 2.2.1.		
Additional	chemicals	(specific	to	the	experiments	in	this	Chapter)	include	magnesium	
chloride	 hexahydrate	 (MgCl2.6H2O,	 ≥99%)	 and	 2-mercaptoethanol	 (>98%),	 which	
were	 purchased	 from	 Sigma	 Aldrich	 (St	 Louis,	 USA).	 Quick	StartTM	 Bradford	 Dye	
Reagent,	1×	and	Quick	StartTM	bovine	serum	albumin	(BSA)	standard	set	(2	mg,	1.5	mg,	
1	mg,	0.75	mg,	0.5	mg,	0.25	mg	and	0.125	mg)	were	acquired	from	Bio-Rad	(Hercules	
CA,	 USA).	 Analytical	 grade	 ammonium	 acetate	(≥97%),	 chloroform	 (≥99.5%),	 and	
methanol	(≥99.7%)	and	were	sourced	from	Ajax	Finechem	(Seven	Hills,	Australia).	 	A	
methanolic	 internal	 standard	 mix	 (comprised	 of	 PC	 (19:0/19:0),	 20	µM;	 PE	
(17:0/17:0),	 20	 µM;	 PS	 (17:0/17:0),	 20	 µM)	 was	 generously	 provided	 by	
Associate	Professor	Todd	Mitchell	(School	of	Medicine,	University	of	Wollongong)	and	
prepared	 by	 Dr	 Jennifer	 Saville	 (School	 of	 Chemistry,	 University	 of	 Wollongong).	
The	glycerophospholipid	standards	were	originally	procured	from	Avanti	Polar	Lipids	
(Alabaster,	USA).	
5.2.2 Cell	lines	
HCT-8	cells	were	sourced	and	employed	as	described	in	Section	2.2.3.	
5.2.3 Preparation	of	cell	lipid	extracts	
HCT-8	 cells	 (1	×	106	 cells,	 5	mL)	were	 seeded	 in	60-mm	cell	 culture	dishes	and	
incubated	 for	24	h,	after	which	the	growth	medium	was	removed	and	the	cells	were	
washed	 twice	 with	 PBS	 solution.	 	 Treatment	 solutions	 of	 the	 BiNSAID	 (Bi(tolf)3	 or	
Bi(difl)3)	 or	 NSAID	 (tolfH	 or	 diflH)	 were	 added	 to	 each	 dish	 (3	 mL	 RPMI-1640,	
2%	DMSO	v/v),	while	the	control	cells	were	incubated	with	vehicle	(3	mL	RPMI-1640,	
2%	DMSO	v/v)	for	24	h.		HCT-8	cells	were	treated	with	the	approximate	IC50	doses	of	
each	 BiNSAID	 (as	 determined	 by	 MTT	 assays,	 Section	 2.3.2),	 or	 an	 equimolar	
concentration	 of	 the	 corresponding	 free	 NSAID.	 	 Following	 treatment,	 any	 detached	
cells	were	collected.	 	The	adherent	 cells	were	washed	with	PBS	solution	 (1	mL)	and	
any	displaced	cells	were	collected.	 	Trypsin	(0.25%	in	PBS,	2	mL)	was	then	added	to	
each	dish	and	 the	 remainder	of	 the	 cells	was	 combined	with	 the	previous	washings.		
The	 resultant	 suspension	 was	 centrifuged	 (300	 g,	 5	 min)	 and	 the	 cell	 pellet	 was	
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washed	 with	 PBS	 solution	 to	 remove	 any	 trypsin.	 	The	 cells	 were	 resuspended	 in	
treatment	 medium	(1	mL)	 and	 the	 cell	 suspension	 was	 divided	 into	 two	 500-µL	
aliquots;	one	aliquot	was	immediately	assessed	for	protein	content,	while	the	second	
aliquot	was	stored	(37	°C,	5%	CO2)	for	lipid	extraction	and	ESI-MS/MS	analysis.		
The	cells	in	the	first	aliquot	were	centrifuged	and	washed	once	with	PBS	solution.		
The	 cells	 were	 then	 resuspended	 in	 ice-cold	 osmotic	 lysis	 buffer	 (200	 µL,	 10	 mM	
HEPES,	 5	 mM	 MgCl2.6H20	 and	 20	 mM	 2-mercaptoethanol)	 and	 incubated	 on	
ice	(30	min).	 	 Following	 this	 incubation	 the	 swollen	 cells	 were	 sheared	 10	 times	
through	a	29-gauge	syringe	to	cause	disruption	of	the	cell	membrane.		Lysis	efficiency	
was	confirmed	by	light	microscopy.		The	disrupted	cells	were	centrifuged	(20,000	g,	5	
min)	 to	 collect	 lysed	 cellular	 debris	 and	 the	 supernatant	 (20	 µL)	 was	 assayed	 for	
protein	concentration	with	Bradford	reagent	using	BSA	as	a	standard.		
The	second	aliquot	of	cells,	to	be	used	for	lipid	extraction,	was	removed	from	the	
incubator	and	the	cells	were	resuspended.		A	calculated	volume	of	the	cell	suspension	
(normalised	 to	 protein	 concentration)	 was	 removed	 and	 the	 cells	 were	 centrifuged	
and	washed	with	 PBS	 solution.	 	 They	were	 then	 resuspended	 in	methanol	 (500	 µL)	
and	stored	overnight	at	−80	°C.		The	cell	samples	(in	methanol)	were	transferred	to	a	
glass	 test	 tube,	 chloroform	(1	mL)	was	added	and	 the	 solution	was	vortexed	briefly.		
The	cell	samples	were	placed	on	an	orbital	shaker	at	 low	speed	for	1	h	to	allow	lipid	
extraction	 to	 occur.	 	 Samples	 were	 spiked	with	 a	methanolic	 internal	 standard	mix	
(50	µL)	 such	 that	 he	 final	 concentration	 of	 each	 internal	 standard	 in	 all	 the	 cell	
samples	 was	 50	nmol/mg	 protein.	 	 Following	 brief	 vortexing,	 ammonium	 acetate	
solution	 (1	mL,	 0.15	 M)	 was	 added	 and	 the	 solution	 was	 vortexed	 and	 centrifuged	
(5	min,	2,000	g).	 	The	organic	phase	was	 removed	and	1	mL	of	 chloroform:methanol	
(2:1	 v/v)	 was	 added	 to	 the	 aqueous	 phase	 and	 vortexed	 and	 centrifuged	 (5	 min,	
2,000g).		The	organic	phase	was	combined	with	the	previously	collected	organic	phase	
and	a	fresh	aliquot	of	ammonium	acetate			(500	μL)	was	added.	The	resultant	solution	
was	vortexed	and	centrifuged	(5	min,	2,000g)	following	which,	the	aqueous	phase	was	
removed	using	a	Pasteur	pipette.		Care	was	taken	to	ensure	that	the	organic	phase	was	
not	disturbed.		The	organic	phase	was	then	dried	under	nitrogen	before	reconstitution	
in	 chloroform:methanol	 (1:2	v/v,	 500	 μL).	 	Samples	 were	 stored	 at	 −80	°C	 until	
ESI-MS/MS	analysis	was	performed.	
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5.2.4 Mass	spectrometry	
ESI-MS/MS	 analysis	 was	 performed	 on	 a	 Waters	 QuattroMicro™	 QqQ	 mass	
spectrometer	with	Masslynx	 4.0	 software	 (Waters,	Milford,	 USA).	 	 Prior	 to	 infusion,	
aqueous	ammonium	acetate	(1	M,	25	μL)	was	added	to	all	samples	to	produce	a	final	
concentration	of	50	mM.	 	For	ESI-MS	analysis,	samples	were	infused	at	a	flow	rate	of	
10	μL/min.	 	 Table	5.1	 contains	 the	 parameters	 used	 for	 ESI-MS	 and	 targeted	 ion	
scan	(MS/MS)	 analysis	 in	 positive	 ion	mode.	 	 The	 collision	 energies	 for	 the	 targeted	
ion	scans	used	in	this	project	are	shown	in	Table	5.2.		Spectra	were	typically	obtained	
over	a	mass	range	of	m/z	600-900	in	positive	ion	mode.		For	ESI-MS/MS,	a	scan	rate	of	
200	Th/s	was	used,	and	100	scans	were	combined.	 	The	spectra	were	then	processed	
using	background	subtraction	and	smoothing	with	a	Savitsky-Golay	algorithm.	
Table	 5.1:	 Instrument	 parameters	 used	 for	 ESI-MS	 and	 targeted	 ion	 scan	 (MS/MS)	
analysis	on	the	Waters	QuattroMicroTM	triple	quadrupole	mass	spectrometer.	
Parameter	 MS	 MS/MS	
Capillary	(kV)	 3.0	 3.0	
Cone	(V)	 50.0	 50.0	
Extractor	(V)	 2.00	 2.00	
RF	lens	(V)	 0.0	 0.0	
Source	temperature	(°C)	 80	 80	
Desolvation	gas	flow	rate	(L/h)	 320	 320	
LM	1	resolution	 15.0	 15.0	
HM	1	resolution	 15.0	 15.0	
Ion	energy	1	 0.5	 1.0	
Entrance	 50	 −2	
Collision	energy	 2	 see	Table	4.2	
Exit	 50	 1	
LM	2	resolution		 15.0	 15.0	
HM	2	resolution	 15.0	 15.0	
Ion	energy	2	 0.6	 1	
Multiplier	(V)	 650	 650	
Gas	cell	pirani	pressure	 <	1.0e−4	 3.0e−3	
	
Table	5.2:	Targeted	ion	(MS/MS)	scans.	
Scan	Type	 Targeted	ion	 Collision	energy	(eV)	 Feature	identified*	
Precursor	 m/z	184.1	 35	 PC	
Neutral	loss	 141.0	Da	 25	 PE	
Neutral	loss	 185.0	Da	 22	 PS	
*PC,	phosphatidylcholine;	PE,	phosphatidylethanolamine;	PS,	phosphatidylserine.	
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5.2.5 Data	analysis	
In	 order	 to	 determine	 the	 limit	 of	 detection	 (LOD)	 and	 limit	 of	 quantification	
(LOQ)	of	the	instrument	for	each	set	of	samples	that	were	run	over	different	days,	the	
LOD	and	LOQ	were	calculated	for	all	precursor	scans	and	neutral	loss	scans	following	
the	 conclusion	 of	 each	 run.	 	 Following	 background	 subtraction	 and	 smoothing,	 the	
average	noise	was	calculated	in	a	region	of	the	spectrum	where	no	ionized	lipids	were	
expected	 by	 averaging	 the	 total	 noise	 intensity	 over	 a	 3	 Th	 region.	 	 The	mean	 and	
standard	deviation	(s.d.)	were	calculated	from	the	average	of	the	total	noise	intensity	
and	the	LOD	and	LOQ	were	determined	using	the	following	equations:		
LOD	=	mean	+	(3	×	s.d.)												(1)	
LOQ	=	mean	+	(10	×	s.d.)										(2)	
The	centroid	 function	was	applied	 to	 the	spectra	using	peak	areas	 to	determine	
the	area	under	the	curve.		Any	peaks	with	intensity	below	the	LOD	were	not	included	
in	further	analysis.		Peak	intensities	above	the	LOD,	but	below	the	LOQ,	were	reported	
in	the	identification,	but	were	excluded	from	quantitative	analysis.	
An	Excel	 template	 (provided	by	Associate	Professor	Todd	Mitchell)	was	used	 to	
simulate	 isotopic	distributions	and	 the	necessary	corrections	were	applied	 to	enable	
quantification	 of	 individual	 and	 total	 lipids	 within	 the	 PC,	 PE	 and	 PS	 classes	 as	
described	 in	 previous	 studies	 [35].	 	The	 relative	 ion	 abundance	 of	 the	 three	
isotopologues	 was	 determined	 using	 the	 MassLynx	 isotope	 modeling	 function	 by	
calculating	 the	 13C	 isotopic	distribution	 for	each	molecule	and	 input	as	a	 ratio	of	 the	
molecular	 ion.	 	 The	 analysis	 began	with	 the	 smallest	 ion	 in	 order	 to	 correct	 for	 an	
isotopologue	of	a	 lower	m/z ion	contributing	at	 the	mono-isotopic	peak	of	a	heavier	
ion.		The	abundance	could	then	be	summed	for	all	isotopes,	eliminating	discrimination	
based	 on	 size	 and	 isotopic	 ratio	 differences.	 	 In	 order	 to	 quantify	 each	 individual	
glycerophospholipid	 present	 within	 the	 class,	 the	 isotope	 sum	 for	 each	 ion	 was	
normalised	to	the	isotope	sum	of	the	internal	standard.	
5.2.6 Statistical	analysis	
Statistical	analysis	was	performed	using	one-way	ANOVA,	followed	by	the	Tukey-
Kramer	multiple	 comparison	 test	 using	 GraphPad	 Prism,	 Version	 5.04	 for	Windows	
(GraphPad	Software,	La	 Jolla,	USA).	 	The	results	were	analysed	as	 the	vehicle	versus	
BiNSAID	versus	the	corresponding	NSAID,	in	order	to	draw	a	statistical	comparison	at	
the	same	NSAID	treatment	concentration.		In	the	cases	where	the	ion	abundance	was	
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not	 detected	 above	 the	 LOD	 or	 LOQ	 in	 at	 least	 75%	 of	 the	 samples,	 the	 ion	 was	
excluded	from	the	statistical	analysis	[36].		Results	are	presented	as	mean	±	standard	
deviation	(s.d.).		A	value	of	P	≤	0.05	was	considered	statistically	significant.	 	
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5.3 Results	
5.3.1 Phosphatidylcholine	(PC)	
The	 effect	 of	 BiNSAID	 and	 NSAID	 treatment	 on	 the	 individual	 and	 total	 PC	
molecules	in	HCT-8	cells	was	examined	in	two	ways:	(i)	inspecting	the	changes	in	the	
overall	profile	of	 the	PC	molecules	(i.e.	 changes	 in	 the	relative	abundance	of	each	PC	
molecule	as	a	proportion	of	the	total	of	PC,	Fig.	5.3−5.5)	and	(ii)	calculating	the	overall	
changes	to	the	relative	concentration	of	PC	molecules	(Fig.	5.6).	
The	profiles	of	the	PC	molecules	(calculated	as	a	percentage	of	total	PC)	detected	
above	 the	 LOD	 using	 ESI-MS/MS	 in	 HCT-8	 cell	 lipid	 extracts	 treated	 with	 vehicle,	
Bi(tolf)3	or	tolfH	are	shown	in	Figure	5.3,	while	the	profiles	following	treatment	with	
vehicle,	 Bi(difl)3	 or	 diflH	 are	 shown	 in	 Figure	 5.4.	 	 For	 clarity,	 only	 molecules	 that	
accounted	 for	 >0.5%	 relative	 abundance	 of	 the	 total	 PC	 molecules	 have	 been	
presented	in	Figures	5.3	and	5.4.	 	A	summary	of	all	the	identified	PC	molecules	above	
the	LOD	can	be	found	in	Appendix	4.1.		As	shown	in	the	left-most	graphs	of	Figures	5.3	
and	 5.4,	 the	 three	 most	 abundant	 PC	 molecules	 present	 in	 the	 vehicle-	 and	
BiNSAID/NSAID-treated	 HCT-8	 cell	 lipid	 extracts	 were	 PC	 34:1	 (m/z	 760),	
PC	32:1	(m/z	 732)	 and	 PC	P-32:0/O-32:1	 (m/z	 718).	 	 Notably,	 Bi(tolf)3	 and	 tolfH	
treatment	exhibited	very	similar	profile	changes,	which	differed	significantly	from	the	
profile	 obtained	 from	 vehicle-treated	 cells	 (Fig.	 5.3).	 	 Additionally,	 the	 Bi(difl)3	 and	
diflH	 treatment	 exhibited	 very	 similar	 profile	 changes,	 which	 differed	 significantly	
from	 the	 profile	 obtained	 from	 vehicle-treated	 cells	(Fig	 5.4).	 	 However,	 the	 profile	
changes	 induced	 by	 Bi(tolf)3/tolfH	 (Fig.	 5.3)	 compared	 to	 Bi(difl)3/diflH	 (Fig.	 5.4)	
differed	somewhat.		For	instance,	the	relative	abundance	of	the	most	predominant	PC	
molecule,	PC	34:1,	decreased	in	the	Bi(tolf)3/tolfH-treated	cells	(Fig	5.3),	but	increased	
in	the	Bi(difl)3/diflH-treated	cells	(Fig	5.4)	compared	to	the	vehicle.		
	
Chapter	5.	Lipidomic	profiling	of	glycerophospholipids	using	ESI-MS/MS	
	
	 224	
	 Fi
gu
re
	5
.3
:	P
ro
fil
e	
of
	p
ho
sp
ha
tid
yl
ch
ol
in
e	
(P
C)
	m
ol
ec
ul
es
	in
	H
CT
-8
	c
el
ls
	fo
llo
w
in
g	
24
-h
	tr
ea
tm
en
t	w
ith
	v
eh
ic
le
	(
RP
M
I-
16
40
,	D
M
SO
	
2%
	v
/v
),	
Bi
(t
ol
f)
3	(
15
	µ
M
),	
or
	to
lfH
	(4
5	
µM
),	
ca
lc
ul
at
ed
	a
s	
a	
pe
rc
en
ta
ge
	o
f	t
ot
al
	P
C.
		D
at
a	
ar
e	
pr
es
en
te
d	
as
	m
ea
n	
±	
s.d
.	(
n	
=	
3	
(v
eh
ic
le
)	
or
	n
	=
	4
	(
Bi
(t
ol
f)
3	
an
d	
to
lfH
)	
re
pl
ic
at
es
	fr
om
	o
ne
	e
xp
er
im
en
t.	
	S
ig
ni
fic
an
ce
	w
ith
	r
es
pe
ct
	t
o	
th
e	
co
nt
ro
l	i
s	
in
di
ca
te
d	
by
	l
	p
	≤
	0
.0
5	
(B
iN
SA
ID
	a
nd
	N
SA
ID
),	
u
	p
	≤
	0
.0
5	
(B
iN
SA
ID
	o
nl
y)
,	o
r	
n
	p
	≤
	0
.0
5	
(N
SA
ID
	o
nl
y)
.		
Fo
r	
cl
ar
ity
	o
nl
y	
m
ol
ec
ul
es
	th
at
	a
cc
ou
nt
ed
	fo
r	
>	
0.
5%
	
re
la
tiv
e	
ab
un
da
nc
e	
of
	th
e	
to
ta
l	P
C	
m
ol
ec
ul
es
	h
av
e	
be
en
	p
re
se
nt
ed
.		N
ot
e:
	O
dd
	o
r	e
th
er
-li
nk
ed
	fa
tt
y	
ac
yl
	c
ha
in
	(e
.g
.	P
C	
O-
34
:0
/P
C	
33
:1
)	
ca
nn
ot
	b
e	
di
ffe
re
nt
ia
te
d	
in
	th
is
	e
xp
er
im
en
t.	
		
	
	
Chapter	5.	Lipidomic	profiling	of	glycerophospholipids	using	ESI-MS/MS	
	
	 225	
	
Fi
gu
re
	5
.4
:	P
ro
fil
e	
of
	p
ho
sp
ha
tid
yl
ch
ol
in
e	
(P
C)
	m
ol
ec
ul
es
	in
	H
CT
-8
	c
el
ls
	fo
llo
w
in
g	
24
-h
	tr
ea
tm
en
t	w
ith
	v
eh
ic
le
	(
RP
M
I-
16
40
,	D
M
SO
	
2%
	v
/v
),	
Bi
(d
ifl
) 3
	(
75
	µ
M
),	
or
	d
ifl
H
	(
22
5	
µM
),	
ca
lc
ul
at
ed
	a
s	
a	
pe
rc
en
ta
ge
	o
f	
to
ta
l	P
C.
		
D
at
a	
ar
e	
pr
es
en
te
d	
as
	m
ea
n	
±	
s.d
.	(
n	
=	
4	
re
pl
ic
at
es
	fr
om
	o
ne
	e
xp
er
im
en
t)
.		
Si
gn
ifi
ca
nc
e	
w
ith
	re
sp
ec
t	t
o	
th
e	
co
nt
ro
l	i
s	
in
di
ca
te
d	
by
	l
	p
	≤
	0
.0
5	
(B
iN
SA
ID
	a
nd
	N
SA
ID
),	
u
	p
	≤
	0
.0
5	
(B
iN
SA
ID
	o
nl
y)
,	o
r	
n
	p
	≤
	0
.0
5	
(N
SA
ID
	o
nl
y)
.		
Fo
r	
cl
ar
ity
	o
nl
y	
m
ol
ec
ul
es
	th
at
	a
cc
ou
nt
ed
	fo
r	
>	
0.
5%
	r
el
at
iv
e	
ab
un
da
nc
e	
of
	th
e	
to
ta
l	P
C	
m
ol
ec
ul
es
	h
av
e	
be
en
	p
re
se
nt
ed
.		
N
ot
e:
	O
dd
	o
r	
et
he
r-
lin
ke
d	
fa
tt
y	
ac
yl
	c
ha
in
	(
e.
g.
	P
C	
O-
34
:0
/P
C	
33
:1
)	
ca
nn
ot
	b
e	
di
ffe
re
nt
ia
te
d	
in
	th
is
	
ex
pe
ri
m
en
t.	
		
	
Chapter	5.	Lipidomic	profiling	of	glycerophospholipids	using	ESI-MS/MS	
	
	 226	
In	 order	 to	 identify	 if	 fatty	 acid	 composition	 accounts	 for	 the	 changes	 seen	 in	
Figures	 5.3	 and	 5.4,	 the	 PC	molecules	 were	 classified	 into	 the	 following	 categories:	
those	 that	 contained	 fatty	 acids	with	no	double	 bonds	 (saturated),	 one	double	 bond	
(monounsaturated),	 ≥	two	 double	 bonds	 (polyunsaturated),	 or	 an	 ether-linked	 fatty	
acid.	 	These	were	summed	within	 the	aforementioned	categories	and	 the	results	are	
presented	 in	 Figure	 5.5.	 	It	 is	 important	 to	 note	 that	 in	 this	 context,	 the	 sum	
composition	 of	 the	 two	 fatty	 acids	 have	 been	 reported	 and	 therefore	 saturated,	
monounsaturated	 and	 polyunsaturated	 refers	 to	 the	 total	 number	 of	 double	 bonds	
present.	 	Although	 the	 identity	of	both	acyl	chains	could	not	be	determined	with	 the	
methodology	used	in	the	present	study,	it	has	been	reported	that	the	typical	PC	carries	
one	saturated	and	one	unsaturated	chain	[1].		Following	24-h	treatment	with	Bi(tolf)3	
or	 tolfH,	 there	 was	 a	 slight,	 but	 significant	 decrease	 (Bi(tolf)3,	 P	 ≤	 0.01;	
tolfH,	P	≤	0.001)	 in	 the	 proportion	 of	 PC	 molecules	 containing	 monounsaturated	 or	
polyunsaturated	 fatty	 acids	 compared	 to	 the	 cells	 treated	 with	 vehicle	
alone	(Fig.	5.5a).		These	changes	were	concurrent	with	a	significant	increase	(Bi(tolf)3,	
P	 ≤	 0.01;	 tolfH,	 P	≤	 0.001)	 in	 the	 proportion	 of	 PC	 molecules	 that	 contained	
ether-linked	 fatty	acids	 following	24-h	 treatment	with	Bi(tolf)3	or	 tolfH	compared	 to	
treatment	with	 vehicle	 alone	 (Fig.	 5.5a).	 	 No	 significant	 change	 to	 the	 proportion	 of	
saturated	 PC	 molecules	 was	 observed	 (Fig.	 5.5a).	 Additionally,	 no	 significant	
differences	 were	 observed	 between	 the	 changes	 in	 the	 PC	 composition	 in	
Bi(tolf)3-treated	cells	when	compared	to	tolfH-treated	cells	(Fig.	5.5a).	
Interestingly,	Figure	5.5b	shows	that	the	opposite	trends	could	be	identified	when	
the	Bi(difl)3-	and	diflH-treated	samples	were	compared	to	the	vehicle-treated	samples	
whereby	there	was	a	small	(but	significant)	increase	in	the	percentage	of	PC	molecules	
containing	monounsaturated	(Bi(difl)3,	P	≤	0.01;	diflH,	P	≤	0.001),	or	polyunsaturated	
fatty	acids	 (both	P	≤	0.001)	compared	 to	 the	cells	 treated	with	vehicle	alone.	 	These	
observations	 (Fig.	 5.5b)	 were	 concurrent	 with	 a	 significant	 decrease	 in	 saturated	
(P	≤	0.001)	 and	 ether-linked	 PC	 molecules	 (both	 P	≤	0.001).	 	 Furthermore,	 while	
Bi(difl)3	 and	 diflH	 induced	 the	 same	 overall	 trends	 (i.e.	 concurrent	 increase	 or	
decrease	 in	 relative	 proportion	 of	 PC	 in	 each	 fatty	 acid	 category,	 Fig.	 5.5b),	 the	
composition	 of	 PC	 between	 the	 Bi(difl)3	 and	 diflH	 differed	 significantly	 in	 all	 cases	
(unsaturated,	 P	≤	0.001;	 monounsaturated,	 P	 ≤	 0.01;	 polyunsaturated	 P	 ≤	 0.01;	 and	
ether-linked,	P	≤	0.001).	 	
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Figure	 5.5:	 The	 proportion	 of	 phosphatidylcholine	 (PC)	 molecules	 with	 fatty	 acid	 chains	
containing	saturated,	monounsaturated,	polyunsaturated	or	ether-linked	fatty	acids	calculated	
as	a	percentage	of	the	total	PC	molecules	identified	in	HCT-8	cell	lipid	extracts	treated	for	24	h	
with:	 (a)	 vehicle	 (RPMI-1640,	 2%	DMSO	 v/v),	 Bi(tolf)3	 (15	 µM)	 or	 tolfH	 (45	 µM);	 and	
(b)	vehicle	 (RPMI-1640,	 2%	DMSO	v/v),	 Bi(difl)3	 (75	 µM)	 or	 diflH	 (225	 µM).	 	 Data	 are	
presented	as	mean	±	s.d.	((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	replicates	from	one	
experiment;	 and	 (b)	 n	 =	 4	 (vehicle,	 Bi(difl)3	 and	 diflH)	 replicates	 from	 one	 experiment.		
Significance	 with	 respect	 to	 the	 control	 (lower	 marking)	 or	 corresponding	 NSAID	 (upper	
marking)	is	indicated	by	**	P	≤	0.01,	***	P	≤	0.001;	ns	=	not	significant.	
Figure	5.6	shows	the	comparison	of	the	relative	concentration	of	PC	(normalised	
to	the	respective	total	PC	concentration	of	the	vehicle-treated	samples)	extracted	from	
the	 HCT-8	 cells	 following	 24-h	 treatment	 with	 vehicle,	 BiNSAIDs	 or	 NSAIDs.	 A	
significant	decrease	in	the	total	PC	concentration	was	observed	between	the	Bi(tolf)3-,	
tolfH-	and	diflH-treated	cells	compared	to	the	vehicle-treated	cells	(Bi(tolf)3	and	tolfH,	
P	≤	0.001;	diflH,	P	≤	0.05)	(Fig.	5.6).		However,	no	significant	decrease	was	observed	in	
the	total	PC	concentration	of	the	Bi(difl)3-treated	cells	compared	to	the	vehicle-treated	
cells	(P	>	0.05,	Fig.	5.6b).		Additionally,	the	total	PC	concentration	in	the	tolfH-treated	
cells	 was	 found	 to	 be	 significantly	 lower	 than	 that	 of	 the	 Bi(tolf)3-	 treated	 cells	
(P	≤	0.05)	when	the	two	treatments	were	compared	(Fig.	5.6a).			
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Figure	5.6:	The	normalised	 concentration	of	 phosphatidylcholine	 (PC)	molecules	 containing	
saturated,	 monounsaturated,	 polyunsaturated	 or	 ether-linked	 fatty	 acids	 in	 HCT-8	 cell	 lipid	
extracts	 treated	 for	 24	h	with:	 (a)	 vehicle	 (RPMI-1640,	DMSO	2%	v/v),	 Bi(tolf)3	 (15	µM)	 or	
tolfH	 (45	 µM);	 and	 (b)	 vehicle	 (RPMI-1640,	 DMSO	 2%	 v/v),	 Bi(difl)3	 (75	 µM)	 or	 diflH	
(225	µM).		The	values	are	normalised	to	the	respective	vehicle	total	PC	concentration.		Data	are	
presented	as	mean	±	s.d.	((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	replicates	from	one	
experiment;	 and	 (b)	 n	 =	 4	 (vehicle,	 Bi(difl)3	 and	 diflH)	 replicates	 from	 one	 experiment).		
Significance	 with	 respect	 to	 the	 control	 (lower	 marking)	 or	 corresponding	 NSAID	 (upper	
marking)	is	indicated	by	*	P	≤	0.05,	**	P	≤	0.01,	***	P	≤	0.001;	ns	=	not	significant.		
When	 the	 PC	 molecules	 were	 analysed	 by	 each	 fatty	 acid	 category	 (right-hand	
side,	 Fig.	 5.6)	 an	 overall	 decreases	 in	 the	 concentration	 of	 PC	molecules	 containing	
fatty	 acyl	 chains	 with	 saturated,	 monounsaturated,	 polyunsaturated	 and	 an	 ether-
linked	 fatty	 acyl	 chains	 were	 observed	 in	 the	 Bi(tolf)3-	 and	 tolfH-treated	 cells	
compared	 to	 the	 vehicle-treated	 cells	(Fig.	 5.6a).	 	 Notably,	 the	 diflH-treated	 samples	
showed	 the	 same	 trends	 (Fig.	 5.6b);	 however,	 the	 decrease	 was	 not	 significant	
(P	>	0.05)	 in	 the	 monounsaturated	 and	 polyunsaturated	 fatty	 acyl	 chain	 categories.		
The	Bi(difl)3-treated	samples	showed	a	decrease	in	the	concentration	of	PC	molecules	
containing	 fatty	 acids	 with	 saturated	 (P	 ≤	 0.01,	 Fig.	5.5b).	 	 However,	 there	 was	 no	
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significant	decrease	 in	the	concentration	of	PC	molecules	with	monounsaturated	and	
ether-linked	fatty	acids	(P	>	0.05,	Fig.	5.5b).		The	slight	increase	in	concentration	of	PC	
molecules	 with	 polyunsaturated	 fatty	 acids	 in	 the	 Bi(difl)3-treated	 samples	 was	 not	
found	to	be	significant	compared	to	the	vehicle-treated	samples	(P	>	0.05,	Fig.	5.5b).		
5.3.2 Phosphatidylethanolamine	(PE)	
Figure	5.7	shows	 the	profiles	of	 the	PE	molecules	 (calculated	as	a	percentage	of	
total	PE)	detected	above	the	LOD	using	ESI-MS/MS	in	HCT-8	cell	lipid	extracts	treated	
with	vehicle,	BiNSAIDs,	or	NSAIDs.		As	indicated	in	the	left-most	graphs	of	Figure	5.7,	
the	 most	 abundant	 PE	 molecules	 identified	 in	 HCT-8	 cells	 treated	 with	 vehicle,	
BiNSAIDs	or	NSAIDs	were	PE	34:1,	PE	36:2,	PE	36:1,	and	PE	38:4.	 	A	summary	of	all	
the	 identified	 PE	 molecules	 above	 the	 LOD	 is	 shown	 in	 the	 Appendix	 4.1.	 The	
calculated	 LOD	 and	 LOQ	 values	 were	 slightly	 higher	 for	 the	 Bi(difl)3/diflH-treated	
samples	 compared	 to	 the	Bi(tolf)3/tolfH-treated	samples.	 	As	a	 result	 ion	abundance	
did	not	 reach	 the	LOD	 threshold	and	several	molecules	of	very	 low	abundance	were	
omitted	from	the	results	presented	in	Figure	5.7b.	
Analysis	of	PE	profiles	reveals	changes	to	the	relative	abundance	of	PE	molecules	
in	vehicle-treated	cells	compared	to	the	Bi(tolf)3-	and	tolfH-treated	cells	(Fig.	5.7).		The	
most	prominent	difference	is	seen	in	the	ether-linked	PE	molecules,	PE	P-38:5/O-38:6	
(m/z	750)	 and	 PE	 P-38:4/O-38:5	 (m/z	 752),	 which	 were	 approximately	 twice	 the	
abundance	 in	 the	 Bi(tolf)3-	 and	 tolfH-treated	 cell	 samples	 compared	 to	 the	 vehicle-
treated	 cell	 sample	 (P	≤	 0.05).	 	 Additionally,	 other	 lower	 abundance	 ether-linked	
molecules	 showed	 an	 increase	 in	 relative	 abundance	 of	 PE	 molecules	 following	
treatment	with	Bi(tolf)3	and	tolfH,	 including	PE	P-32:0/O-32:1,	PE	P-36:4/O-36:5,	PE	
P-36:3/O-36:4,	 and	 PE	P-40:5/O-40:6	 (Fig.	 5.7a).		 This	 was	 accompanied	 by	 a	
significant	decrease	 in	 the	proportion	of	diacyl	glycerol	PE	molecules,	specifically	PE	
34:2,	PE	36:2,	PE	38:5,	and	PE	38:4.		
Analysis	 of	 PE	 profiles	 also	 revealed	 changes	 to	 the	 relative	 abundance	 of	 PE	
molecules	 between	 vehicle-treated	 cells,	 and	 the	 Bi(difl)3-	 and	 diflH-treated	 cell	
samples	 (Fig.	 5.7b).	 	 Similarly	 to	 the	 Bi(tolf)3/tolfH-treated	 series	 (Fig.	 5.7a),	 a	
significant	increase	was	observed	in	the	abundance	of	the	ether-linked	PE	molecules,	
PE	P-38:5/O-38:6	 (m/z	 750)	 and	 PE	 P-38:4/O-38:5	 (m/z	 752)	 in	 the	 Bi(difl)3-	 and	
diflH-treated	cell	samples	compared	to	the	vehicle-treated	cell	sample	(P	≤	0.05).		
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Figure	5.7:		Profile	of	phosphatidylethanolamine	(PE)	molecules	in	HCT-8	cells	following	24	h	
treatment	with:	(a)	vehicle	(DMSO	2%	v/v),	Bi(tolf)3	(15	µM),	or	tolfH	(45	µM);	and	(b)	vehicle	
(RPMI-1640,	DMSO	2%	v/v),	Bi(difl)3	(75	µM),	or	diflH	(225	µM),	calculated	as	a	percentage	of	
total	PE.	Data	are	presented	as	the	mean	±	s.d.	((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	
replicates	 from	 one	 experiment;	 (b)	 n	 =	 4	 (vehicle,	 Bi(difl)3	 and	 diflH)	 replicates	 from	 one	
experiment).		Significance	with	respect	to	the	control	is	indicated	by	l	p	<	0.05	(both	BiNSAID	
and	NSAID),	u	p	<	0.05	(BiNSAID	only),	or	n	p	<	0.05	(NSAID	only).		Note:	Odd	or	ether-linked	
fatty	acyl	chains	(e.g.	PE	O-34:0/PE	33:1)	cannot	be	differentiated	in	this	experiment.	 	
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The	proportion	of	 fatty	acyl	 chain	unsaturation	or	ether-linked	 fatty	acyl	 chains	
calculated	as	a	percentage	of	the	total	PE	molecules	identified	in	the	vehicle-,	Bi(tolf)3-	
and	tolfH-treated	HCT-8	cell	 lipid	extracts	 is	presented	in	Figure	5.8a.	 	Following	the	
24-h	treatment	with	Bi(tolf)3	or	tolfH,	there	was	a	slight	(but	insignificant)	decrease	in	
the	 percentage	 of	 monounsaturated	 PE	 molecules,	 but	 a	 significant	 decrease	 (P	 ≤	
0.001)	 in	 the	 percentage	 of	 polyunsaturated	 PE	 molecules	 compared	 to	 the	 cells	
treated	 with	 vehicle	 alone	 (Fig.	 5.8a).	 	These	 changes	 were	 concurrent	 with	 a	
significant	 increase	 (P	 ≤	 0.001)	 in	 the	 percentage	 of	 PE	molecules	 containing	 ether-
linked	fatty	acyl	chains	following	the	24-h	treatment	with	Bi(tolf)3	or	tolfH	(Fig.	5.8a).		
No	significant	variation	was	observed	between	the	Bi(tolf)3-	or	tolfH-treated	samples.	
The	 changes	 in	 the	 PE	 profile	 of	 the	 Bi(difl)3/diflH	 series	 (Fig.	 5.8b)	 differed	
slightly	from	the	Bi(tolf)3/tolfH	series	(Fig.	5.8a)	whereby	Bi(difl)3	and	diflH	treatment	
resulted	in	a	significant	decrease	(P	≤	0.001)	in	the	percentage	of	monounsaturated	PE	
molecules,	but	a	smaller	decrease	(Bi(difl)3,	P	≤	0.001;	diflH,	P	>	0.05,	not	significant)	
in	the	percentage	of	polyunsaturated	PE	molecules	compared	to	the	cells	treated	with	
vehicle	 alone.	 	 However,	 similar	 to	 the	 result	 in	 Fig.	 5.8a,	 a	 significant	 increase	
(P	≤	0.001)	in	the	percentage	of	PE	molecules	containing	ether-linked	fatty	acyl	chains	
was	observed	following	24-h	treatment	with	Bi(difl)3	or	diflH	(Fig.	5.8b).		As	observed	
in	 Figure	 5.8b,	 Bi(difl)3	 treatment	 caused	 more	 pronounced	 changes	 to	 the	 overall	
proportion	 of	 PE	 containing	monounsaturated	 (P	 ≤	 0.01)	 and	 polyunsaturated	 (P	 ≤	
0.05)	fatty	acyl	chains	when	compared	to	treatment	with	diflH.	
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Figure	 5.8:	 The	 proportion	 of	 phosphatidylethanolamine	 (PE)	 molecules	 containing	
monounsaturated,	polyunsaturated	or	ether-linked	fatty	acids	calculated	as	a	percentage	of	the	
total	 PE	 molecules	 identified	 in	 HCT-8	 cell	 lipid	 extracts	 treated	 for	 24	 h	 with:	 (a)	 vehicle	
(RPMI-1640,	DMSO	2%	v/v),	Bi(tolf)3	 (15	µM)	or	 tolfH	 (45	µM);	 or	 (b)	 vehicle	 (RPMI-1640,	
DMSO	 2%	 v/v),	 Bi(difl)3	 (75	µM)	 or	 diflH	 (225	 µM).	 	 Data	 are	 presented	 as	 mean	 ±	 s.d.	
((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	replicates	from	one	experiment;	and	(b)	n	=	4	
(vehicle,	Bi(difl)3	and	diflH)	replicates	from	one	experiment).		Significance	with	respect	to	the	
control	 (lower	marking)	or	 corresponding	NSAID	 (upper	marking)	 is	 indicated	by	 *	P	≤	0.05,	
**	P	≤	0.01,	***	P	≤	0.001;	ns	=	not	significant.	
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A	 comparison	 of	 the	 relative	 concentration	 of	 PE	 (normalised	 to	 the	 respective	
total	 concentration	 of	 the	 vehicle-treated	 samples)	 from	 the	 HCT-8	 cells	 following	
24-h	treatment	with	vehicle,	BiNSAIDs	or	NSAIDs	is	presented	in	Figure	5.9.		Following	
24-h	 treatment,	 an	 overall	 decrease	 in	 the	 total	 PE	 concentration	 of	 the	 Bi(tolf)3-	
(P	>	0.05),	tolfH-	(P	≤	0.01)	and	diflH-treated	(P	>	0.05,	not	significant)	cells	compared	
to	 the	vehicle-treated	 cells	 (Fig.	 5.9)	was	observed.	 	However,	 an	overall	 increase	 in	
the	 concentration	 of	 PE	 was	 observed	 in	 Bi(difl)3-treated	 cells	 compared	 to	 the	
vehicle-treated	 cells,	 although	 this	 was	 not	 statistically	 significant	 (Fig.	 5.9b).	 	 As	
shown	in	Figure	5.8a,	the	total	PE	was	significantly	decreased	by	tolfH	treatment	when	
compared	to	Bi(tolf)3	treatment.	
When	the	PE	molecules	were	grouped	according	to	fatty	acid	category	(Fig.	5.9),	it	
was	 apparent	 that	 there	 was	 an	 overall	 decrease	 in	 the	 concentration	 of	
monounsaturated	PE	molecules	in	the	Bi(tolf)3-	(P	≤	0.05),	tolfH-	(P	≤	0.01)	and	diflH-
treated	(P	≤	0.05)	cells	compared	to	the	cells	treated	with	vehicle	alone.		No	decrease	
was	 observed	 following	 Bi(difl)3	 treatment	 (Fig.	 5.9b).	 	 As	 shown	 in	 Figure	 5.9a,	
Bi(tolf)3	and	tolfH	treatment	also	resulted	in	a	significant	decrease	(both	P	≤	0.001)	in	
the	 relative	 concentration	 of	 polyunsaturated	 PE	 molecules	 relative	 to	 the	 vehicle	
treatment.	 	Treatment	with	diflH	also	resulted	in	a	decrease	(P	>	0.05)	in	the	relative	
concentration	 of	 polyunsaturated	 PE	 molecules	 relative	 to	 the	 vehicle	 treatment;	
however,	 no	 change	 was	 observed	 in	 the	 Bi(difl)3-treated	 samples	 (Fig.	 5.9b).	 	 As	
Figure	 5.9	 shows,	 all	 BiNSAID	 and	 NSAID	 treatments	 resulted	 in	 an	 increase	 in	 the	
concentration	of	ether-linked	fatty	acid	PE	molecules	compared	to	the	vehicle-treated	
cells,	 however,	 this	was	 only	 statistically	 significant	 in	 the	 BiNSAID-treated	 samples	
compared	 to	 the	 controls	 (P	 ≤	 0.01).	 	 In	 both	 treatment	 sets	 the	 BiNSAID-treated	
samples	showed	a	significant	(P	≤	0.05)	increase	in	the	concentration	of	ether-linked	
molecules	when	compared	to	the	NSAID	treatment	alone	(Fig.	5.9a	and	5.9b).	
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Figure	 5.9:	 The	 normalised	 concentration	 of	 phosphatidylethanolamine	 (PE)	 molecules	
containing	monounsaturated,	 polyunsaturated	 or	 ether-linked	 fatty	 acids	 in	 HCT-8	 cell	 lipid	
extracts	 treated	 for	 24	h	with:	 (a)	 vehicle	 (RPMI-1640,	DMSO	2%	v/v),	 Bi(tolf)3	 (15	µM)	 or	
tolfH	(45	 µM);	 and	 (b)	 vehicle	 (RPMI-1640,	 DMSO	 2%	 v/v),	 Bi(difl)3	 (75	 µM)	 or	 diflH	
(225	µM).		The	values	are	normalised	to	the	respective	total	PE	vehicle	concentration.		Data	are	
presented	as	mean	±	s.d.	((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	replicates	from	one	
experiment;	 and	 (b)	 n=4	 (vehicle,	 Bi(difl)3	 and	 diflH)	 replicates	 from	 one	 experiment).		
Significance	 with	 respect	 to	 the	 control	 (lower	 marking)	 or	 corresponding	 NSAID	 (upper	
marking)	is	indicated	by	*	P	≤	0.05,	**	P	≤	0.01,	***	P	≤	0.001;	ns	=	not	significant.	
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5.3.3 Phosphatidylserine	(PS)	
The	relative	abundances	of	PS	molecules	(calculated	as	a	percentage	of	total	PS)	
detected	above	the	LOD	are	presented	in	Figure	5.10.		A	summary	of	all	the	identified	
PS	 molecules	 above	 the	 LOD	 can	 be	 found	 in	 Appendix	 4.1.	 	 Due	 to	 the	 low	
concentration	of	PS	present	in	the	cell	samples,	only	a	small	number	of	PS	molecules	
could	be	reliably	detected	above	the	LOD	(Fig.	5.10).		The	most	abundant	PS	molecules	
identified	were	PS	34:1	(m/z	762)	and	PS	36:1	(m/z	790)	(Fig.	5.10).		The	proportion	
of	the	most	abundant	PS	molecule,	PS	36:1,	was	increased	in	all	BiNSAID-	and	NSAID-
treated	samples	compared	to	the	vehicle-treated	samples	(Fig.	5.10),	although	this	was	
only	significant	in	the	Bi(tolf)3-treated	samples	(P	≤	0.05).		The	relative	abundance	of	
PS	36:2	 was	 significantly	 decreased	 in	 the	 Bi(tolf)3-	 and	 NSAID-treated	
samples	(P	≤	0.05)	compared	to	 the	vehicle.	 	As	Figure	5.10	shows,	 the	change	 in	 the	
proportion	of	PS	34:1	differed	between	the	two	treatment	sets	whereby	its	abundance	
significantly	 increased	 in	 the	 Bi(tolf)3-	 and	 tolfH-treated	 samples	 compared	 to	 the	
vehicle,	 but	was	 slightly	 (but	 not	 significantly)	 decreased	 in	 the	 Bi(difl)3-	 and	 diflH-
treated	 samples	 compared	 to	 the	 vehicle.	 	 Additionally,	 there	was	 some	variation	 in	
the	 detection	 of	 the	 lower	 abundance	 molecules	 between	 the	 two	 treatment	
sets	(Fig.	5.10).	
	
Figure	 5.10:	 Profile	 of	 phosphatidylserine	 (PS)	 molecules	 in	 HCT-8	 cells	 following	 24	 h	
treatment	with:	(a)	 vehicle	 (RPMI-1640,	DMSO	2%	v/v),	Bi(tolf)3	 (15	µM),	or	 tolfH	(45	µM);	
and	(b)	vehicle	(RPMI-1640,	DMSO	2%	v/v),	Bi(difl)3	(75	µM),	or	diflH	(225	µM),	calculated	as	
a	percentage	of	 total	PS.	 	Data	are	presented	as	 the	mean	±	s.d,	 ((a)	n	=	3	 (vehicle)	or	n	=	4	
(Bi(tolf)3	and	tolfH)	replicates	from	one	experiment;	and	(b)	n=4	(vehicle,	Bi(difl)3	and	diflH)	
replicates	from	one	experiment).		Significance	with	respect	to	the	control	is	indicated	by	l	p	≤	
0.05	(both	BiNSAID	and	NSAID),	u	p	≤	0.05	(BiNSAID	only),	or	n	p	≤	0.05	(NSAID	only).		 	
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Fig	5.11	shows	the	comparison	of	the	relative	concentration	of	PS	(normalised	to	
the	respective	total	concentration	of	the	vehicle-treated	samples)	from	the	HCT-8	cells	
following	 the	 24-h	 treatment	 with	 vehicle,	 BiNSAIDs	 or	 NSAIDs.	 	 A	 decrease	 was	
apparent	in	the	total	PS	concentration	of	the	Bi(tolf)3-	(P	≤	0.05),	tolfH-	(P	≤	0.01)	and	
diflH-treated	(P	≤	0.05)	cells	compared	to	the	vehicle-treated	cells	(Fig.	5.11).		Similar	
to	the	PE	results	(Fig.	5.9),	an	increase	in	the	total	concentration	of	PS	was	observed	in	
Bi(difl)3-treated	cells	compared	to	the	vehicle-treated	cells	(Fig.	5.11b);	however,	this	
result	was	not	statistically	significant	(P	>	0.05).	
	
Figure	5.11:	The	normalised	concentration	of	phosphatidylserine	(PS)	molecules	in	HCT-8	cell	
lipid	extracts	treated	for	24	h	with:	(a)	vehicle	(RPMI-1640,	DMSO	2%	v/v),	Bi(tolf)3	(15	µM)	
or	 tolfH	 (45	 µM);	 and	 (b)	 vehicle	 (RPMI-1640,	 DMSO	 2%	 v/v),	 Bi(difl)3	 (75	 µM)	 or	 diflH	
(225	µM).		The	values	are	normalised	to	the	respective	total	PE	vehicle	concentration.		Data	are	
presented	as	mean	±	s.d.	((a)	n	=	3	(vehicle)	or	n	=	4	(Bi(tolf)3	and	tolfH)	replicates	from	one	
experiment;	 and	 (b)	 n	 =	 4	 (vehicle,	 Bi(difl)3	 and	 diflH)	 replicates	 from	 one	 experiments).		
Significance	 with	 respect	 to	 the	 control	 (lower	 marking)	 or	 corresponding	 NSAID	 (upper	
marking)	is	indicated	by	*	P	≤	0.05,	**	P	≤	0.01,	ns	=	not	significant.	
5.3.4 Summary	of	results	
The	 overall	 trends	 observed	 in	 Sections	 5.3.1-5.3.3	 are	 presented	 in	 Tables	 5.3	
and	5.4.		In	Table	5.3	and	5.4,	a	red	colour	indicates	a	decrease	in	prevalence,	while	a	
green	 colour	 represents	 an	 increase,	 and	grey	 indicates	no	 change.	 	 The	 intensity	 of	
the	colour	reflects	the	significance	level,	whereby	the	darkest	shade	indicates	the	most	
significance	(P	≤	0.001).	 	Table	5.3	shows	the	PC	and	PE	profiles	of	 the	Bi(tolf)3-	and	
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tolfH-treated	 samples	 exhibited	 the	 same	 general	 overall	 changes	 compared	 to	 the	
vehicle-treated	 cells.	 	The	 Bi(difl)3-	 and	 diflH-treated	 cells	 also	 showed	 the	 similar	
trends	when	 compared	 to	 each	other	 (Table	5.3).	 	 The	PC	 results	 for	Bi(difl)3/diflH-
treated	 cells	 exhibited	 changes	 that	 were	 opposite	 to	 those	 observed	 for	 the	
Bi(tolf)3/tolfH-treated	cells	(Table	5.3).			In		contrast,		the		same		overall		changes		were	
Table	 5.3:	 Summary	 of	 the	 overall	 trend	 in	 glycerophospholipid	 (PC	 and	 PE)	 profile	 (%	 of	
total)	 following	 treatment	 of	 HCT-8	 cells	 with	 BiNSAIDs	 of	 NSAIDs	 (24	 h)	 compared	 to	
vehicle-treated	cells	(DMSO	2%	v/v,	24	h).	
	 	 Bi(tolf)3,	15	µM	
tolfH,	
45	µM	
Bi(difl)3,	
75	µM	
diflH,	
225	µM	
PC	 Saturated	 −	 á 	 â 	 â 	
	 Monounsaturated	 â 	 â 	 á 	 á 	
	 Polyunsaturated	 â 	 â 	 á 	 á 	
	 Ether-linked	 á 	 á 	 â 	 â 	
PE	 Monounsaturated	 â 	 â 	 â 	 â 	
	 Polyunsaturated	 â 	 â 	 â 	 â 	
	 Ether-linked	 á 	 á 	 á 	 á 	
	
-	 No	change	 â 	 Decreased	abundance,	P	>	0.05	 â 	 Decreased	abundance	P	≤	0.01	
	
â 	 Decreased	abundance,	P	≤	0.001	 á 	 Increased	abundance,	P	≤	0.05	
	
á 	 Increased	abundance,	P	≤	0.01	 á 	 Increased	abundance,	P	≤	0.001	
	
Table	 5.4:	 Summary	 of	 the	 overall	 changes	 in	 glycerophospholipid	 (PC,	 PE	 or	 PS)	
concentration	following	treatment	of	HCT-8	cells	with	BiNSAIDs	of	NSAIDs	(24	h)	compared	to	
vehicle-treated	cells	(DMSO	2%	v/v,	24	h).	
	 	 Bi(tolf)3,	15	µM	
tolfH,	
45	µM	
Bi(difl)3,	
75	µM	
diflH,	
225	µM	
PC	 Saturated	 â 	 â 	 â 	 â 	
	 Monounsaturated	 â 	 â 	 −	 â 	
	 Polyunsaturated	 â 	 â 	 á 	 â 	
	 Ether-linked	 â 	 â 	 â 	 â 	
	 Total	 â 	 â 	 â 	 â 	
PE	 Monounsaturated	 â 	 â 	 −	 â 	
	 Polyunsaturated	 â 	 â 	 −	 â 	
	 Ether-linked	 á 	 á 	 á 	 á 	
	 Total	PE	 â 	 â 	   á 	 â 	
PS	 Total	PS	 â 	 â 	 á 	 â 	
	
-	 No	change	 â 	 Decreased	concentration,	P	>	0.05	 â 	 Decreased	concentration,	P	≤	0.05	
	
â 	 Decreased	concentration,	P	≤	0.01	 â 	 Decreased	concentration,	P	≤	0.001	
	
á 	 Increased	concentration,	P	>	0.05	 á 	 Increased	concentration,	P	≤	0.01	
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observed	 for	 PE	 composition	 following	 Bi(tolf)3/tolfH	 and	 Bi(difl)3/diflH	
treatment	(Table	5.3).	
When	examining	 the	overall	changes	 to	 the	relative	concentration	of	PC,	PE	and	
PS	induced	by	BiNSAID	or	NSAID	treatment	in	Table	5.4,	it	was	observed	that	Bi(tolf)3,	
tolfH		and		diflH		exhibited		a		similar		overall		trend,		whereby		an		overall		decrease		in	
concentration	 is	 observed	 in	 all	 PC	 and	 PE	 categories	 (with	 the	 exception	 of	 an	
increase	 in	 PE	 ether-linked	 molecules),	 and	 total	 PS	 concentration	 following	
treatment.	 	 As	 observed	 in	 Table	 5.4,	 the	 Bi(difl)3-treated	 cell	 samples	 displayed	
several	 differences	 from	 the	 three	 other	 treatments	 examined,	 whereby	 some	
categories	showed	an	overall	increase	or	no	change	in	PC,	PE	and	PS	concentration.	 	
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5.4 Discussion	
The	 overall	 aim	 of	 the	 experiments	 described	 in	 this	 Chapter	was	 to	 study	 the	
most	 abundant	 glycerophospholipid	 classes	 in	 BiNSAID-	 and	 NSAID-treated	 HCT-8	
cells	using	methods	established	within	the	laboratory	[35-38].	The	purpose	of	this	was	
to	further	investigate	the	results	obtained	in	Chapter	4	which	showed	lipid	changes	in	
BiNSAID/NSAID-treated	 cells.	 	 Specifically	 lipidomic	 analysis	 of	 the	
glycerophospholipids,	 PC,	 PE	 and	 PS,	 using	 ESI-MS/MS	 was	 applied	 to	 two	 sets	 of	
BiNSAID/NSAID-treated	HCT-8	cell	 samples	 to	determine:	 (i)	whether	changes	could	
be	detected	in	the	glycerophospholipid	profiles	of	the	drug-treated	cells	compared	to	
the	 vehicle-treated	 cells;	 	 (ii)	 if	 the	 relative	 concentrations	 of	 glycerophospholipids	
were	 affected	 by	 BiNSAID/NSAID	 treatment;	 	 (iii)	 whether	 each	 BiNSAID	 and	 the	
parent	 NSAID	 induced	 similar	 or	 different	 changes	 in	 the	 glycerophospholipid	
composition	 or	 concentration;	 and	 (iv)	 whether	 any	 glycerophospholipid	 changes	
induced	 by	 drug	 treatment	were	 similar	 or	 differed	 between	 the	 two	BiNSAIDs	 and	
corresponding	NSAIDs	 examined.	 	 The	discussion	will	 focus	 on	 these	 outcomes	with	
respect	 to	 several	 key	 observations	 that	 stemmed	 from	 changes	 to	 the	 relative	
concentrations	 of	 glycerophospholipids	 (Section	5.4.1),	 the	 changes	 within	 the	
glycerophospholipid	 saturation	 categories	 (Section	 5.4.2),	 and	 the	 changes	 in	 the	
abundance	 and	 relative	 concentrations	 of	 ether-linked	 glycerophospholipids	
(Section	5.4.3).	
5.4.1 Effect	of	BiNSAID	and	NSAID	treatment	on	phospholipid	concentration	
The	 results	 in	 Section	 5.3.1−5.3.3	 indicated	 that	 the	 ESI-MS/MS	 technique	 was	
sensitive	 enough	 to	 detect	 changes	 in	 the	 overall	 composition	 of	 the	
glycerophospholipids	 selected	 for	 analysis.	 	Additionally,	 the	 use	 of	 lipid	 internal	
standards	allowed	for	the	relative	quantification	of	individual	PC,	PE	and	PS	molecules.	
The	technique	was	particularly	successful	for	analysing	PC	molecules,	which	generally	
exhibit	 the	 highest	 abundance	 in	 mammalian	 cells	 [1].	 	The	 analysis	 of	 the	 lower	
abundance	 molecules	 in	 the	 PE	 and	 PS	 samples	 approached	 the	 LOD	 for	 the	
experimental	 conditions	 used.	 	 As	 such,	 a	 more	 sensitive	 instrument	 such	 as	 a	
nano-ESI	 [39]	 would	 improve	 the	 detection	 of	 low	 abundance	 molecules	 if	 future	
investigations	 were	 required.	 	 Overall,	 however,	 the	 ESI-MS/MS	 experiments	
performed	in	this	Chapter	were	a	suitable	starting	point	to	investigate	changes	in	the	
dominant	lipids	and	promising	results	have	revealed	some	interesting	changes	in	the	
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relative	concentrations	of	the	PC,	PE	and	PS	molecules	in	HCT-8	cell	samples	following	
treatment	with	BiNSAIDs	and	NSAIDs.	
			 The	 overall	 decrease	 in	 the	 relative	 concentration	 of	 glycerophospholipids	
following	Bi(tolf)3,	 tolfH	and	diflH	 treatment	 (summarised	 in	Table	5.4)	 is	 consistent	
with	 other	 studies	 wherein	 a	 decrease	 in	 the	 concentration	 of	 PC	 and	 PE	 has	 been	
reported	 in	 a	 number	 of	 cell	 lines	 undergoing	 apoptosis	 [3,	 40,	 41].	 	 For	 instance,	
Anthony	 et	 al.	[40]	 showed	 that	 drug-induced	 apoptosis	 results	 in	 inhibition	 of	 PC	
synthesis	 in	 HL-60	 leukaemia	 cells.	 	Niebergall	 and	 Vance	 [41]	 determined	 that	 the	
percentage	of	apoptotic	cells	increased	when	both	membrane	PC	and	PE	decreased	in	
mutant	Chinese	hamster	ovary	cell	line,	MT58.		Finally,	Li	and	Yuan	[3]	report	that	the	
concentration	of	PC	and	PE	decreased	 in	HeLa	human	cervical	cancer	cells	 following	
treatment	with	 the	anti-cancer	drug	paclitaxel.	However,	no	change	was	observed	 in	
the	 concentration	 of	 PS	 in	 the	 study	[3],	 which	 contrasts	 the	 results	 in	 Section	
5.3.3.	 	The	results	 from	the	 tolfH-treated	cells	 is	consistent	with	 the	results	 from	the	
SR-IRMS	studies,	which	suggested	that	following	24-h	treatment	with	tolfH	the	HCT-8	
cells	 have	 lower	 lipid	 concentration	 than	 the	 vehicle-treated	 cells.	 	 The	 results	 from	
the	 lipidomic	analysis	of	HCT-8	cells	 indicate	 that	 the	SR-IRMS	observation	could	be	
contributed	 to	by	 lowered	glycerophospholipid	 (PC,	PE	and	PS)	 concentration	 in	 the	
tolfH-treated	cells.		
Interestingly,	Bi(difl)3	treatment	resulted	in	no	significant	changes	to	PC,	PE	or	PS	
concentration	 in	HCT-8	cells	 (Table	5.4).	 	However,	 the	diflH-treated	cell	samples	(at	
an	equimolar	 treatment	concentration),	showed	a	significant	decrease	 in	 the	relative	
concentration	 of	 PC	 and	 PS,	 similar	 to	 the	 Bi(tolf)3/tolfH-treated	 samples	 (albeit	 a	
slightly	less	significant	decrease,	Table	5.4).		The	results	observed	from	the	ESI-MS/MS	
analysis	 for	 the	 Bi(difl)3-treated	 cells	 were	 consistent	 with	 some	 of	 the	 other	
experimental	 observations	 reported	 in	 this	 Thesis	 (PGE2	 assays	 and	 SR-IRMS	
experiments,	 Chapter	 2	 and	 Chapter	 4,	 respectively),	 whereby	 Bi(difl)3	 displayed	 a	
different	 effect	 on	 the	 HCT-8	 cells	 compared	 to	 the	 Bi(III)	 fenamate	 complexes,	
Bi(tolf)3	and	Bi(mef)3.		The	difference	in	the	biomolecular	response	of	the	HCT-8	cells	
to	Bi(difl)3	versus	diflH	was	evident	in	the	SR-IRMS	results	(Chapter	4),	although	there	
is	some	deviation	from	the	results	observed	from	the	lipidomic	analysis	(Section	5.3).		
Specifically,	the	SR-IRMS	results	suggested	that	24-h	treatment	of	the	HCT-8	cells	with	
diflH	caused	an	increase	in	lipids,	which	was	hypothesised	to	occur	as	a	result	of	the	
accumulation	of	 lipid	droplets.	 	Lipid	droplets	are	composed	of	a	core	containing	the	
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neutral	 lipids,	 triacylglycerols	 and	 cholesterol	 esters,	 surrounded	 by	 a	 phospholipid	
monolayer	 (generally	 comprised	 of	 PC,	 PE,	 phosphatidylinositol	 and	 lysoPC,	 and	
lysoPE)	[42].	 The	 results	 obtained	 from	 the	 lipidomic	 analysis	 (Section	5.3)	 suggest	
that	this	increase	is	not	due	to	an	increase	in	PC,	PE	or	PS	concentration.	This	implies	
that	 instead	 an	 increase	 in	 the	 relative	 concentration	 of	 neutral	 lipids	 (such	 as	
triacylglycerols	 and	 cholesterol	 esters)	may	 be	 responsible	 for	 the	 large	 increase	 in	
lipid	SR-IRMS	bands	observed	in	the	spectra	of	 the	24-h	diflH-treated	cells.	 	As	such,	
future	work	could	potentially	expand	the	lipidomic	analysis	to	include	neutral	species	
including	triacylglycerols,	cholesterol	esters	and	diacylglycerols.		
	
5.4.2 The	effects	of	BiNSAID	and	NSAID	treatment	on	fatty	acyl	chain	saturation	
While	DNA	is	considered	an	important	target	for	chemotherapeutics,	researchers	
have	 also	 considered	 the	 importance	 of	 the	 plasma	 membrane	 as	 a	 target	 for	
anticancer	 therapies	 for	 a	number	of	decades	 [43,	44].	 	As	 there	 is	 little	 evidence	 to	
suggest	 that	NSAIDs	 (or	BiNSAIDs,	 Section	3.3.2)	 interact	with	DNA,	 other	means	 of	
cell	 death	 have	 been	 previously	 discussed,	 as	 described	 in	 Section	 1.2.4.		 It	 is	
important	to	consider	the	plasma	membrane	as	a	target	for	NSAIDs,	since	a	number	of	
NSAIDs	have	been	shown	to	interact	with	lipids,	and	in	particular,	phospholipids	[13,	
15,	45]	as	previously	discussed	in	Section	4.4.4.2.		One	particularly	important	property	
of	 the	plasma	membrane	is	 fluidity.	This	comes	from	recognising	that	molecules	that	
modulate	membrane	 fluidity	may	 sensitise	 resistant	 tumour	 cells	 to	 chemotherapy-
induced	 cell	 death	 [46].	 	 The	 level	 of	 unsaturation	 of	 fatty	 acids	 is	 an	 important	
influence	 on	 the	 fluidity	 of	 membranes.	 	 For	 instance,	 the	 greater	 the	 number	 of	
double	 bonds	 a	 fatty	 acyl	 molecule	 contains,	 the	 more	 physical	 space	 it	 occupies,	
therefore	 influencing	 the	 fluidity	 of	 the	 bilayer.	 	 As	 such,	 changes	 in	 the	 relative	
abundance	and	concentrations	of	the	saturated	and	unsaturated	PC	and	PE	molecules	
were	compared	between	vehicle-,	BiNSAID-,	and	NSAID-treated	cells.		
In	the	current	study,	the	Bi(tolf)3-	and	tolfH-treated	cells	displayed	a	decrease	in	
the	 relative	 abundance	 and	 concentration	 of	 PC	 and	 PE	 molecules	 containing	
monounsaturated	 and	 polyunsaturated	 fatty	 acids	 compared	 to	 the	 vehicle-treated	
cells	(Table	5.3).		This	is	consistent	with	other	studies	[3]	that	reported	that	a	decrease	
in	polyunsaturated	fatty	acids	primarily	correlated	with	the	overall	reduction	in	the	PE	
concentration	 in	 HeLa	 cells	 following	 paclitaxel-induced	 apoptosis.	 Li	 and	 Yuan	 [3]	
also	 observed	 that	 in	 the	 PC	 class	 both	 polyunsaturated	 fatty	 acids	 and	
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monounsaturated	 fatty	acids	contributed	almost	equally	 to	 the	observed	decrease	 in	
concentration	 in	 the	 HeLa	 cells,	 with	 a	 substantial	 decrease	 in	 saturated	 PCs	 also	
observed.	 	The	marked	reduction	in	the	quantity	of	unsaturated	fatty	acids	suggested	
there	was	a	potential	decrease	of	membrane	fluidity	in	HeLa	cells	following	paclitaxel-
induced	apoptosis	[3].			
In	 contrast,	 no	 significant	 decreases	 were	 observed	 in	 the	 concentration	 of	 PC	
molecules	containing	polyunsaturated	fatty	acids	following	treatment	with	Bi(difl)3	or	
diflH	 in	 the	HCT-8	 cell	 lipid	 extracts.	 	 Instead,	 the	 abundance	 of	 the	 unsaturated	PC	
molecules	was	significantly	 increased	 in	 the	Bi(difl)3/diflH-treated	cells	compared	 to	
the	 vehicle-treated	 cells,	 which	 was	 opposite	 to	 the	 trend	 observed	 in	 the	
Bi(tolf)3/tolfH-treated	 samples.	 	 These	 results	might	 suggest	 that	Bi(difl)3	 and	diflH-
treated	cells,	experience	an	increase	in	membrane	fluidity.	It	has	been	suggested	that	
polyunsaturated	fatty	acyl	chains	are	more	susceptible	to	peroxidation,	rendering	cells	
more	susceptible	to	oxidative	stress-induced	cell	death	[10].		Therefore,	an	increase	in	
the	abundance	of	polyunsaturated	PC	and	PE	molecules	stimulated	by	Bi(difl)3	or	diflH	
treatment	may	be	an	advantage	for	inducing	cell	death	in	the	HCT-8	cells	as	there	may	
be	 increased	 potential	 for	 lipid	 peroxidation	 to	 occur.	 	Future	 experiments	 could	 be	
performed	 to	 examine	 whether	 the	 generation	 of	 reactive	 oxygen	 species	 (ROS)	 is	
implicated	 in	 the	apoptotic	pathways	 induced	by	 the	BiNSAIDs/NSAIDs	examined	 in	
this	Thesis	and	whether	there	is	any	potential	correlation	with	lipid	peroxidation.	
The	 differences	 in	 the	 abundance	 and	 the	 saturation	 levels	 of	 the	 PC	 and	 PE	
molecules	may,	in	turn,	result	in	variations	in	fluidity	between	the	membranes	of	the	
Bi(tolf)3-	and	Bi(difl)3-treated	cells.		It	is	not	yet	clear	if	the	insertion	of	Bi(tolf)3	versus	
Bi(difl)3	 into	 the	phospholipid	 bilayer	 surrounding	 the	 cell	may	 affect	 the	 fluidity	 of	
the	cell	membrane,	or	if	cellular	events	related	to	cell	death	(or	a	combination	of	both	
factors)	 cause	 the	observed	changes.	 	As	mentioned	previously	 (Section	3.4.1),	work	
has	commenced	to	examine	the	interactions	of	BiNSAIDs	with	bilayer	mimetics	using	
neutron	reflectometry	(Brown	and	Dillon	[47]	and	unpublished	work).	The	results	to	
date	 show	 that	 Bi(tolf)3	 interacts	 with	 the	 head	 groups	 of	 lipid	 bilayer	 membrane	
mimics	 and	 partitions	 into	 the	 tail	 region	 of	 the	 membranes	 (comprised	 of	 POPC	
molecules).	 	While	 these	results	were	determined	 in	a	cell-free	system,	 it	shows	that	
the	Bi(tolf)3	complex	 is	able	to	displace	 lipid	molecules	and	potentially	partition	 into	
lipid	 bilayers.	 	 Further	 studies	 are	 planned	 to	 introduce	 other	 integral	 membrane	
components	 (including	cholesterol	and	membrane-bound	proteins)	 in	order	 to	more	
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closely	 mimic	 the	 cell	 membrane	 (personal	 communication).	 Additionally,	 it	 is	
tempting	 to	speculate	 that	subsequent	cell	membrane	variations	(such	as	membrane	
fluidity	and	the	implications	for	active	or	passive	drug	uptake)	may	be	responsible	(in	
part)	for	the	large	proportional	difference	in	the	uptake	in	Bi	observed	in	the	Bi(tolf)3	
and	Bi(difl)3-treated	cells	(Chapter	3),	although	further	work	is	needed	to	determine	if	
this	is	the	case.	
	
5.4.3 The	effects	of	BiNSAID	and	NSAID	treatment	on	ether-linked	molecules	
One	 of	 the	most	 interesting	 observations	 from	 the	 combined	 PC	 and	 PE	 profile	
comparisons	was	 the	 effect	 that	 the	BiNSAID	 and	NSAID	 treatment	 imparted	 on	 the	
relative	abundance	(Fig.	5.5	and	Fig.	5.8)	and	relative	concentration	(Fig.	5.6	and	Fig.	
5.9)	of	ether-linked	molecules.		Some	caution	must	be	taken	when	interpreting	ether-
linked	molecules	 due	 to	 the	 inability	 to	 distinguish	 these	molecules	 from	 odd-chain	
molecules	 as	 explained	 in	 Section	 5.1.4.	 	 However,	 it	 is	 reported	 that	 plasmalogens	
constitute	 ~	15−20%	 of	 total	 phospholipids	 in	 cell	 membranes	 [32].	 As	 such,	 it	 is	
reasonable	 to	 assume	 that	 a	 substantial	 number	 of	 plasmalogens,	 and	 other	 ether-
linked	species,	are	present	in	the	HCT-8	cells.			
The	results	from	the	BiNSAID-	and	NSAID-treated	cells	indicate	a	general	increase	
in	the	abundance	of	ether-linked	PE	molecules	(Table	5.3),	accompanied	by	an	overall	
increase	 in	 the	 relative	 concentration	 of	 the	 ether-linked	 PE	 molecules	 (Table	 5.4).		
Additionally,	 it	 was	 observed	 that	 Bi(tolf)3	 and	 tolfH	 caused	 an	 increase	 in	 the	
abundance	of	PC	molecules	containing	ether-linked	fatty	acids	when	compared	to	the	
percent	 of	 the	 total	 PC	 (Fig.	 5.5),	 although	 the	 relative	 concentration	 of	 all	 PCs	
decreased	 (Fig.	 5.6).	 	An	 increase	 in	PC	 and	PE	 ether-linked	phospholipids	has	been	
observed	 in	 hematopoietic	 progenitor	 cells	 undergoing	 apoptosis	 following	 growth	
factor	withdrawal,	 which	was	 accompanied	 by	 a	 decrease	 in	 the	 relative	 content	 of	
glycerophospholipids	 [48].	 	 Fuchs	 et	 al.	 [48]	 speculated	 that	 an	 increase	 in	 ether-
linked	phospholipids	may	serve	as	a	reservoir	 for	arachidonoyl	 residues	released	by	
the	breakdown	of	diacyl-glycerophospholipids,	in	order	to	reduce	further	metabolism	
of	arachidonic	acid	to	pro-inflammatory	prostaglandins.		The	BiNSAID/NSAID-treated	
HCT-8	cells	may	cause	accumulation	of	arachidonic	acid	since	they	act	at	the	active	site	
of	 the	 COX-1/COX-2	 enzymes	 to	 prevent	 arachidonic	 acid	 conversion	 to	
prostaglandins.	 	 Additionally,	 the	 HCT-8	 cells	 may	 upregulate	 arachidonic	 acid	 to	
compete	 with	 the	 NSAIDs	 as	 tolfH	 and	 diflH	 are	 competitive/reversible	 COX-1/-2	
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inhibitors.		As	such,	the	aforementioned	hypothesis	proposed	by	Fuchs	et	al.	[48]	may	
potentially	provide	one	explanation	 for	 the	 increase	 in	ether-linked	molecules	 in	 the	
BiNSAID/NSAID-treated	 HCT-8	 cells	 since	 the	 cells	 would	 require	 a	 mechanism	 to	
remove	excess	arachidonic	acid.			
Schonfeld	et	al.	[49]	observed	the	enhanced	synthesis	of	PE	plasmalogens	in	PC12	
cells	stimulated	with	nerve	growth	factor	and	docosahexaenoic	acid.		The	authors	[49]	
speculated	 that	 an	 increase	 in	 plasmalogen	 content	 was	 a	 possible	 reason	 for	
enhanced	 resistance	 of	 nerve	 growth	 factor-differentiated	 cells	 to	 oxidative	 stress	
allowing	 the	 cells	 to	 accumulate	 excessive	 intracellular	 Fe	 without	 undergoing	 cell	
death.	 	A	number	of	studies	[50-54]	have	reported	that	NSAIDs	can	cause	uncoupling	
of	 oxidative	 phosphorylation	 mitochondria,	 an	 event	 that	 is	 synonymous	 with	 the	
production	of	ROS	production	and	oxidative	stress	during	apoptosis.	 	As	such,	 future	
experiments	should	be	performed	to	determine	if	BiNSAID-induced	apoptosis	leads	to	
ROS	 production	 in	 HCT-8	 cells	 in	 order	 to	 shed	 light	 onto	 the	 importance	 of	 ether-
linked	phospholipid	production.			
One	of	the	disadvantages	of	using	constant	neutral	loss	of	141	Da	(as	performed	
in	the	present	study),	in	order	to	determine	ether-linked	PE	content	in	lipid	mixtures,	
is	that	plasmalogen	PE	do	not	undergo	neutral	loss	of	the	PE	head	group	to	the	same	
extent	 as	 diacyl-PE	molecules	 [21].	 	 This	 is	most	 likely	 attributed	 to	 the	 unique	 gas	
phase	ion	chemistry	imparted	by	the	vinyl	ether	substituent	which	alters	the	favorable	
CID	 mechanism	 of	 the	 neutral	 loss	 of	 141	 Da	 from	 PE	 species	 [21].	 	 As	 such,	 the	
experimental	conditions	employed	in	the	present	study	may	potentially	underestimate	
the	 presence	 of	 ether-linked	 PE	 species.	 	Overall,	 the	 results	 from	 the	 ESI-MS/MS	
analysis	of	the	HCT-8	cells	suggested	that	ether-linked	PC	and	PE	molecules	may	play	
an	 important	 role	 in	 response	 to	 BiNSAID/NSAID	 treatment	 and	 the	 implications	 of	
this	response	should	be	investigated	further.	
	
5.4.4 Overall	summary	of	the	results	and	future	directions	
The	 lipidomic	 analysis	 of	 vehicle-,	 BiNSAID-	 or	 NSAID-treated	 HCT-8	 cells	
suggested	 that,	 in	 addition	 to	 the	 glycerophospholipid	 changes	which	 occurred	 as	 a	
result	 of	 apoptosis,	 there	 were	 also	 additional	 effects	 resulting	 from	 each	 drug	
treatment.		A	combination	of	these	effects	has	resulted	in	substantial	differences	of	the	
PC	and	PE	profiles	(and	to	a	lesser	extent	the	PS	profile)	of	the	BiNSAID-	and	NSAID-
treated	 cells	 compared	 to	 the	 vehicle-treated	 cells.		 The	 lipidomic	 analysis	 of	 HCT-8	
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cell	 lipid	 extracts	 suggests	 that	 Bi(tolf)3/tolfH	 treatment	 results	 in	 the	 activation	 of	
different	 apoptotic	 responses	 compared	 to	 Bi(difl)3/diflH	 that	 influence	 the	 cellular	
composition	 and	 relative	 concentrations	 of	 PC,	 PE	 and	PS	 in	 the	HCT-8	 cells.	 	 These	
results	 further	 demonstrate	 the	 difference	 in	 the	 biological	 response	 induced	 by	
Bi(tolf)3	 and	 Bi(difl)3	 on	 the	 HCT-8	 cells,	 which	was	 observed	 in	 other	 experiments	
presented	in	this	Thesis	(reported	in	Chapters	2-4).		
While	there	were	some	consistencies	between	the	observations	obtained	from	the	
two	 techniques,	 the	 connection	 is	 speculative	 at	 this	 stage	 since	 it	 remains	 unclear	
whether	 the	 glycerophospholipid	 changes	 detected	 using	 ESI-MS/MS	 analysis	 are	
directly	responsible	for	the	changes	detected	in	the	SR-IRMS	experiments	(Chapter	4).		
Gasper	 et	 al.	 were	 not	 able	 to	 correlate	mass	 spectra	 and	 infrared	 bands	 related	 to	
νas(CH2),	νs(CH2),	νas(CH3),	νs(CH3)	(i.e.	between	3025	and	2800	cm−1)	[5].		As	such,	the	
authors	 concluded	 that	 the	 overall	 global	 changes	 in	 lipid	 chains	 could	 not	 be	
correlated	with	any	particular	lipid	species	resolved	by	mass	spectrometry	as	all	lipid	
contributions	are	overlapped	in	this	spectral	range	[5].		Consequently,	the	results	from	
the	 ESI-MS/MS	 experiments	 performed	 in	 this	 study	 should	 be	 considered	 as	 a	
compliment	to	the	data	obtained	using	SR-IRMS	(Chapter	4).		
While	 the	 results	 from	 the	 current	 study	 show	 that	 there	 are	 changes	 to	 the	
profile	 and	 relative	 concentrations	 of	 PC,	 PE	 and	 PS	 in	 HCT-8	 cells	 treated	 with	
BiNSAIDs	 or	 NSAIDs	 when	 compared	 to	 vehicle-treated	 cells,	 it	 could	 not	 be	
determined	whether	these	changes	are	a	direct	or	indirect	effect	of	the	drug	treatment.		
That	 is	 to	 say,	 it	 remains	 unknown	whether	BiNSAID	 or	NSAID	 interaction	with	 the	
identified	 glycerophospholipids	 leads	 to	 apoptosis,	 or	 whether	 the	 BiNSAID-	 or	
NSAID-induced	 apoptosis	 results	 in	 the	 observed	 changes	 to	 the	 profiled	
glycerophospholipids.		Further	experiments	(lipidomic	and	apoptosis	assays)	could	be	
performed	at	earlier	time	points	(<	24	h)	to	determine	if	glycerophospholipid	profile	
changes	 are	 observed	prior	 to	 the	 appearance	 of	 early	 apoptotic	 biomarkers	 (i.e.	PS	
exposure).	 	Any	 future	ESI-MS/MS	experiments	should	also	examine	the	effects	of	Bi	
alone	 and	 other	 anti-cancer	 agents,	 such	 as	 cisplatin,	 to	 draw	 a	 direct	 comparison	
between	 these	 drugs	 and	 the	 BiNSAIDs/NSAIDs	 in	 HCT-8	 cells.	 	 Unfortunately,	 the	
preparation	 of	 the	 aforementioned	 samples	 was	 limited	 by	 time	 and	 resources	 (in	
particular,	 the	 expense	 of	 phospholipid	 internal	 standards	 required	 to	 prepare	 an	
increased	number	of	samples)	 in	 the	present	study.	 	 If	 this	barrier	can	be	overcome,	
further	 ESI-MS/MS	 experiments	 could	 also	 be	 expanded	 to	 other	 lipid	 species	 with	
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relatively	high	abundance	 in	mammalian	cells	 including:	 sphingomyelins,	 cholesterol	
esters,	triacylglycerols,	diacylglycerols,	and	cardiolipins.	
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5.5 Chapter	Summary	
Lipidomic	analysis	of	treated	HCT-8	cells	using	ESI-MS/MS	was	used	to	determine	
whether	BiNSAID/NSAID	treatment	affects	the	composition	of	common	phospholipids,	
namely	PC,	PE	and	PS.		Specific	observations	included:	
(i) Treatment	 of	 the	 HCT-8	 cells	 with	 BiNSAIDs	 or	 NSAIDs	 significantly	
altered	 the	 abundance	 of	 several	 individual	 PC,	 PE	 and	 PS	 molecules	
compared	to	treatment	with	vehicle	alone.	
(ii) The	changes	to	the	abundance	of	the	individual	PC,	PE	and	PS	molecules	in	
the	overall	profiles	of	the	BiNSAID-,	and	the	respective	NSAID-treated	cells	
also	displayed	many	similar	changes	when	compared	to	the	vehicle.		There	
were	 some	 differences	 between	 the	 changes	 induced	 by	 Bi(tolf)3/tolfH	
treatments	compared	to	the	Bi(difl)3/diflH	treatments,	suggesting	that	the	
HCT-8	 cells	 responded	differently	 to	 the	 fenamate	 compounds	 compared	
to	the	salicylate	compounds.		
(iii) Changes	 were	 observed	 in	 the	 total	 concentration	 of	 PC,	 PE	 and	 PS	
between	 the	 BiNSAID	 and	 NSAID-treated	 cells	 compared	 to	 the	 vehicle-
treated	 cells.	 	 However,	 when	 the	 PC	 and	 PE	 molecules	 were	 grouped	
according	 to	 fatty	 acid	 categories,	 it	was	 observed	 that	 there	were	 some	
differences	 to	 the	 overall	 trend	 (i.e.	 increase	 or	 decrease)	 between	 the	
Bi(difl)3	 and	 diflH-treated	 cells	 compared	 to	 the	 vehicle-treated	 cells,	
whereas	the	Bi(tolf)-	and	tolfH-treated	cells	induced	similar	changes.	
(iv) The	 overall	 abundance	 of	 the	 ether-linked	 PC	 and	 PE	 molecules	 was	
increased	by	all	BiNSAID	and	NSAID	treatments,	which	was	accompanied	
by	an	 increase	 in	 the	 relative	 concentration	of	 ether-linked	PE	molecules	
(but	not	ether-linked	PC	molecules).	
In	summary,	BiNSAID	and	NSAID	treatment	resulted	in	changes	to	the	PC,	PE	and	
PS	 composition	 of	 HCT-8	 cells	 that	 was	 detected	 using	 ESI-MS/MS	 analysis.	 	 The	
general	observation	 from	the	 lipidomic	analysis	was	 that	BiNSAID-	and	NSAIDs	alter	
glycerophospholipid	 abundance	 and	 concentration	 in	HCT-8	 cancer	 cells.	 	 Similar	 to	
the	 results	 obtained	 from	 the	 MTT	 assays,	 flow	 cytometry,	 and	 PGE2	 assays	
(Chapter	2),	the	presence	of	Bi	in	the	Bi(tolf)3	complex	did	not	appear	to	substantially	
alter	 the	effects	of	 tolfH,	whereby	 the	glycerophospholipid	 changes	 induced	by	 tolfH	
were	minimally	 affected	 by	 the	 presence	 of	 Bi	 in	 the	Bi(tolf)3	 complex.	 	 In	 contrast,	
there	was	some	variation	between	the	results	obtained	from	Bi(difl)3	and	diflH-treated	
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HCT-8	 cells.	 	 As	 such,	 further	work	 into	 the	 implications	 of	 phospholipid	 changes	 in	
drug-induced	apoptosis	should	be	investigated	as	these	may	have	implications	for	the	
mechanism	of	action	for	the	BiNSAIDs	and	NSAIDs	(in	addition	to	COX	inhibition).	
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Exploration	of	the	in	vitro	toxicity	of	new	Bi(III)	
aminoarenesulfonate,	indole-carboxylate,	and	
hydroxamate	complexes	
	
	
	
Following	 promising	 results	 (Chapter	 2)	 that	 showed	 that	 a	 selection	 of	 BiNSAIDs	
exhibited	toxicity	towards	the	HCT-8	colon	cancer	cells,	other	Bi	complexes	were	also	
investigated	 for	 prospective	 anti-cancer	 activity	 against	 this	 cell	 line.	 	 Several	 non-
NSAID	Bi(III)	complexes,	which	included	homoleptic	tris-Bi(III)	aminoarenesulfonates,	
indole-carboxylates,	and	hydroxamates,	were	selected	for	this	in	vitro	screening	based	
on	 the	 fact	 that	 the	 ligands	were	 derivatives	 of	 biologically	 active	 compounds.	 	 The	
purpose	 of	 the	 work	 described	 in	 this	 Chapter	 was	 to	 identify	 new	 lead	 Bi(III)	
complexes	 to	 provide	 direction	 for	 future	 studies	 (such	 as	 those	 described	 in	
Chapters	2−5).	
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6.1 Introduction	
As	 previously	 discussed	 in	 Section	 1.4.1.4,	 several	 classes	 of	 Bi(III)	 complexes	
have	shown	both	in	vitro	and	in	vivo	anti-cancer	potential.		The	focus	in	Chapters	2−5	
has	 been	 on	 the	 anti-cancer	 potential	 of	 Bi	 complexes	 of	 NSAIDs	 based	 on	 the	
hypothesis	that	COX-2	over-expression	is	associated	with	cancer	and	that	NSAIDs	are	
strong	 inhibitors	 of	 COX.	 	It	 is	 evident	 from	 the	 literature	 (Chapter	 1)	 that	 Bi(III)	
complexes	of	other	 ligands	also	display	anti-cancer	potential	 in	vitro.	 	To	date,	 there	
have	 been	 no	 investigations	 of	 homoleptic	 Bi(III)	 complexes	 of	 aminoarenesulfonic	
acids	 (Section	 6.1.1)	 [1],	 indole-carboxylic	 acids	 (Section	 6.1.2)	 [2],	 and	 hydroxamic	
acids	(Section	6.1.3)	[3,	4].		While	most	of	these	ligands	are	not	known	to	inhibit	COX,	
they	 have	 been	 shown	 to	 be	 biologically	 active,	 as	 discussed	 in	 Sections	 6.1.1−6.1.3.		
As	such,	the	Bi(III)	complexes	of	these	ligands	warrant	investigation.	
6.1.1 Sulfonic	acids	and	Bi(III)	aminoarenesulfonates	
A	 number	 of	 simple	 sulfonic	 acid	 (general	 formula	 RSO3H)	 molecules	 play	
important	 roles	 in	 biological	 systems.	 For	 instance,	 the	 glycine	 analogue,	
aminomethanesulfonic	 acid	 (Fig.	 6.1),	 has	 demonstrated	 similar	 hepatoprotective	
effects	 as	 glycine	 in	 isolated	 Kuppfer	 (liver)	 cells	 [5].	 	 The	 aspartate	 analogue,	
L-cysteic	acid	 (Fig.	 6.1),	 is	 a	 potent	 and	 effective	 agonist	 towards	 several	 rat	
metabotropic	glutamate	receptors	[6].	 	Taurine	(Fig.	6.1),	 is	naturally	present	 in	high	
levels	 in	 the	 brain	 and	 is	 believed	 to	 play	 a	 role	 in	 neurological	 processes	 including	
osmoregulation,	 antioxidant	 activity,	 neuromodulation,	 and	 the	 control	 of	 calcium	
influx	[7].	 	In	addition,	experimental	evidence	suggests	that	taurine	and	the	synthetic	
analogue,	 homotaurine	 (Fig.	 6.1),	 reduce	 protein	 aggregation	 of	 amyloid-β	 proteins	
involved	 in	 the	 formation	 of	 plaques	 in	 Alzheimer’s	 disease	[8,	 9].	 	 Recently,	 it	 has	
been	 shown	 that	 a	 synthetic	 sulfonic	 acid,	 anthraquinone-2-sulfonic	 acid	 (Fig.	6.1)	
confers	 protection	 in	 primary	 rat	 cortical	 neurons	 exposed	 to	 hydrogen	peroxide	 or 
staurosporine;	as	a	result	this	sulfonic	acid	may	present	a	novel	therapeutic	agent	for	
neurological	protection	[10].		
Of	relevance	to	this	work	are	reports	of	the	anti-cancer	potential	of	a	number	of	
sulfonic	acid	derivatives,	whereby	 it	was	 shown	 that,	 in	 some	 instances,	 the	 sulfonic	
acid	 derivative	 showed	 improved	 activity	 compared	 to	 the	 original	 drug	 [11,	 12].		
For	instance,	indirubin-5-sulfonic	acid	(Fig.	6.1),	a	derivative	of	the	anti-leukemia	drug	
indirubin,	was	found	to	be	a	more	potent	inhibitor	of	cyclin-dependent	kinases	when	
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compared	 to	 indirubin	 [11].			However,	 indirubin-5-sulfonic	 acid	 showed	 limited	
activity	when	tested	against	the	T-lymphoblastic	Jurkat	cell	line,	which	was	believed	to	
be	a	result	of	poor	cell	uptake	of	the	compound	[11].		In	another	study,	the	vitamin	E	
analogue,	RRR-α-tocopheryloxybutyl	sulfonic	acid	(Fig.	6.1),	was	designed	to	prevent	
hydrolysis	by	gastric	esterases,	a	problem	which	is	believed	to	compromise	the	in	vivo	
anti-tumour	activity	of	α-vitamin	E	succinate	[12].		The	analogue	showed	significantly	
reduced	 tumour	 volumes	 compared	 to	 α-vitamin	E	 succinate	 following	 the	 6-week	
treatment	of	PC3	prostate	cancer	cell	xenografted	nude	mice	[12].		The	serum	levels	of	
RRR-α-tocopheryloxybutyl	sulfonic	acid-	and	α-vitamin	E	succinate-treated	mice	were	
determined	 to	be	15	μM	and	2	μM	after	one	month	of	dosing,	 respectively,	which	 is	
consistent	 with	 the	 improved	 bioavailability	 and	 anti-tumour	 activity	 of	 the	
analogue	[12].	
	
Figure	6.1:	The	chemical	structures	of	biologically	active	sulfonic	acids.	
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Importantly,	 a	 wide	 range	 of	 sulfonic	 acids	 have	 been	 shown	 to	 be	 relatively	
benign	 in	mammals;	 for	 example,	 LD50	 doses	 in	 excess	 of	 1000	mg/kg	 body	weight	
(often	 exceeding	 5000	mg/kg	 body	weight)	 are	 required	 to	 induce	 acute	 toxicity	 in	
rats	 dosed	 orally,	 regardless	 of	 the	 sulfonic	 acid	 tested	 [13].	 	 In	 addition,	 a	 large	
number	 of	 sulfonic	 acids	 possess	 little	 to	 no	 mutagenic	 and	 carcinogenic	 activity	
towards	mammalian	cells	[13].			
The	Andrews	group	have	investigated	sulfonates	as	ligands	for	Bi(III)	complexes	
in	 the	development	of	 anti-bacterial	drugs	with	 improved	potency	over	 traditionally	
used	 Bi	 compounds	 (BSS,	 CBS	 and	 RBC)	 for	 the	 treatment	 of	 H.	 pylori														
infections	[1,	14-16].		To	this	end,	several	homoleptic	tris-Bi(III)	aminoarenesulfonate	
complexes	 of	 the	 form	 [Bi(O3S-RN)3]	 (where	 O3S-RN	 represents	 the	 deprotonated	
ligands	 of:	 ortho-aminobenzenesulfonic	 acid	 (oAB-SO3H,	 Fig.	 6.2);	 meta-
aminobenzenesulfonic	 acid;	 para-aminobenzenesulfonic	 acid	 (pAB-SO3H,	 Fig.	6.2);	
6-amino-3-methoxybenzenesulfonic	acid;	2-pyridinesulfonic	acid;	4-amino-3-hydroxy-
1-naphthalenesulfonic	 acid	 (4A3HN-SO3H,	 Fig.	6.2);	 2-amino-1-naphthalensulfonic	
acid	(2AN-SO3H,	Fig.	6.2);	5-amino-1-naphthalensulfonic	acid	(5AN-SO3H,	Fig.	6.2);	or	
5-isoquinolinesulfonic		acid)		were		synthesised		and		tested		for		in		vitro		anti-bacterial		
	
Figure	6.2:	The	chemical	structures	of	the	aminoarenesulfonic	acids	used	to	synthesis	the	five	
Bi(III)	 aminoarenesulfonate	 complexes,	 (Bi(oAB-SO3)3,	 Bi(pAB-SO3)3,	 Bi(4A3HN-SO3)3,	
Bi(2AN-SO3)3,	and	Bi(5AN-SO3)3),	investigated	in	the	present	study.	
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activity	against	H.	pylori	 [1].	 	 Importantly,	 the	associated	poor	aqueous	solubility	did	
not	 appear	 to	 affect	 the	 bactericidal	 properties	 of	 the	 Bi(III)	 aminoarenesulfonate	
complexes	 against	 three	 standard	 laboratory	 strains	 of	 H.	 pylori	 [1].			The	 Bi(III)	
aminoarenesulfonate	complexes	showed	increased	anti-bacterial	activity	compared	to	
BSS,	CBS,	RBC,	and	the	uncomplexed	aminoarenesulfonic	acids	[1].			
In	the	present	study,	five	Bi(III)	aminoarenesulfonate	complexes	were	chosen	for	
in	vitro	anti-cancer	screening	based	on	their	ease	of	solubility	in	the	vehicle	used	in	the	
MTT	 assays	 (Chapter	 2).	 	The	 complexes,	 (Bi(oAB-SO3)3,	 Bi(pAB-SO3)3,	
Bi(4A3HN-SO3)3,	 Bi(2AN-SO3)3,	 and	 Bi(5AN-SO3)3),	 and	 the	 corresponding	
uncomplexed	aminoarenesulfonic	acids,	were	selected	for	screening.	
6.1.2 Indoles	and	Bi(III)	indole-carboxylates		
Indoles	 are	 heterocyclic	 compounds	 that	 consist	 of	 a	 fused	 six-membered	
and			five-membered	 nitrogen-containing	 pyrrole	 ring.	 	Naturally	 occurring	 indole	
molecules	 that	 confer	 biological	 activity	 include	 tryptophan	 (Fig.	 6.3),	 which	 is	 the	
precursor	of	 the	neurotransmitter	 serotonin.	 	 Indole-3-lactic	 acid	 (ILA-H,	 Fig.	 6.3)	 is	
one	example	of	 a	number	of	 tryptophan	metabolites	 found	 in	human	plasma,	 serum	
and	urine	[17,	18].		A	diverse	range	of	drugs	exist	that	incorporate	an	indole	moiety	in	
their	structures	(reviewed	in	[19]).	 	 Indole-containing	molecules	have	a	wide	variety	
of	 medicinal	 uses,	 including	 treatment	 of	 asthma,	 cancer,	 depression,	 HIV	 infection,	
hypertension,	microbial	infection,	and	inflammation	(reviewed	in	[19]).		Of	particular	
interest	 to	 the	 work	 performed	 in	 this	 Thesis	 are	 the	 anti-cancer	 and	
anti-inflammatory	effects	of	 indole-based	compounds.	 	For	 instance,	some	commonly	
used	 NSAIDs	 (e.g.	 indoH,	 Fig.	 1.2)	 contain	 an	 indole	 moiety.	 	While	 several	 high	
molecular	weight	 indole-containing	molecules	are	 currently	marketed	as	anti-cancer	
drugs	 (e.g.	 Vincristine,	 Fig.	 6.3)	 [19],	 a	 relatively	 simple,	 low	 molecular	 weight	
compound,	 indole-3-carbinol	 (Fig.	6.3),	 has	 been	 extensively	 studied	 as	 a	 potential	
anti-cancer	agent	against	several	cancer	cell	types,	namely	breast,	colon,	endometrium	
and	prostate	(reviewed	in	[20]).	
Pathak	et	al.	[2]	have	recently	synthesised	and	evaluated	the	in	vitro	anti-bacterial	
and	 anti-parasitic	 activity	 (against	 H.	 pylori	 and	 Leishmania	 promastigotes,	
respectively)	 of	 several	 homoleptic	Bi(III)	 complexes	derived	 from	 indole-carboxylic	
acids,	 namely	 Bi(2-(1H-indol-3-yl)acetate)3,	 Bi(3-(1H-indol-3-yl)propanoate)3,	
Bi(4-(1H-indol-3-yl)butanoate)3,	 Bi(1-methyl-1H-indole-3-carboxylate)3,	 or	 Bi(2-(1H-
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indol-3-yl)-2-oxoacetate)3	 (referred	 to	 herein	 as	 Bi(IGA)3,	 where	 IGA-H	 =	 indole-3-
glyoxylic	acid	(Fig.	6.3)).			
In	the	present	study,	two	Bi(III)	indole-carboxylates,	Bi(IGA)3	and	Bi(ILA)3,	will	be	
assessed	for	anti-cancer	activity	against	the	HCT-8	cell	 line	since	their	potential	anti-
cancer	properties	had	not	been	assessed	previously.		
	
	
Figure	 6.3:	 The	 chemical	 structures	 of	 biologically	 active	 indoles,	 and	 the	 indole-carboxylic	
acids	used	 to	 synthesise	 the	 two	Bi(III)	 indole-carboxylate	 complexes,	Bi(ILA)3	and	Bi(IGA)3,	
investigated	in	this	study.	
6.1.3 Hydroxamic	acids	and	Bi(III)	hydroxamates	
Hydroxamic	acids	(general	formula	RCONR´OH)	are	weak	acids	that	represent	an	
important	family	of	organic	bioligands	[21].		Hydroxamic	acids	play	a	role	in	a	variety	
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of	biological	processes,	which	is	largely	due	to	the	ability	of	hydroxamic	acids	to	form	
stable	 chelates	 with	 metals	 such	 as	 Fe(III)	 [21,	 22].	 One	 of	 the	 first	 recognised	
biological	roles	of	hydroxamic	acids	was	their	use	as	siderophores	in	microbial	Fe(III)	
sequestration	 and	 transport	 [21].	 	 Hydroxamic	 acids	 are	 used	 in	 the	 treatment	 of	
bacterial	 infections	 [23],	 thalassemia	 [24],	 and	 inflammation	 [25].	 	Additionally,	
hydroxamic	 acid	 molecules	 have	 been	 investigated	 as	 potential	 treatments	 for	 a	
variety	of	ailments	including	cancer	[26],	malaria	[27],	and	Alzheimer’s	disease	[28].		
The	 structurally	 simple	 hydroxamic	 acid,	 acetohydroxamic	 acid	 (Fig.	6.4),	 is	 a	
potent	 inhibitor	 of	 nickel-dependent	 ureases	 [29,	 30].	 	 In	 1983,	 the	 FDA	 approved	
acetohydroxamic	 acid	 for	 the	 treatment	 of	 urinary	 tract	 infections	 [23].		
Benzohydroxamic	 acid	 (BHA-H,	Fig.	 6.4)	has	 also	been	 shown	 to	 inhibit	 urease	 [31].	
The	 similarly	 structured	 salicylhydroxamic	 acid	 (SHA-H,	 Fig.	6.4)	 is	 employed	 in	 the	
treatment	 of	 urinary	 tract	 infections	 and	 urolithiasis	 [32].	 	 SHA-H	 has	 also	 shown	
potential	in	the	treatment	of	Candida	albicans	infection	[32,	33].		
Importantly	 hydroxamic	 acids	 also	 inhibit	 enzymes	 including	 Zn-dependent	
MMPs	[34,	35],	histone	deacetylases,	and	COX	[36-38],	which	has	sparked	interest	 in	
their	 use	 as	 potential	 anti-cancer	 drugs.	 The	 hydroxamic	 acid-based	 drugs,	
Batimastat	(Fig.	 6.4)	 and	 Marimastat	 (Fig.	6.4),	 are	 MMP	 inhibitors	 that	 have	 been	
investigated	 in	 Phase	 III	 clinical	 trials	 for	 the	 treatment	 of	 cancer	 [39,	 40].		
Unfortunately,	neither	drug	has	progressed	beyond	Phase	III	trials	due	to	poor	efficacy	
and	 adverse	 side	 effects	 [40].	 	 Vorinostat	 (Merck	 &	 Co.,	 Inc.,	 Fig.	 6.4)	 is	 an	 orally	
delivered,	 potent	 inhibitor	 of	 histone	deacetylase	 that	was	 approved	by	 the	 FDA	 for	
the	 treatment	 of	 cutaneous	 T-cell	 lymphoma	 in	 2006	 [41,	 42].	 	 More	 recently,	 the	
histone	 deacetylase	 inhibitor,	 Belinostat	 (Spectrum	 Pharmaceuticals,	 Fig.	 6.4)	 was	
approved	 by	 the	 FDA	 for	 the	 treatment	 of	 peripheral	 T-cell	 lymphoma	 [43].		
The	development	 of	 diverse	 new	 ranges	 of	 hydroxamic	 acid-based	 molecules	 that	
inhibit	histone	deacetylases	can	be	found	in	a	recent	review	[44].	
A	 number	 of	 hydroxamic	 acids	 inhibit	 the	 activity	 of	 COX	 [36-38],	 an	 enzyme	
implicated	 in	 the	 formation	 and	 progression	 of	 a	 number	 of	 types	 of	 cancer	 (as	
discussed	 in	 Section	 1.2.3).	 	 Notably,	 some	 hydroxamic	 acid	 molecules	 are	 able	 to	
interact		with		both		the		POX		and		COX		active		sites;		for		example,		tepoxalin		(Fig.		6.4)	
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Figure	6.4:	The	chemical	structures	of	a	selection	of	biologically	active	hydroxamic	acids,	and	
the	hydroxamic	acids	used	 to	 synthesise	 the	 three	Bi(III)	hydroxamate	complexes,	Bi(BHA)3,	
Bi(SHA)3,	and	Bi(O-AcSHA)3,	investigated	in	this	study.	
is	a	dual-inhibitor	of	the	COX	and	POX	active	sites	[36],	and	has	also	been	reported	to	
inhibit	lipoxygenase	[25].		There	is	an	interest	in	developing	hydroxamic	acids	as	new	
generation	COX	inhibitors	since	hydroxamic	acids	may	potentially	provide	potent	COX	
inhibition	 through	 dual	 COX	 and	 POX	 active	 site	 inhibition	while	 also	 reducing	 side	
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effects	such	as	topical	irritation,	partially	due	to	the	fact	hydroxamic	acids	are	weaker	
acids	 than	 the	 analogous	 carboxylic	 acids	 [21].	 	 Two	hydroxamic	 acids	 developed	
specifically	 to	 target	 COX,	 O-acetylsalicylhydroxamic	 acid	 (O-AcSHA-H,	 Fig.	6.4)	 and	
triacetylsalicylhydroxamic	acid	(Fig.	6.4),	exhibited	irreversible,	non-selective	binding	
to	both	COX-1	and	COX-2	with	comparable	or	 improved	potency	to	aspH	[37,	38].	 	 It	
has	 been	 shown	 that	 the	 mechanism	 of	 COX	 inhibition	 by	 O-AcSHA-H	 and	
triacetylsalicylhydroxamic	 acid	 is	 the	 same	 as	 that	 exhibited	 by	 aspH	 whereby	
Ser530	(COX-1)	 is	 irreversibly	 acetylated	 [37,	 38].	 	 Given	 this	 evidence,	 it	 may	 be	
possible	 that	 hydroxamic	 acid	 inhibitors	 of	 COX	 may	 confer	 potential	 anti-cancer	
activity,	in	a	manner	similar	to	traditional	NSAIDs,	particularly	against	cancer	cell	lines	
that	express	upregulated	levels	of	COX-2.	
Due	 to	 the	 ability	 of	 several	 hydroxamic	 acids	 (e.g.	 acetohydroxamic	 acid,	
BHA-H	and	 SHA-H)	 to	 inhibit	 bacterial	 urease	 and	 their	 use	 as	 anti-bacterial	 agents,	
Pathak	et	al.	[3,	4]	have	synthesised	several	Bi(III)	hydroxamate	complexes	under	the	
premise	 that	 they	may	exhibit	 improved	anti-bacterial	 activity	 against	H.	pylori	 than	
currently	used	Bi(III)	compounds,	BSS,	CBS	and	RBC.	 	Additionally,	 the	toxicity	of	the	
Bi(III)	 hydroxamates	 has	 been	 assessed	 against	 human	 fibroblasts	 [4];	 however,	
currently	 no	 studies	 have	 investigated	 the	 anti-cancer	 activity	 of	 these	 complexes	
against	 human	 cancer	 cell	 lines.	 	 Three	 Bi(III)	 hydroxamate	 complexes,	 Bi(BHA)3,	
Bi(SHA)3,	 and	Bi(O-AcSHA)3,	were	chosen	 for	assessment	 in	 the	present	 study	based	
on	their	ease	of	solubility	in	the	vehicle	used	in	the	MTT	assays	(Chapter	2).	
6.1.4 Scope	of	this	chapter	
Following	results	that	showed	that	BiNSAIDs	exhibited	in	vitro	toxicity	toward	the	
HCT-8	colon	cancer	cell	line	(Chapter	2)	it	was	of	interest	to	expand	the	range	of	Bi(III)	
compounds	and	 identify	other	potential	 lead	compounds.	 	As	such,	Bi(III)	complexes	
derived	from	biologically	relevant	ligands	were	studied	with	the	specific	aims	of:	
1. Assessing	 the	 in	 vitro	 toxicity	 of	 Bi(III)	 aminoarenesulfonate	 complexes,	
Bi(III)	 indole-carboxylate	complexes,	and	Bi(III)	hydroxamate	complexes,	
and	
2. Comparing	 the	 toxicity	 of	 the	 above-mentioned	 Bi	 complexes	 to	 the	
uncomplexed	 aminoarenesulfonic	 acids,	 indole-carboxylic	 acids	 and	
hydroxamic	acids	using	the	human	colon	cancer	cell	line,	HCT-8.	 	
Chapter	6.	Anti-cancer	activity	of	Bi(III)	complexes	
	
	 262	
6.2 Materials	and	Methods	
6.2.1 Materials	
The	 Bi(III)	 aminoarenesulfonate	 complexes,	 Bi(oAB-SO3)3,	 Bi(pAB-SO3)3,	
Bi(4A3HN-SO3)3,	Bi(2AN-SO3)3,	and	Bi(5AN-SO3)3,	were	synthesised	and	characterised	
by	 Dr	 Madleen	 Busse	 (Monash	 University,	 Australia)	 as	 previously	 described	[1].	
The		Bi(III)	 indole-carboxylate	 complexes,	 Bi(IGA)3,	 and	 Bi(ILA)3,	 and	 the	 Bi(III)	
hydroxamate	complexes,	Bi(BHA)3,	Bi(SHA)3,	and	Bi(O-AcSHA)3,	were	synthesised	and	
characterised	 by	 Dr	 Amita	 Pathak	 (Monash	 University,	 Australia)	 as	 previously	
described	 [2-4].	 	 All	 aminoarenesulfonic	 acids	 (oAB-SO3H,	 pAB-SO3H,	 4A3HN-SO3H,	
2AN-SO3H,	 and	 5AN-SO3H),	 indole-carboxylic	 acids	 (IGA-H	 and	 ILA-H),	 and	
hydroxamic	 acids	 (BHA-H,	 SHA-H,	 and	 O-AcSHA)	 were	 supplied	 by	 Professor	Philip	
Andrews	 (Monash	University,	 Australia)	 and	were	 originally	 purchased	 from	Sigma-
Aldrich	(St	Louis,	 USA)	 or	 TCI	 America	 (Portland,	 USA)	 and	 used	 without	 further	
purification	 as	 previously	 described	 [1-4].	 	 The	 materials	 used	 for	 the	 cell	 culture	
experiments	described	in	this	Chapter	have	been	previously	described	in	Section	2.2.1. 
6.2.2 Cell	Lines	
HCT-8	cells	were	sourced	and	employed	as	described	in	Section	2.2.3.	
6.2.3 MTT	Assay	
The	MTT	assay	was	performed	as	previously	described	in	Section	2.2.4.	 	
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6.3 Results	
The	 MTT	 assay	 was	 used	 to	 evaluate	 the	 effects	 of	 the	 Bi(III)	 complexes	 and	
ligands	on	 cell	 viability	 in	HCT-8	 cells	 following	24	h	 exposure.	 Figure	6.5a-d	 shows	
the	 representative	 concentration-response	 curves,	 graphed	 for	 the	 concentration	 of	
each	 ligand	 (acknowledging	 that	 three	 mol	 of	 ligand	 are	 present	 per	 mol	 of	 Bi(III)	
complex).	 	For	clarity,	the	MTT	results	for	the	less	active	compounds	are	provided	in	
Appendix	5.1.		The	IC50	values	determined	after	24-h	exposure	to	the	Bi(III)	complexes	
and	ligands	are	summarised	in	Table	6.1.			
The	 Bi(III)	 aminoarenesulfonates	 and	 corresponding	 aminoarenesulfonic	 acids	
demonstrated	 little	 to	 no	 activity	 towards	 HCT-8	 cells	 (Appendix	 5.1),	 with	 the	
exception	 of	 Bi(4A3HN-SO3)3	 and	 4A3HN-SO3H	 (Fig.	 6.5a).	 	 The	 complexation	 of	
4A3HN-SO3	 to	 Bi(III)	 increased	 the	 potency	 of	 the	 free	 4A3HN-SO3H	 towards	 the	
HCT-8	cells	by	approximately	11	times	(Table	6.1).	
The	Bi(III)	 indolates,	 Bi(IGA)3	 and	Bi(ILA)3,	 exhibited	 low	 IC50	 values	 (Fig.	 6.5b,	
Table	6.1)	of	10	µM	and	17	µM,	respectively.	 	As	evident	in	Figure	6.5b,	however,	the	
ligands	 exhibited	 low	 toxicity.	 For	 instance,	 IGA-H	 demonstrated	 no	 significant	
reduction	 in	 MTT	 conversion	 up	 to	 100	µM	 (Fig.	 6.5b),	 and	 while	 this	 decreased	
between	 100-1000	 µM	with	 a	 small	 increase	 between	 1000	 µM	 to	 2000	 µM,	 IGA-H	
failed	 to	 achieve	 greater	 than	 50%	 inhibition	 of	 MTT	 conversion	 (Fig.	 6.5b).	
Comparatively,	 ILA-H	 demonstrated	 consistently	 low	 toxicity	 up	 to	 the	 highest	
concentration	assessed,	2000	µM	(Fig.	6.5b).		In	both	instances,	it	is	apparent	that	the	
Bi(III)	indole-carboxylates	exhibited	greater	toxicity	than	predicted	for	the	ligands.	
As	summarised	in	Table	6.1,	the	IC50	values	obtained	for	the	Bi(III)	hydroxamate	
complexes,	 Bi(BHA)3	 and	 Bi(SHA)3,	 were	 approximately	 10	 and	 15	 times	 higher,	
respectively,	than	Bi(IGA)3.		However,	Bi(BHA)3	demonstrated	the	lowest	IC50	value	of	
the	 three	Bi(III)	hydroxamates	 tested,	and	nearly	5.5	 times	greater	activity	 than	 free	
BHA-H	 (Table	 6.1).	 	 Additionally,	 Bi(SHA)3	 demonstrated	 greater	 toxicity	 than	 free	
SHA-H,	 whereby	 the	 latter	 did	 not	 inhibit	 MTT	 conversion	 below	 50%	 over	 the	
concentration	 range	 tested	 (up	 to	 2000	 µM,	 Fig.	 6.5d).	 	 As	 observed	 in	 Figure	6.5d,	
Bi(O-AcSHA)3	induced	some	reduction	in	cell	viability	compared	to	the	vehicle-treated	
cells,	but	 failed	to	produce	50%	inhibition	(maximum	inhibition	~	52%	at	1000	µM).		
Uncomplexed	O-AcSHA-H	 (IC50	 =	 94	 ±	 13	 µM)	 showed	 substantially	 greater	 toxicity	
towards	the	HCT-8	cells	in	comparison	to	Bi(O-AcSHA)3		(Fig.	6.5d).	
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Finally,	the	compounds,	Bi(4A3HN-SO3)3,	Bi(IGA)3,	and	Bi(ILA)3,	were	more	toxic	
towards	HCT-8	cells	than	the	anti-cancer	drug,	cisplatin	(IC50	=	50	µM,	Section	2.3.2),	
and	their	respective	free	ligands,	as	indicated	by	their	lower	IC50	values	(Table	6.1	and	
Section	2.3.2).	
	
Figure	 6.5:	 Concentration-response	 curves	 obtained	 from	 the	 MTT	 assays	 of	 HCT-8	 cells	
treated	 (24	 h)	 with	 the	 specified	 compounds	 and	 corresponding	 Bi(III)	 complexes:	
(a)	4A3HN-SO3H	 or	 Bi(4A3HN-SO3)3;	 (b)	 IGA-H,	 	 Bi(IGA)3,	 ILA-H,	 or	 Bi(ILA)3;	 (c)	 BHA-H	 or	
Bi(BHA)3;	 and	 (d)	 SHA-H,	 Bi(SHA)3,	O-AcSHA-H	 or	 Bi(O-AcSHA)3.	 	 Error	 bars	 represent	 the	
standard	 deviation	 from	 the	 mean	 (n	 =	 6).	 	 One	 representative	 of	 three	 independent	
experiments	is	shown.		 	
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Table	6.1:	 IC50	 values	determined	by	MTT	 toxicity	 assays	 following	 treatment	 (24	h)	 of	
HCT-8	colon	cancer	cells	with	the	specified	compounds.	
	 															IC50	(µM)a	 IC50	ratio	
LH:Bi(L)3	Ligand	(LH)	 		Complex	[Bi(L)3]	
Aminoarenesulfonic	acids	
oAB-SO3	
	
>	2000	
	
>	2000	
	
-	
pAB-SO3	 >	2000	 >	2000	 -	
4A3HN-SO3	 131	±	12	 12	±	0.2	 10.9	
2AN-SO3	 >	2000	 >	2000	 -	
5AN-SO3	 >	2000	 >	2000	 -	
Indole-carboxylic	acids	
IGA	
	
>	2000	
	
10	±	2	
	
>	200	
ILA	 >	2000	 17	±	1	 >	118	
Hydroxamic	acids	
BHA	
	
582	±	32	
	
106	±	8	
	
5.5	
SHA	 >	2000	 159	±	13	 >	12.6	
O-AcSHA	 94	±	13	 >	1000	 <	0.1	
aIC50	value	was	determined	using	at	least	three	independent	MTT	assays.		 	
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6.4 Discussion	
6.4.1 Bi(III)	aminoarenesulfonates	
The	 MTT	 assay	 results	 (Section	 6.3.1,	 Table	 6.1)	 showed	 that	 the	 Bi(III)	
aminoarenesulfonates	 and	 the	 corresponding	 free	 ligands	 showed	 little	 activity	
towards	HCT-8	cells,	with	 the	exception	of	Bi(4A3HN-SO3)3	and	4A3HN-SO3H.	 	 Since	
most	of	 these	Bi-aminosulfonates	exhibited	no	 toxicity	against	human	cancer	cells	 in	
the	 present	 study,	 and	 have	 exhibited	 anti-bacterial	 activity	 in	 other	 studies	 [1],	 it	
would	 be	 worthwhile	 to	 determine	 if	 the	 complexes	 also	 show	 a	 lack	 of	 activity	
towards	non-cancerous	human	cells	as	this	would	be	a	beneficial	property	for	the	use	
of	the	Bi(III)	aminoarenesulfonates	for	the	treatment	of	H.	pylori	infection.			
There	 are	 no	 recent	 publications	 that	 report	 the	 in	 vitro	 or	 in	 vivo	 anti-cancer	
activity	of	 the	aminoarenesulfonic	acids	used	 in	 the	present	 study	 [45-49].	 	As	 such,	
the	 reasons	 why	 Bi(4A3HN-SO3)3	 and	 4A3HN-SO3H	 showed	 substantial	 toxicity	
compared	to	the	other	Bi(aminoarenesulfonates)3	(Table	6.1)	can	only	be	speculated.		
Factors	such	as	pKa	and	logP	may	be	less	likely	to	contribute	to	the	variation	in	activity	
as	the	five	tested	sulfonic	acids	display	similar	pKa	values	(ranging	from	1−3,	[1])	and	
logP	values	[45-49].	 	Additionally,	 the	 influence	of	 chemical	 substituents	needs	 to	be	
considered.		For	instance,	the	presence	of	a	phenyl	ring,	a	sulfonyl	group	and	an	amino	
group	are	common	features	among	the	chemical	structures	of	the	aminoarenesulfonic	
acids	 tested.	 	While	4A3HN-SO3H	shares	a	naphthalene	skeleton	with	2AN-SO3H	and	
5AN-SO3H,	 the	 presence	 of	 the	 hydroxyl	 group	 is	 unique	 to	 the	 structure	 of	
4A3HN-SO3H.	 	It	 is	not	clear	whether	the	hydroxyl	group	(and	the	extra	H-bonding	it	
provides),	or	its	adjacent	position	to	the	amino	group	bears	influence	on	the	activity	of	
4A3HN-SO3H.		However,	it	is	more	likely	that	the	poor	aqueous	solubility	contributes	
to	the	 lack	of	 in	vitro	activity	of	 the	oAB-SO3,	pAB-SO3,	2AN-SO3H,	and	5AN-SO3H	and	
the	respective	Bi(III)	complexes	against	the	HCT-8	cells.			
Interestingly,	complexation	of	4A3HN-SO3H	with	Bi(III)	resulted	in	an	increase	in	
toxicity	of	approximately	11-fold	(Table	6.1).	 	This	was	far	higher	than	that	observed	
for	 Bi(difl)3	 and	 diflH	 (Section	 2.3.2)	 where	 it	 was	 speculated	 that	 the	 increase	 in	
toxicity	 of	 Bi(difl)3	might	 be	 due	 to	 an	 additive	 effect	 between	 the	 Bi	 and	 the	 diflH	
based	on	the	comparable	IC50	values	of	BiCl3	(383	µM)	and	diflH	(401	µM).		Instead	it	
could	be	speculated	that	Bi(4A3HN-SO3)3	 is	 likely	to	remain	 intact	upon	entering	the	
cell.	 	 While	 it	 is	 beyond	 the	 scope	 of	 the	 aims	 of	 this	 Chapter,	 the	 stability	 of	 the	
complexes	 in	 cell	medium	 and	 cellular	 uptake	 of	 Bi	 and	 potential	 targets	 should	 be	
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examined	 in	 future	 work.	 	 For	 instance,	 it	 has	 previously	 been	 shown	 that	 the	
compound,	sodium	4-amino-3-hydroxy-1-naphthalene-sulfonate,	which	is	structurally	
similar	 to	 4A3HN-SO3H,	 caused	 a	 substantial	 decrease	 in	mitogenesis	 in	 Balb/c	3T3	
fibroblasts	 that	 were	 stimulated	by	acidic	 fibroblast	 growth	 factor	 (an	 important	
angiogenesis-promoting	 polypeptide)	 [50].	 These	 results	 give	 credence	 to	 a	
mechanism	of	toxicity	of	4A3HN-SO3H	that	 involves	targeting	an	enzyme	essential	 to	
the	cancer	cell	growth.	
The	 fact	 that	 the	 toxicity	 of	 Bi(4A3HN-SO3)3	 was	 comparable	 to	 the	
BiNSAIDs	(Section	2.3.2)	 provides	 precedence	 to	 explore	 the	 non-NSAID	 derived	
Bi(4A3HN-SO3)3	 in	 future	 experiments.	 	 Consequently,	 studies	 of	 the	 toxicity	 of	
Bi(4A3HN-SO3)3	towards	normal	human	cell	lines	(e.g.	healthy	colon	cells	and	human	
peripheral	blood	mononuclear	cells	(hPBMCs))	would	be	worthwhile	to	determine	the	
potential	 effect	 on	 healthy	 colon	 cells	 if	 administered	 as	 a	 chemotherapeutic	 or	
chemopreventive	 agent.	 	The	benefit	 of	 screening	Bi(4A3HN-SO3)3	 on	non-cancerous	
cells	will	be	 two-fold,	whereby	 the	 results	will	not	only	establish	 selectivity	 towards	
cancer	cells,	but	will	also	provide	insight	 into	whether	any	potential	side	effects	may	
result	from	the	administration	of	the	complex	as	an	anti-bacterial	agent,	as	originally	
proposed	by	Busse	et	al.	[1]. 
6.4.2 Bi(III)	indole-carboxylates	
The	 MTT	 results	 (Section	 6.3.1,	 Table	 6.1)	 showed	 that	 the	 indole-carboxylic	
acids,	 IGA-H	 and	 ILA-H,	 only	 displayed	 high	 toxicity	 towards	 HCT-8	 cells	 when	
coordinated	 to	 Bi	 as	 the	 Bi(III)	complexes.	 	 Furthermore,	 the	 resultant	 complexes	
displayed	 some	 of	 the	 lowest	 IC50	values	 (highest	 toxicity)	 of	 all	 the	 compounds	
assessed.	 	 Since	 ILA-H	 is	 a	 product	 of	 tryptophan	 metabolism	 [17],	 it	 was	 not	
surprising	that	ILA-H	did	not	show	any	toxicity	towards	the	HCT-8	cells	(up	to	2	mM).		
The	 comparatively	 lower	 IC50	 values	 of	 the	Bi(IGA)3	 and	Bi(ILA)3	 (IC50	 =	 10	 µM	and	
17	µM,	 respectively)	 cannot	 be	 explained	 by	 Bi(III)	 toxicity	 alone	 since	 it	 was	
previously	 established	 (Chapter	 2)	 that	when	Bi(III)	was	 bound	 to	 the	 non-toxic	 Cl−	
anion	 the	 IC50	value	 (383	µM)	was	considerably	higher.	 	 If	 the	Bi(IGA)3	and	Bi(ILA)3	
complexes	remain	intact,	alternative	toxicity	pathways,	mechanisms	or	targets	would	
be	responsible	for	the	toxicity.	
Importantly,	 the	 homoleptic	 Bi(III)	 indole-carboxylate	 complexes,	 including	
Bi(IGA)3,	 showed	 little	 toxicity	 towards	human	 fibroblasts	 (up	 to	 100	µM,	 48	h)	 [2],	
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making	 them	 excellent	 candidates	 for	 further	 testing	 as	 chemopreventive	 and	
chemotherapeutic	properties.	 	 Therefore,	 further	 investigation	 into	 their	mechanism	
of	toxicity	including	determining	mode	of	cell	death	and	potential	intracellular	targets	
should	be	performed.	 	There	is	also	scope	to	expand	the	compound	library	for	future	
testing	 as	 Pathak	et	al.	 [2]	 have	 synthesised	 several	 other	 Bi(III)	 indole-carboxylate	
complexes.			
6.4.3 Bi(III)	hydroxamates	
The	 results	 of	 the	MTT	 assays	 (Section	6.3.1,	 Table	 6.1)	 showed	 that	 the	Bi(III)	
hydroxamates,	 Bi(BHA)3	 and	 Bi(SHA)3,	 exhibited	 moderate	 toxicity	 towards	 HCT-8	
cells	with	increased	activity	compared	to	the	corresponding	hydroxamic	acids,	BHA-H	
and	 SHA-H,	 at	 equimolar	 concentrations.	 	 Interestingly,	 Bi(O-AcSHA)3	 demonstrated	
substantially	reduced	toxicity	compared	to	the	free	O-AcSHA-H	ligand,	which	was	the	
only	 Bi(III)	 complex	 observed	 to	 exhibit	 such	 a	 reduced	 effect	 (Sections	 2.3.2	
and	6.3.1).		
There	are	several	possible	reasons	that	Bi(O-AcSHA)3	displayed	reduced	toxicity	
compared	to	O-AcSHA-H.		Firstly,	it	was	observed	that,	following	the	treatment	period,	
Bi(O-AcSHA)3-treated	 wells	 showed	 signs	 of	 precipitation	 in	 cell	 medium	 at	
approximately	300	µM.		Therefore	the	poor	solubility	of	Bi(O-AcSHA)3	may	contribute	
to	its	limited	toxicity.			Secondly,	as	previously	discussed	in	Section	6.1.3,	O-AcSHA-H	is	
an	irreversible	COX	inhibitor	similar	to	aspH	[37].	 	 If	 the	mechanism	of	toxicity	of	O-
AcSHA-H	proceeds	via	 inhibition	of	COX	then	 it	 is	conceivable	that	 the	 lower	activity	
could	be	 the	 result	of	 the	 inability	of	 the	acetyl	 group	 to	acetylate	 the	Ser530	of	 the	
active	 site	 of	 COX	 if	 the	 Bi(O-AcSHA)3	 remains	 intact	 inside	 the	 cell.	 	 In	 order	 to	
explicitly	 prove	 that	 this	 is	 the	 case,	 further	 work	 to	 determine	 the	 exact	 chemical	
nature	 of	 the	 complex	 in	 the	 cell	 would	 be	 required;	 however,	 this	 would	 be	 quite	
challenging.	 	 In	 addition,	 COX	 inhibition	 assays	 (with	 and	 without	 cells)	 should	 be	
performed.	 	Additionally,	 ELISA	 assays	 may	 be	 utilised	 to	 assess	 the	 ability	 of	
Bi(O-AcSHA)3	 and	O-AcSHA-H	 to	 inhibit	PGE2	production	 in	order	 to	determine	how	
effectively	 the	 compounds	 inhibit	 intracellular	 COX	 in	 vitro	 (as	 performed	 in	
Chapter	2).	
The	 improved	 toxicity	 of	 BHA-H	 (IC50	 =	 582	 μM)	 over	 SHA-H	 (IC50	 >	 2000	 μM)	
may	 be	 attributed	 to	 the	 difference	 in	 the	 chemical	 structure	 and	 the	 resultant	
physicochemical	 properties.		 The	 same	 trend	 was	 observed	 in	 another	 study	 [51],	
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whereby	BHA-H	was	found	to	be	more	cytotoxic	than	SHA-H,	towards	neuroblastoma	
IMR-32	cells	 (IC50	=	218	μM	and	249	μM,	 respectively)	 following	48-h	 treatment.	 	 In	
the	 same	 study	 the	 Ru(III)	 complexes,	 [RuCl(H2O)BHA2]	 and	 [RuCl(H2O)SHA2],	 also	
showed	 toxicity	 towards	 the	 IMR-32	cells	 (IC50	=	166	μM	and	221	μM,	 respectively);	
however,	the	Ru(III)	complexes	would	be	considered	less	toxic	when	accounting	that	
there	are	two	moles	of	ligand	per	mole	of	Ru(III).	 	It	is	notable	that	[RuCl(H2O)BHA2]	
was	determined	to	be	more	toxic	than	[RuCl(H2O)SHA2],	which	is	consistent	with	the	
trend	observed	for	the	Bi(BHA)3	and	Bi(SHA)3	complexes	assessed	in	Section	6.3.1.		
The	 chemical	 structures	 of	 BHA-H	 and	 SHA-H	 differ	 only	 by	 the	 presence	 of	 a	
phenolic	 –OH	 group	 in	 the	 SHA-H	 structure.	 	Pathak	 et	 al.	 [4]	 determined	 that	 the	
bidentate	complexation	of	Bi(III)	to	these	ligands	occurs	through	the	carbonyl	and	the	
hydroxamic	acid	–OH	group.	 	The	pKa	values	of	 the	hydroxamic	acid	group	of	BHA-H	
and	 SHA-H	 have	 been	 reported	 as	 8.71	 and	 7.40,	 respectively	 [52].		 The	 SHA-H	
hydroxamic	acid	proton	is	more	acidic	due	to	intramolecular	bonding	of	the	conjugate	
base	with	the	phenolic	OH	(pKa	9.81)	[52].		Due	to	the	higher	pKa,	the	BHA	ligand	may	
elicit	 a	 stronger	 affinity	 for	 Bi	 at	 physiological	 pH	 (which	 is	 maintained	 in	 the	 cell	
medium)	 compared	 to	 SHA;	 hence	 the	 increased	 propensity	 for	 coordination	 may	
improve	the	stability	and	toxicity	of	the	Bi(BHA)3	complex.		
Alternatively,	 it	 cannot	be	 ruled	out	 that	 the	BHA-H	structure	provides	a	higher	
affinity	towards	an	enzyme	important	to	cancer	cell	function.		For	instance,	BHA-H	and	
SHA-H	 both	 inhibit	 the	 enzyme	 ribonucleotide	 reductase	 [53],	 which	 catalyses	 the	
formation	of	deoxyribonucleotides	from	ribonucleotides.		In	one	study,	SHA-H	activity	
was	 higher	 than	 BHA-H	 (IC50	=	 150	μM	 and	 400	 μM,	 respectively)	 when	 assessed	
against	purified	enzymes	 [53];	however,	 these	experiments	do	not	 take	 into	account	
the	cell	medium	or	intracellular	environment	of	the	compounds.		BHA-H	has	also	been	
shown	 to	be	 a	potent	 inhibitor	of	 histone	deacetylase	6	 [54].	While	determining	 the	
aqueous	stability,	uptake	and	mechanisms	of	action	was	beyond	the	scope	of	the	aims	
of	this	Chapter,	these	criteria	could	be	potentially	examined	in	future	studies.	 	
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6.5 Chapter	summary	
The	 overall	 aim	 of	 this	 Chapter	 was	 to	 determine	 the	 cytotoxicity	 of	 Bi(III)	
derivatives	of	aminoarenesulfonic	acids,	indole-carboxylic	acids,	and	hydroxamic	acids	
against	 the	 human	 colorectal	 cancer	 cell	 line,	 HCT-8,	 in	 order	 to	 identify	 new	 lead	
compounds	 for	 future	 studies.	 	The	 results	 obtained	 from	 the	MTT	 assays	 indicated	
that	the	toxicity	of	the	complexes	is	highly	variable	with	respect	to	the	ligands	in	the	
Bi(III)	complex.		Specific	observations	included	the	following:	
i. Bi(III)	 aminoarenesulfonates	 displayed	 no	 toxicity	 towards	 HCT-8	 cells	
with	 the	 exception	 of	 Bi(4A3HN-SO3)3,	 which	 demonstrated	 reasonably	
high	 toxicity,	 which	 was	 superior	 to	 the	 anti-cancer	 drug,	 cisplatin.	
Additionally,	 the	 IC50	 value	 obtained	 for	 Bi(4A3HN-SO3)3	 was	
approximately	11	times	lower	than	4A3HN-SO3H.	
ii. Bi(III)	 indole-carboxylates,	 Bi(IGA)3	 and	 Bi(ILA)3,	 displayed	 the	 highest	
toxicities	 towards	the	HCT-8	cells,	which	were	superior	 to	 the	anti-cancer	
drug,	 cisplatin.	 	 Bi(III)	 coordination	 enhanced	 the	 toxicity	 of	 the	 free	
ligands,	which	showed	little	toxicity	against	the	HCT-8	cells	(up	to	2	mM).	
iii. Bi(III)	 hydroxamates,	 Bi(BHA)3	 and	 Bi(SHA)3,	 showed	 higher	 toxicity	
against	 the	 HCT-8	 cells	 compared	 to	 the	 free	 ligands,	 BHA-H	 and	 SHA-H.	
Conversely,	 the	 toxicity	 of	 Bi(O-AcSHA)3	was	 lower	 than	O-AcSHA-H.	 The	
IC50	values	of	Bi(BHA)3	and	Bi(SHA)3	were	2-3	times	lower	than	cisplatin.			
This	 Chapter	 confirms	 for	 the	 first	 time	 that	 Bi(III)	 derivatives	 of	 selected	
aminoarenesulfonic	 acids,	 indole-carboxylic	 acids,	 and	 hydroxamic	 acids	 display	
cytotoxicity	 towards	 a	 human	 colon	 cancer	 cell	 line	 in	 vitro.	 	 The	Bi(IGA)3,	 Bi(ILA)3,	
and	Bi(4A3HN-SO3)3	complexes	showed	promising	toxicity,	which	was	comparable	to	
Bi(tolf)3,	 assessed	 in	Section	2.3.2.	 	This	 is	 an	 important	 result	 and	warrants	 further	
investigation	 into	 the	 solution	 stability,	 drug	 uptake,	mechanisms	 of	 action,	 and	 the	
toxicity	 of	 these	Bi(III)	 complexes	 against	 normal	 cells	 (e.g.	 fibroblast,	 hPBMCs)	 and	
other	cancer	cell	 lines.	 	Although	many	of	the	complexes	tested	in	this	study	showed	
positive	activity	against	 the	HCT-8	colon	cancer	cells,	 the	activity	of	Bi(4A3HN-SO3)3	
against	a	non-cancerous	cell	line	remains	to	be	tested	in	order	to	assess	the	degree	of	
selectivity	and	subsequent	adverse	side	effects.		Further	studies	investigating	whether	
these	Bi(III)	complexes	possess	any	anti-tumour	activity	in	vivo	could	also	potentially	
be	pursued.	 	
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7.1			Conclusions	
CRC	 is	 the	 second	most	 common	 cancer	 in	 both	 men	 and	 women	 in	 Australia.		
As	the	incidence	of	CRC	has	not	improved	since	the	1980s,	chemoprevention	(the	use	
of	a	pharmacological	or	nutritional	agent	to	prevent,	reverse,	or	delay	the	progression	
of	carcinogenesis)	has	been	suggested	as	a	primary	prevention	strategy	to	reduce	the	
burden	 of	 this	 disease.	 	The	 upregulation	 of	 COX-2,	 an	 enzyme	 expressed	 during	
inflammation	 response,	 has	 been	 linked	 to	 a	 number	 of	 cancers,	 including	 CRC.		
As	such,	inhibition	of	COX-2	may	present	a	target	for	chemoprevention/chemotherapy.		
To	 this	 end,	 over-the-counter	 COX	 inhibitors,	 NSAIDs,	 have	 been	 investigated	 as	
potential	 chemopreventives.	 	Several	 epidemiological	 and	 clinical	 studies	 provided	
evidence	that	NSAIDs	(in	particular,	aspirin	and	sulindac)	reduce	the	risk	of	CRC	when	
taken	 regularly	 over	 periods	 of	 months	 to	 years.	 	However,	 side	 effects,	 such	 as	
GI	bleeding,	 CV	 abnormalities	 and	 hepatotoxicity,	 limit	 the	 daily	 use	 of	 NSAIDs	 over	
prolonged	 periods	 of	 time.	 	As	 such,	 a	 method	 to	 make	 NSAIDs	 safer	 for	 long-term	
administration	 is	 needed,	 without	 diminishing	 the	 chemotherapeutic	 potential	 of	
the	NSAIDs.	
Several	studies	have	shown	that	a	number	of	metal-NSAID	complexes	reduce	the	
formation	of	GI	ulceration	compared	to	the	non-complexed	NSAIDs	in	animal	models.		
Importantly,	[Cu2(indo)4(DMF)2]	reduced	aberrant	crypt	formation	in	the	rodent	colon	
cancer	 model,	 while	 also	 exhibiting	 GI	 sparing	 properties.			Bismuth,	 a	 group	 15	
post-transition	metal,	has	been	used	to	treat	an	array	of	GI	diseases	for	centuries,	with	
an	acceptable	toxicity	profile	at	low	doses	when	administered	over	extended	periods.		
Thus,	 it	 is	hypothesised	 that	 the	combination	of	Bi	 and	NSAID	 in	a	 single	 compound	
may	 potentially	 relieve	 the	 adverse	 GI	 side	 effects	 of	 NSAIDs	 if	 used	 daily	 as	 a	
chemopreventive	 agent.				 To	 this	 end,	 the	 suitability	 of	 Bi	 complexes	 of	
NSAIDs		 (BiNSAIDs)	 as	 potential	 chemotherapeutics	 or	 chemopreventives	 needs	 to	
be	examined.		
In	 order	 to	 determine	 the	 suitability	 of	 the	 BiNSAIDs,	 Bi(tolf)3,	 Bi(mef)3	 and	
Bi(difl)3,	 as	 a	 potential	 chemotherapeutic	 or	 chemopreventive	 agents	 against	 CRC,	 it	
was	necessary	to	evaluate	the	in	vitro	potential	of	the	BiNSAIDs	as	a	prelude	to	future	
work	 that	 would	 involve	 in	 vivo	 studies.	 	 The	 experiments	 described	 in	 this	 Thesis	
were	 divided	 into	 two	 goals:	 (i)	 to	 establish	 the	 chemotherapeutic	 potential	 of	
BiNSAIDs	by	determining	whether	BiNSAIDs	are	able	to	kill	transformed	cells	(toxicity	
and	 cell	 death	 assays),	 and	 (ii)	 to	 establish	 whether	 BiNSAIDs	 demonstrate	
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chemopreventive	potential	by	determining	whether	BiNSAIDs	are	able	 to	 inhibit	 the	
production	 of	 PGE2	 (and	 thus	 inhibit	 COX)	 in	 transformed	 cells.	 	 A	 human	 epithelial	
ileocecal	colon	cancer	cell	 line,	HCT-8,	was	employed	as	a	model	CRC	cell	 line	for	the	
evaluation	 of	 the	 BiNSAIDs,	 and	 the	 respective	 uncomplexed	 NSAIDs,	 tolfH,	 mefH	
and	diflH.	
One	specific	aim	of	this	project	was	to	compare	the	toxicity	of	BiNSAIDs	to	that	of	
the	 uncomplexed	 NSAIDs.	 	The	 toxicity	 of	 the	 BiNSAIDs	 and	 NSAIDs	 towards	 the	
HCT-8	cells	was	assessed	using	the	MTT	assay	(Chapter	2).	 	The	results	showed	that	
the	 toxicity	 ranking	 of	 the	 BiNSAIDs	 paralleled	 those	 of	 the	 respective	 free	
NSAIDs:	diflH	<	mefH	<	tolfH.		While	the	IC50	values	of	the	BiNSAIDs	(ranging	between	
16−81	μM)	 were	 lower	 than	 the	 free	 NSAIDs	 (ranging	 between	 37−403	μM),	 it	 was	
apparent	that	the	toxicity	of	the	BiNSAIDs	was	reflective	of	the	molar	ratio	of	the	three	
NSAID	molecules	contained	in	the	BiNSAIDs,	with	the	exception	of	Bi(difl)3.		One	of	the	
most	 important	results	 from	the	MTT	assays	was	the	micromolar	 toxicity	of	Bi(tolf)3	
and	 Bi(mef)3	 towards	 HCT-8	 cells	 which	 was	 comparable	 to	 the	 anti-cancer	 drug,	
cisplatin	(IC50	=	16	μM,	41	μM,	and	50	μM,	respectively).	
The	mechanism	of	 cell	 death	was	 investigated	using	 phase	 contrast	microscopy	
and	 AnnV/7AAD	 staining	 (Chapter	 2).		 The	 results	 from	 these	 experiments	 showed	
that	 treatment	 with	 all	 BiNSAIDs	 and	 NSAIDs	 induced	 morphological	 changes	
indicative	of	cell	death	via	apoptosis.		When	considered	with	the	results	from	the	MTT	
assays,	it	appeared	most	likely	that	the	NSAID	is	the	main	contributor	of	the	toxicity	of	
the	BiNSAID	complexes.		The	experiments	described	in	Chapter	2	showed	for	the	first	
time	 that	 BiNSAIDs	 exhibit	 potential	 anti-cancer	 activity	 towards	 a	 human	 colon	
cancer	 cell	 line	 in	 vitro	 and	 that	 cell	 death	 occurred	 via	 apoptotic	 pathway.	
Furthermore,	 the	 toxicity	of	 the	BiNSAIDs	was	 similar	or	 improved	compared	 to	 the	
respective	NSAIDs,	indicating	that	the	complexation	with	Bi	did	not	negatively	impact	
the	bioactivity	of	the	NSAIDs.	
The	 second	 focus	 of	 the	 in	 vitro	 studies	was	 to	 determine	 if	 the	BiNSAID	 could	
inhibit	COX	activity	in	the	colon	cancer	cells	since	this	was	the	underlying	mechanism	
that	 had	been	hypothesised	 for	NSAID	 chemopreventive	 behaviour.	 	 As	 such,	 assays	
were	performed	to	determine	whether	complexation	with	Bi	affects	the	ability	of	the	
NSAIDs,	 tolfH,	 mefH	 and	 diflH,	 to	 interact	 with	 COX	 in	 vitro,	 by	 quantifying	 PGE2	
production	by	HCT-8	cells	(Chapter	2).		The	inhibition	of	the	prostaglandin,	PGE2,	was	
studied	since	PGE2	has	an	established	role	in	the	promotion	of	cancer	cell	growth	and	
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fortification	 (Fig.	 1.5).	 	The	 results	 showed	 that	 the	 inhibition	of	PGE2	production	of	
HCT-8	cells	treated	with	the	BiNSAIDs	paralleled	those	of	the	respective	free	NSAIDs:	
diflH	 <	 mefH	 <	 tolfH.		 There	 are	 two	 important	 conclusions	 from	 these	
experiments.		Firstly,	the	results	indicated	that	the	anti-cancer	effects	of	the	examined	
NSAIDs	were	 not	 substantially	 diminished	 by	 the	 coordination	 of	 Bi	 to	 the	 NSAIDs.		
Furthermore,	 the	 results	 confirmed	 that	 treatment	 of	 HCT-8	 cells	 with	 BiNSAIDs	
caused	 a	 reduction	 in	 PGE2	 (via	 COX	 inhibition),	which	 is	 one	 of	 the	mechanisms	 of	
action	hypothesised	for	the	NSAID-chemoprevention	of	CRC.	
Once	 the	 biological	 potential	 of	 the	 BiNSAIDs	 had	 been	 established	 in	 vitro,	
Bi	uptake	and	localisation	studies	were	performed	to	further	probe	their	intracellular	
behaviour.	 	Bi	 uptake	 was	 quantified	 using	 GFAAS	 (Chapter	 3)	 where	 the	 highest	
cellular	 Bi	 was	 observed	 following	 treatment	 with	 Bi(tolf)3.		 Since	 the	 NMR	 studies	
(Chapter	 2)	 indicated	 that	 Bi(tolf)3	 was	 the	most	 stable	 BiNSAID	 in	 cell	 medium,	 it	
appears	 that	 Bi	 uptake	 is	 most	 likely	 facilitated	 by	 the	 NSAID.	 	Treatment	 with	
Bi(mef)3	and	Bi(difl)3	resulted	in	substantial,	but	much	lower	uptake	of	Bi	compared	to	
Bi(tolf)3,	 which	 correlated	 with	 their	 lower	 toxicities	 and	 increased	 reactivity	
(potential	dissociation)	in	cell	medium	as	determined	by	NMR	spectroscopy.	
Microprobe	 SRXRF	 imaging	 (Chapter	 3)	 showed	 that	 the	 intracellular	 fate	 of	 Bi	
was	 similar	 for	 all	 BiNSAID	 treatments	 irrespective	 of	 the	 coordinated	 NSAID.		
For		instance,	 all	 BiNSAID-treated	 cells	 showed	 Bi	 accumulation	 in	 the	 cytoplasm	
within	24-h	exposure,	typically	in	discrete	hot	spots.		A	number	of	possible	reasons	for	
the	localisation	(including	targeting	of	the	nucleus	and	mitochondria)	were	considered	
and	two	more	feasible	options	were	concluded	based	on	correlation	maps	and	reports	
from	the	literature.		The	first	was	that	hot	spots	correlated	with	lysosomes	since	the	Bi	
location	and	the	size	of	the	hot	spots	(0.3–5.8	μm2)	were	consistent.		It	was	postulated	
that	 this	packaging	of	Bi	might	be	 the	cells	mechanism	of	detoxification.	 	As	many	of	
the	hot	spots	were	located	near	the	nucleus,	and	acknowledging	that	COX-2	is	located	
the	 on	 nuclear	 membrane,	 the	 SRXRF	 results	 also	 indicate	 that	 Bi	 is	 capable	 of	
intracellular	 movement.	 	 In	 the	 instance	 that	 the	 BiNSAID	 has	 remained	 intact	 this	
would	 suggest	 that	 BiNSAIDs	 could	 locate	 in	 the	 vicinity	 of	 and	 target	 COX-2.	 	It	 is	
important	to	note,	however,	that	the	experimental	methods	utilised	in	this	study	only	
provided	 information	about	 the	uptake	and	 localisation	of	Bi.	 	Consequently,	 it	 is	not	
possible	 to	make	any	evidence-based	 conclusions	about	 the	uptake	and	 intracellular	
fate	of	the	NSAIDs.		While	this	could	be	addressed	by	tagging	the	NSAID,	this	too	would	
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be	inconclusive	if	the	tagging	altered	the	cellular	distribution	of	the	BiNSAID.	
SR-IRMS	was	utilised	to	probe	cellular	biomolecular	changes	associated	with	the	
treatment	 of	 live	HCT-8	 cells	with	 BiNSAIDs	 and	NSAIDs	 (Chapter	 4).	 	 A	 number	 of	
factors	 were	 considered	 when	 analysing	 the	 spectra	 obtained	 from	 the	 live	 cell	
populations.	 	Firstly,	 while	 live	 cell	 analysis	 can	 reduce	 spectral	 artifacts,	 such	 as	
RMieS,	the	IR	spectra	of	water	contains	a	vibrational	mode	(visualised	as	a	broad	band	
at	~1643	cm−1)	that	overlaps	with	the	amide	I	band,	and	to	a	lesser	extent	the	amide	II	
band.		The	concern	is	that	this	can	result	in	the	distortion	of	the	intensity	ratio	of	the	
amide	 I/amide	 II	bands,	 thus	confounding	biomolecular	changes	resulting	 from	drug	
treatment.		In	order	to	determine	whether	the	water	band	substantially	influences	the	
biological	 information	 contained	 in	 the	 amide	 region,	 a	 correction	 strategy	 was	
applied	to	remove	the	water	bands	from	the	cell	spectra.		The	resultant	PCA	scores	and	
loadings	 plots	 revealed	 very	 little	 difference	 before	 and	 after	 the	 application	 of	 the	
water	band	correction	applied	in	this	study.		However,	due	to	continued	debate	in	the	
literature	about	the	ideal	correction	strategy,	more	work	will	need	to	be	performed	in	
this	area.	
	Subsequently,	the	SR-IRMS	cell	spectra	were	analysed	in	two	ways,	whereby	the	
spectra	were	analysed	with	and	without	the	inclusion	of	the	amide	region.		It	was	clear	
from	the	PCA	scores	plots	that	intra-sample	and	inter-sample	variance	existed	within	
the	 vehicle-,	 BiNSAID-,	 and	 NSAID-treated	 populations.	 	Examination	 of	 the	 PCA	
loadings	 plots	 indicated	 that	 in	 the	 majority	 of	 BiNSAID-	 and	 NSAID-treated	 cell	
populations,	the	loadings	associated	with	lipids	dominated	the	PCA	loadings	plots.		
Following	4-h	treatment,	Bi(tolf)3	and	tolfH	induced	similar	biomolecular	effects	
on	 the	HCT-8	 cells	 in	 comparison	 to	 the	 vehicle,	which	were	primarily	 attributed	 to	
effects	 on	 the	 lipids	 with	 some	 contribution	 from	 proteins.	 	However,	 following	
removal	 of	 the	 amide	 region,	 discrimination	 between	 the	 two	 compounds	 was	
apparent	and	attributable	to	ν(C=O)	and	νas(PO2−),	suggestive	of	difference	in	the	effect	
of	the	two	compounds	on	phospholipids.		Bi(mef)3	or	mefH	induced	similar	effects	on	
the	HCT-8	cells,	which	were	primarily	attributed	to	lipids.		DiflH	induced	biomolecular	
effects	 on	 the	 HCT-8	 cells,	 which	 were	 primarily	 attributed	 to	 proteins.	 	However,	
following	amide	removal	from	PCA	analysis,	diflH	no	longer	showed	any	changes	from	
the	vehicle.	 	 Treatment	with	Bi(difl)3	was	distinguishable	 from	diflH	and	 the	vehicle	
following	amide	removal,	which	was	primarily	attributed	to	lipids.	
Following	24-h	treatment,	tolfH	induced	biomolecular	effects	on	the	HCT-8	cells,	
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which	 were	 primarily	 attributed	 to	 a	 possible	 reduction	 in	 lipids	 with	 some	
contribution	 from	 proteins.	 	Treatment	 of	 the	 cells	 with	 Bi(tolf)3	 induced	 a	 varied	
response	within	the	Bi(tolf)3-treated	population.	 	Treatment	with	Bi(mef)3	and	mefH	
induced	 similar	 biomolecular	 effects	 on	 the	 HCT-8	 cells,	 which	 were	 primarily	
attributed	to	lipids.		This	result	might	be	a	reflection	of	the	Bi(mef)3	dissociation	such	
that	 the	effect	of	Bi(mef)3	 treatment	 is	primarily	attributable	 to	mefH.		 Interestingly,	
treatment	 with	 Bi(difl)3	 resulted	 in	 no	 distinguishable	 difference	 from	 the	 vehicle-
treated	cell	SR-IRMS	spectra.		However,	treatment	with	diflH	was	distinguishable	from	
Bi(difl)3	 and	 vehicle	 scores,	 which	 was	 primarily	 attributed	 to	 a	 strong	 association	
with	 lipids.	 	 This	 was	 due	 to	 a	 large	 increase	 in	 the	 lipids	 contributions	 that	 were	
visualised	in	the	averaged	SR-IRMS	spectra	of	the	24-h	diflH-treated	cells.	
Recognising	that	an	overall	change	 in	 lipids	was	 the	dominant	observation	 from	
the	SR-IRMS	experiments,	ESI-MS/MS	was	used	as	a	complimentary	technique	to	shed	
light	on	whether	 lipid	changes	were	truly	associated	with	BiNSAID/NSAID	treatment	
rather	 than	 intra-sample	 variation.	 	The	 most	 abundant	 glycerophospholipids	 in	
mammalian	cells,	PC,	PE	and	PS,	were	chosen	as	a	 starting	point	 to	begin	examining	
the	effects	of	BiNSAID/NSAID	treatment.			
The	 changes	 to	 the	 abundance	of	 the	 individual	PC,	 PE	 and	PS	molecules	 in	 the	
overall	 profiles	 of	 the	 Bi(tolf)3-	 and	 Bi(difl)3-treated	 cells,	 and	 the	 respective	
NSAID-treated	 cells,	 displayed	many	 similar	 changes	when	 compared	 to	 the	 vehicle-
treated	 cells.	 	There	 were	 some	 differences	 between	 the	 changes	 induced	 by	
Bi(tolf)3/tolfH	 treatments	 compared	 to	 the	 Bi(difl)3/diflH	 treatments.	 	When	 the	 PC	
and	 PE	 molecules	 were	 grouped	 according	 to	 fatty	 acid	 categories,	 the	 observed	
changes	in	the	Bi(tolf)-	and	tolfH-treated	cells	were	similar	to	each	other	and	showed	
a	 significant	decrease	 in	 the	 contribution	of	unsaturated	PC	and	PE	molecules,	but	a	
significant	increase	in	ether-linked	molecules.		The	results	obtained	from	the	Bi(difl)3-	
and	 diflH-treated	 cells	 showed	 similar	 changes	 in	 the	 grouped	 PE	 profile,	 but	
conversely,	 the	 reverse	 trend	was	 observed	 in	 the	 grouped	PC	profiles	whereby	 the	
contribution	 of	 the	 unsaturated	 PC	 and	 PE	 molecules	 significantly	 increased,	 but	 a	
significant	 decrease	 in	 ether-linked	molecules	was	 observed.	 	This	may	 suggest	 that	
while	 Bi(tolf)3	 and	 Bi(difl)3	 both	 induced	 cell	 death	 via	 apoptosis,	 the	 biomolecular	
events	 that	 precede	 or	 occur	 during	 apoptosis	 differ	 between	 the	 two	 complexes	
whereby	the	HCT-8	cells	respond	differently	to	the	fenamate	compounds	compared	to	
the	salicylate	compounds.	
Chapter	7.	Conclusions	and	Future	Directions	
	281	
Additionally,	 changes	were	observed	 in	 the	 relative	concentration	of	PC,	PE	and	
PS	 in	 the	 BiNSAID	 and	 NSAID-treated	 cells	 compared	 to	 the	 vehicle-treated	 cells.		
However,	 when	 the	 PC	 and	 PE	 molecules	 were	 grouped	 according	 to	 fatty	 acid	
categories,	 it	 was	 observed	 that	 there	 were	 some	 differences	 to	 the	 overall	 trend	
between	 the	 Bi(tolf)3	 and	 tolfH-treated	 cells	 compared	 to	 the	 vehicle-treated	 cells.	
Specifically,	 an	 overall	 decrease	 in	 the	 relative	 concentrations	 of	 PC,	 PE	 and	 PS	was	
also	 observed.		 This	 result	 was	 consistent	 with	 literature	 reports	 that	 PC	 and	 PE	
concentrations	 are	 reduced	 in	 apoptotic	 cells,	 and	 the	 SR-IRMS	 studies,	 which	
suggested	 that	 tolfH	 (and	 potentially	 Bi(tolf)3)	 were	 associated	 with	 lower	 lipid	
content.		
	In	 contrast,	 some	 variation	 was	 observed	 between	 the	 response	 elicited	 by	
Bi(difl)3	compared	to	diflH,	whereby	the	diflH-treated	cells	exhibited	lower	PC,	PE	and	
PS	 than	 the	 Bi(difl)3-treated	 cells.				This	 was	 inconsistent	 with	 the	 SR-IRMS	
experiments	that	showed	that	diflH-treated	cells	were	associated	with	increased	lipid	
content	 in	 the	 PCA	 results	 (24-h	 results).	 	As	 such,	 this	 result	 may	 indicate	 that	
glycerophospholipids	 (specifically	 PC,	 PE	 and	 PS)	 were	 not	 associated	 with	 the	
increase	 in	 the	 lipid	 signals	and	 that	other	 lipids,	 including	neutral	 lipid	classes	 (e.g.	
cholesterol	esters,	triacylglycerides)	should	be	examined	in	future	studies.	
Encouraged	 by	 the	 promising	 in	 vitro	 anti-cancer	 activity	 of	 the	 BiNSAIDs	
against	the	 HCT-8	 cells,	 and	 recognising	 that	 Bi	 itself	 possesses	 anti-cancer	
activity		 (Section	1.4.1.4),	 several	 Bi(III)	 complexes	 of	 aminoarenesulfonates,	
indole-carboxylates,	 hydroxamates	 were	 screened	 for	 potential	 anti-cancer	 activity	
in	vitro	using	the	MTT	assay.	 	The	complexes	were	chosen	for	 investigation	since	the	
aforementioned	chemical	classes	comprise	examples	of	biologically	active	molecules,	
including	anti-cancer	drugs.		The	results	from	the	MTT	assays	showed	that	of	the	five	
Bi(III)-aminoarenesulfonate	 complexes	 tested,	 only	 Bi(4A3HN-SO3)3	 and	 its	 ligand,	
4A3HN-SO3H,	 displayed	 toxicity	 (IC50	 =	 12	μM	 and	 131	 μM,	 respectively)	 in	 the	
concentration	range	tested	(up	to	2	mM).		The	Bi(III)	indole-carboxylates,	Bi(IGA)3	and	
Bi(ILA)3,	displayed	two	of	the	highest	IC50	values	(10	μM	and	17	μM,	respectively)	of	
all	 the	 tested	 Bi(III)	 complexes	 assayed	 in	 this	 Thesis,	 and	 were	 superior	 to	 the	
anti-cancer	drug,	cisplatin	(IC50	=	50	μM)	when	tested	in	the	HCT-8	cells.		In	contrast,	
the	 free	 ligands,	 IGA-H	 and	 ILA-H	 showed	 little	 to	 no	 toxicity	 against	 the	 HCT-8	
cells	(up	to	2	mM)	indicating	that	the	complexation	to	Bi	is	essential	for	toxicity.		The	
Bi(III)	hydroxamates,	Bi(BHA)3	and	Bi(SHA)3,	 showed	higher	activity	 (IC50	=	106	μM	
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and	 159	μM,	 respectively)	 against	 the	 HCT-8	 cells	 than	 that	 expected	 for	 the	molar	
equivalent	 of	 the	 free	 ligands	 BHA-H	 and	 SHA-H	 (IC50	 =	 582	 μM	 and	 >	 2,000	 μM,	
respectively).	 	 Conversely,	 the	 toxicity	 of	 Bi(O-AcSHA)3	 was	 lower	 than	 O-AcSHA-H		
(IC50	=	>	1,000	μM	and	94	μM,	respectively).		
The	studies	reported	in	this	Thesis	suggest	that	Bi(tolf)3	is	a	strong	candidate	for	
further	 testing	 in	 an	 animal	model.	 	 Specifically,	 the	 Bi(tolf)3	 complex	was	 the	most	
potent	BiNSAID	 towards	 cancer	 cells	 in	 vitro	 (displaying	 toxicity	 at	 a	physiologically	
relevant	 concentration),	 and	 appeared	 to	 maintain	 stability	 in	 the	 aqueous	
environment	 used	 to	 simulate	 physiological	 conditions	 in	 vitro.	 	Additionally,	 the	
Bi(tolf)3	 showed	 similar	 ability	 to	 inhibit	 the	 production	 of	 PGE2	 (Chapter	 2)	 and	
induced	similar	changes	to	the	phospholipid	profile	compared	to	tolfH	at	an	equimolar	
treatment	concentration.		
7.2				Future	Directions	
Overall,	 the	 results	 reported	 in	 this	 Thesis	 indicate	 that	 BiNSAIDs	 display	
potential	 chemotherapeutic	 and	 chemopreventive	 properties	 against	 transformed	
cells	 in	vitro.	 	In	addition	to	the	future	directions	suggested	in	the	previous	Chapters,	
the	longer	term	direction	of	the	projects	should	include	two	general	aims:	(i)	 further	
in	vitro	 work,	 including	 screening	 against	 other	 cancer	 and	 healthy	 cell	 lines,	 and	
(ii)	ultimately,	in	vivo	studies.	
The	studies	reported	in	this	Thesis	were	purposely	limited	to	one	cell	line	to	gain	
a	 fundamental	 understanding	 of	 the	 interactions	 of	 BiNSAIDs	with	 a	 representative	
CRC	cell	line.		In	future	studies,	it	would	be	of	interest	to	assess	whether	the	BiNSAIDs	
display	 greater	 potency	 towards	 cell	 lines	 that	 overexpress	 COX-2	 (e.g.	HT-29	 colon	
cancer	cells)	compared	to	a	cell	line	that	exhibits	no	expression	of	COX-2	(e.g.	HCT-116	
colon	 cancer	 cells),	 and	 thus	 whether	 there	 is	 any	 correlation	 between	 COX-2	
expression	and	BiNSAID	toxicity.		These	experiments	have	been	commenced	by	Dillon,	
Brown	and	Ranson	(personal	communication).		It	is	anticipated	that	these	studies	will	
provide	 insight	 into	 whether	 the	 inhibition	 of	 COX-2	 or	 other	 off-target	 effects	 are	
essential	 for	 the	 in	 vitro	 toxicity	 of	 BiNSAIDs.	 	Furthermore,	 BiNSAIDs	 could	 also	 be	
assessed	 in	 vitro	 against	 other	 types	 of	 GI	 cancer	 cell	 lines,	 including	 esophageal,	
gastric	 and	 other	 cancers	 of	 the	 upper	 intestinal	 tract.	 	 It	 will	 also	 be	 essential	 to	
determine	 whether	 the	 BiNSAIDs	 display	 any	 toxicity	 towards	 non-cancerous	 cells	
including	 primary	 fibroblasts	 (as	 a	 non-cancerous	 colon	 cell	 line)	 and	
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hPBMCs	(isolated	from	human	blood).	
In	order	for	the	BiNSAIDs	to	have	any	potential	for	use	as	chemotherapeutics	or	
chemopreventives,	several	outcomes	must	first	be	established	in	vivo.	 	These	include:	
(i)	 comparing	 the	 GI	 toxicity	 of	 the	 BiNSAIDs	 to	 the	 free	 NSAIDs	 following	 dosing	
(short-	 and	 long-term)	 in	 order	 to	 establish	 if	 the	 BiNSAIDs	 protect	 against	 GI	
ulceration;	 (ii)	 comparing	 the	 BiNSAIDs	 and	 NSAIDs	 for	 the	 prevention	 of	 tumour	
formation	 in	 the	 GI	 tract	 as	 a	measure	 of	 chemoprevention,	 and	 (iii)	measuring	 the	
accumulation	 of	 Bi	 in	 the	 GI	 tract	 and	 vital	 organs	 (such	 as	 the	 liver,	 kidneys,	 and	
brain)	in	order	to	determine	the	safety	of	the	BiNSAIDs	following	long-term	dosing.	
Based	 on	 the	 work	 presented	 here,	 studies	 to	 examine	 the	 aforementioned	
outcomes	have	been	commenced	(initially	for	Bi(indo)3,	indoH,	Bi(asp)3	and	aspH)	by	
Dillon	 and	 Brown,	 et	 al.	 using	 rodent	 models	 (personal	 communication).	
The	preliminary	data	shows	that	BiNSAIDs	are	able	to	reduce	the	formation	of	lesions	
in	 the	 small	 intestine	 of	 rats	 following	 a	 single	 dose	 (unpublished	 results).	 	 A	 long-
term	 study	 is	 planned	 whereby	 the	 ability	 of	 the	 BiNSAIDs	 to	 prevent	 tumour	
formation	 in	 an	 azoxymethane/dextran	 sulfate	 sodium	 colitis	 mouse	 model.		
As		discussed	 in	 Section	 1.4.2,	 the	 accumulation	 of	 Bi	 in	 animal	 models	 has	 been	
established	 and	Bi	 toxicity	 has	 occurred	 in	 humans	 (albeit	 patients	who	 have	 taken	
extremely	large	doses	of	Bi).	 	As	such,	it	 is	important	that	animal	studies	address	the	
potential	for	accumulation	and	toxicity	of	Bi	following	treatment	with	BiNSAIDs.		The	
accumulation	of	Bi	 in	 the	organs	of	 the	mice	dosed	with	BiNSAIDs	will	 be	examined	
using	 GFAAS	 to	 provide	 insight	 into	 the	 potential	 for	 Bi	 toxicity,	 and	 therefore,	 the	
safety	of	the	BiNSAIDs	(Dillon	and	Brown	et	al.,	personal	communication).		
Overall,	 the	 results	 reported	 in	 this	 Thesis	 provide	 an	 indication	 that	 BiNSAIDs	
display	chemotherapeutic	and	chemoprevention	properties	against	transformed	cells.		
The	SR-IRMS	and	lipid	ESI-MS/MS	experiments	indicate	that	the	mechanism	of	action	
of	 the	 BiNSAIDs	 may	 be	 multi-faceted	 and	 may	 provide	 a	 more	 robust	
chemotherapeutic	approach	than	some	traditional	chemotherapeutic	drugs,	whereby	
cancer	 cells	 often	 develop	 chemoresistance.		 Additionally,	 the	 employment	 of	
chemopreventive	medications	(particularly	 in	populations	at	risk	of	developing	CRC)	
could	 be	 beneficial	 to	 society	 and	 reduce	 the	 costs	 associated	 with	 treating	 cancer.		
Additional	 in	 vivo	 work	 will	 need	 to	 be	 performed	 in	 order	 to	 further	 reveal	 the	
therapeutic	potential	of	the	BiNSAIDs.	
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Appendix	1.		Additional	MTT	assay	and	PGE2	assay	results	
	
	
	
Appendix	1.1:	Concentration-response	curve	obtained	from	the	MTT	assay	of	DMSO	(%	v/v	in	
RPMI-1640)	in	HCT-8	cells	after	24-h	treatment.		Error	bars	represent	the	standard	deviation	
from	the	mean	(n	=	6).		One	representative	of	two	independent	experiments	is	shown.	 	
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Appendix	1.2:	Concentration-response	curves	obtained	from	the	MTT	assays	of:	(a)	tolfH	and	
Bi(tolf)3;	(b)	mefH	and	Bi(mef)3;	and	(c)	diflH	and	Bi(difl)3;	in	HCT-8	cells	after	4-h	treatment.		
Error	 bars	 represent	 the	 standard	 deviation	 from	 the	mean	 (n	 =	 6).	 	 One	 representative	 of	
three	independent	experiments	is	shown.		
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Appendix	1.3:	Concentration-response	curves	obtained	from	the	MTT	assays	of	cisplatin,	BiCl3	
and	 BSS	 after	 24-h	 treatment.	 	 Error	 bars	 represent	 the	 standard	 deviation	 from	 the	
mean	(n	=	6).		One	representative	of	three	independent	experiments	is	shown.	
	
	
Appendix	 1.4:	 PGE2	 production	 in	 HCT-8	 cells	 after	 4-h	 treatment	 with	 BSS.	 Results	 are	
expressed	as	mean	±	SD	(n	=	3	from	three	independent	experiments).	
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Appendix	1.5:	Concentration-response	curve	obtained	from	the	MTT	assays	of	aspH	in	HCT-8	
cells	after	24-h	treatment.		Error	bars	represent	the	standard	deviation	from	the	mean	(n	=	6).	
One	representative	of	three	independent	experiments	is	shown.	
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Appendix	2.	 Additional	 microprobe	 SRXRF	 thin-sectioned	 cell	
maps	
	
	
Appendix	2.1:	Graphite	furnace	operating	conditions	used	for	the	analysis	of	Bi.	
Stage	 Temperature		
(°C)	
Ramp		
(sec)	
Hold		
(sec)	
Gas	flow		
(mL.min-1)	
Dry	1	 110	 1	 30	 250	
Dry	2		 130	 15	 30	 250	
Ash	 1100	 10	 20	 250	
Atomisation	 1700	 0	 5	 0	
Clean	out	 2450	 1	 3	 250	
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Appendix	 2.2:	Microprobe	 SRXRF	 elemental	maps	 for	 toluidine-blue	 stained	 thin-section	 of	
HCT-8	cells	following	24-h	treatment	with:	(a)	vehicle	only;	(b)	Bi(difl)3	(40	μM);	(c)	Bi(mef)3	
(40	μM);	(d)	Bi(tolf)3	(40	μM),	and	(e)	BSS	(40	μM).		The	elements	are	specified	to	the	left	of	
each	row.		Operating	conditions	include:	beam	energy	=	13.45	keV,	beam	size	=	0.3	×	0.3	μm2;	
step	 size	 =	 0.3	 μm;	 dwell	 time	 =	 2.5	 s/pt	 and	 scan	 dimensions	 (H	 ×	 V)	 =	 (a)	 13	 ×	 13	 μm2;	
(b)	19	×	19	μm2;	(c)	17	×	14	μm2;	(d)	21	×	22	μm2	and	(e)	12	×	14	μm2.	
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Appendix	 2.3:	Microprobe	 SRXRF	 elemental	maps	 for	 toluidine-blue	 stained	 thin-section	 of	
HCT-8	cells	following	4-h	treatment	with	Bi(mef)3	(40	μM).		The	elements	are	specified	to	the	
left	 of	 each	 row.	 	 Operating	 conditions	 include:	 beam	 energy	 =	 13.45	 keV,	 beam	 size	 =	
0.3	×	0.3	μm2;	 step	 size	 =	 0.3	μm;	 dwell	 time	 =	 2.5	 s/pt	 and	 scan	 dimensions	 (H	 ×	 V)	 =	 (a),	
14	×	11	μm2;	(b)	22	×	14	μm2.	
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Appendix	2.5:	Correlative	 light	micrograph	of	a	toluidine-blue	stained	thin-section	of	HCT-8	
cells	 following	 24-h	 treatment	 with:	 (a)	 Bi(difl)3	 (40	 μM);	 (b)	 Bi(mef)3	 (40	μM);	 and	
(c)	Bi(tolf)3	 (40	 μM)	 and	 the	 corresponding	 microprobe	 SRXRF	 maps	 of	 P,	 Zn,	 Bi,	 and	 the	
colocalisation	 (Col)	 of	 the	 three	 elements.	 	 Operating	 conditions	 include:	 beam	 energy	 =	
13.45	keV,	 beam	 size	 =	 0.3	 ×	 0.3	μm2;	 step	 size	 =	 0.3	μm;	 dwell	 time	 =	 2.5	 s/pt	 and	 scan	
dimensions	 (H	 ×	 V)	 =	 (a)	 19	 ×	 16	μm2	 (i)	 and	 19	 ×	 19	μm2	 (ii);	 (b)	 22	 ×	 15	μm2	 (i)	 and	
17	×	14	μm2	(ii);	(c)	31	×	21	μm2	(i)	and	21	×	22	μm2	(ii).	
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Appendix	3.		Additional	SR-IRMS	spectra	
	
	
	
	
Appendix	3.1:	 (a)	Averaged	(n	=	54),	baseline	corrected	(rubberband	baseline	corrected,	64	
baseline	 points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 4-h	 incubation	 in	 vehicle	
(RPMI-1640,	 DMSO	 2%	 v/v)	 before	 (—)	 and	 after	 (—)	 water	 band	 compensation.	 Black	
arrows	 indicate	 the	 spectral	 features	 affected	 by	 water	 compensation.	 (b)	 Unit	 vector	
normalised,	second	derivative	of	the	spectra	shown	in	(a).	
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Appendix	 3.2:	 Averaged,	 baseline	 corrected	 (rubberband	 baseline	 corrected,	 64	 baseline	
points),	 vector	 normalised,	 HCT-8	 cell	 spectra	 following	 4-h	 incubation	 in	 cell	 medium	
(RPMI-1640;	— ,	n	=	54),	or	vehicle	(RPMI-1640,	2%	DMSO	v/v;	— ,	n	=	59):	(a)	without	the	
application	 of	 water	 band	 subtraction,	 and	 (b)	 following	 water	 band	 subtraction.	 The	
wavenumbers	 in	 black	 represent	 the	 medium-treated	 band	 positions,	 while	 band	 positions	
that	were	shifted	in	the	vehicle-treated	spectra	are	represented	in	red.	
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Appendix	3.3:	Averaged	second	derivative	(Savitzky	Golay,	13	smoothing	points),	unit	vector	
normalised,	 HCT-8	 cell	 spectra	 following	 4-h	 incubation	 in	 cell	 medium	 (RPMI-1640;	 — ,	
n	=	54),	or	vehicle	(RPMI-1640,	2%	DMSO	v/v;	— ,	n	=	59):	(a)	without	the	application	of	water	
band	 correction,	 and	 (b)	 following	 water	 band	 correction.	 The	 wavenumbers	 in	 black	
represent	 the	medium-treated	band	positions,	while	 band	positions	 that	were	 shifted	 in	 the	
vehicle-treated	spectra	are	represented	in	red	(sh	=	shoulder).	
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Appendix	 3.4:	 Averaged,	 baseline	 corrected	 (rubberband	 baseline	 corrected,	 64	 baseline	
points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 24-h	 incubation	 in	 cell	 medium	
(RPMI-1640	alone;	— ,	n	=	39),	or	vehicle	(RPMI-1640,	2%	DMSO	v/v;	— ,	n	=	54):	(a)	without	
the	 application	 of	 water	 band	 correction,	 and	 (b)	 following	 water	 band	 correction.	 The	
wavenumbers	 in	 black	 represent	 the	 medium-treated	 band	 positions,	 while	 band	 positions	
that	were	shifted	in	the	vehicle-treated	spectra	are	represented	in	red.	
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Appendix	3.5:	Averaged	second	derivative	(Savitzky	Golay,	13	smoothing	points),	unit	vector	
normalised,	HCT-8	cell	spectra	following	24-h	incubation	in	RPMI-1640	alone	(— ,	n	=	39),	or	
vehicle	 (RPMI-1640,	 2%	DMSO	 v/v;	— ,	 n	 =	 54):	 (a)	 without	 the	 application	 of	 water	 band	
correction,	and	(b)	following	water	band	correction.	The	wavenumbers	in	black	represent	the	
medium-treated	band	positions,	while	band	positions	that	were	shifted	in	the	vehicle-treated	
spectra	are	represented	in	red	(sh	=	shoulder).	
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Appendix	3.6:	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	vector	normalised	HCT-8	cell	spectra	following	4-h	incubation	in	vehicle	(RPMI-1640,	
DMSO	2%	v/v,	— ,	n	=	59),	Bi(tolf)3	(15	µM, — ,	n	=	45)	or	tolfH	(45	µM, — ,	n	=	29).		(b)	Unit	
vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
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Appendix	3.7:	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 24-h	 incubation	 in	 vehicle	
(RPMI-1640,	DMSO	2%	v/v,	— ,	 n	 =	 54),	 Bi(tolf)3	 (15	 µM, — ,	 n	 =	 33)	 or	 tolfH	 (45	 µM, — ,	
n	=	100).	(b)	Unit	vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
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Appendix	3.8:	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	vector	normalised	HCT-8	cell	spectra	following	4-h	incubation	in	vehicle	(RPMI-1640,	
DMSO	2%	v/v;	— ,	n	=	83),	Bi(mef)3	(40	µM, — ,	n	=	42)	or	mefH	(120	µM, — ,	n	=	54).	(b)	Unit	
vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
	 	
(a) 
(b) 
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Appendix	3.9:	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 24-h	 incubation	 in	 vehicle	
(RPMI-1640,	DMSO	2%	v/v;	— ,	n	=	54),	Bi(mef)3	(40	µM, — ,	n	=	95)	or	mefH	(120	µM, — ,	
n	=	90).	(b)	Unit	vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
	 	
(a) 
(b) 
Appendix	3	
	
	301	
	
Appendix	3.10.	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	vector	normalised	HCT-8	cell	spectra	following	4-h	incubation	in	vehicle	(RPMI-1640,	
DMSO	2%	v/v,	— ,	n	=	59),	Bi(difl)3	(75	µM, — ,	n	=	34)	or	diflH	(225	µM, — ,	n	=	41).	(b)	Unit	
vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
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Appendix	3.11:	(a)	Averaged,	baseline	corrected	(rubberband	baseline	corrected,	64	baseline	
points),	 vector	 normalised	 HCT-8	 cell	 spectra	 following	 24-h	 incubation	 in	 vehicle	
(RPMI-1640,	DMSO	2%	v/v,	— ,	 n	=	54),	Bi(difl)3	 (75	µM, — ,	 n	=	66)	or	diflH	 (225	µM, — ,	
n	=	38).	(b)	Unit	vector	normalised,	second	derivative	of	the	spectra	shown	in	(a).	
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Appendix	 3.12:	 Percentage	 of	 early	 apoptotic	 and	 late	 apoptotic	 cells	 based	 on	 flow	
cytometric	 analysis	 of	 cell	 death	 in	 the	 adherent	 only	 HCT-8	 cells	 treated	 for	 24	 h	 with	
vehicle	(RPMI-1640,	2%	v/v	DMSO;	Control),	BiNSAIDs	(Bi(tolf)3	(15	µM),	Bi(mef)3	(40	µM)	or	
Bi(difl)3	(75	µM));	or	the	respective	equimolar	free	NSAIDs.	Each	segment	represents	the	mean	
±	s.d.	(n	=	3	replicates	from	one	experiment).		Statistical	significance	of	the	population	of	dying	
cells	(encompassing	early	apoptotic,	late	apoptotic	and	necrotic	cell	populations)	compared	to	
the	 control	 is	 indicated	 by	 ***	 =	 P	 ≤	 0.001.	 	 Statistical	 significance	 of	 the	 BiNSAID-treated	
samples	compared	to	the	respective	NSAID-treated	samples	is	indicated	by	‡	=	P	≤	0.001.		The	
viable	(AnnV−/7AAD−)	and	early	necrotic	(AnnV−/7AAD+)	cell	populations	have	been	omitted	
from	the	graph	for	clarity.	
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Appendix	4.		Additional	ESI-MS/MS	results	
	
	
Appendix	4.1:	Analytes	identified	above	the	LOD	in	HCT-8	cell	lipid	extracts	treated	with	
vehicle	(2%	v/v	DMSO,	24-h)	using	ESI-MS/MS.	
Analyte	 	 Analyte	 	 Analyte	 	
Precursor	m/z	184.1	 m/z	 Precursor	m/z	184.1	 m/z	 Neutral	loss	141.0	Da	 m/z	
PC	27:0	 664	 PC	O-38:4	 794	 PE	O-32:0	 676	
PC	28:0	 678	 PC	O-38:3/37:4	 796	 PE	32:1	 690	
PC	29:0	 692	 PC	O-38:2p	 798	 PE	O-34:1	 702	
PC	30:1	 704	 PC	O-38:1p	 800	 PE	O-34:0/33:1	 704	
PC	30:0	 706	 PC	O-38:0p	 802	 PE	34:2	 716	
PC	O-32:1	 716	 PC	38:6	 806	 PE	34:1	 718	
PC	O-32:0p	 718	 PC	38:5	 808	 PE	O-36:4	 724	
PC	31:0	 720	 PC	38:4	 810	 PE	O-36:3	 726	
PC	32:2	 730	 PC	38:3	 812	 PE	O-36:2/35:3	 728	
PC	32:1	 732	 PC	38:2	 814	 PE	O-36:1/35:2	 730	
PC	32:0	 734	 PC	38:1	 816	 PE	O-36:0/35:1	 732	
PC	O-34:2	 742	 PC	O-40:5	 820	 PE	36:4	 740	
PC	O-34:1	 744	 PC	O-40:4	 822	 PE	36:3	 742	
PC	O-34:0/33:1	 746	 PC	O-40:3	 824	 PE	36:2	 744	
PC	33:0	 748	 PC	O-40:0	 830	 PE	36:1	 746	
PC	34:3	 756	 PC	40:7	 832	 PE	O-38:6/36:0	 748	
PC	34:2	 758	 PC	40:6	 834	 PE	O-38:5	 750	
PC	34:1	 760	 PC	40:5	 836	 PE	O-38:4	 752	
PC	34:0	 762	 PC	40:2	 842	 PE	O-38:3/37:4	 754	
PC	O-36:4	 766	 	 	 PE	38:6	 764	
PC	O-36:3	 768	 Neutral	loss	185.0	Da	 m/z	 PE	38:5	 766	
PC	O-36:2/35:3	 770	 PS	32:1	 734	 PE	38:4	 768	
PC	O-36:1/35:2	 772	 PS	33:1	 748	 PE	38:3	 770	
PC	O-36:0/35:1	 774	 PS	34:1	 762	 PE	O-40:6/38:0	 776	
PC	35:0	 776	 PS	35:1	 776	 PE	O-40:5	 778	
PC	36:6	 778	 PS	36:2	 788	 PE	O-40:4	 780	
PC	36:5	 780	 PS	36:1	 790	 PE	40:6	 792	
PC	36:4	 782	 PS	38:4	 812	 PE	40:5	 794	
PC	36:3	 784	 PS	38:3	 814	 	 	
PC	36:2	 786	 PS	38:2	 816	 	 	
PC	36:1	 788	 PS	38:1	 818	 	 	
PC	O-38:6/36:0	 790	 PS	40:6	 836	 	 	
PC	O-38:5	 792	 PS	40:5	 838	 	 	
	 	 PS	40:1	 846	 	 	
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Appendix	 5.1:	 Concentration-response	 curves	 obtained	 from	 MTT	 assays	 of	 HCT-8	 cells	
treated	 (24	 h)	 with	 the	 specified	 aminoarenesulfonic	 acids	 and	 corresponding	 Bi(III)	
complexes:	 (a)	 oAB-SO3H	 or	 Bi(oAB-SO3)3;	 (b)	 pAB-SO3H	 or	 Bi(pAB-SO3)3;	 (c)	2AN-SO3H	 or	
Bi(2AN-SO3)3;	 and	 (d)	 5AN-SO3H	 or	 Bi(5AN-SO3)3.	 	 Error	 bars	 represent	 the	 standard	
deviation	 from	 the	mean	 (n	 =	 6).	 	 One	 representative	 of	 three	 independent	 experiments	 is	
shown.		
	
